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The origin of life is based on carbon, since it constitutes the framework of all biomolecules.[1] 
The biological events of life rely on intricate functions of these organic molecules, owing to 
their structural complexity. This renders organic chemistry an important discipline to study life 
sciences as it is highly related to organic molecule interactions. It furthermore arms chemists 
for creating novel organic molecules to thus interfere life activities on behalf of human health. 
To this end, the development of novel and efficient synthetic strategies is highly desired. A 
brilliant strategy to access value-added organic molecules is the direct transformation of 
omnipresent C─H bonds to versatile functional groups. Moreover, as one of the twelve green 
chemistry principles,[2] catalysis[3] has proven to be a powerful tool for performing C─H 
functionalization in a sustainable and efficient manner. 
1.1 Transition Metal-Catalyzed C–H Functionalizations 
The development of highly efficient transition metal-catalyzed organic reactions for 
carbon─carbon and carbon─heteroatom bond formations had a huge impact on organic 
synthesis. Early examples for this kind of transformations are the copper-catalyzed coupling 
reactions developed by Glaser,[4] Goldberg[5] and Ullman.[6] In recent decades, a variety of 
transition metal-catalyzed cross couplings were developed for a broad range of applications 
in organic syntheses, for instance, Kumada-Corriu-,[7] Mizoroki-Heck-,[8] Negishi-,[9] Stille-,[10] 
Hiyama-,[11] Suzuki-Miyaura-,[12] and Sonogashira-Hagihara-reactions.[13] These discoveries 
proved highly practical in the pharmaceutical industry and natural product synthesis.[14] These 
achievements featured the transition metal-catalyzed cross-couplings elegant strategy for 
modern organic synthesis, awarded with the Nobel Prize for Chemistry in 2010 for Professors 
Heck, Negishi and Suzuki. 
Although cross-coupling reactions have enormously contributed to confronting problems in 
organic synthesis, their drawback of largely relying on lengthy substrate prefunctionalizations, 
such as the preparation of organic halides and organometallic reagents, remain a major 
limitation.[15] Many of these reagents are sensitive towards air and moisture, and difficult to 




activations[16] emerged as an atom-[17] and step-economic[18] strategy for environmentally 
friendly organic synthesis (Scheme 1.1.1). Besides widely used 4d and 5d metal catalysis, 
earth-abundant 3d metal-catalyzed C–H activation[19] offers further advantages in terms of 
sustainability and resource-economy. Thus, the development of manganese-catalyzed C–H 
functionalizations[20] has made among others great contribution to sustainable organic 
transformations. 
 
Scheme 1.1.1 Transition metal-catalyzed C─H functionalization vs cross-coupling. 
1.1.1 Mechanistic Manifolds 
In general, the catalytic cycle of transition-metal catalyzed C─H functionalizations is 
constituted of 3 main steps: i) C─H activation; ii) organometallic species functionalization; iii) 
regeneration of the active catalyst (Scheme 1.1.1.1). In some cases, an oxidant is required 





Scheme 1.1.1.1. General catalytic cycle of transition metal-catalyzed C─H activation. 
For the development of novel transition-metal catalyzed C─H functionalizations, a detailed 
understanding of the reaction mechanism is of utmost importance. C─H activation is usually 
the key step of these reactions, and mechanistic insights including computational studies 
assisted in classifying the nature of the C─H cleavage[21] in distinct pathways: a) oxidative 
addition,[22] b) electrophilic substitution,[23] internal electrophilic substitution (IES),[24] c) 1,2-
addition[25], d) σ-bond metathesis [26] and e) base-assisted C─H cleavage[27] (Scheme 1.1.1.2). 
C─H cleavage by oxidative addition generally takes place with electron-rich complexes of 
late transition metals in low oxidation states,[27] whereas electrophilic substitution was 
observed for cationic complexes of late transition metals and involves an electrophilic attack 
of the metal on the carbon. For alkoxide bases, internal electrophilic substitution proceeds by 
electrophilic attack of the metal and a deprotonation through a highly strained, four-
membered transition state. 1,2-addition is a feasible pathway for early transition metals and 
generally occurs via a [2σ + 2π] reaction. Similarly, σ-bond metathesis is also a possible 





Scheme 1.1.1.2. Predominant mechanistic pathways for C─H activation. 
In addition to these pathways, more recent studies also revealed the existence of base-
assisted C─H metalation processes (Scheme 1.1.1.3). The CMD[28] (concerted metalation 
deprotonation) or AMLA[29] (ambiphilic metal-ligand activation) processes take place via a six-
membered transition state, describing the interaction of the C─H bond with the transition 
metal and carboxylate-ligand. This process predominantly occurs with electron-poor 
substrates at the kinetically most acidic C─H bond. Recently, more reports have explored an 
electrophilic substitution type C–H activation by carboxylate additives, which was described 
as base-assisted internal electrophilic substitution (BIES).[30] In contrast to CMD/AMLA 
mechanisms, BIES is generally more favorable for electron-rich substrates, and the selectivity 





Scheme 1.1.1.3. Comparison of transition state structures in base-assisted metalation. 
1.1.2 Selectivity Control of C─H Functionalizations  
Although C–H activation has enormously contributed to modern organic synthesis, it is 
challenged by the full control of the regioselectivity in modifications of complex molecules, 
especially due to the existence of many C–H bonds with similar bond dissociation energies 
within one compound. Weakly-coordinating[32] and removable[33] directing groups have been 
developed for elegantly addressing this problem by precisely controlling the site-selectivities, 
or directly employing internal directing groups. A Lewis basic atom of the directing group 
coordinates to the metal, thus activating the proximal C─H bond and further facilitating the 
key C─H activation step selectively (Scheme 1.1.2.1). 
 
Scheme 1.1.2.1. Representative directing groups for C─H activation. 
1.2 Traditional Chemical Late-Stage Peptide Modifications 
As a class of important biomolecules, peptides are of key importance for various research 




toolbox for exploring biological events, designing pharmaceuticals and evolving new proteins. 
Compared with their parental structures, unnatural peptides largely feature improved 
biological and pharmacokinetic properties,[35] thus making peptide modifications an important 
subject for interdisciplinary studies. Peptide modifications can be accomplished in a 
biosynthesis approach by proteins, which is referred to as post-translational modification 
(PTM).[36] Despite the diversity of peptides derived from PTM and the great success of solid 
phase peptide synthesis (SPPS) for peptide assembly,[37] peptide modifications remain to be 
highly restricted due to limitations of the respective chemical transformations. Valuable 
peptide modifications usually focus on mimicking PTM, such as acylation, methylation, 
phosphorylation, sulfation, ubiquitination and glycosylation. Additionally, peptide 
modifications should ideally be mild, efficient, non-toxic and tolerant of aqueous conditions to 
ensure biocompatibility. 
An early example of chemical peptide modifications was demonstrated by Wilchek and 
coworkers (Scheme 1.2.1).[38] They performed nucleophilic substitutions of OH-activated 
serine 1 with thionucleophiles 2, thus generating non-native cysteine derivatives 3 (Scheme 
1.2.1). 
 
Scheme 1.2.1. Peptide modification by nucleophilic substitution. 
Afterwards, numerous peptide and protein modifications were realized by site-specific 




between peptides/proteins and functional groups in a positional selective fashion (Scheme 
1.2.2). 
Among these approaches, nucleophilic or electrophilic reactions on various amino acid 
residues[40] have especially contributed to this field. For example, the nucleophilic amine 
group of lysine can be easily reacted with electrophiles, e.g. in esterifications with activated 
carbonyls, condensations with carbonyls as well as Michael additions with thiocyanates 
(Scheme 1.2.2a). The SH-group of cysteine is more nucleophilic and can be transformed 
through nucleophilic substitutions with activated alkyl halides or through oxidations with thiols 
to form disulfides (Scheme 1.2.2b). Furthermore, diazonium salts are also employed for 
peptide modifications by electrophilic substitutions on tyrosine residues, thereby making use 
of the activated aromatic ring of tyrosine (Scheme 1.2.2c). 
 
Scheme 1.2.2. Peptide modification at lysine, cysteine and tyrosine. 
Besides nucleophilic and electrophilic substitution reactions for peptide modifications, 
transition metal catalysis has also been employed for peptide transformations in a “tag-and-
modify” strategy.[41] Numerous reactions were thus employed for peptide modifications, such 
as click-reactions,[42] Staudinger ligations,[43] olefin metathesis[44] and cross-coupling 
reactions[14c, 45] (Scheme 1.2.3a). To prefunctionalize the target peptides, lysine is widely used 
as an anchor for the installation of reactive scaffolds, followed by the encoding of the formed 





Scheme 1.2.3. a) Transition metal-catalyzed peptide modification strategies. b) Examples of 
genetically encoded lysine-based amino acids for biocompatible reactions. 
1.3 Palladium-Catalyzed C─H Activations for Late-Stage Peptide 
Diversifications 
Peptide modifications by classic reactions including enzymatic resolution, elaborate on 
asymmetric syntheses,[46] as well as transition metal-catalyzed cross-coupling reactions,[47] 
both of which typically require lengthy prefunctionalizations. In order to address these 
limitations, direct C‒H activation has been successfully applied for amino acid and late-stage 
peptide functionalizations[48] and shows significant advantages in terms of: i) site-selectivity 
control, ii) racemization-free conditions, and iii) effective catalytic turnover. Therefore, C‒H 
activation reactions for transformations of amino acids and peptides contributes productively 
to drug discovery and pharmaceutical industries. Until now, palladium catalysis represents 





1.3.1 Early Examples of Simple Amino Acid C─H Activations  
An early example of functionalizations of amino acids by C‒H activation was developed by 
Corey and coworkers.[49] They reported on a palladium-catalyzed β-hydroxylation of the N-
phthaloyl-substituted amino acids including leucine, alanine, homoalanine and phenylalanine 
(Scheme 1.3.1.1). The employed bidentate[50] chelation-assisted strategy was earlier 
developed by Daugulis.[51] Among a variety of directing groups, the 8-aminoquinoline (8-AQ) 
was found to be optimal for C‒H oxygenations.[52] In this reaction, the oxidation of Mn(OAc)2 
to Lewis-acidic Mn3O(OAc)7 proved crucial for achieving the C‒H activation,[49] along with 
Pd(OAc)2 as the catalyst to give good yields and excellent trans-diastereoselectivities via 
intermediate 10. 
 
Scheme 1.3.1.1 C‒H acetoxylation of amino acids 8. 
With the bidentate strategy,[51] Corey and coworkers further developed stereoselective 
arylation reactions of amino acid derivatives,[49] employing iodides as the arylating reagent 
(Scheme 1.3.1.2). The β-arylation was efficiently applied to the modification of leucine and 
phenylalanine derivatives and both electron-rich and electro-poor aryl iodides 11 were 
tolerated, yielding the products in high yield and diastereoselectivity. Two-fold β-arylation 
occurred for alanine derivatives with 12d as the product, while for valine and isoleucine 
derivatives with a tertiary C(sp3)‒H bond in the β-position the reaction took place at the γ-





Scheme 1.3.1.2. Palladium-catalyzed C(sp3)‒H arylation of amino acids 1. 
The proposed mechanism for the C(sp3)–H arylation of alanine derivative 1 with the bidentate 
directing group 8-AQ generally involves a Pd(II)/Pd(IV) pathway (Scheme 1.3.1.3). 
Carboxylate assisted C–H palladation results in the formation of the trans-palladacycle 10 as 
the key intermediate with high diastereoselectivity.[27] Then, the oxidative addition of aryl 
halide 11 takes place to deliver palladium(IV)-intermediate[53] 10b. Reductive elimination with 
retention of the configuration by ligand exchange follows, thus generating the arylated amino 





Scheme 1.3.1.3. Proposed mechanism for palladium-catalyzed C(sp3)–H arylation. 
1.3.2 Simple Amino Acid C─H Activations 
In addition to 8-aminoquinoline, the use of 2-thiomethylaniline as a directing group was 
reported by Daugulis and coworkers[54] for the mono-arylation reaction of alanine derivatives. 
Importantly, 2-thiomethylaniline could be removed in high yield without significant loss of the 
enantiomeric excess. (Scheme 1.3.2.1). 
 




The power of the C(sp3)‒H activation strategy was also demonstrated by Chen and 
coworkers with the development of a diastereoselective indolylation[55] of leucine derivatives, 
which formed the key intermediate in the subsequent synthesis of natural product Celogentin 
C (17) (Scheme 1.3.2.2).[56] 
 
Scheme 1.3.2.2. Palladium-catalyzed C‒H indolylation for the total synthesis of Celogentin C (17). 
Yu and coworkers devised a monodentate directing group for the arylation of alanine 
derivatives in a racemization-free manner with 2-picoline (20) being employed as a crucial 
ligand.[57] Furthermore, traceless removal of the directing group yielded 15 as an arylated, 





Scheme 1.3.2.3. Palladium-catalyzed C(sp3)‒H arylation of amino acid 18. 
Furthermore, Yu and coworkers explored simple and practical N-methoxyamide 21, a 
masked ester, as the directing group.[58] Promoted by the ligand 2-picoline (20), the arylation 
reaction proceeded efficiently in a site-selective and racemization-free manner. Afterwards, 
the auxiliary group could be modified in high yield (Scheme 1.3.2.4). 
 
Scheme 1.3.2.4. Palladium-catalyzed C(sp3)‒H arylation by N-methoxyamide auxiliary. 
Importantly, Yu and coworkers highlighted the power of pyridine-type ligands by developing 
carboxylic acid-directed arylations.[59] This strategy allowed for amino acid racemization-free 
arylations without installing exogenous directing groups. This transformation is more step-





Scheme 1.3.2.5. Palladium-catalyzed C(sp3)‒H arylation directed by carboxylic acid. 
In addition to the amino acid arylation approaches mentioned above, various 
functionalizations via C(sp3)‒H activations were developed. For example, employing similar 
conditions to the C‒H arylation by Corey,[49] Yu and coworkers reported on a palladium-
catalyzed, ligand controlled olefination of alanine derivative 18 and a successive 
intramolecular Michael addition to give γ-lactam 29 as the product (Scheme 1.3.2.6).[57] 
 
Scheme 1.3.2.6. Palladium-catalyzed one-pot C(sp3)‒H olefination and intramolecular lactamization 
of amino acid 18. 
Earlier, Chen and coworkers demonstrated the alkenylation of alanine derivatives at room 
temperature.[60] They employed various vinyl iodides, yielding the corresponding β-olefinated 
alanine derivatives in a diastereo-retentive manner (Scheme 1.3.2.7). 
 




Furthermore, Shi and coworkers developed picolinamide-directed C(sp3)–H activations, such 
as unusual δ-C(sp3)–H alkenylations, yielding alkenes 34 with high regioselectivity (Scheme 
1.3.2.8).[61] 
 
Scheme 1.3.2.8. Palladium-catalyzed δ-C(sp3)–H alkenylation. 
Besides the C─C bond formation strategy for amino acid modification, Shi and coworkers 
also developed diastereoselective C─F bond formations[62] (scheme 1.3.2.9) and C─Si bond 
formations[63] (scheme 1.3.2.10) for amino acid modification, thereby providing access to 
biological and pharmaceutically relevant fluorinated and silylated amino acids.  
 
Scheme 1.3.2.9. Palladium-catalyzed secondary phenylalanine C(sp3)–H fluorination. 
 





1.3.3 Palladium-Catalyzed C(sp2)─H Activations for Late-Stage Peptide 
Diversifications 
Tryptophan, an indole-based natural amino acid, is a widely studied amino acid for C(sp2)─H 
activations on late-stage peptides. Tryptophan has an unique impact on biological events 
such as protein biosynthesis.[64] The low natural abundance, the inherent photo-electronic 
properties and the indole-based chemistry of tryptophan makes it an ideal and valuable 
C(sp2)─H activation site for the modification of tryptophan-based peptides and proteins.[65] 
Studies of tryptophan modification expanded the applications of tryptophan besides its usage 
in protein quantification and exploration. Thus, direct C‒H activation of tryptophan containing 
peptides is of great value. 
1.3.3.1 Late-Stage Peptide Diversifications via C(sp2)─H Activations on 
Tryptophan 
Palladium-catalyzed C(sp2)‒H functionalizations of indoles have seen great success in the 
past decades.[66] Compared to the indole moiety, the tryptophan scaffold contains the amino 
acid backbone on the C3 position, thus leaving the C2 position a prior activation site to be 
explored. Hence, palladium-catalyzed tryptophan transformations were developed by 
Albericio, Lavilla and coworkers for the direct arylation of NH-free tryptophan.[67] Here, 
Pd(OAc)2 was found to be the optimal precatalyst along with AgBF4 and 2-nitrobenzoic acid[68] 
as the crucial additives. Aryl iodides 11 were found to be efficient arylating reagents and 
microwave irradiation allowed for very short reaction times (Scheme 1.3.3.1.1).  
 




In the same publication, Albericio, Lavilla and coworkers applied the palladium catalysis to 
more challenging peptide C–H arylations.[67] The reactions proceeded efficiently irrespective 
of the position of the tryptophan in the peptide in a racemization-free manner. Importantly, 
the reaction tolerated aqueous media, which has the potential to be compatible with biological 
systems. Furthermore, the reaction was highly selective for tryptophan C─H activation and 
compatible with various amino acids with functional sidechains, such as Arg, Asp, His, Lys, 
Ser, Tyr, Gln as well as free carboxylic acids (Scheme 1.3.3.1.2). 
 
Scheme 1.3.3.1.2. Palladium-catalyzed direct C‒H arylation of tryptophan-containing peptide. 
Based on this palladium-catalyzed tryptophan C‒H arylation strategy, James and 
coworkers[69] further demonstrated the synthesis of macrocyclic peptides,[70] which were 
previously accessed by inter alia ring-closing olefin metathesis,[44c, 71] amide-coupling[72] or 
copper-catalyzed azide–alkyne cycloaddition reactions.[73] In this work, a linkage was devised 
for connecting the tryptophan and iodo-phenylalanie/tyrosine on the peptide substrate 
(Scheme 1.3.3.1.3). An evaluation of various reaction conditions showed the importance of 
the silver salt and the carboxylic acid additive, among which AgBF4 and o-NO2-C6H4CO2H 




ranged in size from 15 to 25-membered rings, with different peptidic amino acid sequences 
of the substrates and meta- or para-aryl bridges. It is noteworthy that intermolecular 
cyclodimerizations were not observed.[74] 
 
Scheme 1.3.3.1.3. Palladium-catalyzed C─H arylation for cyclic peptide synthesis. 
Although the synthesis of cyclic peptidomimetics was found to be viable, the synthesis of 
stapled peptides through direct, linker-free C─H arylation is of great importance, since the 
exogenous linkers may have effects on the properties of the corresponding cyclic peptides. 
Lavilla, Albericio and coworkers thus developed intramolecular C─H arylations for the 
synthesis of stapled peptides 47 (Scheme 1.3.3.1.4).[75] The staple took place between 
tryptophan and iodo-phenylalanine or iodo-tyrosine, with the substituent located at the meta-
position of the arene. o-Nitrobenzoic acid and trifluoroacetic acid were the optimal 
carboxylate additives, along with AgBF4 as the silver salt of choice. Microwave irradiation 




wide range of amino acid sequences was compatible, such as biologically functional NGR (-
Asn-Gly-Arg-) and RGD (-Arg-Gly-Asp-) sequences as well as versatile functional groups.[76] 
 
Scheme 1.3.3.1.4. Palladium-catalyzed C─H arylation for linker-free stapled peptides. 
However, for synthesis of cyclic peptides through intramolecular C─H arylations the problem 
of dimerization cannot be ignored. Thus, Albericio, Lavilla and coworkers studied the effect 
of the number of amino acids between iodo-phenylalanine and tryptophan on dimerization 




dimerization took place (Entry 1). Similarly, with one amino acid between the iodo-
phenylalanine and tryptophan only cyclodimeric peptide 50 was formed (Entry 2). However, 
with two amino acids in between both cyclodimeric and cyclomonomeric peptides were 
obtained, with the desired cyclomonomeric peptide 49a as the major product (Entry 3). 
Notably, when the number of amino acids was increased to 3, only cyclopeptide 49b was 
observed (Entry 4). These results illustrated that the structure and regiochemistry of the 
peptide substrate is crucial for the formation of cyclodimerization or peptide stapling, as well 
as the Ruggli-Ziegler high-dilution conditions.[77] 
Table 1. Cyclodimerization versus cyclization effect 
 
Entry Peptide sequence Cyclodimeric 50 Cyclomonomeric 49 
1 Ala-(p-I)Phe-Trp-Ala (48l) 50a: 60% n.d. 
2 (p-I)Phe-Ala-Trp-Lys (48m) 50b: 54% n.d. 
3 Ala-(p-I)Phe-Lys-Gly-Trp-Ala (48n) 50c: 23% 49a:51% 
4 Ala-(p-I)Phe-Arg-Lys-Gly-Trp-Ala (48o) n.d. 49b: 81% 




1.3.3.2 Late-Stage Peptide Diversifications via C(sp2)─H Activations on 
Tryptophan Under Mild Conditions 
Although great contributions have been made by the palladium-catalyzed tryptophan C–H 
arylations, these synthetic route face major limitations, such as high catalyst loadings, use of 
stoichiometric amounts of silver salts, excessive use of aryl iodides and high reaction 
temperatures, restricting the potential for broader applications. To address these problems, 
Ackermann and coworkers[78] devised a peptide C─H arylation strategy employing 
diaryliodonium salts 52[79] as the arylating reagents (Scheme 1.3.3.2.1). Importantly, the 
reaction proceeded efficiently at ambient temperature, thereby setting the stage for 
bioorthogonal applications. Moreover, the reaction could be conducted with a catalyst loading 
of only 0.5 mol % without hampering the site- and chemo-selectivity. The reaction proved its 
robustness with high reaction efficiency in non-toxic and bio-compatible water.[80] 
 
Scheme 1.3.3.2.1. Palladium-catalyzed peptide C─H arylation with diaryliodonium salts 52. 
Similarly, Fairlamb and coworkers[81] reported peptide C─H arylations with aryl boronic acids 




efficiently at a temperature of 40 °C and tolerated free NH2 and CO2H functional groups 
(Scheme 1.3.3.2.2). 
 
Scheme 1.3.3.2.2. Palladium-catalyzed C─H peptide arylation with aryl boronic acid 55. 
Furthermore, Fairlamb and coworkers elegantly employed aryldiazonium salt 60 for peptide 
arylations (Scheme 1.3.3.2.3).[82]  TsOH was used as a promoter, allowing the reaction to 
be efficient with a catalyst loading of 1.0 mol %. Notably, this room temperature reaction 





Scheme 1.3.3.2.3. Palladium-catalyzed C─H peptide arylation with aryldiazonium salts 
Generally, two different pathways were proposed for palladium-catalyzed tryptophan 
arylations (Scheme 1.3.3.2.4).[83] The Pd(II)/Pd(IV) pathway (Scheme 1.3.3.2.4a) is initiated 
by C─H palladation and followed by oxidative addition, delivering palladium(IV) intermediate 
40c. Subsequent reductive elimination yields the arylated product and regenerates the active 
palladium(II) catalyst. However, with aryl boronic acids as the arylating reagent, the 
palladium(II) intermediate is favored for a transmetallation process, generating Ar-Pd(II) 
intermediate 40d. The reductive elimination then delivers the arylated product and a 
palladium(0) complex, which undergoes a reoxidation step for regenerating the active 





Scheme 1.3.3.2.4. Proposed mechanisms for palladium-catalyzed tryptophan C─H arylations. 
1.3.3.3 Late-Stage Peptide Diversifications via C(sp2)─H Activations on 
Phenylalanine 
Other than tryptophan, phenylalanine offers potential for peptide diversifications via C─H 
bond activation as well. Wang and coworkers[84] reported on the δ-C(sp2)─H olefination of 




1.3.3.3.1b). The reaction was proposed to proceed through a 6/5-bicyclic palladacycle with 
the assistance of the peptide backbone as an internal weakly coordinating directing group. 
Scheme 1.3.3.3.1. Peptide modifications by phenylalanine C─H arylations. 
1.3.4 Palladium-Catalyzed C(sp3)─H Activations for Late-Stage Peptide 
Diversifications 
In spite of major advances of late-stage peptide modifications through tryptophan C(sp2)─H 
activation, challenging C(sp3)‒H activation[85] for peptide diversifications is of great 
importance and remains to be addressed, as C(sp3)‒H bonds are omnipresent in peptide 
backbones, offering the chance of utilizing the positional selectivities for late-stage peptide 




1.3.4.1 Branched Late-Stage Peptides by Palladium-Catalyzed C(sp3)─H 
Activations 
As one of the strategies for late-stage peptide diversification, modifications on the side chains 
of the parent peptides delivers unnatural branched peptides. In this context, Yu and 
coworkers[86] developed the N-terminus-selective arylation of peptides through C(sp3)─H 
activations of alanine motifs (Scheme 1.3.4.1.1). Stoichiometric amounts of silver(I) were 
necessary for high reaction efficiencies. In this work, the peptide backbone acted as a weakly 
coordinating bidentate directing group, thus enabling site-selective arylations and di-, tri- and 
tetra-peptides were transformed in a racemization-free manner. 
Scheme 1.3.4.1.1. N-terminus selective peptide C(sp3)–H arylation. 
Furthermore, an alkynylation reaction[87] was developed by Yu and coworkers for the 
formation of new branches with excellent site-selectivity for the N-terminus alanine residue. 
Free carboxylic acid groups were compatible in this reaction along with efficient conjugations 





Scheme 1.3.4.1.2. N-terminus selective peptide C(sp3)–H alkynylation 
Additionally, Shi and coworkers[88] discovered that with bulky amino acid branches positioned 
in the C-terminus of C-free acid peptides, the C-terminus C(sp3)─H bond was selectively 
activated by means of palladium catalysis (Scheme 1.3.4.1.3). The weakly coordinating 
carboxylic acid directing group formed a 6-membered palladation, outcompeting the bicyclic 
palladation. 
 
Scheme 1.3.4.1.3. C-terminus-selective peptide C(sp3)–H arylation. 
As discussed above, Shi and coworkers previously employed picolinamide (PA)[61] as an 
efficient directing group for amino acid C─H activations. This strategy was further employed 
by the same group for peptide N-terminus δ-C(sp3)‒H alkylation[89] via a 6-membered 




benzoquinone was both used as a ligand and as the crucial cooxidant. The PA group was 
easily removable, enabling further N-terminus diversifications. 
 
Scheme 1.3.4.1.4. Selective peptide N-terminus δ-C(sp3)–H alkylation. 
Shi and coworkers also employed the PA group for late-stage γ-C(sp3)─Si bond formations[90] 
utilizing hexamethyldisilane (38) as the silylation reagent, thus synthesized a variety of 
silicon-containing peptides, which represent a class of peptides that have improved biological 
properties.[35b, 91] In this work, the quinone ligand played an important role for the selective 
silylation. Notably, various amino acid residues were tolerated as the N-terminus C─H 
activation site, including Val, Ile, Thr, Tle and Abu (Scheme 1.3.4.1.5). 
 




In contrast to advances in primary C(sp3)‒H activations for peptide diversifications mainly by 
alanine residue modifications, secondary C(sp3)‒H activation offers new possibilities for late-
stage peptide diversifications. Kazmaier and coworkers[92] established peptide 
functionalizations by arylation on proline secondary C(sp3)‒H bond. The reaction proved 
efficient for short peptides with the easily accessible and removable Boc protecting group 
being fully compatible with the catalyst (Scheme 1.3.4.1.6). 
 
Scheme 1.3.4.1.6. Peptide diversification by proline arylations. 
1.3.4.2 Cyclic Late-Stage Peptides by Palladium-Catalyzed C(sp3)─H Activations 
Besides peptide modifications for novel peptide branches, synthesis of cyclic peptides 
focuses on precise connections between intramolecular amino acids to deliver peptidic rings. 
Cyclic peptides have unique biological or material properties compared to their parent 
branched peptides.[70] However, the synthesis of cyclic peptides is typically lengthy and easily 
generates undesired byproducts such as cyclodimerized products, thus emphasizing the 
need for direct site-selective C─H activations to achieve a precise cyclic peptide synthesis. 
On the basis of Yu’s peptide backbone-induced C(sp3)‒H arylation[86] and their own stapling 
strategy,[75] Albericio, Noisier and coworkers applied these strategies to the synthesis of 
spacer-free cyclic peptides, connecting the two amino acid residues alanine and iodo-
phenylalanine[93] (Scheme 1.3.4.2.1a). The solvent was crucial in this work, since t-BuOH as 




compatible with this transformation as well as different space between the two cross-link 
positions. Thus, a variety of cyclic peptides were obtained, featuring different ring sizes. 
Similarly, Wang and coworkers[94] employed DCE as the solvent, enabling the cyclizations 
through both primary and secondary C(sp3)‒H arylation with excellent levels of 
diastereoselectivity (Scheme 1.3.4.2.1b). 
 
Scheme 1.3.4.2.1. C(sp3)–H arylation for stapled peptides. 
As previously explored, the 8-AQ group[51] exhibits a great efficiency in promoting C(sp3)‒H 
activations. Thus, Chen and coworkers[95] developed an elegant C(sp3)‒H macrocyclization 
for cyclophane-embraced peptides (Scheme 1.3.4.2.2). The stapling took place between the 
aryl iodide C-terminus-modified amino acid residue and an alkyl chain at the N-terminus, 
bearing 8-AQ as the directing group. Various cyclophane-based stapled peptides were 
obtained in different ring sizes and the reaction was found to be compatible with different 






Scheme 1.3.4.2.2. C(sp3)–H arylation for cyclophane-based cyclic peptides 
1.4 Rhodium-Catalyzed C─H Activations for Late-Stage Peptide 
Diversifications 
Similar to palladium, rhodium catalysis has contributed enormously to the development of 
catalyzed C─H activations. Although rhodium(III) catalysis[16j, 96] has been thoroughly studied 
for highly efficient C─H bond transformations, especially for applications in indole chemistry, 
rhodium(III) catalysis for amino acid and late-stage peptide diversifications is still rare. 
Employing rhodium(III) catalysis, Ma and coworkers[97] employed a N-pivaloyl directing group 
for highly regioselective indole C7 C─C bond formations by C─H alkenylation and further 
applied this strategy to simple tryptophan and short dipeptide modifications (Scheme 1.4.1). 
Rhodium(III) catalysis and the N-pivaloyl group are pivotal for this transformation, with the 






Scheme 1.4.1. Rhodium-catalyzed indole/tryptophan C─H alkenylation 
Furthermore, Liu and coworkers[98] employed a rhodium(III)-catalyzed alkenylation strategy 
for late-stage peptide modifications, with widely applied maleimide 76 as the alkenylating 
reagent in a racemization-free manner (Scheme 1.4.2). The N-pyridyl directing group, which 
was previously employed for late-stage peptide diversifications by Ackermann and 
coworkers[99] was employed in this transformation, allowing for tryptophan C2 site-selectivity 
and reaction robustness. Moreover, rhodium(III) catalysis is compatible with various 
functional groups and protecting groups on the peptides, thus delivering a wide range of 





Scheme 1.4.2. Rhodium-catalyzed peptide C─H alkenylation. 
1.5 Manganese-Catalyzed C─H Activations for Late-Stage Peptide 
Diversifications 
Precious 4d and 5d transition metals have undeniably achieved great success in the area of 
peptide C─H functionalizations. However, drawbacks such as the high price and toxicity of 
these metals limit further applications in peptide C─H functionalizations. In recent years, 3d 
transition metals emerged as naturally abundant, less-toxic and user-friendly catalysts,[19, 100] 
with considerable contributions by manganese catalysis.[20a, 101] Ackermann and coworkers 
pioneered the field of late-stage peptide diversifications employing manganese-catalyzed 
C─H activations. Early examples by Ackermann and coworkers showed tryptophan 
transformations by manganese(I) catalysis, such as C–H cyanations[102] and allylations[99, 103] 





Scheme 1.5.1. Manganese-catalyzed tryptophan C─H activations. 
Alkynes are synthetically useful for further transformations, such as 1,3-dipolar 
cycloadditions,[104] Ackermann and coworkers[105] developed manganese(I)-catalyzed 
chemo-selective peptide C─H alkynylations, delivering various tryptophan-based peptides 
bearing alkyne motifs (Scheme 1.5.2). Employing bromoalkynes as the alkynylating reagents, 
this late-stage peptide diversification proceeded efficiently in a racemization-free manner. 
Moreover, this strategy was compatible with various functional groups, such as the native 
NH-free tryptophan, azide and iodide groups, thereby outcompeting palladium catalysis. A 
tryptophan-natural product hybrid was efficiently delivered as well. Furthermore, an 
intramolecular macrocyclization was conducted, delivering a 21-membered cyclic peptide 





Scheme 1.5.2. Manganese-catalyzed peptide C─H alkynylations 
To get mechanistic insights into the manganese catalysis, a KIE study was performed, 
revealing a facile C–H metalation step with kH/kD ≈ 1.0. This result suggested a fast initiating 
C─H activation step for the C─Mn bond formation, further supported by the isolation of the 
key 5-membered manganacycle intermediate 96a, which could be used as the catalyst. 
Migratory insertion further delivers intermediate 96b, which yields the desired alkynylation 





Scheme 1.5.3. Proposed mechanism of manganese-catalyzed C‒H alkynylations 
To further explore the manganese(I)-catalyzed peptide transformations, Ackermann and 
coworkers[106] demonstrated a bioorthogonal C─H allylation reaction for late-stage peptide 
diversifications under racemization-free conditions, using easily accessible Morita-Baylis-
Hillman adducts[107] as the allylating reagents (Scheme 1.5.4a). The robustness of the 
manganese(I) catalysis was shown by tolerating various functional groups, such as iodides, 
esters, amides and free hydroxyl groups.[106] Moreover, peptide-conjugates were obtained 
under the manganese catalysis with various steroid and drug molecules. Notably, an 
intramolecular allylation enabled the assembly of a 15-membered cyclic peptide (Scheme 
1.5.4b), further highlighting the importance of manganese catalysis in peptide diversifications. 
The pyridyl group was removed in a traceless fashion under mild conditions, delivering native 













The transition metal-catalyzed C─H activations have been explored as powerful strategy for 
sustainable organic syntheses.[108] Prof. Dr. Lutz Ackermann and coworkers have achieved 
landmark progress in this field, focusing on establishing highly chemo- and site-selective 
C─H bond transformations of synthetically useful and valuable organic molecules, which 
further proved powerful in the applications to medicinal chemistry, material sciences, and 
electrochemistry.[109] In this context, major efforts were made to establish novel and highly 
positional selective late-stage peptide diversifications by C─H activations, under palladium, 
rhodium and Earth-abundant manganese catalysis. 
Peptides are of great importance for medicinal chemistry and drug discovery.[34] Numerous 
efforts have been made in the field of peptide modifications for improved biological and 
pharmacokinetic properties. In the past few years, C(sp3)–H activations have been developed 
as powerful tools for peptide diversifications.[48] Major advances have been limited to the 
alanine primary C(sp3)–H activations at the peptide N-terminus. In a sharp contrast, 
secondary C(sp3)–H arylations are more challenging and important due to its stereo 
chemistry and structural complexity. The strategy was envisioned by the assistance of peptide 
bond isosteric triazoles in palladium catalysis, the power of this internal triazole assistance 
was reflected by establishing the secondary C(sp3)–H functionalizations on terminal peptides 
as well as the unprecedented positional-selective C(sp3)–H functionalization of internal 
peptides (Scheme 2.1).  
 




As the late-stage peptide diversifications bears potential for drug discovery and 
pharmaceutical industries,[34] peptide labeling technology enabled the molecular insight into 
biological events and real-time therapy.[110] Although BODIPY fluorescent dyes proved 
biocompatible and benign optical properties,[111] BODIPY peptide labeling largely rely on 
lengthy prefunctionalizations. Internal peptide C─H activations offered direct functionalization 
strategy, thus the direct peptide BODIPY fluorescent labeling should be developed. 
 
Scheme 2.2. Internal peptide BODIPY fluorescent labeling. 
In the field of C(sp3)–H functionalizations, cyclobutanes are of the great importance as well 
as amino acids and peptides. Because cyclobutanes represent important building blocks for 
complex natural molecules with relevant biological activities, and are found as common motifs 
in several natural products.[112] C(sp3)–H activations of cyclobutanes enabled a direct strategy 
for cyclobutane derivative assembly other than [2+2] photocycloaddition[113] which is usually 
associated with mixtures of isomers. With the established triazole assisted C─H activations, 





Scheme 2.3. Cyclobutane BODIPY fluorescent labeling. 
C─H activation proved powerful and step-economical for peptide modifications,[48] but it is 
largely restricted to C─C bond formations. C─N bond formations[114] represent established 
strategies for medicinal chemistry and drug discovery, but rarely employed for peptide 
diversifications. And late-stage tryptophan containing peptide diversifications are severely 
restricted to the tryptophan C2 position. In sharp contrast, highly selective C7 [115] amidation 
reaction should be explored by rhodium catalysis. 
 




Glycopeptides and glycoproteins are largely related to key biological events.[116] Naturally and 
synthetic glycopeptides serve as effective therapies against infections.[117] However, 
glycopeptide assemblies are largely limited to lengthy prefunctionalizations. As C─H 
activation has seen its great success in peptide functionalizations, manganese(I)[20a, 101] 
catalyzed late-stage peptide C─H glycoconjugation was thus of interest, enabling 
unprecedented direct peptide glycoconjugation in a racemization-free manner. The 
manganese(I) catalyst is earth abundant and non-toxic, featuring a sustainable and user 
friendly peptide bioconjugation process. 
Scheme 2.5. Direct peptide glycoconjugation by manganese(I) catalysis 
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3 Results and Discussion 
3.1 Position-Selective C(sp3)‒H Functionalization by Internal Triazole 
Assistance: Access to Peptidomimetics 
Peptides are linked to biological events, and recognized as therapeutics for the treatment of 
various diseases, especially unnatural peptides with enhanced biological and 
pharmacokinetic properties.[35b, 118] Conventional syntheses of unnatural amino acids and 
peptides have largely relied on biosynthesis and asymmetric synthesis, requiring lengthy 
prefunctionalizations.[46] C─H activations emerged as a powerful strategy for the direct 
peptide modifications, with pioneering studies by Correy,[49] Chen,[48c, 95, 119] 
Lavilla/Albericio[74-75, 93] and Yu.[57-58, 86-87, 120] The development of bidentate directing groups 
such as 8-aminoquinoline (8-AQ),[51] N-(2-pyridyl)sulfamide,[121] 2-methoxyimino acetyl 
(MIA)[122] and 2-(pyridine-2-yl)isopropyl (PIP)[123] enabled amino acid modification and 
peptide terminus modifications. In contrast, easily accessible 1,2,3-triazoles were identified 
as amide surrogates in bioactive peptides (Scheme 3.1.1),[73c, 124] and proved viable for C‒H 
activations within our sustainable chemistry program.[125] We have thus developed internal 
triazoles for peptide modifications by palladium catalysis, featuring positional selective late-
stage peptide modifications. 
 
Scheme 3.1.1. Examples of bioactive internal triazole peptides. 
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3.1.1 Optimization Studies for Peptide C─H Arylations by Internal Triazole 
Assistance 
To study the triazole assisted C(sp3)‒H arylation, the previous optimization was carried on by 
probing reaction conditions for the alanine arylation by Michaela Bauer and Chuan Dong 
(Scheme 3.1.1.1). 
 
Scheme 3.1.1.1. Standard reaction condition for alanine arylation by triazole assistance. 
To further expand the versatility of this reaction, we further studied the peptide arylation by 
internal triazole instead of the terminal triazole amide. These optimization was initiated by 
employing the standard condition of alanine arylation, however, only minor conversion was 
observed (Table 3.1.1, entry 6), and a synthetically useful conversion was obtained only with 
much longer reaction time of 72 h (Table 3.1.1, entry 7), indicating a rather slow reaction rate. 
Decreased amounts of the aryl iodide 11d severely decreased the yields even at high reaction 
temperature and irrespective of the solvents (Table 3.1.1, entries 1-5). Intriguingly, a change 
of the solvent from toluene to DCE led to a similar outcome at a lower reaction temperature 
of 80 °C, indicating DCE to be a better solvent. Thus with an increased reaction temperature 
of 130 °C in DCE, the reaction delivered the desired product 108a in 80% isolated yield (Table 
3.1.1, entry 9), while only 52% isolated yield was obtained at 130 °C in toluene. Changes of 
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Table 3.1.1.1 Optimization of C(sp3)–H arylation on Tzl-containing peptide 107a.[a] 
 
Entry 11d [equiv] Additive Solvent T [°C] Yield [%][b] 
1 1.5 AgOAc o-xylene 130 12 
2 1.5 AgOAc DMF 100 ‒ 
3 1.5 AgOAc AcOH 100 10 
4 1.5 AgOAc DCE 80 25 
5 1.5 AgOAc PhMe 110 30 
6 2.0 AgOAc PhMe 110 40 
7 2.0 AgOAc PhMe 110 60[c] 
8 2.0 AgOAc DCE 80 57[c] 
9 2.0 AgOAc DCE 130 80 
10 2.0 AgOAc PhMe 130 52 
11 2.0 NH4OAc[d] DCE 130 ‒ 
12 2.0 KOAc[d] DCE 130 38 
13 2.0 NaOAc[d] DCE 130 ‒ 
14 2.0 KTFA[d] DCE 130 ‒ 
15 2.0 NaTFA[d] DCE 130 ‒ 
[a] Reaction conditions: 4a (0.20 mmol), 2a (0.40 mmol), [Pd] (10 mol %), AgOAc (0.22 mmol), solvent (2.0 mL), 
T, 20 h. [b] Yields of the isolated products. [c] 72 h. [d] 0.4 mmol. 
3.1.2 Scope of Peptide C(sp3)─H Arylations by Internal Triazole Assistance 
With the optimized internal peptide arylation condition in hand, we probed the scope of the 
reaction by palladium catalysis. 
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For the peptide substrates with different peptidic amino acid sequences of PhthN-Ala-Gly-
Tzl-Gly-AAn-OMe, the arylations occurred site-selectively at the general N-terminus, although 
C─H bonds were available at the C-terminus (Scheme 3.1.2.1). Both electron-withdrawing 
and electron-donating substituents on the aryl iodides were compatible, delivering the 
corresponding arylated peptide products 108 in good to excellent yields with a wealth of 
functional groups being tolerated, such as esters (108c, 108i, 108m), nitro (108d, 108p), 
halides (108h, 108l) and amides (108b, 108f). Arylations of peptides, such as PhthN-Ala-Gly-
Tzl-Gly-Gly-OMe and PhthN-Ala-Gly-Tzl-Gly-Val-OMe, were conducted in HFIP due to 
solubility issues of the starting materials (108q, 108r). Furthermore, unprecedented internal 
peptide chemical ligations took place by palladium catalysis, with the alanine-integrated aryl 
iodide (108s) and iodo-phenylalanine (108t, 108u), featuring novel dipeptide disconnections. 
Internal hexapeptide arylations were successful in HFIP with moderate yields (108v, 108w). 
Furthermore, we envisioned the positional-selective peptide arylations controlled by the 
triazole moiety position. Thus, unprecedented site-selectivity was observed, differentiating 
the N-terminus peptide diversifications (Scheme 3.1.2.2). For the peptide PhthN-Phe-Ala-
Gly-Tzl-Gly-Leu-OMe, the triazole was placed in the middle position of the peptide, with the 
N-terminus being occupied by phenylalanine. Although C─H bonds on several positions of 
the peptide were available, the arylation took place on the C(sp3)─H bond according to the 
position of the internal triazole (Scheme 3.1.2.2a). Moreover, the dipeptide with the sequence 
PhthN-Phe-Ala-TAM was arylated at the C-terminus alanine by the palladium catalysis, due 
to the peptide C-terminus installed by the triazole amide (Scheme 3.1.2.2b). These results 
suggested a position-tunable C─H activation feature of this reaction, largely resulting from 
the crucial bidentate assistance from the position-flexible triazoles on the peptides. The 
mechanism of triazole assisted C(sp3)─H activation was explored by DFT computational 
studies by Michaela Bauer.[126] 




Scheme 3.1.2.1. Internal triazole assisted N-terminus peptide arylations. [a] HFIP as solvent. [b] 
AcOH as solvent. 




Scheme 3.1.2.2. Triazole-assisted internal and C-terminal peptide C(sp3)─H arylations. 
3.1.3 Removal of TAM Directing Group and Protecting Groups 
To access the unnatural amino acids, we developed a traceless[33b, 58, 127] removal strategy of 
the terminal TAM amide directing group. BF3●Et2O was employed at elevated temperature of 
130 °C, giving the ester product (106ba) in moderate yield. Importantly, this approach did not 
lead to a racemization of the stereogenic center of amino acid substrate. Successively, the 
phthaloyl protecting group could be removed with a vicinal diamine, delivering the free amine 
group (106bb).[86] Similarly, the phthaloyl deprotection was also conducted for the internal 
peptide 108r. 
 
Scheme 3.1.3. Removal of TAM and protecting groups. 
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3.1.4 Studies on the Potential Racemizations of Internal Peptide Arylation 
To gain insights into the potential racemization of the internal peptide arylation regime, we 
conducted a racemization study for the peptide C(sp3)─H activation (Scheme 3.1.4.1). 
 
Scheme 3.1.4.1. Racemization study for peptide internal C(sp3)─H arylation. 
The enantiopure substrate were prepared from commercially available L-amino acids, while 
racemized substrates from racemized D/L-amino acids. The (S-S)-107a was identified with 
99% ee by comparison to other racemized substrates in the HPLC studies (Scheme 3.1.4.2). 
Furthermore, the corresponding products were isolated from the catalytic reactions, and 
subjected to HPLC analyses (Scheme 3.1.4.3, Scheme 3.1.4.4, Scheme 3.1.4.5), showing 
the palladium catalyzed internal peptide C(sp3)─H arylation to be racemization-free. 
 









Scheme 3.1.4.2. HPLC analysis of the eantiopure and racemized substrates (S-S)-107a, (S-RS)-
107a and (RS-S)-107a. IC-3 n-hexane/EtOAc 20/80 flow: 1 mL/min, 274 nm. 







Scheme 3.1.4.3. HPLC analysis of the eantiopure and racemized products (S-S)-108a and (S-RS)-












Scheme 3.1.4.4. HPLC analysis of the eantiopure and racemized products (S-S)-108a and (RS-RS)-
108a. IF-3 n-hexane/EtOAc 30/70 flow: 1 mL/min, 274 nm. 
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3.2 BODIPY Peptide Labeling by Late-Stage C(sp3)─H Activation 
The structural complex peptides are important molecules in medicinal chemistry and 
pharmaceutical industries, both as therapeutics for treatment of diseases and as probes for 
exploring biological activities.[34] The fluorescent labeling of the peptides was recognized as 
a powerful strategy for visualizing the interactions of these molecules within biological 
systems.[110] Among various fluorescent labels, BODIPYs were found to be crucial for 
biochemistry and molecular biology studies.[111] BODIPYs were identified as color-tunable 
and biocompatible dyes, due to their structural diversity, high cell-permeability, large stock-
shift, broad emission wavelength and high quantum yields.[128] BODIPYs were developed as 
effective biology sensors and cell imaging fluoregens, especially the advances by peptide-
BODIPY conjugates (Scheme 3.2.1).[129] However, conventional labelling strategies require 
lengthy procedures.[130] We thus devised a direct peptide BODIPY labelling by C(sp3)‒H 
activation, aiming at the BODIPY fluorescent labelings for both primary and secondary 
C(sp3)‒H bonds with versatile BODIPY structures. 
 
Scheme 3.2.1. Bioactive BODIPY-labeled peptide probes. 
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3.2.1 Optimization Studies for BODIPY Amino Acid Labeling 
Based on the previously developed triazole-assisted alanine arylation reaction (Scheme 
3.1.1.1), the initial studies were conducted by probing various reaction parameters for the 
desired C(sp3)–H fluorescence labelling of TAM-Alanine 105a with BODIPY 109a (Table 
3.2.1.1). Iodo-BODIPY 109a was used as the fluorescent labeling reagent. The testing of 
reaction solvents identified toluene as being optimal (Table 3.2.1.1, entries 3-5), with 1,4-
dioxane giving low yield, while o-xylene increased the efficiency. 0.2 M was found to be the 
concentration of choice (Table 3.2.1.1, entries 6-7). To further improve the reaction conditions, 
we optimized carboxylate additives[27, 125a] and obtained improved yields with (1-Ad)CO2H, 
slightly outcompeting PivOH (Table 3.2.1.1, entry 1 and 8). The reaction yield dropped when 
shifting from silver salt to copper salts (Table 3.2.1.1, entry 9). 
Table 3.2.1.1 Optimization of C(sp3)─H labelling with BODIPY 109a.[a] 
 
Entry MOAcn RCO2H Solvent (M) Yield [%][b] 
1 AgOAc (1-Ad)CO2H toluene (0.2) 84 
2 AgOAc (1-Ad)CO2H toluene (0.2) 69[c] 
3 AgOAc -- toluene (0.2) 75 
4 AgOAc -- 1,4-dioxane (0.2) 46 
5 AgOAc -- o-xylene (0.2) 70 
6 AgOAc -- o-xylene (0.4) 67 
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7 AgOAc -- o-xylene (0.1) 49 
8 AgOAc PivOH toluene (0.2) 80 
9 Cu(OAc)2 (1-Ad)CO2H toluene (0.2) 60 
[a] Reaction conditions: 105a (0.10 mmol), 109a (0.12 mmol), Pd(TFA)2 (10 mol%), M(OAc)n (0.12 mmol), 
solvent, N2, 130 °C, 20 h. [b] Yields of isolated products. [c] 15 mol % Pd(TFA)2 was used. 
However, utilizing the optimized conditions for amino acid labeling by green label BODIPY, a 
decreased yield of 60% was obtained for the arylated BODIPY 109b (Table 3.2.1.2, entry 1). 
Thus, identification of the best reaction conditions was further performed. Decreased 
amounts of the silver salt diminished the reaction yield (Table 3.2.1.2, entry 2), but with 
KHCO3 as additive the efficiency was slightly improved (Table 3.2.1.2, entry 4). However, 
AgNO3 almost shut down the reaction, and Ag2CO3 led to satisfactory yield (Table 3.2.1.2, 
entry 2), further emphasizing the crucial effect of the silver salts. Moreover, the use of 
Cu(OAc)2 gave a similar outcome as the Ag2CO3 and was further employed as the optimal 
additive, considering the abundance and lower toxicity of copper (Table 3.2.1.2, entry 8). 
Table 3.2.1.2 Optimization of C(sp3)─H labelling with arylated BODIPY 109b.[a] 
 
Entry MOAcn Additive Yield [%][b] 
1 AgOAc -- 60 
2 AgOAc -- 20[c] 
3 AgOAc KHCO3 59[c] 
4 AgOAc KHCO3 63 
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5 AgNO3 -- -- 
6 Ag2CO3 -- 72 
7 Cu(Opiv)2 -- 50 
8 Cu(OAc)2 -- 73 
[a] Reaction conditions: 105a (0.10 mmol), 109b (0.12 mmol), Pd(TFA)2 (10 mol %), RCO2H (30 mol %), 
M(OAc)n (0.2 mmol), additive (0.12 mmol), PhMe (0.5 mL), N2, 130 °C, 20 h. [b] Yields of isolated products. [c] 
AgOAc (0.12 mmol). 
3.2.2 Scope of BODIPY Amino Acid Labeling 
With the optimized reaction conditions in hand, we tested the product scope by the triazole-
assisted alanine and phenylalanine C(sp3)─H labeling. Excellent yield was obtained with 
tetramethyl iodo-BODIPY 109a, giving the BODIPY inserted amino acid product 110aa with 
an absorption maximum at λmax = 510 nm. While dimethyl iodo-BODIPY led to a slightly 
reduced reaction efficiency (110ab). meta-Iodo-BODIPY was compatible as well (110ac), 
indicating a broad scope with various BODIPY shapes. Moreover, the labeling of 
phenylalanine gave an excellent yield and disastereoselectivity (110ad), featuring the 
reaction a highly precise and efficient fluorescent labeling strategy for amino acids. 
Next, more BODIPY types were probed for a broader scope of BODIPY modified amino acids, 
employing the standard reaction conditions for arylated BODIPY labeling (Scheme 3.2.2.2). 
Both electron-poor and electron-rich BODIPYs were tolerated under the racemization-free 
conditions, with maximum emission wavelengths ranging from 570 to 625 nm. Notably, 
synthetically useful halides were introduced, such as fluoride (110ba) and chloride (110bb). 
And red-shift wavelength was observed with extended π system (110bc) or electron-donating 
substituents (110be-110bk). For secondary C(sp3)─H labeling of phenylalanine, excellent 
levels of diastereo control of > 20:1 was obtained, along with excellent yields (110bk). Except 
for the iodo-BODIPY substitution at the meso-position of BODIPYs, the 2- and 2,6-diiodo 
BODIPYs were well compatible for the labeling, yielding products bearing the active BODIPY 
α-C─H bonds (110bl-110bo). It is noteworthy that mono-selective BODIPY labeling was 
viable with the 2,6-diiodo BODIPY, delivering the BODIPY labeled amino acid with functional 
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group iodide (110bl,110bm). Furthermore, these iodide BODIPY products bear red-shifted 
wavelengths as yellow fluorescence, compared to the green fluorescence of 110bn and 
110bo. 
 
Scheme 3.2.2.1. Primary and secondary C(sp3)─H BODIPY labelling. 




Scheme 3.2.2.2. Primary and secondary C(sp3)─H BODIPY labelling. 
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3.2.3 Optimization Studies for BODIPY Peptide Labeling 
Despite the success of the amino acid BODIPY labeling, standard conditions for both 
alkylated and arylated BODIPYs did not lead to useful yields for the internal peptides. 
Consequently, we conducted further optimizations for the internal peptide labeling with both 
green and red BODIPY labels. Utilizing of Cu(OAc)2 generated more undesired byproducts. 
Pd(OAc)2 was found to be the best catalyst (Table 3.2.3.1, entries 1-2). And toluene was 
found to be the solvent of choice, giving useful yields by carboxylate assistance with (1-
Ad)CO2H. 
Table 3.2.3.1 Optimization of peptide C(sp3)─H green label BODIPY labeling.[a] 
 
Entry [Pd] Additive Solvent Yield [%][b] 
1 Pd(TFA)2 -- o-xylene 20 
2 Pd(OAc)2 -- o-xylene 40 
3 Pd(OAc)2 (1-Ad)CO2H toluene 47 
4 Pd(OAc)2 (1-Ad)CO2H o-xylene 33 
5 Pd(OAc)2 (1-Ad)CO2H DCE -- 
6 Pd(OAc)2 (1-Ad)CO2H DMF -- 
7 Pd(OAc)2 (1-Ad)CO2H HFIP -- 
[a] Reaction conditions: 107c (0.10 mmol), 109a (0.12 mmol), [Pd] (10 mol %), RCO2H (30 mol %), AgOAc (0.12 
mmol), solvent (0.5 mL), N2, 130 °C, 20 h. [b] Yields of isolated products. 
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Based on the above optimizations, further optimizations revealed that for the red label 109i, 
a larger amount of silver salts improved the efficacy (Table 3.2.3.2, entries 1-2). AgOAc was 
found to be more efficient as compared with Ag2CO3 or Cu(OAc)2 (Table 3.2.3.2, entries 3-5). 
Table 3.2.3.2 Optimization of peptide C(sp3)─H red label BODIPY labeling.[a] 
 
Entry M(OAc)n Yield [%][b] 
1 Ag(OAc)2 (2.0 equiv) 74 
2 Ag(OAc)2 (1.0 equiv) 36 
3 Ag2CO3 (2.0 equiv) 40 
4 Ag2CO3 (1.0 equiv) 46 
5 Cu(OAc)2 (2.0 equiv) 31 
[a] Reaction conditions: 107c (0.10 mmol), 109j (0.12 mmol), Pd(OAc)2 (10 mol %), (1-Ad)CO2H (30 mol %), 
M(OAc)n, PhMe (0.5 mL), N2, 130 °C, 20 h. [b] Yields of isolated products. 
However, for peptides with lower solubility levels, the C(sp3)─H BODIPY labeling was almost 
shut down in toluene (Table 3.2.3.3, entries 1-3). Hence, DCE was found to be a suitable 
solvent (Table 3.2.3.3, entry 4). A useful yield was obtained with an increased catalyst loading 
(Table 3.2.3.3, entry 5). 
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Table 3.2.3.3 Optimization of peptide C(sp3)─H red label BODIPY labeling.[a] 
 
Entry Solvent Yield [%][b] 
1 o-xylene <5%[c] 
2 toluene 10 
3 DMF <5%[c] 
4 DCE 15 
5 DCE 55[d] 
[a] Reaction conditions: 107b (0.10 mmol), 109a (0.12 mmol), Pd(OAc)2 (10 mol %), (1-Ad)CO2H (30 mol %), 
AgOAc (0.2 mmol), solvent (0.5 mL), N2, 130 °C, 20 h. [b] Yields of isolated products. [c] Conversion determined 
by LC-MS analysis. [d] Pd(OAc)2 (20 mol %). 
With the peptide BODIPY labeling strategy established by the above optimization studies in 
hand, we expanded the BODIPY peptide scope by probing various peptides with green or 
red label BODIPYs, good to excellent yields were obtained in a racemization-free fashion, 
and the site-selectivity was secured by the assistance of the internal triazole moieties 
(Scheme 3.2.3.1). Furthermore, the N-terminus of peptide 111a was deprotected, then the 
deprotected peptide was used for sequential peptide synthesis (111i, 111j), featuring the 
reported BODIPY peptides stable and a unique potential for modification of structural 
complex peptide sensors. 




Scheme 3.2.3.1. BODIPY C(sp3)‒H labeling of internal Tzl-peptides. [a] DCE as the solvent. [b] 
Sequentially synthesized from 111a. 
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3.2.4 Removal of TAM and Protecting Groups 
Additionally, we established the traceless removal of the TAM group and the protecting 
groups, to gain access to free BODIPY amino acids and peptides (Scheme 3.2.4.1). To 
proceed the multiple removals, several steps have been conducted (Scheme 3.2.4.2). 
Initiating work was the removal of TAM group, with masked amino acid ester as the product. 
However, due to the strong acidic condition, the boron center of BODIPY was cleaved as well, 
which could be reinstalled by Et3N and BF3ꞏEt2O in excellent yields. Afterwards, the phthaloyl 
protecting group was deprotected by ethylene diamine, followed by the deprotection of ester 
to give the desired amino acids. For internal triazole peptide BODIPY, the phthaloyl group 
and ester could be sequentially removed. 
 
Scheme 3.2.4.1. Traceless removal towards BODIPY labeled parent amino acids 110 and peptides 
111. 




Scheme 3.2.4.2. Sequential removal towards BODIPY labeled parent amino acids 110 and peptides 
111. 
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3.2.5 Studies on Potential Racemizations 
To explore the possible racemizations on amino acid stereogenic center during the palladium-
catalyzed BODIPY labeling, we performed the C─H activation with both racemized substrates 
and enantiopure substrates, followed by HPLC studies. The comparison showed no loss of 
stereoinformation of the substrate during the reaction, for both the amino acid 105a and the 
peptide 107c. 
 
Scheme 3.2.5.1. Racemization study of peptide internal BODIPY labeling. 
 
 









Scheme 3.2.5.2. HPLC analysis of the enantiopure and racemized substrates (S-S)-107c and (RS-











Scheme 3.2.5.3. HPLC analysis of the enantiopure and racemized products (S-S)-111a and (RS-S)-
111a. IE n-hexane/EtOAc 30/70 flow: 1 mL/min, 274 nm. 









Scheme 3.2.5.5. HPLC analysis of the enantiopure and racemized amino acid substrates (L)-105a 
and (rac)-105a. IE n-hexane/EtOAc 30/70 flow: 1 mL/min, 274 nm. 







Scheme 3.2.5.6. HPLC analysis of the enantiopure and racemized amino acid products (L)-110bg 
and (rac)-110bg. IE n-hexane/EtOAc 30/70 flow: 1 mL/min, 274 nm. 
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3.3 BODIPY-Labeled Cyclobutanes by Secondary C(sp3)─H 
Arylations 
Cyclobutanes are known as important building blocks for structural complex bioactive natural 
products, such as Pipercyclobutanamides, Piperchabamides, Nigramides, and 
Dipiperamides (Scheme 3.3.1).[131] The strained ring could be obtained by [2+2] 
photocycloaddition strategy.[113] Alternatively, C─H activations have met with undisputable 
success in sustainable and selective transformations, as employed by Baran[132] and Yu.[133] 
Also azetidine modifications for drug discovery was noted by Schreiber.[134] To further explore 
the synthetic strategy for cyclobutane derivatives synthesis, we developed palladium-
catalyzed secondary C(sp3)─H arylations of the cyclobutane and BODIPY labelings by 
triazole assistance. The unprecedented BODIPY cyclobutanes by this pathway were further 
applied for live cell imaging as an efficient probe.[135] 
Scheme 3.3.1. Examples of bioactive cyclobutane natural products. 
Preliminary studies were performed for the optimization of the TAM-cyclobutane arylation. 
ortho-Xylene was identified as the optimal solvent, and Pd(TFA)2 with AgOAc as the silver 
salt. The desired functionalization occurred also at decreased reaction temperatures, while 
optimal results were achieved at 130 °C. Thus, the standard reaction condition was 
established by Dr. Matteo Virelli for the diarylations, affording the cis-diarylated cyclobutanes 
(Scheme 3.3.2).[136] 




Scheme 3.3.2. Standard condition for cyclobutane arylations with TAM assistance. 
With the cyclobutane secondary C(sp3)─H arylation in hand, we further envisioned the 
cyclobutane BODIPY labeling by iodo-BODIPY scaffolds. No di-substituted cyclobutane-
BODIPY was observed even with 4.0 equivalents of iodo-BODIPYs 109. The optimal outcome 
was obtained with 1.2 equivalent of iodo-BODIPYs 109 for the mono BODIPY labeled 
cyclobutanes (Scheme 3.3.3). Both green and red label BODIPYs proved to be compatible, 
as well as various substituents of the BODIPYs. Notably, BODIPY-labeled cyclobutane-1-
carboxylate 114e, as an unprecedented fluorescent core of natural product derivatives, was 
obtained. 
Scheme 3.3.3. BODIPY mono-labeling of cyclobutanes assisted by TAM. 
Moreover, successive modification of the mono-BODIPY labeled cyclobutane derivatives 
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proceeded with iodoarenes 11 by a two-fold C─H activations (Scheme 3.3.4). The di-
functionalized unsymmetrical cyclobutane products contain one aryl moiety and one BODIPY 
fluorescent dye, featuring fluorescent mimics of bio relevant natural products. 
 
Scheme 3.3.4. Twofold C(sp3)–H BODIPY labeling and arylation of cyclobutanes. 
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3.4 Peptide Late-Stage Diversifications by Rhodium-Catalyzed 
Tryptophan C7 Amidation 
Functionalized peptides are of great importance to drug discovery. Consequently, the precise 
synthesis of structural complex peptides is of urgent need. Although peptide syntheses are 
still largely limited to classic approaches, transition metal catalyzed C─H activation[16] have 
contributed enormously to the late-stage peptide functionalizations, mostly by Corey,[49] 
Chen,[48c, 95, 119] Lavilla/Albericio,[74-75, 137] Daugulis,[50a, 54] Shi,[89, 138] Wang,[84, 94, 139] Yu,[57-58, 86-
87] and Ackermann.[78, 99, 103, 105-106, 140] The efficient functionalization of peptides was 
established through selective tryptophan modifications, due to its low natural abundance as 
well as its unique impact on biological events.[141] However, all the late-stage peptide 
diversifications of tryptophan are restricted to the tryptophan C2 position, limiting the 
structural diversity of the peptides. In sharp contrast, indole/tryptophan C7 decorated 
products are of great importance as bioactive natural products and reagents (Scheme 
3.4.1).[115] 
 
Scheme 3.4.1. Bioactive C7 decorated indole and tryptophan derivatives. 
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3.4.1 Optimization Studies for Tryptophan C7 Amidation 
To further address the limitations of tryptophan-peptide diversifications, we initiated our 
exploration by C─N bond formation of peptides compared to the widely developed C─C 
formation of peptides. In this context, 3-phenyl-1,4,2-dioxazol-5-one was used as the efficient 
amidating reagent[103, 142] under rhodium(III)[16j, 96, 143] catalysis. Carboxylic acid additives[27, 
125a] were found to be pivotal for the C7 amidation (Table 3.4.1.1, entries 1-8), among which 
MesCO2H proved to be optimal (entry 2). A change from AgSbF6 to other silver salts led to 
diminished yields (entry 5). TFE outperformed other solvents in the reaction (entries 9-11). 
Excessive amount of the silver salts (entries 12, 13) or the acid additives (entry 14) gave 
diminished reaction yields. Decreased reaction temperatures led to a drop of the efficacy 
(entries 15, 16). Changing or omitting the rhodium catalyst shut down this reaction (entries 
17-20). N-Substituents other than pyrimidyl on the indole did not lead to a superior reaction 
outcome (entries 21, 22). 
Table 3.4.1.1. Optimization of C–H amidation of tryptophan[a] 
 
Entry [TM]/[Ag] Additives Solvent Time/h T/°
C 
Yield [b] 
1 [RhCp*Cl2]2 (2.5 mol %)/[Ag] -- DCE 16 110 -- 
2 [RhCp*Cl2]2 (2.5 mol %)/[Ag] MesCO2H (15 mol %) DCE 16 110 58% 
3 [RhCp*Cl2]2 (2.5 mol %)/[Ag] (1-Ad)CO2H (15 mol %) DCE 16 110 57% 
4 [RhCp*Cl2]2 (2.5 mol %)/[Ag] C6F5CO2H (15 mol %) DCE 16 110 42% 
5 [RhCp*Cl2]2 (2.5 mol %)/[Ag] C6F5CO2H (15 mol %) DCE 16 110 15%
[c] 
6 [RhCp*Cl2]2 (2.5 mol %)/[Ag] m-CF3 C6H4CO2H (15 mol %) DCE 16 110 39% 
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[a] Reaction conditions: 96aa (0.2 mmol), 116a (0.4 mmol), [TM] (5.0ꟷ10 mol %), [Ag] = AgSbF6 (10 mol %), 
additives (15ꟷ30 mol %), solvent (0.4 mL), under N2; [b] Yield of isolated products; [c] [Ag] = AgNTf2 (10 mol %); 
[d] [Ag] = AgSbF6 (20 mol %); [e] R = pivaloyl; [f] R = 2-pyridyl. 
3.4.2 Scope for Tryptophan C(7)─H Amidation 
With the optimized reaction conditions in hand, we explored the scope of the tryptophan 
diversification employing various 1,4,2-dioxazol-5-ones 116. Both aryl and alkyl dioxazolones 
were thus well tolerated (Scheme 3.4.2.1). Acetyl- and phthaloyl protecting groups both gave 
excellent yields (117aa, 117ab), and importantly, tryptophan with a free carboxylic acid 
selectively gave the C7 amidated product 117ac, illustrating the robustness of this C(7)─H 
reaction. Besides arenes, heterocyclic thiophene was efficiently converted into the C7-
modified product 117ad. Various alkyl dioxazolones could also be introduced to give the C7-
alkylated products 117ae, 117af. Notably, amide group was also compatible in this C7 
transformation (117ag). Intrigued by the compatibility of alkyl groups, we employed the C─H 
7 [RhCp*Cl2]2 (2.5 mol %)/[Ag] 4-Toluic acid (15 mol %) DCE 16 110 -- 
8 [RhCp*Cl2]2 (2.5 mol %)/[Ag] TFA (15 mol %) DCE 16 110 12% 
9 [RhCp*Cl2]2 (2.5 mol %)/[Ag] MesCO2H (15 mol %) DCE 24 110 65% 
10 [RhCp*Cl2]2 (2.5 mol %)/[Ag] MesCO2H (15 mol %) 1,4-dioxane 24 110 49% 
11 [RhCp*Cl2]2 (2.5 mol %)/[Ag] MesCO2H (15 mol %) TFE 24 110 92% 
12 [RhCp*Cl2]2 (2.5 mol %)/[Ag] MesCO2H (15 mol %) TFE 24 110 76%
[d] 
13 [RhCp*Cl2]2 (2.5 mol %)/[Ag] MesCO2H (15 mol %) DCE 24 110 53%
[d] 
14 [RhCp*Cl2]2 (2.5 mol %)/[Ag] MesCO2H (1.0 equiv) DCE 24 110 57% 
15 [RhCp*Cl2]2 (2.5 mol %)/[Ag] MesCO2H (15 mol %) TFE 24 90 61% 
16 [RhCp*Cl2]2 (2.5 mol %)/[Ag] MesCO2H (15 mol %) TFE 24 26 24% 
17 CoCp*(CO)I2 (10 mol %)/[Ag] MesCO2H (30 mol %) TFE 24 110 -- 
18 MnBr(CO)5 (10 mol %) MesCO2H (30 mol %) TFE 24 110 -- 
19 Pd(OAc)2 (10 mol %) MesCO2H (30 mol %) TFE 24 110 -- 
20 [RhCp*Cl2]2 (--)/[Ag] MesCO2H (15 mol %) TFE 16 110 -- 
21 [RhCp*Cl2]2 (2.5 mol %)/[Ag] MesCO2H (15 mol %) TFE 24 110 --[e] 
22 [RhCp*Cl2]2 (2.5 mol %)/[Ag] MesCO2H (15 mol %) TFE 24 110 74%[f] 
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amidation for the direct chemical ligation with various amino acid-derived dioxazolones 116, 
thus, enabling new disconnections towards dipeptides. Thereby, both α-amino acids and β-
amino acids were introduced to the C7 position of tryptophans 117ah-117ak. 
 
Scheme 3.4.2.1. Tryptophan C7 amidations by various dioxazolones. 
With the success on C7 amidation of tryptophan, we further probed the peptide 
diversifications (Scheme 3.4.2.2) with this C7 amidation strategy. Dipeptides, tripeptides and 
hexapeptides were all transformed into C7 amidated products in a site-selective fashion. The 
reaction retained the site-selectivity irrespective of the peptidic amino acid sequence. Free 
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hydroxyl group of serine was compatible with this reaction, thus, giving the desired products 
with the free OH-group 117bb and 117bd. Notably, peptide-natural product hybrids 117bd, 
117be, 117bi and late-stage modified peptide 117bj were obtained by the C7 amidation, 
highlighting the potential to assemble structurally complex peptides. 
 
Scheme 3.4.2.2. Tryptophan C7 amidations by dioxazolones 116. 
Results and Discussion 
77 
 
Next, we developed the double C─H activations by tryptophan C7 amidation and then C2 
position modifications, further enhancing the structural complexity (Scheme 3.4.2.3). The 
twofold rhodium-catalyzed amidation with dioxazolones 116 was thus conducted for di-
amidated product 118a. And another amidating reagent TsN3 was also employed 
successively, delivering di-amidated products 118b. Furthermore, manganese catalyzed 
CꟷH alkynylation[105] enabled the successive functionalization, giving di-functionalized amino 
acid 118c, which should bear great potential for subsequent diversifications by click-reactions. 
Moreover, successive C─H allylations were also enabled by manganese catalysis,[106] 
furnishing peptides 118d and 118e, bearing erucic acid amide and allyl-tryptophan. 
Scheme 3.4.2.3. Peptide sequential double C─H activations. 




Scheme 3.4.2.4. Sequential diversifications of C7 products. 
3.4.3 Traceless Removal of Pyridyl Group of C7 Amidated Product 
The N-pyridyl group of C7 amidated products could be removed in a traceless manner. The 
first step was a methylation of the pyridyl group, which was followed by a palladium-catalyzed 
hydrogenation in the second step, thus delivering the C7 amidated native NH-free tryptophan 
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product 3c (Scheme 3.4.3.1).[140b],[144] 
 
Scheme 3.4.3.1. Traceless removal of the pyridyl group. 
3.4.4 Pyrimidyl Transformation by Hydrogenations 
Furthermore, we devised a novel hydrogenation strategy of the C7 amidated product 117ae, 
which selectively took place at the N-pyrimidyl substituent to furnish the tetrahydropyrimidine 
117aea and hexahydropyrimidine 117aeb by the judicious choice of the reaction time 
(Scheme 3.4.4.1). Thereby, the hydrogen-bond acceptor is transformed into a donor motif, 
which should prove instrumental for medicinal chemistry. 
 
Scheme 3.4.4.1. Pyrimidyl transformation by palladium-catalyzed hydrogenation. 
3.4.5 Studies on Potential Racemization 
To explore the potential racemizations of this tryptophan C7 amidation reaction, studies were 
carried on the C7-amidation (Scheme 3.4.5.1). The substrates tryptophan (L)-96aa and 
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tryptophan (rac)-96aa were subjected to the C─H amidation under the optimized reaction 
conditions. A comparison between substrates and the corresponding products by HPLC 
analysis showed that no racemization occurred during the C‒H amidation process, furnishing 
the site-selectively amidated products in 99% ee (Scheme 3.4.5.2).  
 





Scheme 3.4.5.2. HPLC analysis of products (rac)-117aa, (L)-117aa. IC n-hexane/EtOAc 30/70 flow: 
1 mL/min, 274 nm. 
Results and Discussion 
81 
 
3.4.6 Mechanism Insights into C7 Positional Selectivity 
To rationalize the C7 selectivity, we tested whether an H/D exchange occurred on the 
tryptophan 96aa in the presence of [D]3-MeOH (Scheme 3.4.6.1). Unexpectedly, a reversible 
CꟷH activation at both the C7 and the C2 position was observed. 
 
Scheme 3.4.6.1. H/D exchange experiment on substrate 96aa. 
 
The site-selectivity was related to the substrates (Scheme 3.4.6.2). The C─H amidation 
reaction with indole substrate 96a resulted in the preferential C2 amidation, while tryptophan 
substrate 96aa underwent C7 amidation with excellent site-selectivity, indicating an increased 
impact of the steric[145] hindrance from the substrates 96.  




Scheme 3.4.6.2. C–H amidation of substrates 96a and 96aa. 
According to these experiments, the reversible CꟷH activation step was revealed, and 
according to the H/D exchange studies, both C7 and C2 position has a similar chance for the 
CꟷH activation. Furthermore, according to the DFT studies by Dr. Rositha Kuniyil, for the C7 
position, both the decarboxylation step for 96aa(III) and also the CꟷN bond formation through 
96aa(IV) went through lower energy barriers than the C2 position steps. According to all these 
results, we thus proposed a plausible catalytic cycle of the C7 amidation reaction shown in 
Scheme 3.4.6.3. 




Scheme 3.4.6.3. Proposed catalytic cycle for rhodium-catalyzed tryptophan C7 amidation. 
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3.5 C─H Activations for Peptide-Carbohydrate Conjugation by 
Manganese(I)-Catalysis 
As an endogenous post-translational process, protein glycosylation is of crucial importance 
to glycobiology.[116] Glycopeptides and glycoproteins are highly related to key biological 
events, such as cell adhesion, cell growth, and cell-cell communication.[146] Structurally novel 
glycoproteins were developed as diagnostic tools[147] and as vaccines.[148] Moreover, 
glycopeptide antibiotics (GPA) are known as effective therapy for the treatment of bacterial 
infections.[117] For instance, the C-mannosyl tryptophan was identified as endogenous glycol-
amino acid, and mannosyl tryptophan-containing peptides were discovered as naturally 
occurring alkaloids (Scheme 3.5.1).[149] These building blocks are potential for late-stage 
glycopeptide syntheses. Compared to the classical chemical transformations for peptide 
assembly with lengthy prefunctionalizations,[150] C–H activation[16] provided a step-
economical and efficient strategy for late-stage peptide direct functionalizations. However, 
the fast assembly of glycopeptides by C–H activation remained elusive. In this context, within 
our sustainable chemistry program,[125] we devised the metal-catalyzed late-stage peptide C–
H glycoconjugation. Manganese[19-20, 101, 151],[152],[153] was employed due to its earth-abundant, 
non-toxic properties and robustness. Structurally complex peptide-saccharides were thus 
obtained in a racemization-free manner. 
Scheme 3.5.1. Naturally occuring glycopeptides and alkaloids. 
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3.5.1 Scope for Tryptophan C─H Glycoconjugation 
Preliminary studies were carried out by probing the indole glycosylations with glucosyl 
carbonate. The optimized reaction conditions of this manganese-catalyzed allylation-based 
glycoconjugation was established by Dr. Parthasarathi Subramanian (Scheme 3.5.1.1).  
 
Scheme 3.5.1.1. Indole glycoconjugation by manganese(I) catalysis. 
Intrigued by the indole glycosylation results, we applied this reaction to enantiopure 
tryptophan glycosylations (Scheme 3.5.1.2). The glycosylation approach was compatible with 
various carbonates, delivering various glycotryptophans in a racemization-free manner, 
introducing furanose (119a, 119c), ribose (119b) as well as galactose (119d) to the 
tryptophans. The E-/Z-isomers could be easily isolated separately, providing potential for 
structure-activity studies. Moreover, the derivative 120af of brevianamide F,[154] a scaffold of 
a plethora of natural products, was efficiently transformed into the natural product-gluco 
hybrid. Notably, a higher E/Z ratio was obtained for tryptophan glycosylations. 




Scheme 3.5.1.2. C–H glycoconjugation of tryptophans 
3.5.2 Optimization for Peptide C─H Glycoconjugation 
To further explore the reaction for late-stage peptide glycosylations, orienting studies were 
conducted on the optimization for dipeptide glycosylations (Table 3.5.2.1). The standard 
conditions for tryptophan glycosylations did not lead to the best outcome (entry 3). Increased 
equivalents of the additive gave an improved result (entry 4). With an increased catalyst 
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Table 3.5.2.1. Optimization of C–H glycoconjugation of dipeptide Boc-Gly-TrpPy-OMe 88bd with 
furanose carbonate 119a.[a] 
 
Entry [Mn] (mol %) Additive (mol %) Solvent Yield [%][b] 
1 MnBr(CO)5 (20) NaOAc (30) DCE 68 (E/Z = 14:1) 
2 Mn2(CO)10 (20) NaOAc (30) DCE 20 
3 Mn2(CO)10 (10) NaOAc (30) DCE nd 
4 Mn2(CO)10 (10) NaOAc (200) DCE 50 (E/Z = 10:1) 
5 Mn2(CO)10 (10) NaOAc (30) DCE nd 
6 Mn2(CO)10 (10) NaOAc (30) m-xylene 12 
7 Mn2(CO)10 (10) Cy2NH (200) DCE traces 
[a] Reaction conditions: 88bd (0.10 mmol), 119a (0.20 mmol), [Mn], additive, solvent (0.5 mL), 120 °C, 
24 h. [b] Yields of isolated products. E/Z ratio in parentheses was determined by 1H NMR. 
3.5.3 Scope for Peptide C─H Glycoconjugation 
With the success of the tryptophan C─H glycoconjugations, we next employed the strategy 
for a broad range of structural complex glycopeptides (Scheme 3.5.3.1) with high levels of 
regio- and stereo-selectivities. The glycosylation on peptides provided the glycoconjugated 
peptide products with higher E/Z ratio than the mono tryptophan as substrates. Notably, the 
native tryptophan with the free NH-group was tolerated (120bc), highlighting the potential for 
further peptide modifications. Both furanose and galactose motifs were introduced to the 
peptides chemo-selectively by the manganese(I) catalysis. 
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Scheme 3.5.3.1. C–H glycoconjugation of tryptophan-containing peptides. 
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Other than the dipeptides, we further showed the unique power of the late-stage peptide 
glycoconjugations (Scheme 3.5.3.2). The hexapeptide was thus transformed by this 
manganese(I) catalysis into a glycopeptide conjugate 120ca with a furanose scaffold, 
featuring as the peptide with both improved structural and functional complexity. Also, the 
C─H glycosylation strategy was conducted for BODPY integrated fluorescent peptide with 
galactose motif, unprecedentedly delivering a fluorescent glycopeptide 120cb, which should 
prove invaluable for in-vivo fluorescent microscopy.[128c, 155] 
 
Scheme 3.5.3.2. C–H glycoconjugation of hexapeptide and fluorescent peptide 
3.5.4 Traceless Removal of Glycopeptide Pyridyl and Protecting Groups 
To further develop the molecular functions of the glycopeptides, we conducted the traceless 
removal of the pyridyl group,[140b, 144] and the protecting groups. After the removal of the 
pyridyl group, TFA was employed for the removal of the carbonate protecting groups. With 
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this strategy, NH and OH-free glycopeptides was delivered in a chemo-selective fashion. 
Thereby, we obtained 120aa’ as a novel C-galactosyl tryptophan[156] derivative, which is of 
key importance in modulating the functions of proteins in cellular processes (Scheme 3.5.4.1).  
 
Scheme 3.5.4.1. Traceless removal for OH and NH free glycotryptophan. 
3.5.5 Studies on Potential Racemization of C─H Glycoconjugation 
To probe if the unprecedented C─H peptide glycosylation proceeded in a racemization-free 
manner, D/L-tryptophan and the enantiopure substrates were subjected to the glycosylation 
reaction (Scheme 3.5.5.1). Both the substrates and the glycoconjugated products were 
analyzed by HPLC comparisons (Scheme 3.5.5.2 and Scheme 3.5.5.3). The developed C─H 
glycosylation reaction did not cause any loss of the stereogenic integrity on the tryptophan 
substrates. 














Scheme 3.5.5.2. HPLC analysis of substrate (S)-88ae, (rac)-88ae. IC n-hexane/EtOAc 50/50 flow: 1 






Scheme 3.5.5.3. HPLC analysis of products (S)-120ac, (rac)-120ac. IC n-hexane/EtOAc 50/50 flow: 
1 mL/min, 274 nm. 
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4 Summary and Outlook 
The late-stage modification of peptides is of great value to drug discovery and medicinal 
chemistry. Conventional syntheses of peptides are largely limited to lengthy procedures and 
conventional reactions. In contrast, metal catalyzed C─H activation catalysis has emerged 
as efficient and step-economic strategy for post-translational peptide engineering. However, 
a diversity of positional-selective transformation is highly desirable. Moreover, besides 
peptide C─C formations, C─N formation is of key importance for peptide modifications due 
to the pharmaceutical features and applications of C─N bond, and C─X bond formation 
should be studied for the diversity of novel peptide structures. Other than precious 4d and 5d 
metals, 3d metal manganese has recently emerged as an efficient, earth-abundant and non-
toxic metal for the late-stage peptide modifications, enabling green and sustainable 
syntheses of structural complex peptides. 
In the first project, a palladium-catalyzed internal triazole peptide C(sp3)‒H arylation was 
achieved (Scheme 4.1). This diversification features various functional group tolerance, and 
enabled the racemization-free late-stage transformation of peptides. Through this arylation 
reaction, a variety of functional groups was introduced to amino acids and peptides, as well 
as the site-selective chemical ligations through iodo-phenylalanine for new peptide 
disconnections. Importantly, limitations of traditional bidentate chelation strategy for 
challenging peptide C(sp3)─H modifications were addressed in this work through the 
unprecedented internal triazole assistance. The positional control of peptide C─H 
functionalization was thus realized, enabling a precise late-stage peptide assembly at the C-
terminal, N-terminal and internal position in a programmable fashion. 




Scheme 4.1. Position-selective functionalization of C(sp3)‒H by internal triazole assistance: access 
to peptidomimetics. 
In the second project, we reported on the first peptide BODIPY-labeling by C(sp3)─H 
activation (Scheme 4.2). Through the palladium-catalyzed C(sp3)─H BODIPY labeling, we 
synthesized various fluorescent BODIPY amino acids and peptides with high levels of chemo-, 
diastereo- and positional-selectivities. A wide range of BODIPYs with different emission 
wavelengths were compatible with this chemistry, delivering the BODIPY labeled amino acids 
and peptides with various fluorescent colors in a linker-free fashion. Notably, the isosteric 
triazoles were employed as the bidentate chelation assistance for this precise chemical 
labeling control. Furthermore, the triazole groups of BODIPY amino acid were removed in a 
traceless manner, giving free BODIPY-labeled amino acids as potential building blocks for 
the assembly of peptidic fluorescent sensors for in-vivo imaging studies. 




Scheme 4.2. BODIPY peptide labeling by late-stage C(sp3)─H activation. 
In the third project, the secondary C(sp3)─H arylation was developed by triazole assistance, 
providing various cyclobutane natural product analogs. With our program of late-stage 
peptide and natural product fluorescent labeling, the unprecedented cyclobutane BODIPY 
labeling was thus realized (Scheme 4.3). A wide range of BODIPYs were tolerated in this 
work, delivering the fluorescent cyclobutane natural product derivatives. Notably, the BODIPY 
labeling of cyclobutanes was highly mono-selective, thus paving the way for the successive 
cyclobutane functionalizations, enabling synthesis of unsymmetrical fluorescent 
cyclobutanes, featuring a class of functional and structural complex cyclobutane derivatives. 




Scheme 4.3. BODIPY-labeled cyclobutanes by secondary C(sp3)─H arylation. 
In the fourth project, a robust positional-selective tryptophan C7 amidation reaction was 
developed by rhodium(III) catalysis (Scheme 4.4). Versatile functional groups were installed 
on the tryptophan containing peptides through this unprecedented C7 amidation. In contrast 
to all other metal-catalyzed late-stage peptide modifications, this chemistry was of significant 
selectivity on the unusual C7 tryptophan position as well as natural products conjugations. 
This enabled a sequential peptide C(2)─H activations, delivering structurally complex 
peptides. 
Scheme 4.4. Peptide late-stage diversifications by rhodium-catalyzed tryptophan C7 amidation. 
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In the fifth project, the manganese(I)-catalyzed peptide allylation reaction was developed to 
introduce the glycol motifs (Scheme 4.5). Through this unprecedented peptide linchpin C–H 
glycoconjugation, various glycopeptides were assembled with high levels of chemo- and 
positional selectivity in a racemization-free manner. The pyridyl group was removed in a 
traceless manner, affording the native glycotryptophan. Notably, late-stage peptide and 
BODIPY labeled peptide were successfully transformed by the C─H glycoconjugation for 
structurally complex glycopeptides. 
 






5 Experimental Section 
5.1 General Remarks 
Unless otherwise noticed, all reactions were carried out under an atmosphere of N2 using 
pre-dried glassware and standard Schlenk techniques. If not otherwise noted, yields refer to 
isolated compounds, estimated to be >95% pure as determined by 1H-NMR. 
Vacuum 
The following pressure were measured on the used vacuum pump and were not corrected: 
Membrane pump vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 mbar. 
Melting Points (M.p.) 
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 from 
BARLOWORLD SCIENTIFIC. The reported values are uncorrected. 
Chromatography 
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-plates 
(MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. Plates were 
visualized under UV-light or developed by treatment with a KMnO4 solution followed by 
carefully applying a heating gun. Chromatographic purification of products was accomplished 
by manual flash column chromatography on MERCK silica gel, grade 60 (0.040–0.063 mm 
and 0.063–0.200 mm).  
Gel Permeation Chromatography (GPC)  
GPC purifications were performed on a JAI® system (JAI-LC-9260 II NEXT, injection- and 
control-valve, UV and RI detector) connected to JAIGEL HH series columns (JAIGEL-2HR, 
gradient rate: 5.000; JAIGEL-2.5HR, gradient rate: 20.000; internal diameter = 20 mm; length 
= 600 mm; Flush rate = 10.0 mL/min). Chloroform of HPLC-grade stabilized with 0.6% EtOH 






HPLC chromatograms were recorded on an Agilent 1290 Infinity using the column 
CHIRALPAK® IA, IC, IE, IF columns and n-hexanes/EtOAc (1 mL/min, detection at 274 nm).  
LC-MS 
LC-MS chromatograms were recorded on an Agilent 6100s Series Single Quad using the RP 
column ZORBAX SB-C18, 5 µm. The flow rate was set to 0.5 mL/min, detection at 270 and 
290 nm. The methods used are as follows: 
Table XX: LC-MS methods 
Measuring time t/min MeCN (0.1% TFA) H2O (0.1% TFA) 
15 min 0 60% 40% 
 5 100% 0 
 13 100% 0 
 15 60% 40% 
22 min 0 60% 40% 
 5 100% 0% 
 20 100% 0% 
 22 60% 400% 
 
Fluorescence Spectroscopy 
Fluorescence excitation and emission data in solution were recorded on a Jasco® FP-8500 
spectrofluorometer. The scan speed was adjusted to 200 nm/min. All compounds were 
measured at a concentration of 1 mg/L solution.  
UV-VIS Spectroscopy 
UV-Visible Spectroscopy was performed on a Jasco® V-770 spectrophotometer. A baseline 
in the appropriate solvent was obtained prior to recording spectra. All compounds were 





Infrared Spectroscopy  
Infrared spectra were recorded at a BRUKER Alpha-P ATR FT-IR spectrometer. Liquid 
samples were measured as a film, solid samples neat. The analysis of the spectra was carried 
out using the software from BRUKER OPUS 6. The absorption is given in wave numbers 
(cm−1) and the spectra were recorded in the range of 4000–400 cm‒1. in-situ-IR studies were 
performed on METTLER TOLEDO ReactIR™ 15 with an iC IR 4.3 software. 
Mass Spectrometry  
Electron ionization (EI) and EI high resolution mass spectra (HR-MS) were measured on a 
time-of-flight mass spectrometer AccuTOF from JOEL. Electrospray ionization (ESI) mass 
spectra were recorded on an Ion-Trap mass spectrometer LCQ from FINNIGAN, a 
quadrupole time-of-flight maXis from BRUKER DALTONIC or on a time-of-flight mass 
spectrometer microTOF from BRUKER DALTONIC. ESI-HRMS spectra were recorded on a 
BRUKER Apex IV or a BRUKER Daltonic 7T, fourier transform ion cyclotron resonance 
(FTICR) mass spectrometer. The ratios of mass to charge (m/z) are indicated and intensities 
relative to the base peak (I = 100) are written in parentheses. 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectra were recorded on VARIAN Inova 500, 600, 
VARIAN Mercury 300, VX 300, VARIAN Avance 300, VARIAN VNMRS 300 and BRUKER 
Avance III 300, 400 and HD 500 spectrometers. All chemical shifts are given as δ-values in 
ppm relative to the residual proton peak of the deuterated solvent or its carbon atom, 
respectively. 1H and 13C NMR spectra were referenced using the residual proton or solvent 
carbon peak (see table), respectively. 13C and 19F NMR were measured as proton-decoupled 
spectra. 
 1H-NMR 13C-NMR 
CDCl3 7.26 77.16 




The observed resonance-multiplicities were described by the following abbreviations: s 
(singlet), d (doublet), t (triplet), q (quartet), hept (heptet), m (multiplet) or analogous 
representations. The coupling constants J are reported in Hertz (Hz). Analysis of the recorded 
spectra was carried out with MestReNova 10 software. 
Solvents 
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and stored 
under an inert atmosphere (Ar or N2) according to the following standard procedures.  
1,2-Dichloroethane (DCE) were dried over CaH2 for 8 h, degassed and distilled under 
reduced pressure.  
1,4-Dioxane were distilled from sodium benzophenone ketyl. 
1,1,1,3,3,3-Hexafluoropropan-2-ol (HFIP) were distilled from 3 Å molecular sieves. 
Methanol (MeOH) was stirred over magnesium turnings at 65 °C for 3 h prior to distillation 
from Mg(OMe)2. 
Acetonitrile (MeCN) was dried over P2O5 for 24 h degassed and distilled under reduced 
pressure.  
Toluene (PhMe) was pre-dried over KH and distilled over sodium/benzophenone. 
Tetrahydrofuran (THF), Dichloromethane were purified using a solvent purification system 
(SPS-800) from M. BRAUN. 
o-Xylene was stirred at 160 °C over sodium/benzophenone and distilled under ambient 
pressure. 
2,2,2-Trifluoroethanol (TFE) was stirred over CaSO4 and distilled under reduced pressure. 
For synthesis grade solvents for reactions under air were used without further purification: 
DMF, trifluoroacetic acid, acetic acid, toluene, hexanes, aq. HCl (12 M). 
Reagents 
Chemicals obtained from commercial sources with purity above 95% were used without 
further purification. 





TAM amide, TAM amino acids 105, and TAM cyclobutanes 112,[127, 157] iodo-BODIPYs 109,[158] 
N-pyridyl/pyrimidyl tryptophans[140c, 159] and successive couplings for N-pyridyl/pyrimidyl 
tryptophan containing peptides,[160] 1,4,2-dioxazol-5-ones 116,[142d, 142f, 161] ally carbonates 
119.[162] 
The following compounds were obtained by the generous courtesy of the following persons: 
M. Sc. Michaela Bauer: (S)-N-[2-(1-benzyl-1H-1,2,3-triazol-4-yl)propan-2-yl]-2-(1,3-
dioxoisoindolin-2-yl)propanamide 105a; (2S,3R)-N-[2-(1-benzyl-1H-1,2,3-triazol-4-
yl)propan-2-yl]-2-(1,3-dioxoisoindolin-2-yl)-3-(4-nitrophenyl)-3-phenylpropanamide 106b. 
Dr. Mélanie M. Lorion:  
(S)-N-[2-(1-Benzyl-1H-1,2,3-triazol-4-yl)propan-2-yl]-3-[5,5-difluoro-8-iodo-10-(4-
methoxyphenyl)-5H-5λ4,6λ4-dipyrrolo(1,2-c:2',1'-f)(1,3,2)diazaborinin-2-yl]-2-(1,3-
dioxoisoindolin-2-yl) propanamide 110bm. 
Dr. Matteo Virelli: 
N-[2-(1-benzyl-1H-1,2,3-triazol-4-yl)propan-2-yl]cyclobutanecarboxamide 112a, methyl 
(1S,3S)-3-[(2-(1-benzyl-1H-1,2,3-triazol-4-yl)propan-2-yl)carbamoyl]cyclobutane-1-
carboxylate 112b. 




Dr. Parthasarathi Subramanian: (R)-1-{(3aR,5R,6S,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl}allyl methyl carbonate 119a, (1R)-1-
{(3aR,6R,6aS)-6-[((tert-butyldimethylsilyl)oxy)methyl]-2,2-dimethyltetrahydrofuro[3,4-





5.2 General Procedures 
General Procedure A: C(sp3)─H Arylation on Tzl-Containing Peptides 
A mixture of Tzl-containing peptide 107 (0.20 mmol, 1.00 equiv), iodoarene 11 (0.40 mmol, 
2.00 equiv), Pd(TFA)2 (0.02 mmol, 10 mol %) and AgOAc (0.22 mmol, 1.10 equiv) in DCE 
(2 mL) was stirred at 130 °C for 20 h in a pressure tube. At ambient temperature, the reaction 
was diluted with CH2Cl2 (15 mL) and then filtered through a pad of Celite and washed with 
CH2Cl2 (50 mL). The solvent was removed in vacuo and the crude product was purified by 
column chromatography on silica gel or HPLC to yield the desired product 108. 
General Procedure B: BODIPY Amino Acid C(sp3)─H Labeling 
A mixture of TAM amino acid 105 (0.10 mmol, 1.0 equiv), iodo-BODIPY 109 (0.12 mmol, 1.2 
equiv), Pd(TFA)2 (3.3 mg, 10 mol %), (1-Ad)CO2H (5.4 mg, 30 mol %) and M(OAc)n in PhMe 
(0.5 mL) was stirred at 130 °C for 20 h. At ambient temperature, the reaction was diluted with 
CH2Cl2 (10 mL), filtered through a pad of Celite and washed with CH2Cl2 (40 mL). The 
solvents were removed in vacuo and the crude product was purified by column 
chromatography on silica gel or HPLC to yield the desired product 110. 
General Procedure C: BODIPY C(sp3)─H Labeling of Internal Tzl-Peptides 
A mixture of Tzl-containing peptide 107 (0.10 mmol, 1.0 equiv), iodo-BODIPY 109 (0.12 mmol, 
1.20 equiv), Pd(OAc)2 (2.2 mg, 10 mol %), (1-Ad)CO2H (5.4 mg, 30 mol %) and AgOAc (0.20 
mmol, 2.0 equiv) in PhMe (0.5 mL) was stirred at 130 °C for 20 h. At ambient temperature, 
the reaction was diluted with CH2Cl2 (10 mL), filtered through a pad of Celite and washed 
with CH2Cl2 (40 mL). The solvents were removed in vacuo and the crude product was purified 
by HPLC to yield the desired product 111. 
General Procedure D: BODIPY Cyclobutanes C(sp3)─H Labeling 
A mixture of TAM cyclobutane 112 (0.10 mmol, 1.0 equiv), iodo-BODIPY 109 (0.12 mmol, 1.2 
equiv), Pd(TFA)2 (3.3 mg, 10 mol %) and AgOAc (37 mg, 0.22 mmol) in o-xylene (1.0 mL) 
was stirred at 130 °C for 20 h. At ambient temperature, the reaction was diluted with EtOAc 




chromatography on silica gel, giving the corresponding labeled product 114. 
General Procedure E: C–H Arylation of BODIPY Labeled Cyclobutanes 
A solution of BODIPY-cyclobutanecarboxamide 114 (0.2 mmol), Pd(TFA)2 (6.6 mg, 0.02 mmol, 
10 mol %), iodo arenes 11 (0.8 mmol), AgOAc (73 mg, 0.44 mmol) in anhydrous o-xylene 
(2 mL) was heated at 130 °C for 20 h. After the reaction period, the reaction mixture was 
diluted with EtOAc (5 mL) and concentrated in vacuum and the resulting mixture was purified 
by column chromatography (silica gel, 100-200 mesh), furnishing the corresponding bis-
arylatedcyclobutanecarboxamides.  
General Procedure F: C7–H Amidation of Tryptophans and Tryptophan-Containing 
Peptides 
Amino acid or peptide 88/96 (0.2 mmol), 1,4,2-dioxazol-5-one 116 (0.4 mmol), [RhCp*Cl2]2 
(3.0 mg, 2.5 mol %), AgSbF6 (6.8 mg, 10 mol %) and MesCO2H (5.4 mg, 15 mol %) were 
placed in an oven-dried Schlenk tube. The mixture was evacuated and purged with N2 three 
times. Then, TFE (0.4 mL) was added. The tube was sealed and heated at 110 °C for 24 h. 
After cooling to room temperature, the resulting mixture was diluted with CH2Cl2 (10 mL) and 
concentrated in vacuo. Purification of the residue by column chromatography on silica gel 
yielded the products 117. 
General procedure G: C–H Glycoconjugation of Tryptophans 
Indole or tryptophan (0.10 mmol), allyl sugar carbonate 119 (0.20 mmol), Mn2(CO)10 (3.89 mg, 
10 mol %) and NaOAc (2.5 mg, 30 mol %) were placed in an oven-dried Schlenk tube. The 
mixture was evacuated and purged with N2 three times. Then, 1,2-dichloroethane (0.5 mL) 
was added. The mixture was stirred at 120 °C for 24 h. After cooling to room temperature, 
the resulting mixture was diluted with CH2Cl2 and concentrated in vacuo. Purification of the 
residue by column chromatography on silica gel yielded the products 120. 
General Procedure H: C–H Glycoconjugation of Tryptophan-Containing Peptides 
Peptide 88 (0.10 mmol), allyl sugar carbonate 119 (0.20 mmol), MnBr(CO)5 (5.5 mg, 




mixture was evacuated and purged with N2 three times. Then, 1,2-dichloroethane (0.5 mL) 
was added. The mixture was stirred at 120 °C. After 24 h, the resulting mixture was diluted 
with CH2Cl2 and concentrated in vacuo. Purification of the residue by column chromatography 
on silica gel yielded the products 120. 
5.3 Experimental and Analytical Data 
5.3.1 Internal Peptide Late-Stage Diversification: Peptide-Isosteric 
Triazoles for C(sp3)─H Activation 





The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Phe-OMe (107a) 
(103.7 mg, 0.2 mmol) and 4-iodoanisole (11d) (93.6 mg, 0.4 mmol). After 20 h, purification by 
column chromatography on silica gel (EtOAc/n-hexane 8/1 to EtOAc/n-hexane 10/1. Rf 
(EtOAc/n-hexane 8/1): 0.25) yielded 108a (100 mg, 80%) as a white solid (M.p.: 150–152 °C). 
1H NMR (600 MHz, CDCl3): δ = 7.67 (dd, J = 5.4, 3.1 Hz, 2H), 7.65–7.50 (m, 3H), 7.51 (brs, 
1H), 7.25–7.15 (m, 4H), 7.08‒7.04 (m, 2H), 6.99 (d, J = 8.6 Hz, 2H), 6.64 (d, J = 8.6 Hz, 2H), 
5.03 (dd, J = 11.2, 5.5 Hz, 1H), 4.98 (d, J = 16.4 Hz, 1H), 4.85 (d, J = 16.4 Hz, 1H), 4.82–
4.77 (m, 1H), 4.43‒4.32 (m, 2H), 3.64 (s, 3H), 3.63 (s, 3H), 3.49 (dd, J = 14.3, 5.5 Hz, 1H), 
3.41 (dd, J = 14.3, 11.2 Hz, 1H), 3.08 (dd, J = 13.9, 5.5 Hz, 1H), 2.97 (dd, J = 13.9, 7.2 Hz, 
1H). 13C NMR (126 MHz, CDCl3): δ = 171.5 (Cq), 168.7 (Cq), 167.8 (Cq), 164.9 (Cq), 158.3 




(CH), 127.2 (CH), 124.2 (CH), 123.4 (CH), 114.0 (CH), 55.5 (CH), 55.2 (CH3), 53.7 (CH), 52.6 
(CH3) 52.5 (CH2), 37.8 (CH2), 35.2 (CH2), 33.9 (CH2). IR (ATR): ṽ = 2956, 1774, 1711, 1673, 
1612, 1531, 1382, 1246, 1217, 1029 cm-1. MS (ESI) m/z (relative intensity): 1271 (45) 
[2M+Na]+, 647 (100) [M+Na]+, 625 (37) [M+H]+. HR-MS (ESI) m/z calcd for C33H33N6O7 





The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Phe-OMe (107a) 
(103.7 mg, 0.2 mmol) and (9H-fluoren-9-yl)methyl(4-iodo-phenyl)carbamate (11e) (176.5 mg, 
0.4 mmol). After 20 h, purification by column chromatography on silica gel (EtOAc/n-hexane 
8/1 to EtOAc/n-hexane 12/1. Rf (EtOAc/n-hexane 8/1): 0.14) yielded 108b (114.7 mg, 69%) 
as a white solid (M.p.: 144–147 °C). 1H NMR (600 MHz, CDCl3): δ = 7.70 (d, J = 7.6 Hz, 2H), 
7.67‒7.55 (m, 6H), 7.54‒7.50 (m, 2H), 7.37‒7.33 (m, 2H), 7.25–7.08 (m, 9H), 7.04–6.99 (m, 
2H), 6.98–6.96 (m, 2H), 5.04 (dd, J = 10.9, 5.7 Hz, 1H), 4.95 (d, J = 16.3 Hz, 1H), 4.84 (d, J 
= 16.3 Hz, 1H), 4.82–4.75 (m, 1H), 4.43–4.30 (m, 4H), 4.14 (dd, J = 6.7, 6.7 Hz, 1H), 3.60 (s, 
3H), 3.50 (dd, J = 14.1, 5.6 Hz, 1H), 3.40 (dd, J = 14.1, 11.3 Hz, 1H), 3.05 (dd, J = 13.9, 5.5 
Hz, 1H), 2.95 (dd, J = 13.9, 7.2 Hz, 1H). 13C NMR (126 MHz, CDCl3): δ = 171.6 (Cq), 171.1 
(Cq), 168.6 (Cq), 167.9 (Cq), 165.0 (Cq), 144.9 (Cq), 143.7 (Cq), 141.3 (Cq), 135.6 (Cq), 134.2 
(CH), 131.4 (Cq), 129.5 (CH), 129.2 (CH), 128.6 (CH), 127.7 (CH), 127.6 (CH), 127.2 (CH), 
127.1 (CH), 125.0 (CH), 124.2 (CH), 123.5 (CH), 120.0 (CH), 66.9 (CH2), 60.5 (CH2), 55.5 




overlap, two resonances are missing). IR (ATR): ṽ = 3284, 1710, 1667, 1526, 1383, 1350, 
1223, 1051 cm–1. MS (ESI) m/z (relative intensity): 1685 (5) [2M+Na]+, 1267 (15), 854 (100) 






The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Phe-OMe (107a) 
(103.7 mg, 0.2 mmol) and ethyl 4-iodobenzoate (11f) (110.4 mg, 0.4 mmol). After 20 h, 
purification by HPLC (tr: 45.0 min) yielded 108c (96.0 mg, 72%) as a white solid (M.p.: 107‒
108 °C). 1H NMR (300 MHz, CDCl3): δ = 7.81 (d, J = 8.3 Hz, 2H), 7.76–7.57 (m, 5H), 7.32–
7.10 (m, 4H), 7.18 (d, J = 8.3 Hz, 2H), 7.09–6.99 (m, 2H), 6.68 (d, J = 8.0 Hz, 1H), 5.11 (dd, 
J = 10.5, 5.7 Hz, 1H), 5.01 (d, J = 16.3 Hz, 1H), 4.88 (d, J = 16.3 Hz, 1H), 4.87–4.77 (m, 1H), 
4.44 (brs, 2H), 4.29 (ddd, J = 7.1, 7.1, 7.1 Hz, 2H), 3.69 (s, 3H), 3.66–3.47 (m, 2H), 3.12 (dd, 
J = 13.9, 5.4 Hz, 1H), 3.00 (dd, J = 13.9, 6.9 Hz, 1H), 1.33 (dd, J = 7.1, 7.1 Hz, 3H). 13C NMR 
(126 MHz, CDCl3): δ = 171.3 (Cq), 168.3 (Cq), 167.7 (Cq), 166.3 (Cq), 164.7 (Cq), 142.1 (Cq), 
135.5 (Cq), 134.4 (CH), 131.3 (Cq), 129.9 (CH), 129.2 (CH), 129.0 (CH), 128.7 (CH), 127.3 
(CH), 123.7 (CH), 61.1 (CH2), 55.1 (CH), 53.6 (CH), 52.9 (CH2), 52.7 (CH3), 37.8 (CH2), 35.3 
(CH2), 34.8 (CH2), 14.5 (CH3) (due to overlap, three resonances are missing). IR (ATR): ṽ = 
1710, 1381, 1274, 1216, 1177, 1020, 979, 871, 762, 700 cm-1. MS (ESI) m/z (relative 
intensity): 1355 (5) [2M+Na]+, 1020 (15), 751 (10), 689 (100) [M+Na]+, 667 (60) [M+H]+, 353 








The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Phe-OMe (107a) 
(103.7 mg, 0.2 mmol) and 1-iodo-4-nitrobenzene (11g) (99.6 mg, 0.4 mmol). After 20 h, 
purification by HPLC (tr: 45.0 min) yielded 108d (84.4 mg, 66%) as a white solid (M.p.: 147‒
149 °C). 1H NMR (500 MHz, CDCl3): δ = 8.00 (d, J = 8.8 Hz, 2H), 7.73–7.67 (m, 4H), 7.63 
(brs, 1H), 7.35 (brs, 1H), 7.29 (d, J = 8.8 Hz, 2H), 7.28–7.22 (m, 3H), 7.08–7.05 (m, 2H), 6.78 
(d, J = 8.1 Hz, 1H), 5.13 (dd, J = 11.0, 5.4 Hz, 1H), 5.01 (d, J = 16.2 Hz, 1H), 4.87 (d, J = 16.2 
Hz, 1H), 4.85–4.81 (m, 1H), 4.40 (brs, 2H), 3.73–3.67 (m, 5H), 3.11 (dd, J = 13.9, 5.5 Hz, 
1H), 2.99 (dd, J = 13.9, 7.0 Hz, 1H). 13C NMR (126 MHz, CDCl3): δ = 171.7 (Cq), 168.0 (Cq), 
167.8 (Cq), 167.7 (Cq), 164.8 (Cq), 147.1 (Cq), 145.0 (Cq), 135.6 (Cq), 134.7 (CH), 131.3 (Cq), 
130.0 (CH), 129.3 (CH), 128.8 (CH), 127.4 (CH), 124.0 (CH), 123.9 (CH), 123.8 (CH), 54.6 
(CH), 53.6 (CH), 52.7 (CH3), 37.7 (CH2), 35.2 (CH2), 34.6 (CH2), 29.8 (CH2). IR (ATR): ṽ = 
2925, 1715, 1677, 1520, 1382, 1346, 1218, 1111, 722 cm-1. MS (ESI) m/z (relative intensity): 
1301 (8) [2M+Na]+, 979 (28), 662 (100) [M+Na]+. HR-MS (ESI) m/z calcd for C32H29N7O8Na 








(103.7 mg, 0.2 mmol) and 4-iodobiphenyl (11h) (112.0 mg, 0.4 mmol). After 20 h, purification 
by HPLC (tr: 44.0 min) yielded 108e (79.1 mg, 59%) as a white solid (M.p.: 149‒151 °C). 
1H NMR (300 MHz, CDCl3): δ = 7.72 (dd, J = 5.5, 3.0 Hz, 2H), 7.68–7.58 (m, 3H), 7.47 (dd, J 
= 8.3, 1.2 Hz, 2H), 7.37 (ddd, J = 8.3, 8.3, 1.2 Hz, 3H), 7.32–7.17 (m, 8H), 7.08‒7.00 (m, 2H), 
6.78‒6.70 (m, 1H), 5.15 (dd, J = 10.6, 5.9 Hz, 1H), 5.01 (d, J = 16.0 Hz, 1H), 4.89 (d, J = 16.0 
Hz, 1H), 4.86–4.80 (m, 1H), 4.46 (brs, 2H), 3.69 (s, 3H), 3.65–3.49 (m, 2H), 3.12 (dd, J = 
13.9, 5.5 Hz, 1H), 3.00 (dd, J = 13.9, 7.0 Hz, 1H). 13C NMR (126 MHz, CDCl3): δ = 171.3 (Cq), 
168.6 (Cq), 167.8 (Cq), 167.7 (Cq), 164.6 (Cq), 140.5 (Cq), 139.6 (Cq), 137.8 (CH), 135.7 (Cq), 
135.5 (Cq), 134.3 (CH), 131.4 (Cq), 129.5 (CH), 129.3 (CH), 129.2 (CH), 128.7 (CH), 127.3 
(CH), 127.2 (CH), 126.9 (CH), 126.8 (CH), 123.5 (CH), 55.4 (CH), 53.6 (CH), 52.8 (CH2), 
52.7 (CH3), 37.7 (CH2), 35.2 (CH2), 34.6 (CH2). IR (ATR): ṽ = 1715, 1533, 1436, 1384, 1219, 
1119, 764 cm-1. MS (ESI) m/z (relative intensity): 1363 (2) [2M+Na]+, 693 (100) [M+Na]+, 671 





The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Phe-OMe (107a) 
(103.7 mg, 0.2 mmol) and N-(4-iodophenyl)acetamide (11i) (104.4 mg, 0.4 mmol) in HFIP. 
After 20 h, purification by HPLC (tr: 43.0 min) yielded 108f (99.1 mg, 76%) as a white solid 
(M.p.: 145‒148 °C). 1H NMR (500 MHz, CDCl3): δ = 7.76 (brs, 1H), 7.70 (dd, J = 5.5, 3.0 Hz, 
2H), 7.63 (dd, J = 5.5, 3.0 Hz, 2H), 7.47 (brs, 1H), 7.40‒7.39 (m, 1H), 7.25–7.18 (m, 5H), 
7.12 (d, J = 8.0 Hz, 1H), 7.03 (d, J = 8.2 Hz, 2H), 7.00 (d, J = 8.2 Hz, 2H) 5.05 (dd, J = 10.3, 
6.3 Hz, 1H), 5.00 (d, J = 16.4 Hz, 1H), 4.86 (d, J = 16.4 Hz, 1H), 4.82‒4.79 (m, 1H), 4.45 (dd, 
J = 15.2, 5.9 Hz, 1H), 4.37 (dd, J = 15.2, 5.9 Hz, 1H), 3.65 (s, 3H), 3.54 (dd, J = 14.2, 6.3 Hz, 




Hz, 1H), 2.03 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 171.7 (Cq), 168.8 (Cq), 168.7 (Cq), 
168.1 (Cq), 165.2 (Cq), 145.0 (Cq), 137.0 (Cq), 135.6 (Cq), 134.4 (CH), 132.5 (Cq), 131.5 (Cq), 
129.5 (CH), 129.3 (CH), 128.8 (CH), 127.4 (CH), 124.2 (CH), 123.6 (CH), 119.9 (CH), 55.6 
(CH), 53.7 (CH), 52.6 (CH3), 52.5 (CH2), 37.7 (CH2), 35.2 (CH2), 34.3 (CH2), 24.5 (CH3). IR 
(ATR): ṽ = 1712, 1664, 1515, 1411, 1256, 1119, 701 cm-1. MS (ESI) m/z (relative intensity): 
684 (53), 674 (38) [M+Na]+, 652 (100) [M+H]+. HR-MS (ESI) m/z calcd for C34H34N7O7 [M+H]+: 





The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Ala-OMe (107b) 
(88.5 mg, 0.2 mmol) and 4-iodoanisole (11d) (93.6 mg, 0.4 mmol). After 20 h, purification by 
HPLC (tr: 44.0 min) yielded 108g (66.9 mg, 61%) as a white solid (M.p.: 155–156 °C). 1H NMR 
(500 MHz, CDCl3): δ = 7.79‒7.70 (m, 3H), 7.67 (dd, J = 5.4, 3.0 Hz, 2H), 7.16 (brs, 1H), 7.02 
(d, J = 8.6 Hz, 2H), 6.90 (d, J = 6.9 Hz, 1H), 6.67 (d, J = 8.6 Hz, 2H), 5.10‒5.05 (m, 3H), 4.55 
(ddd, J = 7.2, 7.2, 6.9 Hz, 1H), 4.50–4.45 (m, 2H), 3.70 (s, 3H), 3.68 (s, 3H), 3.50 (dd, J = 
14.2, 5.6 Hz, 1H), 3.41 (dd, J = 14.2, 11.1 Hz, 1H), 1.38 (d, J = 7.2 Hz, 3H).13C NMR (126 
MHz, CDCl3): δ = 172.9 (Cq), 168.9 (Cq), 168.0 (Cq), 164.9 (Cq), 158.5 (Cq), 134.4 (CH), 131.6 
(Cq), 130.0 (CH), 128.6 (Cq), 123.6 (CH), 114.1 (CH), 55.6 (CH), 55.3 (CH3), 52.9 (CH2), 52.8 
(CH3), 48.5 (CH), 35.4 (CH2), 34.0 (CH2), 18.1 (CH3) (due to overlap, two resonances are 
missing). IR (ATR): ṽ = 1770, 1710, 1654, 1539, 1513, 1382, 1243, 722, 511 cm-1. MS (ESI) 
m/z (relative intensity): 1119 (100) [2M+Na]+, 1097 (60) [2M+H]+, 571 (80) [M+Na]+, 549 (85) 







The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Ala-OMe (107b) 
(88.5 mg, 0.2 mmol) and 1-Fluoro-4-iodobenzene (11j) (88.8 mg, 0.4 mmol). After 20 h, 
purification by HPLC (tr: 45.0 min) yielded 108h (76.2 mg, 71%) as a white solid (M.p.: 117–
118 °C). 1H NMR (600 MHz, CDCl3): δ = 7.72‒7.68 (m, 5H), 7.21 (br s, 1H), 7.07 (dd, J = 8.4, 
5.4 Hz, 2H), 6.91 (d, J = 7.3 Hz, 1H), 6.82 (dd, J = 8.7, 8.7 Hz, 2H), 5.09–5.02 (m, 2H), 4.99 
(d, J = 16.4 Hz, 1H), 4.55 (dddd, J = 7.3, 7.1, 7.1, 7.1 Hz, 1H), 4.49‒4.46 (m, 2H), 3.70 (s, 
3H), 3.53 (dd, J = 14.2, 5.4 Hz, 1H), 3.45 (dd, J = 14.2, 11.3 Hz, 1H), 1.37 (d, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.8 (Cq), 168.5 (Cq), 167.8 (Cq), 164.6 (Cq), 161.8 (d, 1JC-
F = 244.8 Hz, Cq), 134.4 (CH), 132.4 (d, 4JC-F = 3.3 Hz, Cq), 131.4 (Cq), 130.5 (d, 3JC-F = 8.0 
Hz, CH), 123.6 (CH), 115.5 (d, 2JC-F = 21.3 Hz, CH), 55.5 (CH), 52.9 (CH2), 52.8 (CH3), 48.6 
(CH), 35.4 (CH2), 34.1 (CH2), 18.2 (CH3) (due to overlap, two resonances are missing). 19F 
NMR (282 MHz, CDCl3): δ = -115.74 (tt, J = 8.7, 5.4 Hz). IR (ATR): ṽ = 2921, 1712, 1667, 
1536, 1509, 1455, 1381, 1258, 1219, 1157, 1106, 1052, 880, 794, 719, 530, 396 cm-1. MS 
(ESI) m/z (relative intensity): 1095 (90) [2M+Na]+, 559 (92) [M+Na]+, 537 (100) [M+H]+. HR-








(88.5 mg, 0.2 mmol) and ethyl 4-iodobenzoate (11f) (110.4 mg, 0.4 mmol). After 20 h, 
purification by HPLC (tr: 45.0 min) yielded 108i (65.0 mg, 55%) as a white solid (M.p.: 105‒
107 °C). 1H NMR (300 MHz, CDCl3): δ = 7.90 (brs, 1H), 7.81 (d, J = 8.1 Hz, 2H), 7.73–7.63 
(m, 4H), 7.35 (brs, 1H), 7.19 (d, J = 8.1 Hz, 2H), 6.94 (d, J = 7.3 Hz, 1H), 5.15‒5.03 (m, 3H), 
4.55 (dddd, J = 7.3, 7.2, 7.2, 7.2 Hz, 1H) 4.49–4.41 (m, 1H), 4.29 (ddd, J = 7.1, 7.1, 7.1 Hz, 
2H), 3.70 (s, 3H), 3.64–3.50 (m, 2H), 1.37 (d, J = 7.2 Hz, 3H), 1.33 (dd, J = 7.1, 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.8 (Cq), 168.4 (Cq), 167.9 (Cq), 167.8 (Cq), 166.3 (Cq), 
164.8 (Cq), 142.1 (Cq), 134.4 (CH), 131.4 (Cq), 129.9 (CH), 129.8 (CH), 129.2 (Cq), 128.9 
(CH), 123.7 (CH), 61.1 (CH2), 55.0 (CH), 53.1 (CH2), 53.0 (CH2), 52.8 (CH3), 48.6 (CH), 34.8 
(CH2), 18.2 (CH3), 14.5 (CH3). IR (ATR): ṽ = 3065, 2926, 1774, 1713, 1535, 1382, 1277, 1054, 
763 cm-1. MS (ESI) m/z (relative intensity): 1203 (33) [2M+Na]+, 1181 (27) [2M+H]+, 613 (53) 




methyl} -1H-1,2,3-triazol-1-yl)acetamido]propanoate (108j) 
The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Ala-OMe (107b) 
(88.5 mg, 0.2 mmol) and 4-iodobiphenyl (11h) (112.0 mg, 0.4 mmol). After 20 h, purification 
by HPLC (tr: 43.0 min) yielded 108j (71.4 mg, 60%) as a white solid (M.p.: 138‒140 °C). 
1H NMR (300 MHz, CDCl3): δ = 7.77 (brs, 1H), 7.71 (dd, J = 5.7, 3.1 Hz, 2H), 7.64 (dd, J = 
5.7, 3.1 Hz, 2H), 7.47–7.44 (m, 2H), 7.39–7.24 (m, 6H), 7.18 (dd, J = 8.4, 1.9 Hz, 2H), 7.08 
(d, J = 7.4 Hz, 1H), 5.15 (dd, J = 10.7, 5.6 Hz, 1H), 4.99 (dd, J = 16.6, 8.8 Hz, 2H), 4.54 (dddd, 
J = 7.4, 7.1, 7.1, 7.1 Hz, 1H), 4.51–4.45 (m, 2H), 3.68 (s, 3H), 3.66–3.44 (m, 2H), 1.37 (d, J 
= 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 173.0 (Cq), 168.8 (Cq), 168.0 (Cq), 164.9 (Cq), 




129.8 (CH), 128.7 (CH), 127.2 (CH), 127.0 (CH), 123.6 (CH), 55.4 (CH), 52.7 (CH3), 48.5 
(CH), 48.4 (CH2), 35.2 (CH2), 29.8 (CH2), 18.1 (CH3). IR (ATR): ṽ = 1716, 1533, 1383, 1219, 
1120, 764 cm-1. MS (ESI) m/z (relative intensity): 1211 (7) [2M+Na]+, 912 (17), 617 (100) 





The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) 
(96.9 mg, 0.2 mmol) and 4-iodoanisole (11d) (93.6 mg, 0.4 mmol). After 20 h, purification by 
HPLC (tr: 45.0 min) yielded 108k (72.1 mg, 61%) as a white solid (M.p.: 99–100 °C). 1H NMR 
(500 MHz, CDCl3): δ = 7.81‒7.62 (m, 5H), 7.16 (brs, 1H), 7.02 (d, J = 8.5 Hz, 2H), 6.86 (d, J 
= 6.4 Hz, 1H), 6.67 (d, J = 8.5 Hz, 2H), 5.12–4.98 (m, 3H), 4.60–4.40 (m, 3H), 3.68 (s, 3H), 
3.67 (s, 3H), 3.47–3.35 (m, 2H), 1.64–1.57 (m, 2H), 1.56–1.49 (m, 1H), 0.89 (d, J = 5.4 Hz, 
6H). 13C NMR (126 MHz, CDCl3): δ = 173.1 (Cq), 168.9 (Cq), 168.0 (Cq), 168.0 (Cq), 165.3 
(Cq), 158.5 (Cq), 134.4 (CH), 131.6 (Cq), 130.0 (CH), 128.6 (Cq), 123.7 (CH), 114.1 (CH), 
114.1 (CH), 55.6 (CH), 55.3 (CH3), 52.9 (CH2), 52.6 (CH3) 51.2 (CH), 41.2 (CH2), 35.3 (CH2), 
33.9 (CH2), 25.0 (CH), 22.9 (CH3), 21.9 (CH3). IR (ATR): ṽ = 2962, 2537, 2361, 2340, 2160, 
2026, 1071, 809, 668 cm-1. MS (ESI) m/z (relative intensity): 1203 (100) [2M+Na]+, 1181 (45) 
[2M+H]+, 613 (90) [M+Na]+, 591 (85) [M+H]+. HR-MS (ESI) m/z calcd for C30H34N6O7Na 








The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) 
(96.9 mg, 0.2 mmol) and 1-Fluoro-4-iodobenzene (11j) (88.8 mg, 0.4 mmol). After 20 h, 
purification by HPLC (tr: 47.0 min) yielded 108l (86.8 mg, 75%) as a white solid (M.p.: 101–
102 °C). 1H NMR (500 MHz, CDCl3): δ = 7.75‒7.68 (m, 3H), 7.67 (dd, J = 5.5, 3.0 Hz, 2H), 
7.27 (br s, 1H), 7.07 (dd, J = 8.5, 5.4 Hz, 2H), 6.94 (d, J = 8.1 Hz, 1H), 6.82 (d, J = 8.5, 8.5 
Hz, 2H), 5.06 (d, J = 16.4 Hz, 1H), 5.03 (dd, J = 11.3, 5.5 Hz, 1H), 4.97 (d, J = 16.4 Hz, 1H), 
4.60‒4.54 (m, 1H), 4.52‒4.40 (m, 2H), 3.66 (s, 3H), 3.53 (dd, J = 14.3, 5.5 Hz, 1H), 3.45 (dd, 
J = 14.3, 11.3 Hz, 1H), 1.63–1.49 (m, 3H), 0.89 (d, J = 5.9 Hz, 6H). 13C NMR (126 MHz, 
CDCl3): δ = 173.2 (Cq), 168.6 (Cq), 167.9 (Cq), 165.1 (Cq), 161.8 (d, 1JC-F = 245.2 Hz, Cq), 
134.5 (CH), 134.4 (CH), 132.5 (d, 4JC-F = 3.2 Hz, Cq), 131.9 (Cq), 131.4 (Cq), 130.5 (d, 3JC-F = 
8.0 Hz, CH), 123.7 (CH), 115.6 (d, 2JC-F = 21.3 Hz, CH), 55.4 (CH), 52.8 (CH2), 52.6 (CH3), 
51.2 (CH), 41.2 (CH2), 35.2 (CH2), 33.9 (CH2), 25.0 (CH), 22.8 (CH3), 21.9 (CH3). 19F NMR 
(376 MHz, CDCl3): δ = -115.73 (ddd, J = 14.0, 8.8, 5.3 Hz). IR (ATR): ṽ = 2955, 1666, 1533, 
1509, 1382, 1221, 1156, 1106, 1052, 719 cm-1. MS (ESI) m/z (relative intensity): 1179 (95) 
[2M+Na]+, 1157 (65) [2M+H]+, 1085 (45), 1063 (35), 601 (85) [M+Na]+, 579 (100) [M+H]+, 507 





The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) 
(96.9 mg, 0.2 mmol) and ethyl 4-iodobenzoate (11f) (110.4 mg, 0.4 mmol). After 20 h, 




100 °C). 1H NMR (600 MHz, CDCl3): δ = 7.80 (d, J = 8.2 Hz, 2H), 7.78‒7.63 (m, 5H), 7.18‒
7.14 (m, 3H), 6.77 (d, J = 8.1 Hz, 1H), 5.09 (dd, J = 11.1, 5.3 Hz, 1H), 5.05 (d, J = 16.4 Hz, 
1H), 4.97 (d, J = 16.4 Hz, 1H), 4.60‒4.56 (m, 1H), 4.46 (s, 2H), 4.27 (ddd, J = 7.1, 7.1, 7.1 
Hz, 2H), 3.66 (s, 3H), 3.60 (dd, J = 14.1, 5.3 Hz, 1H), 3.53 (dd, J = 14.1, 11.1 Hz, 1H), 1.60‒
1.54 (m, 2H), 1.53‒1.49 (m, 1H), 1.31 (dd, J = 7.1, 7.1 Hz, 3H), 0.87 (d, J = 6.1 Hz, 6H). 
13C NMR (126 MHz, CDCl3): δ = 172.9 (Cq), 168.3 (Cq), 167.7 (Cq), 167.7 (Cq), 166.3 (Cq), 
164.9 (Cq), 142.1 (Cq), 134.4 (CH), 131.3 (Cq), 129.9 (CH), 129.2 (Cq), 129.0 (CH), 123.7 
(CH), 61.1 (CH2), 55.1 (CH), 52.9 (CH2), 52.6 (CH3), 51.3 (CH), 41.3 (CH2), 35.3 (CH2), 34.8 
(CH2), 25.1 (CH), 22.9 (CH3), 22.0 (CH3), 14.5 (CH3) (due to overlap, one resonance is 
missing). IR (ATR): ṽ = 2956, 1711, 1381, 1274, 1178, 1105, 1052, 1021, 976, 720, 636 cm-
1. MS (ESI) m/z (relative intensity): 1265 (30) [2M+H]+, 655 (33) [M+Na]+, 633 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C32H37N6O8 [M+H]+: 633.2667; found: 633.2670. 
 
(S)-Methyl-2-[2-(4-{[(S)-3-{[1,1'-biphenyl]-4-yl}-2-(1,3-dioxoisoindolin-2-
yl)propanamido] methyl}-1H-1,2,3-triazol-1-yl)acetamido]-4-methylpentanoate (108n) 
The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) 
(96.9 mg, 0.2 mmol) and 4-iodobiphenyl (11h) (112.0 mg, 0.4 mmol). After 20 h, purification 
by HPLC (tr: 43.0 min) yielded 108n (95.5 mg, 75%) as a white solid (M.p.: 116–117 °C). 
1H NMR (500 MHz, CDCl3): δ = 7.79‒7.63 (m, 5H), 7.48‒7.46 (m, 2H), 7.39‒7.35 (m, 4H), 
7.28 (ddd, J = 7.3, 7.3, 1.0 Hz, 1H), 7.20‒7.16 (m, 3H), 6.83 (d, J = 7.8 Hz, 1H), 5.15 (dd, J 
= 10.4, 5.2 Hz, 1H), 5.10 (d, J = 15.2 Hz, 1H), 5.00 (d, J = 15.2 Hz, 1H), 4.61‒4.56 (m, 1H), 
4.48 (s, 2H), 3.66 (s, 3H), 3.64‒6.49 (m, 2H), 1.61‒1.49 (m, 3H), 0.87 (d, J = 5.5 Hz, 6H). 13C 
NMR (126 MHz, CDCl3): δ = 173.1 (Cq), 168.8 (Cq), 168.0 (Cq), 167.9 (Cq), 165.1 (Cq), 140.6 




128.8 (CH), 127.3 (CH), 127.0 (CH), 123.7 (CH), 55.4 (CH), 52.9 (CH2), 52.6 (CH3), 51.2 
(CH), 41.2 (CH2), 35.3 (CH2), 34.4 (CH2), 25.0 (CH), 22.9 (CH3), 21.9 (CH3). IR (ATR): ṽ = 
2953, 1712, 1667, 1100, 975, 881, 805, 760, 697, 620 cm-1. MS (ESI) m/z (relative intensity): 
1295 (22) [2M+Na]+, 974 (37), 659 (63) [M+Na]+, 338 (100). HR-MS (ESI) m/z calcd for 
C35H36N6O6Na [M+Na]+: 659.2589; found: 659.2585. 
 
(S)-Methyl-2-[2-(4-{[(S)-2-(1,3-dioxoisoindolin-2-yl)-3-phenylpropanamido]methyl}-1H-
1,2,3-tri azol-1-yl)acetamido]-4-methylpentanoate (108o) 
The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) 
(96.9 mg, 0.2 mmol) and iodobenzene (11a) (81.6 mg, 0.4 mmol). After 20 h, purification by 
HPLC (tr: 47.0 min) yielded 108o (72.9 mg, 65%) as a white solid (M.p.: 104–105 °C). 
1H NMR (300 MHz, CDCl3): δ = 7.74‒7.70 (m, 3H), 7.66 (dd, J = 5.7, 2.9 Hz, 2H), 7.20–7.03 
(m, 6H), 6.85 (d, J = 8.0 Hz, 1H), 5.16–4.86 (m, 3H), 4.67–4.53 (m, 1H), 4.48 (d, J = 4.7 Hz, 
2H), 3.68 (s, 3H), 3.57 (dd, J = 14.0, 5.6 Hz, 1H), 3.46 (dd, J = 14.0, 11.0 Hz, 1H), 1.70–1.47 
(m, 3H), 0.89 (d, J = 5.6 Hz, 6H). 13C NMR (126 MHz, CDCl3): δ = 173.1 (Cq), 168.8 (Cq), 
167.9 (Cq), 165.1 (Cq), 136.8 (Cq), 134.4 (CH), 131.9 (Cq), 131.5 (Cq), 129.0 (CH), 128.7 (CH), 
127.0 (CH), 124.4 (CH), 123.7 (CH), 55.5 (CH), 52.8 (CH2), 52.6 (CH3), 51.2 (CH), 41.2 (CH2), 
35.2 (CH2), 34.8 (CH2), 25.0 (CH), 22.9 (CH3), 21.9 (CH3). IR (ATR): ṽ = 2956, 1711, 1667, 
1531, 1382, 1207, 719, 700, 529 cm-1. MS (ESI) m/z (relative intensity): 1143 (80) [2M+Na]+, 
1067 (44), 1045 (30), 583 (75) [M+Na]+, 561 (100) [M+H]+, 507 (25), 485 (30). HR-MS (ESI) 








The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) 
(96.9 mg, 0.2 mmol) and 1-iodo-4-nitrobenzene (11g) (99.6 mg, 0.4 mmol). After 20 h, 
purification by HPLC (tr: 45.0 min) yielded 108p (86.0 mg, 71%) as a white solid (M.p.: 100–
101 °C). 1H NMR (600 MHz, CDCl3): δ = 8.01 (d, J = 8.7 Hz, 2H), 7.76‒7.68 (m, 5H), 7.35‒
7.30 (m, 3H), 6.90 (d, J = 8.2 Hz, 1H), 5.13 (dd, J = 11.3, 5.4 Hz, 1H), 5.08 (d, J = 16.3 Hz, 
1H), 4.99 (d, J = 16.3 Hz, 1H), 4.61‒4.57 (m, 1H), 4.53–4.39 (m, 2H), 3.70 (dd, J = 14.3, 5.4 
Hz, 1H), 3.66 (s, 3H), 3.64‒3.57 (m, 1H), 1.64‒1.58 (m, 2H), 1.55‒1.50 (m, 1H),0.87 (d, J = 
6.1 Hz, 6H). 13C NMR (126 MHz, CDCl3): δ = 173.0 (Cq), 167.9 (Cq), 167.8 (Cq), 167.6 (Cq), 
164.9 (Cq), 147.0 (Cq), 144.8 (Cq), 134.6 (CH), 131.2 (Cq), 129.9 (CH), 123.9 (CH), 123.8 
(CH), 54.7 (CH), 52.8 (CH2), 52.6 (CH3), 51.3 (CH), 41.3 (CH2), 35.3 (CH2), 34.7 (CH2), 25.1 
(CH), 22.9 (CH3), 22.0 (CH3) (due to overlap, one resonance is missing). IR (ATR): ṽ = 2956, 
1716, 1677, 1521, 1383, 1346, 722 cm-1. MS (ESI) m/z (relative intensity): 1233 (50) 
[2M+Na]+, 1211 (55) [2M+H]+, 628 (52) [M+Na]+, 606 (100) [M+H]+. HR-MS (ESI) m/z calcd 




The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Gly-OMe (107d) 
(85.7 mg, 0.2 mmol) and 4-iodoanisole (11d) (93.6 mg, 0.4 mmol) in HFIP. After 20 h, 
purification by HPLC (tr: 44.0 min) yielded 108q (87.7 mg, 82%) as a white solid (M.p.: 103‒
105 °C). 1H NMR (500 MHz, CDCl3): δ = 7.72 (brs, 1H), 7.71–7.65 (m, 4H), 7.29 (brs, 1H), 
7.01 (d, J = 8.6 Hz, 2H), 6.95 (dd, J = 5.5, 5.5 Hz, 1H), 6.67 (d, J = 8.6 Hz, 2H), 5.09–5.00 




2H), 3.70 (s, 3H), 3.68 (s, 3H), 3.49 (dd, J = 14.3, 5.5 Hz, 1H), 3.37 (dd, J = 14.3, 11.0 Hz, 
1H). 13C NMR (126 MHz, CDCl3): δ = 169.7 (Cq), 168.8 (Cq), 167.9 (Cq), 165.5 (Cq), 158.4 
(Cq), 145.2 (Cq), 134.2 (CH), 131.4 (Cq), 129.8 (CH), 128.5 (Cq), 124.3 (CH), 123.4 (CH), 
113.9 (CH), 59.3 (CH), 55.1 (CH3), 52.7 (CH2), 52.4 (CH3), 41.2 (CH2), 34.9 (CH2), 33.7 (CH2). 
IR (ATR): ṽ = 1749, 1714, 1612, 1514, 1384, 1247, 1180, 721 cm-1. MS (ESI) m/z (relative 
intensity): 1091 (47) [2M+Na]+, 1069 (35) [2M+H]+, 557 (47) [M+Na]+, 535 (100) [M+H]+. HR-





The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Val-OMe (107e) (94.1 
mg, 0.2 mmol) and 4-iodoanisole (11d) (93.6 mg, 0.4 mmol) in HFIP. After 20 h, purification 
by HPLC (tr: 45.0 min) yielded 108r (91.1 mg, 79%) as a white solid (M.p.: 136‒138 °C). 
1H NMR (400 MHz, CDCl3): δ = 7.77–7.65 (m, 5H), 7.21 (brs, 1H), 7.10 (d, J = 8.7 Hz, 1H), 
7.02 (d, J = 8.6 Hz, 2H), 6.67 (d, J = 8.6 Hz, 2H), 5.15 (d, J = 16.3 Hz, 1H), 5.07–4.99 (m, 
1H), 5.01 (d, J = 16.3 Hz, 1H), 4.57–4.50 (m, 1H), 4.51‒4.46 (m, 2H), 3.68 (s, 3H), 3.65 (s, 
3H), 3.53–3.41 (m, 2H), 2.16–2.11 (m, 1H), 0.87 (dd, J = 15.6, 6.9 Hz, 6H). 13C NMR 
(101 MHz, CDCl3): δ = 172.2 (Cq), 168.9 (Cq), 168.1 (Cq), 168.0 (Cq), 165.3 (Cq), 158.5 
(Cq), 134.3 (CH), 131.6 (Cq), 129.9 (CH), 128.7 (Cq), 124.5 (CH), 123.6 (CH), 114.1 (CH), 
57.6 (CH3), 55.8 (CH), 55.3 (CH), 52.8 (CH2), 52.4 (CH3), 35.3 (CH2), 33.9 (CH2), 31.2 (CH), 
19.1 (CH3), 17.8 (CH3). IR (ATR): ṽ = 1774, 1714, 1612, 1514, 1467, 1384, 1248, 722 cm-1. 
MS (ESI) m/z (relative intensity): 1175 (52) [2M+Na]+, 1153 (35) [2M+H]+, 599 (51) [M+Na]+, 









The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) 
(96.9 mg, 0.2 mmol) and (S)-2-Acetamido-N-(4-iodophenyl) propanamide (11k) (132.9 mg, 
0.4 mmol) in HFIP. After 20 h, purification by HPLC (tr: 45.0 min) yielded 108s (115.7 mg, 
84%) as a white solid (M.p.: 127–128 °C). 1H NMR (300 MHz, CDCl3): δ = 9.26 (s, 1H), 7.89 
(d, J = 7.6 Hz, 1H), 7.78 (dd, J = 5.5, 3.0 Hz, 2H), 7.69 (dd, J = 5.5, 3.0 Hz, 2H), 7.42 (d, J = 
8.4 Hz, 2H), 7.22‒7.16 (m, 3H), 6.84–6.78 (m, 2H), 5.17–5.06 (m, 2H), 4.76 (d, J = 16.7 Hz, 
1H), 4.63–4.56 (m, 2H), 4.51–4.36 (m, 2H), 3.76 (m, 4H), 3.33‒3.25 (m, 1H), 1.99 (s, 3H), 
1.72–1.57 (m, 3H), 1.42 (d, J = 7.1 Hz, 3H), 0.90 (dd, J = 6.2, 2.3 Hz, 6H). 13C NMR (126 MHz, 
CDCl3): δ = 174.8 (Cq), 171.2 (Cq), 171.0 (Cq), 168.1 (Cq), 168.0 (Cq), 165.6 (Cq), 144.9 (Cq), 
137.0 (Cq), 134.3 (CH), 132.7 (Cq), 131.6 (Cq), 129.9 (CH), 129.6 (CH), 123.6 (CH), 119.9 
(CH), 55.9 (CH), 52.9 (CH3), 52.2 (CH2), 51.5 (CH), 50.1 (CH), 41.0 (CH2), 35.6 (CH2), 34.6 
(CH2), 25.1 (CH), 23.2 (CH3), 23.1 (CH3), 21.9 (CH3), 18.2 (CH3). IR (ATR): ṽ = 2958, 1712, 
1651, 1257, 1153, 1087, 1052, 975, 879, 801, 719 cm-1. MS (ESI) m/z (relative intensity): 
1053 (15), 711 (100) [M+Na]+, 364 (55). HR-MS (ESI) m/z calcd for C34H40N8O8Na [M+Na]+: 







oxopropyl]phenyl} propanoate (108t) 
The general procedure A was using PhthN-Ala-Gly-Tzl-Gly-Phe-OMe (107a) (103.7 mg, 
0.2 mmol) and (S)-methyl 2-acetamido-3-(4-iodophenyl)propanoate (11l) (138.9 mg, 
0.4 mmol). After 20 h, purification by HPLC (tr: 47.0 min) yielded 108t (64.9 mg, 44%) as a 
white solid (M.p.: 110‒111 °C). 1H NMR (300 MHz, CDCl3): δ = 7.74 (dd, J = 5.7, 2.9 Hz, 2H), 
7.70–7.64 (m, 2H), 7.61 (br s, 1H), 7.30–7.21 (m, 3H), 7.04 (brs, 1H), 7.06–6.98 (m, 4H), 
6.87 (d, J = 8.0 Hz, 2H), 6.75 (d, J = 8.0 Hz, 1H), 5.88 (d, J = 7.7 Hz, 1H), 5.05 (dd, J = 10.6, 
5.6 Hz, 1H), 4.96 (d, J = 17.8 Hz, 2H), 4.90–4.79 (m, 1H), 4.74 (dt, J = 7.7, 5.9 Hz, 1H), 4.45 
(br s, 2H), 3.69 (s, 3H), 3.62 (s, 3H), 3.49–3.34 (m, 2H), 3.12 (dd, J = 14.0, 5.6 Hz, 1H), 3.00 
(dd, J = 13.9, 6.5 Hz, 2H), 2.91 (dd, J = 13.9, 5.9 Hz, 1H), 1.89 (s, 3H). 13C NMR (126 MHz, 
CDCl3): δ = 171.9 (Cq), 171.3 (Cq), 169.5 (Cq), 168.5 (Cq), 167.9 (Cq), 167.8 (Cq), 164.7 (Cq), 
135.6 (Cq), 135.5 (Cq), 134.6 (Cq), 134.3 (CH), 131.5 (Cq), 129.6 (CH), 129.5 (CH), 129.2 
(CH), 129.2 (CH), 128.7 (CH), 127.3 (CH), 123.6 (CH), 55.5 (CH), 53.6 (CH), 53.2 (CH), 52.8 
(CH2), 52.7 (CH3), 52.4 (CH3), 37.8 (CH2), 37.6 (CH2), 35.4 (CH2), 34.6 (CH2), 23.2 (CH3). IR 
(ATR): ṽ = 1740, 1658, 1531, 1435, 1381, 1216, 1175, 1116, 1051, 720 cm-1. MS (ESI) m/z 
(relative intensity): 1497 (20) [2M+Na]+, 760 (100) [M+Na]+, 738 (75) [M+H]+. HR-MS (ESI) 









(96.9 mg, 0.2 mmol) and (S)-methyl 2-acetamido-3-(4-iodophenyl)propanoate (11l) (138.9 
mg, 0.4 mmol) in HFIP. After 20 h, purification by HPLC (tr: 45.0 min) yielded 108u (115.4 mg, 
82%) as a white solid (M.p.: 109–110 °C). 1H NMR (500 MHz, CDCl3): δ = 7.75‒7.67 (m, 5H), 
7.16 (br s, 1H), 7.03 (d, J = 7.9 Hz, 2H), 6.93 (d, J = 7.9 Hz, 1H), 6.87 (d, J = 7.9 Hz, 2H), 
5.91 (d, J = 7.8 Hz, 1H), 5.11–4.97 (m, 3H), 4.77 (dd, J = 13.5, 5.9 Hz, 1H), 4.59 (td, J = 8.5, 
4.9 Hz, 1H), 4.47 (brs, 2H), 3.68 (s, 3H), 3.62 (s, 3H), 3.54 (dd, J = 13.9, 4.8 Hz, 1H), 3.46–
3.37 (m, 1H), 3.00 (dd, J = 13.9, 5.8 Hz, 1H), 2.92 (dd, J = 13.9, 5.9 Hz, 1H), 1.90 (s, 3H), 
1.66–1.57 (m, 2H), 1.56–1.47 (m, 1H), 0.89 (d, J = 5.2 Hz, 6H). 13C NMR (126 MHz, CDCl3): 
δ = 173.1 (Cq), 172.1 (Cq), 169.8 (Cq), 168.7 (Cq), 168.0 (Cq), 167.9 (Cq), 165.1 (Cq), 135.7 
(Cq), 134.6 (Cq), 134.4 (CH), 131.5 (Cq), 129.6 (CH), 129.6 (CH), 129.2 (CH), 123.7 (CH), 
55.4 (CH), 53.2 (CH), 52.8 (CH2), 52.6 (CH3), 52.4 (CH3), 51.2 (CH), 41.2 (CH2), 37.5 (CH2), 
35.3 (CH2), 34.5 (CH2), 25.0 (CH), 23.2 (CH3), 22.9 (CH3), 21.9 (CH3). IR (ATR): ṽ = 3063, 
1714, 1656, 1534, 1382, 1216, 721, 530 cm-1. MS (ESI) m/z (relative intensity): 1075 (23), 
726 (100) [M+Na]+, 704 (60) [M+H]+, 371 (68). HR-MS (ESI) m/z calcd for C35H41N7O9Na 





The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Phe-Val-OMe (107f) 
(123.5 mg, 0.2 mmol) and 4-iodoanisole (11d) (93.6 mg, 0.4 mmol) in HFIP. After 20 h, 
purification by HPLC (tr: 45.0 min) yielded 108v (79.5 mg, 55%) as a white solid (M.p.: 110‒
111 °C). 1H NMR (500 MHz, CDCl3): δ = 7.74‒7.59 (m, 5H), 7.29–7.19 (m, 5H), 7.17‒7.11 (m, 
2H), 7.02 (d, J = 8.6 Hz, 2H), 6.66 (d, J = 8.6 Hz, 2H), 6.37 (d, J = 8.4 Hz, 1H), 5.06 (dd, J = 
10.8, 5.4 Hz, 1H), 5.02‒4.89 (m, 2H), 4.69 (dd, J = 7.1, 7.1Hz, 1H), 4.55‒4.39 (m, 2H), 4.37 




2H), 2.06 (dddd, J = 6.8, 6.8, 6.8, 5.1 Hz, 1H), 0.81 (dd, J = 17.9, 6.8 Hz, 6H). 13C NMR 
(126 MHz, CDCl3): δ = 171.8 (Cq), 170.5 (Cq), 170.4 (Cq), 168.9 (Cq), 168.0 (Cq), 165.3 (Cq), 
158.5 (Cq), 136.2 (Cq), 134.3 (CH), 131.6 (Cq), 130.0 (CH), 129.4 (CH), 128.8 (CH), 128.7 
(Cq), 127.3 (CH), 123.6 (CH), 114.1 (CH), 114.1 (CH), 57.6 (CH), 55.6 (CH), 55.2 (CH3), 55.1 
(CH), 52.7 (CH2), 52.3 (CH3), 38.1 (CH2), 35.3 (CH2), 34.0 (CH2), 31.1 (CH), 19.0 (CH3), 17.9 
(CH3). IR (ATR): ṽ = 2957, 1713, 1647, 1535, 1512, 1382, 1245, 1205, 1178, 1152, 718 cm-
1. MS (ESI) m/z (relative intensity): 1105 (20), 746 (100) [M+Na]+, 381 (100). HR-MS (ESI) 





The general procedure A was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-AspOMe-OMe (107g) 
(123.5 mg, 0.2 mmol) and 4-iodoanisole (11d) (93.6 mg, 0.4 mmol) in HFIP. After 20 h, 
purification by HPLC (tr: 47.0 min) yielded 108w (90.7 mg, 63%) as a white solid (M.p.: 109 
‒ 110 °C). 1H NMR (600 MHz, CDCl3): δ = 7.73–7.65 (m, 5H), 7.26–7.21 (m, 1H), 7.19 (d, J 
= 8.0 Hz, 1H), 7.04–7.00 (m, 3H), 6.65 (d, J = 8.7 Hz, 2H), 5.05 (dd, J = 11.4, 5.7 Hz, 1H), 
5.04–5.00 (m, 2H), 4.77 (ddd, J = 8.7, 4.7, 4.7 Hz, 1H), 4.53–4.44 (m, 2H), 4.43–4.35 (m, 
1H), 3.73 (s, 3H), 3.68 (s, 3H), 3.65 (s, 3H), 3.48 (dd, J = 14.2, 5.7 Hz, 1H), 3.43 dd, J = 14.2, 
11.4 Hz, 1H), 2.97 (dd, 17.1, 4.7 Hz, 1H), 2.79 (dd, J = 17.1, 4.7 Hz, 1H), 1.67–1.50 (m, 3H), 
0.89 (dd, J = 8.5, 6.4 Hz, 6H). 13C NMR (126 MHz, CDCl3): δ = 171.5 (Cq), 171.3 (Cq), 170.7 
(Cq), 168.7 (Cq), 167.9 (Cq), 166.7 (Cq), 165.4 (Cq), 158.4 (Cq), 134.2 (CH), 131.6 (Cq), 129.9 
(CH), 128.7 (Cq), 123.5 (CH), 114.1 (CH), 55.7 (CH), 55.3 (CH3), 53.0 (CH3), 52.3 (CH3), 52.2 
(CH), 48.8 (CH), 41.1 (CH2), 36.1 (CH2), 35.1 (CH2), 34.0 (CH2), 33.8 (CH2), 24.9 (CH), 23.0 
(CH3), 22.3 (CH3) (due to overlap, one resonance is missing). IR (ATR): ṽ = 1743, 1711, 1653, 




(25) [2M+Na]+, 1439 (20) [2M+H]+, 742 (100) [M+Na]+, 720 (94) [M+H]+. HR-MS (ESI) m/z 





The general procedure A was followed using PhthN-Phe-Ala-Gly-Tzl-Gly-Leu-OMe (107h) 
(126.3 mg, 0.2 mmol) and 4-iodoanisole (11d) (93.6 mg, 0.4 mmol) in AcOH. After 20 h, 
purification by HPLC (tr: 45.0 min) yielded 108x (73.8 mg, 50%) as a white solid. 1H NMR 
(600 MHz, CDCl3): δ = 7.72 (dd, J = 5.4, 3.1 Hz, 2H), 7.66 (dd, J = 5.4, 3.1 Hz, 2H), 7.55 (s, 
1H), 7.14‒7.11 (m, 2H), 7.10‒7.05 (m, 3H), 6.99‒6.92 (m, 3H), 6.86 (d, J = 8.2 Hz, 1H), 6.83 
(d, J = 8.2 Hz, 1H), 6.63 (d, J = 8.6 Hz, 2H), 5.05 (dd, J = 10.3, 6.3 Hz, 1H), 5.00 (s, 2H), 
4.67‒4.61 (m, 1H), 4.58‒4.54 (m, 1H), 4.47 (dd, J = 15.3, 5.8 Hz, 1H), 4.37 (dd, J = 15.3, 5.3 
Hz, 1H), 3.68 (s, 3H), 3.63 (s, 3H), 3.41 (dd, J = 14.1, 6.3 Hz, 1H), 3.39 (dd, J = 14.1, 10.3 
Hz, 1H), 2.98‒2.92 (m, 2H), 1.83 (s, 1H), 1.58‒1.54 (m, 2H), 0.85 (d, J = 6.0 Hz, 6H). 
13C NMR (126 MHz, CDCl3): δ = 172.8 (Cq), 170.5 (Cq), 168.4 (Cq), 167.5 (Cq), 164.9 (Cq), 
158.4 (Cq), 136.3 (Cq), 134.1 (CH), 131.3 (Cq), 131.2 (Cq), 130.1 (CH), 128.7 (CH), 128.5 
(CH), 128.0 (CH), 126.9 (Cq), 123.9 (CH), 123.4 (CH), 114.0 (CH), 55.2 (CH3), 55.1 (CH3), 
52.7 (CH2), 52.4 (CH), 51.1 (CH), 51.0 (CH), 41.1 (CH2), 37.0 (CH2), 35.2 (CH2), 34.6 (CH2), 
24.9 (CH), 22.8 (CH3), 21.9 (CH3). IR (ATR): ṽ = 2956, 2923, 2853, 1715, 1654, 1513, 1466, 
1382, 1246, 721 cm-1. MS (ESI) m/z (relative intensity): 1497 (10) [2M+Na]+, 760 (100) 







3-phenyl propanamido]-3-(4-methoxyphenyl)propanamide (108y) 
The general procedure A was followed using PhthN-Phe-Ala-NHTAM (105b) (112.9 mg, 
0.2 mmol) and 4-iodoanisole (11d) (93.6 mg, 0.4 mmol). After 20 h, purification by HPLC (tr: 
45.0 min) yielded 108y (80.5 mg, 60%) as a yellow solid (M.p.: 118‒119 °C). 1H NMR (300 
MHz, CDCl3): δ = 7.74 (dd, J = 5.5, 3.0 Hz, 2H), 7.69 (dd, J = 5.5, 3.0 Hz, 2H), 7.40‒7.31 (m, 
4H), 7.25‒7.22 (m, 2H), 7.18‒7.08 (m, 5H), 7.03 (d, J = 8.6 Hz, 2H), 6.68 (d, J = 8.6 Hz, 2H), 
6.59 (d, J = 7.2 Hz, 1H), 6.17 (brs, 1H), 5.45 (s, 2H), 5.10‒5.02 (m, 1H), 4.52‒4.44 (m, 1H), 
3.70 (s, 3H), 3.48‒3.39 (m, 2H), 3.01 (dd, J = 13.6, 6.2 Hz, 1H), 2.85 (dd, J = 13.6, 7.6 Hz, 
1H), 1.61 (s, 3H), 1.57 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 169.3 (Cq), 168.1 (Cq), 167.7 
(Cq), 158.6 (Cq), 153.2 (Cq), 136.5 (Cq), 134.9 (Cq), 134.2 (CH), 131.5 (Cq), 130.4 (CH), 129.1 
(CH), 129.0 (CH), 128.7 (CH), 128.7 (CH), 128.4 (Cq), 128.0 (CH), 127.0 (CH), 123.6 (CH), 
120.4 (CH), 114.1 (CH), 55.6 (CH), 55.4 (CH3), 55.4 (CH), 54.2 (CH2), 51.9 (Cq), 37.4 (CH2), 
34.8 (CH2), 28.3 (CH3), 27.9 (CH3). IR (ATR): ṽ = 1775, 1657, 1512, 1382, 1245, 1177, 1031, 
873, 821, 719 cm–1. MS (ESI) m/z (relative intensity): 1363 (4) [2M+Na]+, 1026 (11), 693 (69) 
[M+Na]+, 671 (100) [M+H]+, 355 (27). HR-MS (ESI) m/z calcd for C39H39N6O5 [M+H]+: 
671.2976; found: 671.2973. 







In a high pressure tube, 106b (153.6 mg, 0.25 mmol) was dissolved in dry MeOH (5.0 mL). 
Under N2, BF3•Et2O (532.2 mg, 3.75 mmol) was then added dropwise at 0 °C. The solution 
was stirred at 130 °C for 16 h. At 0 °C, Et3N (1.0 mL) was added to the solution. The solvent 
was removed in vacuo and the crude product was purified by column chromatography on 
silica gel (n-hexane/EtOAc 3/1. Rf: 0.53) to yield 106ba (66.7 mg, 62%) as a white solid. (M.p.: 
70‒70 °C). 1H NMR (500 MHz, CDCl3): δ = 8.21 (d, J = 8.8 Hz, 2H), 7.75 (dd, J = 5.6, 3.0 Hz, 
2H), 7.68–7.63 (m, 4H), 7.22–7.20 (m, 2H), 7.14–7.11 (m, 2H), 7.01 (dddd, J = 8.2, 6.7, 1.3, 
1.3 Hz, 1H), 5.76 (d, J = 11.9 Hz, 1H), 5.33 (d, J = 11.9 Hz, 1H), 3.61 (s, 3H). 13C NMR (125 
MHz, CDCl3): δ = 168.3 (Cq), 167.1 (Cq), 149.2 (Cq), 146.7 (Cq), 138.7 (Cq), 134.2 (CH), 131.1 
(Cq), 128.9 (CH), 128.5 (CH), 127.9 (CH), 127.5 (CH), 124.0 (CH), 123.5 (CH), 54.0 (CH), 
52.9 (CH), 50.6 (CH3). IR (ATR): ṽ = 1749, 1716, 1518, 1378, 1339, 594, 526 cm-1. MS (ESI) 
m/z (relative intensity) 883 (40) [2M+Na]+, 453 (100) [M+Na]+. HR-MS (ESI): m/z calcd for 
C24H18N2O6Na [M+Na]+: 453.1057; found: 453.1051. 
NMR and HPLC analysis showed that no racemization occurred during the TAM-removal 
process. 
 
(2S,3R)-Methyl -2-amino-3-(4-nitrophenyl)-3-phenylpropanoate (106bb) 
106ba (66.0 mg, 0.15 mmol) was dissolved in a 1/1 mixture of CH2Cl2/EtOH (4.0 mL). 
Ethylenediamine (45.2 mg, 0.75 mmol) was added dropwise. The solution was stirred at 40 °C 
for 4 h. At ambient temperature, the solvent was removed in vacuo and the crude product 
was purified by column chromatography on silica gel (CH2Cl2/MeOH: 40/1. Rf: 0.31) to yield 
106bb (36.2 mg, 80%) as a yellow oil. 1H NMR (500 MHz, CDCl3): δ = 8.14 (d, J = 8.8 Hz ,2H), 
7.55 (d, J = 8.8 Hz, 2H), 7.35–7.32 (m, 2H), 7.29–7.24 (m, 3H), 4.42 (d, J = 8.0 Hz, 1H), 4.24 
(d, J = 8.0 Hz, 1H), 3.58 (s, 3H), 1.54 (brs, 2H). 13C NMR (75 MHz, CDCl3): δ = 174.4 (Cq), 




(CH), 58.2 (CH), 55.4 (CH3), 52.1 (CH). IR (ATR): ṽ = 1737, 1595, 1517, 1498, 1440, 1251, 
1173, 908, 848, 729 cm-1. MS (ESI) m/z (relative intensity) 301 (100) [M+H]+. HR-MS (ESI): 




108r (57.6 mg, 0.1 mmol) was dissolved in a 1/1 mixture of CH2Cl2/EtOH (3.0 mL). 
Ethylenediamine (30.1 mg, 0.5 mmol) was added dropwise. The solution was stirred at 40 °C 
for 4 h. At ambient, the solvent was removed in vacuo and the crude product was purified by 
column chromatography on silica gel (CH2Cl2/MeOH 20/1. Rf: 0.23) to yield 108ra (27.7 mg, 
62%) as a colorless oil. 1H NMR (300 MHz, CDCl3): δ = 7.86 (brs, 1H), 7.63 (s, 1H), 7.11 (d, 
J = 8.3 Hz, 2H), 6.84 (d, J = 8.3 Hz, 2H), 6.53 (d, J = 7.9 Hz, 1H), 5.06 (s, 2H), 4.55–4.49 (m, 
3H), 3.79 (s, 3H), 3.72 (s, 3H), 3.63–3.59 (m, 1H), 3.18 (dd, J = 13.8, 4.1 Hz, 1H), 2.66 (dd, 
J = 13.8, 9.2 Hz, 1H), 2.19–2.12 (m, 1H), 1.82 (brs, 2H), 0.87 (dd, J = 12.8, 6.8 Hz, 6H). 13C 
NMR (75 MHz, CDCl3): δ = 174.4 (Cq), 171.7 (Cq), 164.9 (Cq), 158.5 (Cq), 145.6 (Cq), 130.2 
(CH), 129.6 (Cq), 123.8 (CH), 114.1 (CH), 57.5 (CH3), 56.5 (CH), 55.3 (CH), 52.8 (CH2), 52.3 
(CH3), 40.0 (CH2), 34.6 (CH2), 31.1 (CH), 18.9 (CH3), 17.7 (CH3). IR (ATR): ṽ = 1785, 1705, 
1617, 1524, 1440, 1375, 1250, 719 cm-1. MS (ESI) m/z (relative intensity) 447 (100) [M+H]+, 
469 (5) [M+Na]+. HR-MS (ESI): m/z calcd for C21H30N6O5 [M+H]+: 447.2350; found: 447.2354. 
5.3.2 BODIPY Peptide Labeling by Late-Stage C(sp3)─H Activation 







dioxoisoindolin-2-yl) propanamide (110aa) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109a (54 mg, 0.12 mmol) and AgOAc (20 mg, 0.12 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110aa (62.2 mg, 84%) as a pale orange solid (M.p.: 
146–147 °C). 1H NMR (300 MHz, CDCl3): δ = 7.78–7.67 (m, 4H), 7.43 (s, 1H), 7.42–7.32 (m, 
3H), 7.29–7.24 (m, 4H), 7.05 (d, J = 8.0 Hz, 2H), 6.96 (s, 1H), 5.88 (s, 2H), 5.49 (s, 2H), 5.10 
(dd, J = 11.7, 5.5 Hz, 1H), 3.66 (dd, J = 13.7, 11.7 Hz, 1H), 3.55 (dd, J = 13.7, 5.5 Hz, 1H), 
2.50 (s, 6H), 1.76 (s, 6H), 1.06 (s, 6H). 13C NMR (126 MHz, CDCl3): δ = 167.7 (Cq), 167.1 
(Cq), 155.4 (Cq), 153.5 (Cq), 143.0 (Cq), 141.3 (Cq), 137.9 (Cq), 134.7 (Cq), 134.4 (CH), 133.7 
(Cq), 131.4 (Cq), 129.8 (CH), 129.2 (CH), 128.8 (CH), 128.3 (CH), 128.1 (CH), 123.6 (CH), 
121.2 (CH), 120.3 (CH), 56.2 (CH), 54.4 (CH2), 52.3 (Cq), 34.8 (CH2), 28.2 (CH3), 28.1 (CH3), 
14.8 (CH3), 14.4 (CH3). 19F NMR (282 MHz, CDCl3) δ = -146.40 (q, JB-F = 31.8 Hz). IR (ATR): 
ṽ = 1988, 1969, 1715, 1541, 1508, 531, 501, 410, 401, 389 cm-1. MS (ESI) m/z (relative 
intensity): 762 (100) [M+Na]+, 740 (50) [M+H]+. HR-MS (ESI): m/z calcd for C42H41BF2N7O3 
[M+H]+: 740.3334; found: 740.3328. UV-Vis λmax (1.0 mg/L in EtOAc) = 498 nm. Em λmax (1.0 







2-yl) propanamide (110ab) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109c (51 mg, 0.12 mmol) and AgOAc (20 mg, 0.12 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110ab (51.2 mg, 72%) as a red solid (M.p.: 152–
153 °C). 1H NMR (600 MHz, CDCl3): δ = 7.76 (dd, J = 5.4, 3.0 Hz, 2H), 7.69 (dd, J = 5.4, 3.0 
Hz, 2H), 7.44 (s, 1H), 7.39–7.34 (m, 3H), 7.28–7.25 (m, 3H), 7.24–7.23 (m, 3H), 6.89 (s, 1H), 
6.44 (d, J = 4.2 Hz, 2H), 6.20 (d, J = 4.2 Hz, 2H), 5.48 (s, 2H), 5.08 (dd, J = 10.8, 6.3 Hz, 1H), 
3.62 (dd, J = 14.1, 6.3 Hz, 1H), 3.57 (dd, J = 14.1, 10.8 Hz, 1H), 2.61 (s, 6H), 1.75 (s, 3H), 
1.74 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 167.8 (Cq), 167.1 (Cq), 157.5 (Cq), 153.3 (Cq), 
142.1 (Cq), 139.1 (Cq), 134.6 (Cq), 134.4 (CH), 134.3 (Cq), 132.7 (Cq), 131.4 (Cq), 130.6 (CH), 
130.2 (CH), 129.2 (CH), 129.0 (CH), 128.8 (CH), 128.2 (CH), 123.6 (CH), 120.5 (CH), 119.4 
(CH), 56.2 (CH), 54.4 (CH2), 52.2 (Cq), 34.9 (CH2), 28.2 (CH3), 28.0 (CH3), 15.1 (CH3). 19F 
NMR (282 MHz, CDCl3): δ = -147.69 (q, JB-F = 32.3 Hz). IR (ATR): ṽ = 1711, 1545, 1378, 
1269, 1142, 1006, 985, 716, 433 cm-1. MS (ESI) m/z (relative intensity): 1445 (10) [2M+Na]+, 
734 (80) [M+Na]+, 712 (100) [M+H]+. HR-MS (ESI): m/z calcd for C40H37BF2N7O3 [M+H]+: 
712.3020; found: 712.3025. UV-Vis λmax (1.0 mg/L in EtOAc) = 508 nm. Em λmax (1.0 mg/L 







dioxoisoindolin-2-yl) propanamide (110ac) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109d (54.0 mg, 0.12 mmol) and AgOAc (20.0 mg, 0.12 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110ac (56.0 mg, 76%) as an orange solid (M.p.: 
155–156 °C). 1H NMR (600 MHz, CDCl3): δ = 7.76–7.74 (m, 2H), 7.71–7.68 (m, 2H), 7.43 (s, 
1H), 7.39–7.33 (m, 3H), 7.28–7.26 (m, 3H), 7.25 (s, 1H), 7.07–7.04 (m, 2H), 6.96 (s, 1H), 
5.88 (s, 2H), 5.49 (s, 2H), 5.10 (dd, J = 12.0, 5.2 Hz, 1H), 3.65 (dd, J = 13.9, 12.0 Hz, 1H), 
3.55 (dd, J = 13.9, 5.2 Hz, 1H), 2.50 (s, 6H), 1.76 (s, 3H), 1.75 (s, 3H), 1.06 (s, 6H). 13C NMR 
(126 MHz, CDCl3): δ = 167.7 (Cq), 167.1 (Cq), 155.4 (Cq), 153.7 (CH), 153.5 (Cq), 143.0 (Cq), 
141.3 (Cq), 137.9 (Cq), 134.7 (Cq), 134.4 (CH), 133.71 (Cq), 133.66 (Cq), 131.4 (Cq), 129.8 
(CH), 129.2 (CH), 128.8 (CH), 128.3 (CH), 128.2 (CH), 124.6 (CH), 123.6 (CH), 121.2 (CH), 
120.3 (CH), 56.2 (CH), 54.4 (CH2), 52.3 (Cq), 34.8 (CH2), 28.2 (CH3), 28.1(CH3), 14.8 (CH3), 
14.4 (CH3). 19F NMR (282 MHz, CDCl3): δ = -146.40 (q, JB-F = 32.5 Hz). IR (ATR): ṽ = 1714, 
1547, 1194, 499, 406, 394, 382 cm-1. MS (ESI) m/z (relative intensity): 1501 (5) [2M+Na]+, 
762 (100) [M+Na]+, 740 (50) [M+H]+. HR-MS (ESI): m/z calcd for C42H41BF2N7O3 [M+H]+: 
740.3334; found: 740.3313. UV-Vis λmax (1.0 mg/L in EtOAc) = 498 nm. Em λmax (1.0 mg/L 








The general procedure B was followed using PhthN-Phe-TAM (105c) (49.4 mg, 0.1 mmol), 
iodo-BODIPY 109a (54 mg, 0.12 mmol) and AgOAc (20 mg, 0.12 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110ad (75.0 mg, 92%, d:r > 20:1) as an orange 
solid (M.p.: 147–148 °C). 1H NMR (500 MHz, CDCl3): δ = 7.72 (dd, J = 5.5, 3.1 Hz, 2H), 7.65 
(dd, J = 5.5, 3.1 Hz, 2H), 7.59 (d, J = 8.2 Hz, 2H), 7.35–7.30 (m, 5H), 7.23–7.19 (m, 4H), 7.15 
(d, J = 8.2 Hz, 2H), 7.12–7.09 (m, 2H), 7.03–7.00 (m, 1H), 5.93 (s, 2H), 5.49 (d, J = 12.5 Hz, 
1H), 5.42 (d, J = 14.7 Hz, 1H), 5.38 (d, J = 14.7 Hz, 1H), 5.35 (d, J = 12.5 Hz, 1H), 2.54 (s, 
6H), 1.61 (s, 3H), 1.58 (s, 3H), 1.25 (s, 6H). 13C NMR (126 MHz, CDCl3): δ = 168.1 (Cq), 
166.3 (Cq), 155.5 (Cq), 153.1 (Cq), 143.3 (Cq), 141.7 (Cq), 141.4 (Cq), 140.1 (Cq), 134.8 (Cq), 
134.4 (CH), 133.9 (Cq), 131.5 (Cq), 131.2 (Cq), 129.2 (CH), 128.8 (CH), 128.4 (CH), 128.3 
(CH), 128.2 (CH), 128.0 (CH), 127.9 (CH), 127.3 (CH), 123.7 (CH), 121.3 (CH), 120.7 (CH), 
59.6 (CH), 54.2 (CH2), 51.9 (Cq), 50.2 (CH), 27.9 (CH3), 27.8 (CH3), 14.7 (CH3), 14.6 (CH3). 
19F NMR (471 MHz, CDCl3): δ = -146.31 (q, JB-F = 32.1 Hz). IR (ATR): ṽ = 2925, 1712, 1544, 
1510, 1384, 1194, 1156, 716, 394 cm-1. MS (ESI) m/z (relative intensity): 838 (100) [M+Na]+, 
816 (50) [M+H]+. HR-MS (ESI): m/z calcd for C48H45BF2N7O3 [M+H]+: 816.3648; found: 








dioxoisoindolin-2-yl) propanamide (110ba) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109e (69.8 mg, 0.12 mmol) and Cu(OAc)2 (36.3 mg, 0.20 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110ba (74.0 mg, 85%) as a purple solid (M.p.: 
142–143 °C). 1H NMR (600 MHz, CDCl3): δ = 7.85 (ddd, J = 7.7, 7.7, 1.7 Hz, 2H), 7.80 (dd, 
J = 5.4, 3.0 Hz, 2H), 7.72 (dd, J = 5.4, 3.0 Hz, 2H), 7.44 (s, 1H), 7.39–7.33 (m, 7H), 7.30 (d, 
J = 8.1 Hz, 2H), 7.29–7.26 (m, 2H), 7.18 (ddd, J = 7.7, 7.7, 1.1 Hz, 2H), 7.10 (dd, J = 8.1, 1.1 
Hz, 2H), 6.87 (s, 1H), 6.66 (d, J = 4.2 Hz, 2H), 6.59 (d, J = 4.2 Hz, 2H), 5.49 (s, 2H), 5.11 (dd, 
J = 10.8, 6.0 Hz, 1H), 3.67 (dd, J = 13.8, 6.0 Hz, 1H), 3.61 (dd, J = 13.8, 10.8 Hz, 1H), 1.76 
(s, 3H), 1.75 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 167.8 (Cq), 167.0 (Cq), 161.2 (d, 1JC-F 
= 249 Hz, Cq), 153.4 (Cq), 152.3 (Cq), 144.7 (Cq), 139.7 (Cq), 135.9 (Cq), 134.7 (Cq), 134.5 
(CH), 132.8 (Cq), 132.8 (CH), 132.1 (d, 3JC-F = 9.0 Hz, CH), 131.4 (Cq), 131.2 (d, 3JC-F = 8.3 
Hz, CH), 130.8 (CH), 130.6 (CH), 129.2 (d, 4JC-F = 3.1 Hz, CH), 128.8 (CH), 128.1 (CH), 123.9 
(CH), 123.7 (CH), 122.1 (CH), 120.7 (d, 2JC-F = 13.5 Hz, Cq), 120.4 (CH), 115.7 (d, 2JC-F = 22.1 
Hz, CH), 56.3 (CH), 54.4 (CH2), 52.3 (Cq), 35.0 (CH2), 28.2 (CH3), 28.1 (CH3). 19F NMR (282 
MHz, CDCl3): δ = -112.48 (m), -134.93 (q, JB-F = 31.0 Hz). IR (ATR): ṽ = 2923, 1713, 1569, 
1543, 1465, 1264, 1138, 1071, 759, 721 cm-1. MS (ESI) m/z (relative intensity): 894 (100) 
[M+Na]+, 872 (90) [M+H]+. HR-MS (ESI): m/z calcd for C50H39BF4N7O3 [M+H]+: 872.3146; 








dioxoisoindolin-2-yl) propanamide (110bb) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109f (73.8 mg, 0.12 mmol) and Cu(OAc)2 (36.3 mg, 0.20 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bb (46.1 mg, 51%) as a purple solid (M.p.: 
140–141 °C). 1H NMR (600 MHz, CDCl3): δ = 7.81–7.78 (m, 4H), 7.76–7.71 (m, 4H), 7.44 (s, 
1H), 7.39–7.34 (m, 9H), 7.32–7.26 (m, 4H), 6.90 (s, 1H), 6.66 (d, J = 4.2 Hz, 2H), 6.56 (d, J 
= 4.2 Hz, 2H), 5.50 (s, 2H), 5.11 (dd, J = 10.8, 6.0 Hz, 1H), 3.67 (dd, J = 13.9, 6.0 Hz, 2H), 
3.61 (dd, J = 13.9, 10.8 Hz, 1H), 1.77 (s, 3H). 1.76 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 
167.8 (Cq), 167.1 (Cq), 160.4 (Cq), 157.3 (Cq), 153.4 (Cq), 144.7 (Cq), 139.8 (Cq), 136.5 (Cq), 
135.7 (Cq), 134.5 (CH), 134.2 (Cq), 132.7 (Cq), 131.5 (Cq), 131.2 (CH), 130.8 (CH), 129.7 
(CH), 129.6 (CH), 129.3 (CH), 129.2 (CH), 129.2 (CH), 128.8 (CH), 128.2 (CH), 127.8 (CH), 
123.7 (CH), 121.0 (CH), 120.5 (CH), 56.3 (CH), 54.5 (CH2), 52.3 (Cq), 35.0 (CH2), 28.2 (CH3), 
28.1 (CH3). 19F NMR (282 MHz, CDCl3): δ = -132.44 (q, JB-F = 31.7). IR (ATR): ṽ = 2050, 1715, 
1543, 558, 444, 432, 407, 393 cm-1. MS (ESI) m/z (relative intensity): 926 (100) [M+Na]+ 
(35Cl), 903 (90) [M+H]+ (35Cl). HR-MS (ESI): m/z calcd for C50H39BCl2F2N7O3 [35Cl-M+H]+: 
904.2555; found: 904.2563. UV-Vis λmax (1.0 mg/L in EtOAc) = 548 nm. Em λmax (1.0 mg/L 







dioxo isoindolin-2-yl)propanamide (110bc) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109g (83.7 mg, 0.12 mmol) and Cu(OAc)2 (36.3 mg, 0.20 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bc (79 mg, 80%) as a purple solid (M.p.: 158–
159 °C). 1H NMR (600 MHz, CDCl3): δ = 7.98 (d, J = 8.4 Hz, 4H), 7.81 (dd, J = 5.5, 3.1 Hz, 
2H), 7.73 (dd, J = 5.5, 3.1 Hz, 2H), 7.66 (d, J = 8.4 Hz, 4H), 7.63 (dd, J = 8.3, 1.2 Hz, 4H), 
7.46–7.43 (m, 5H), 7.39–7.34 (m, 7H), 7.31 (d, J = 8.0 Hz, 2H), 7.29–7.27 (m, 2H), 6.90 (s, 
1H), 6.65 (ddd, J = 4.4, 4.4, 4.4 Hz, 4H), 5.50 (s, 2H), 5.12 (dd, J = 10.8, 6.0 Hz, 1H), 3.68 
(dd, J = 13.8, 6.0 Hz, 1H), 3.61 (dd, J = 13.8, 10.8 Hz, 1H), 1.77 (s, 3H), 1.76 (s, 3H). 13C 
NMR (126 MHz, CDCl3): δ = 167.9 (Cq), 167.1 (Cq), 158.4 (Cq), 153.4 (Cq), 143.2 (Cq), 142.3 
(Cq), 140.5 (Cq), 139.4 (Cq), 136.5 (Cq), 134.7 (Cq), 134.5 (CH), 133.1 (Cq), 131.52 (Cq), 
131.49 (Cq), 130.8 (CH), 130.7 (CH), 130.0 (CH), 129.2 (CH), 129.1 (CH), 128.85 (CH), 
128.77 (CH), 128.2 (CH), 127.7 (CH), 127.2 (CH), 127.0 (CH), 123.7 (CH), 121.0 (CH), 120.4 
(CH), 56.3 (CH), 54.4 (CH2), 52.3 (Cq), 35.0 (CH2), 28.2 (CH3), 28.1 (CH3). 19F NMR (282 
MHz, CDCl3) δ = -132.46 (q, JB-F = 31.9 Hz). IR (ATR): ṽ = 2921, 1713, 1569, 1542, 1466, 
1273, 1142, 1074, 764, 720, 697 cm-1. MS (ESI) m/z (relative intensity): 1010 (80) [M+Na]+, 
988 (100) [M+H]+. HR-MS (ESI): m/z calcd for C62H49BF2N7O3 [M+H]+: 988.3963; found: 








2-yl) propanamide (110bd) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109b (65.5 mg, 0.12 mmol) and Cu(OAc)2 (36.3 mg, 0.20 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bd (61.0 mg, 73%) as a purple solid (M.p.: 
143–144 °C). 1H NMR (600 MHz, CDCl3): δ = 7.86–7.82 (m, 4H), 7.80 (dd, J = 5.4, 3.0 Hz, 
2H), 7.72 (dd, J = 5.4, 3.0 Hz, 2H), 7.45 (s, 1H), 7.43–7.34 (m, 11H), 7.31–7.26 (m, 4H), 6.89 
(s, 1H), 6.60 (d, J = 4.2 Hz, 2H), 6.54 (d, J = 4.2 Hz, 2H), 5.49 (s, 2H), 5.11 (dd, J = 10.8, 6.0 
Hz, 1H), 3.66 (dd, J = 13.8, 6.0 Hz, 1H), 3.60 (dd, J = 13.8, 10.8 Hz, 1H), 1.77 (s, 3H), 1.75 
(s, 3H). 13C NMR (126 MHz, CDCl3): δ = 167.8 (Cq), 167.1 (Cq), 158.9 (Cq), 153.4 (Cq), 143.7 
(Cq), 139.4 (Cq), 136.3 (Cq), 134.7 (Cq), 134.5 (CH), 133.0 (Cq), 132.6 (Cq), 131.5 (Cq), 130.8 
(CH), 130.7 (CH), 129.5 (CH), 129.5 (CH), 129.2 (CH), 129.1 (CH), 128.8 (CH), 128.3 (CH), 
128.1 (CH), 123.6 (CH), 120.9 (CH), 120.4 (CH), 56.3 (CH), 54.4 (CH2), 52.3 (Cq), 35.0 (CH2), 
28.2 (CH3), 28.1 (CH3). 19F NMR (282 MHz, CDCl3): δ = -132.61 (q, JB-F = 31.8 Hz). IR (ATR): 
ṽ = 2360, 1994, 1956, 1070, 437, 411, 389 cm-1. MS (ESI) m/z (relative intensity): 858 (90) 
[M+Na]+, 836 (100) [M+H]+. HR-MS (ESI): m/z calcd for C50H41BF2N7O3 [M+H]+: 836.3335; 








yl}phenyl)-2-(1,3-dioxoiso indolin-2-yl)propanamide (110be) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109h (80.0 mg, 0.12 mmol) and Cu(OAc)2 (36.3 mg, 0.20 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110be (52.5 mg, 55%) as a purple solid (M.p.: 
147–148 °C). 1H NMR (600 MHz, CDCl3): δ = 7.79 (dd, J = 5.4, 3.0 Hz, 2H), 7.72 (dd, J = 5.4, 
3.0 Hz, 2H), 7.60 (d, J = 2.1 Hz, 2H), 7.44 (s, 1H), 7.43 (dd, J = 8.4, 2.1 Hz, 2H), 7.39–7.35 
(m, 3H), 7.34–7.32 (m, 2H), 7.29–7.26 (m, 4H), 6.89 (d, J = 8.4 Hz, 2H), 6.88 (s, 1H), 6.60–
6.56 (m, 4H), 5.49 (s, 2H), 5.10 (dd, J = 10.8, 6.0 Hz, 1H), 3.92 (s, 6H), 3.91 (s, 6H), 3.66 
(dd, J = 13.9, 6.0 Hz, 1H), 3.59 (dd, J = 13.9, 10.8 Hz, 1H), 1.76 (s, 3H), 1.75 (s, 3H). 13C 
NMR (126 MHz, CDCl3): δ = 167.8 (Cq), 167.1 (Cq), 158.2 (Cq), 153.4 (Cq), 150.4 (Cq), 148.5 
(Cq), 142.0 (Cq), 139.2 (Cq), 136.2 (Cq), 134.7 (Cq), 134.4 (CH), 133.2 (Cq), 131.5 (Cq), 130.8 
(CH), 130.2 (CH), 129.2 (CH), 129.0 (CH), 128.8 (CH), 128.1 (CH), 125.4 (Cq), 123.6 (CH), 
122.9 (CH), 120.4 (CH), 120.4 (CH), 112.9 (CH), 110.8 (CH), 56.3 (CH), 56.1 (CH3), 56.1 
(CH3), 54.4 (CH2), 52.3(Cq), 35.0 (CH2), 28.2 (CH3), 28.1 (CH3). 19F NMR (376 MHz, CDCl3): 
δ = -132.46 (q, JB-F = 32.6 Hz). IR (ATR): ṽ = 2926, 1714, 1548, 1470, 1258, 1148, 1075, 721 
cm-1. MS (ESI) m/z (relative intensity): 978 (25) [M+Na]+, 956 (100) [M+H]+. HR-MS (ESI): 
m/z calcd for C54H49BF2N7O7 [M+H]+: 956.3758; found: 956.3745. UV-Vis λmax (1.0 mg/L in 








(1,3-dioxoiso indolin-2-yl)propanamide (110bf) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109i (72.7 mg, 0.12 mmol) and Cu(OAc)2 (36.3 mg, 0.20 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bf (79.0 mg, 89%) as a purple solid (M.p.: 152–
153 °C). 1H NMR (600 MHz, CDCl3): δ = 7.79 (dd, J = 5.5, 3.0 Hz, 2H), 7.72 (dd, J = 5.5, 3.0 
Hz, 2H), 7.50 (dd, J = 2.6, 1.7 Hz, 2H), 7.44 (s, 1H), 7.41–7.33 (m, 7H), 7.32–7.27 (m, 6H), 
6.94 (ddd, J = 8.3, 2.6, 0.8 Hz, 2H), 6.88 (s, 1H), 6.61 (d, J = 4.3 Hz, 2H), 6.57 (d, J = 4.3 Hz, 
2H), 5.49 (s, 2H), 5.10 (dd, J = 10.8, 6.0 Hz, 1H), 3.83 (s, 6H), 3.66 (dd, J = 13.9, 6.0 Hz, 1H), 
3.60 (dd, J = 13.9, 10.8 Hz, 1H), 1.76 (s, 3H), 1.75 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 
167.8 (Cq), 167.1 (Cq), 159.2 (Cq), 158.6 (Cq), 153.4 (Cq), 143.6 (Cq), 139.4 (Cq), 136.3 (Cq), 
134.7 (Cq), 134.5 (CH), 133.8 (Cq), 133.0 (Cq), 131.5 (Cq), 130.8 (CH), 130.7 (CH), 129.2 
(CH), 129.1 (CH), 128.8 (CH), 128.1 (CH), 127.6 (CH), 123.6 (CH), 122.0 (CH), 120.8 (CH), 
120.4 (CH), 115.9 (CH), 114.7 (CH), 56.3 (CH), 55.5 (CH3), 54.4 (CH2), 52.3 (Cq), 35.0 (CH2), 
28.2 (CH3), 28.1 (CH3). 19F NMR (282 MHz, CDCl3): δ = -132.31 (q, JB-F = 32.0 Hz). IR (ATR): 
ṽ = 2925, 1713, 1570, 1546, 1468, 1241, 1138, 1069, 721 cm-1. MS (ESI) m/z (relative 
intensity): 1813 (10) [2M+Na]+, 918 (90) [M+Na]+, 896 (100) [M+H]+. HR-MS (ESI): m/z calcd 
for C52H45BF2N7O5 [M+H]+: 896.3546; found: 896.3547. UV-Vis λmax (1.0 mg/L in EtOAc) = 







(1,3-dioxoiso indolin-2-yl)propanamide (110bg) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109j (72.7 mg, 0.12 mmol) and AgOAc (20 mg, 0.12 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bg (86.1 mg, 96%) as a purple solid (M.p.: 
150–151 °C). 1H NMR (300 MHz, CDCl3): δ = 7.85 (d, J = 8.9 Hz, 4H), 7.79 (dd, J = 5.4, 3.3 
Hz, 2H), 7.71 (dd, J = 5.4, 3.3 Hz, 2H), 7.44 (s, 1H), 7.39–7.26 (m, 9H), 6.94 (d, J = 8.9 Hz, 
4H), 6.87 (s, 1H), 6.55 (dd, J = 9.6, 4.5 Hz, 4H), 5.49 (s, 2H), 5.10 (dd, J = 10.2, 6.4 Hz, 1H), 
3.84 (s, 6H), 3.68–3.58 (m, 2H), 1.77 (s, 3H), 1.75 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 
167.8 (Cq), 167.1 (Cq), 160.7 (Cq), 158.3 (Cq), 153.4 (Cq), 142.0 (Cq), 139.1 (Cq), 136.2 (Cq), 
134.7 (Cq), 134.4 (CH), 133.3 (Cq), 131.5 (Cq), 131.1 (CH), 130.8 (CH), 130.2 (CH), 129.2 
(CH), 129.0 (CH), 128.8 (CH), 128.1 (CH), 125.2 (Cq), 123.6 (CH), 120.5 (CH), 120.4 (CH), 
113.9 (CH), 56.3 (CH), 55.5 (CH3), 54.4 (CH2), 52.3 (Cq), 35.0 (CH2), 28.2 (CH3), 28.1 (CH3). 
19F NMR (282 MHz, CDCl3): δ = -133.07 (q, JB-F = 32.4 Hz). IR (ATR): ṽ = 1713, 1544, 1465, 
1432, 1255, 1139, 1071, 1057, 793, 718, 386 cm-1. MS (ESI) m/z (relative intensity): 1813 (5) 
[2M+Na]+, 918 (100) [M+Na]+, 896 (95) [M+H]+. HR-MS (ESI): m/z calcd for C52H45BF2N7O5 
[M+H]+: 896.3546; found: 896.3550. UV-Vis λmax (1.0 mg/L in EtOAc) = 576 nm. Em λmax (1.0 








(1,3-dioxoiso indolin-2-yl)propanamide (110bh) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109k (79.0 mg, 0.12 mmol) and Cu(OAc)2 (36.3 mg, 0.20 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bh (63.5 mg, 67%) as a purple solid (M.p.: 
155–156 °C). 1H NMR (600 MHz, CDCl3): δ = 7.80–7.78 (m, 6H), 7.72 (dd, J = 5.4, 3.1 Hz, 
2H), 7.44 (s, 1H), 7.39–7.33 (m, 5H), 7.29–7.26 (m, 4H), 7.19 (d, J = 8.3 Hz, 4H), 6.87 (s, 
1H), 6.58 (d, J = 4.3 Hz, 2H), 6.56 (d, J = 4.3 Hz, 2H), 5.49 (s, 2H), 5.10 (dd, J = 10.8, 6.1 
Hz, 1H), 3.65 (dd, J = 13.9, 6.1 Hz, 1H), 3.59 (dd, J = 13.9, 10.8 Hz, 1H), 2.51–2.49 (m, 4H), 
1.94–1.86 (m, 2H), 1.77 (s, 3H), 1.75 (s, 3H), 0.93 (s, 6H), 0.92 (s, 6H). 13C NMR (126 MHz, 
CDCl3): δ = 167.9 (Cq), 167.1 (Cq), 158.9 (Cq), 153.4 (Cq), 143.5 (Cq), 142.7 (Cq), 139.2 (Cq), 
136.3 (Cq), 134.7 (Cq), 134.4 (CH), 133.2 (Cq), 131.5 (Cq), 130.8 (CH), 130.3 (CH), 130.1 (Cq), 
129.3 (CH), 129.2 (CH), 129.1 (CH), 129.0 (CH), 128.8 (CH), 128.1 (CH), 123.6 (CH), 120.8 
(CH), 120.4 (CH), 56.3 (CH), 54.4 (Cq), 52.3 (CH2), 45.6 (CH2), 30.3 (CH), 29.9 (CH2), 28.2 
(CH3), 28.1 (CH3), 22.7 (CH3). 19F NMR (282 MHz, CDCl3): δ = -132.99 (q, JB-F = 32.1 Hz). IR 
(ATR): ṽ = 2921, 1714, 1571, 1546, 1467, 1140, 1070, 720 cm-1. MS (ESI) m/z (relative 
intensity): 970 (60) [M+Na]+, 948 (100) [M+H]+. HR-MS (ESI): m/z calcd for C58H57BF2N7O3, 
[M+H]+: 948.4588; found: 948.4589. UV-Vis λmax (1.0 mg/L in EtOAc) = 562 nm. Em λmax (1.0 








dioxoiso indolin-2-yl)propanamide (110bi) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109l (85.2 mg, 0.12 mmol) and Cu(OAc)2 (36.3 mg, 0.20 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bi (68.0 mg, 68%) as a purple solid (M.p.: 159–
160 °C). 1H NMR (600 MHz, CDCl3): δ = 7.81–7.78 (m, 6H), 7.71 (dd, J = 5.4, 3.1 Hz, 2H), 
7.44 (s, 1H), 7.39–7.35 (m, 3H), 7.35–7.33 (m, 2H), 7.29–7.26 (m, 4H), 7.26–7.24 (m, 4H), 
6.87 (s, 1H), 6.58 (d, J = 4.3 Hz, 2H), 6.55 (d, J = 4.3 Hz, 2H), 5.49 (s, 2H), 5.10 (dd, J = 10.7, 
6.1 Hz, 1H), 3.65 (dd, J = 13.8, 6.1 Hz, 1H), 3.59 (dd, J = 13.8, 10.7 Hz, 1H), 2.56–2.50 (m, 
2H), 1.93–1.89 (m, 4H), 1.87–1.82 (m, 4H), 1.77–1.73 (m, 8H), 1.45–1.35 (m, 8H), 1.29–1.24 
(m, 2H). 13C NMR (126 MHz, CDCl3): δ = 167.8 (Cq), 167.1 (Cq), 158.9 (Cq), 153.4 (Cq), 149.6 
(Cq), 142.7 (Cq), 139.2 (Cq), 136.3 (Cq), 134.7 (Cq), 134.4 (CH), 133.2 (Cq), 131.5 (Cq), 130.8 
(CH), 130.3 (CH), 130.2 (Cq), 129.5 (CH), 129.2 (CH), 129.0 (CH), 128.8 (CH), 128.1 (CH), 
126.9 (CH), 123.6 (CH), 120.8 (CH), 120.4 (CH), 56.3 (CH), 54.4 (CH2), 52.3 (Cq), 44.7 (CH), 
35.0 (CH2), 34.4 (CH2), 28.2 (CH3), 28.1 (CH3), 27.1 (CH2), 26.4 (CH2). 19F NMR (376 MHz, 
CDCl3): δ = -132.85 (q, JB-F = 32.0 Hz). IR (ATR): ṽ = 2924, 1714, 1570, 1545, 1468, 1276, 
1141, 1072, 720 cm-1. MS (ESI) m/z (relative intensity): 1022 (40) [M+Na]+, 1000 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C62H61BF2N7O3, [M+H]+: 1000.4902; found: 1000.4904. UV-Vis 







dioxoisoindolin-2-yl) propanamide (110bj) 
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109m (69.0 mg, 0.12 mmol) and Cu(OAc)2 (36.3 mg, 0.20 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bj (57.0 mg, 66%) as a purple solid (M.p.: 147–
148 °C). 1H NMR (600 MHz, CDCl3): δ = 7.81–7.78 (m, 3H), 7.76 (d, J = 8.4 Hz, 4H), 7.71 
(dd, J = 5.5, 3.1 Hz, 2H), 7.45 (s, 1H), 7.39–7.35 (m, 3H), 7.34–7.33 (m, 2H), 7.29–7.27 (m, 
3H), 7.21 (d, J = 8.4 Hz, 4H), 6.88 (s, 1H), 6.59 (d, J = 4.2 Hz, 2H), 6.54 (d, J = 4.2 Hz, 2H), 
5.49 (s, 2H), 5.10 (dd, J = 10.8, 6.0 Hz, 1H), 3.66 (dd, J = 13.8, 6.0 Hz, 1H), 3.60 (dd, J = 
13.8, 10.8 Hz, 1H), 2.38 (s, 6H), 1.76 (s, 3H), 1.75 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 
167.8 (Cq), 167.1 (Cq), 158.9 (Cq), 153.4 (Cq), 142.9 (Cq), 139.7 (Cq), 139.2 (Cq), 136.2 (Cq), 
134.7 (Cq), 134.4 (CH), 133.2 (Cq), 131.5 (Cq), 130.8 (CH), 130.4 (CH), 129.9 (Cq), 129.4 
(CH), 129.2 (CH), 129.1 (CH), 129.0 (CH), 128.8 (CH), 128.1 (CH), 123.6 (CH), 120.7 (CH), 
120.4 (CH), 56.3 (CH), 54.4 (CH2), 52.3 (Cq), 35.0 (CH2), 28.2 (CH3), 28.1 (CH3), 21.7 (CH3). 
19F NMR (376 MHz, CDCl3): δ = -132.76 (q, JB-F = 32.0 Hz). IR (ATR): ṽ = 1715, 1571, 1546, 
1468, 1141, 1072, 447, 428, 410, 379 cm-1. MS (ESI) m/z (relative intensity): 1749 (10) 
[2M+Na]+, 886 (100) [M+Na]+, 864 (50) [M+H]+. HR-MS (ESI): m/z calcd for C52H45BF2N7O3 
[M+H]+: 864.3648; found: 864.3630. UV-Vis λmax (1.0 mg/L in EtOAc) = 560 nm. Em λmax (1.0 








The general procedure B was followed using PhthN-Phe-TAM (105c) (49.4 mg, 0.1 mmol), 
iodo-BODIPY 109j (72.7 mg, 0.12 mmol) and AgOAc (33.3 mg, 0.20 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bk (92.0 mg, 95%, d:r > 20:1) as a purple solid 
(M.p.: 162–163 °C). 1H NMR (500 MHz, CDCl3): δ = 7.87 (d, J = 8.39 Hz, 4H), 7.75 (dd, J = 
5.5, 3.0 Hz, 2H), 7.66 (dd, J = 5.5, 3.0 Hz, 2H), 7.63 (d, J = 8.2 Hz, 2H), 7.42 (d, J = 8.2 Hz, 
2H), 7.36–7.33 (m, 2H), 7.31–7.27 (m, 3H), 7.23 (s, 1H), 7.21–7.14 (m, 4H), 7.11–7.07 (m, 
1H), 6.98–6.94 (m, 5H), 6.80 (d, J = 4.3 Hz, 2H), 6.57 (d, J = 4.3 Hz, 2H), 5.58 (d, J = 12.6 
Hz, 1H), 5.46 (d, J = 12.6 Hz, 1H), 5.37 (d, J = 2.6 Hz, 2H), 3.85 (s, 6H), 1.59 (s, 3H), 1.53 
(s, 3H). 13C NMR (126 MHz, CDCl3): δ = 168.1 (Cq), 166.4 (Cq), 163.3 (Cq), 160.8 (Cq), 158.4 
(Cq), 153.0 (Cq), 142.7 (Cq), 141.9 (Cq), 139.9 (Cq), 136.2 (Cq), 134.8 (Cq), 134.3 (CH), 133.7 
(Cq), 131.4 (CH), 131.3 (CH), 130.6 (CH), 129.1 (CH), 129.0 (CH), 128.7 (CH), 128.3 (CH), 
128.0 (CH), 127.9 (CH), 127.5 (CH), 125.3 (Cq), 123.7 (CH), 120.6 (CH), 120.5 (CH), 113.9 
(CH), 59.4 (CH), 55.4 (CH), 54.1 (CH2), 52.0 (Cq), 50.6 (CH3), 27.8 (CH3), 27.6 (CH3). 
19F NMR (471 MHz, CDCl3): δ = -132.94 (q, JB-F = 32.3 Hz). IR (ATR): ṽ = 2051, 2033, 1992, 
1715, 499, 401, 394, 380 cm-1. MS (ESI) m/z (relative intensity): 994 (100) [M+Na]+, 971 (90) 
[M+H]+. HR-MS (ESI): m/z calcd for C58H49BF2N7O5 [M+H]+: 972.3860; found: 972.3866.  









The general procedure B was followed using PhthN-Ala-NHTAM (105a) (83.4 mg, 0.2 mmol), 
diiodo-BODIPY 109n (128.4 mg, 0.24 mmol) and Cu(OAc)2 (72.6 mg, 0.40 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bl (100.5 mg, 61%) as a red solid (M.p.: 139–
142 °C). 1H NMR (600 MHz, CDCl3): δ = 7.81 (dd, J = 5.5, 3.0 Hz, 2H), 7.75 (s, 1H), 7.73 (dd, 
J = 5.5, 3.0 Hz, 2H), 7.72 (s, 1H), 7.39 (s, 1H), 7.35–7.33 (m, 3H), 7.26–7.23 (m, 6H), 6.96 
(s, 1H), 6.80 (s, 1H), 6.76 (s, 1H), 5.44 (s, 2H), 4.91 (dd, J = 10.1, 6.3 Hz, 1H), 3.43 (dd, J = 
15.0, 10.1 Hz, 1H), 3.37 (dd, J = 15.0, 6.3 Hz, 1H), 2.46 (s, 3H), 1.70 (s, 3H), 1.69 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 167.8 (Cq), 166.7 (Cq), 152.3 (Cq), 146.4 (Cq), 146.3 (Cq), 
145.5 (CH), 141.9 (Cq), 135.9 (CH), 135.7 (Cq), 135.1 (Cq), 134.6 (Cq), 134.4 (CH), 131.5 (Cq), 
130.7 (CH), 130.5 (CH), 130.4 (Cq), 130.3 (Cq), 129.3 (CH), 129.1 (CH), 128.7 (CH), 128.1 
(CH), 123.7 (CH), 120.3 (CH), 120.2 (CH), 55.4 (CH), 54.2 (CH2), 52.2 (Cq), 28.0 (CH3), 27.9 
(CH3), 26.4 (CH2), 21.7 (CH3). 19F NMR (282 MHz, CDCl3): δ = -144.9 – -145.2 (m). IR (ATR): 
ṽ = 1736, 1447, 1372, 1233, 1098, 1043, 938, 786, 634, 608 cm-1. MS (ESI) m/z (relative 
intensity): 846 (100) [M+Na]+, 824 (14) [M+H]+. HR-MS (ESI): m/z calcd for C39H34BF2IN7O3 
[M+H]+: 824.1830; found: 824.1816. UV-Vis λmax (1.0 mg/L in EtOAc) = 530 nm. Em λmax (1.0 








dioxoisoindolin-2-yl) propanamide (110bm)  
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (83.4 mg, 0.2 mmol 
diiodo-BODIPY 109o (132.0 mg, 0.24 mmol) and Cu(OAc)2 (72.6 mg, 0.40 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bm (125.9 mg, 75%) as a red solid (M.p.: 140–
143 °C). 1H NMR (600 MHz, CDCl3): δ = 7.81 (dd, J = 5.4, 3.0 Hz, 2H), 7.74–7.72 (m, 4H), 
7.36 (s, 1H), 7.36–7.34 (m, 5H), 7.25–7.23 (m, 2H), 6.98–6.96 (m, 2H), 6.97 (s, 1H), 6.80 (s, 
1H), 6.78 (s, 1H), 5.45 (s, 2H), 4.92 (dd, J = 10.0, 6.4 Hz, 1H), 3.91 (s, 3H), 3.43 (dd, J = 
15.0, 10.0 Hz, 1H), 3.39 (dd, J = 15.0, 6.4 Hz, 1H), 1.70 (s, 3H), 1.69 (s, 3H). 13C NMR (126 
MHz, CDCl3): δ = 167.8 (Cq), 166.8 (Cq), 162.4 (Cq), 153.3 (Cq), 146.1 (Cq), 145.9 (CH), 145.0 
(CH), 135.8 (CH), 135.7 (Cq), 135.0 (Cq), 134.6 (Cq), 134.4 (CH), 132.5 (CH), 131.5 (Cq), 
131.3 (CH), 130.3 (Cq), 130.2 (Cq), 129.1 (CH), 128.7 (CH), 128.1 (CH), 125.8 (Cq), 123.8 
(CH), 120.4 (CH), 114.4 (CH), 55.8 (CH), 55.4 (CH3), 52.3 (Cq), 52.3 (CH2), 28.1 (CH3), 28.0 
(CH3), 26.4 (CH2). 19F NMR (282 MHz, CDCl3): δ = -144.9 – -145.3 (m). IR (ATR): ṽ = 1733, 
1446, 1373, 1238, 1044, 939, 734, 634, 608, 438 cm-1. MS (ESI) m/z (relative intensity): 840 
(35) [M+H]+, 862 (100) [M+Na]+. HR-MS (ESI): m/z calcd for C39H34BF2IN7O4 [M+H]+: 
840.1779; found: 840.1763. UV-Vis λmax (1.0 mg/L in EtOAc) = 528 nm. Em λmax (1.0 mg/L 







yl)propanamide (110bn)  
The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109p (52.3 mg, 0.12 mmol) and Cu(OAc)2 (36.3 mg, 0.20 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bn (45.7 mg, 63%) as a red solid (M.p.: 136–
137 °C). 1H NMR (600 MHz, CDCl3): δ = 7.82 (s, 1H), 7.78 (dd, J = 5.4, 3.1 Hz, 2H), 7.71 (dd, 
J = 5.4, 3.1 Hz, 2H), 7.66 (s, 1H), 7.39 (s, 1H), 7.36–7.34 (m, 2H), 7.26–7.23 (m, 2H), 6.91 
(s, 1H), 6.82 (s, 1H), 6.69 (s, 1H), 6.60 (d, J = 4.1 Hz, 1H), 6.41 (dd, J = 4.1, 1.7 Hz, 1H), 
6.38 (s, 1H), 5.46 (s, 2H), 4.85 (dd, J = 10.7, 5.9 Hz, 1H), 3.39 (dd, J = 15.0, 10.7 Hz, 1H), 
3.29 (dd, J = 15.0, 5.9 Hz, 1H), 2.34 (s, 3H), 1.98 (s, 3H), 1.84 (s, 3H), 1.69 (s, 3H), 1.68 (s, 
3H). 13C NMR (126 MHz, CDCl3): δ = 167.8 (Cq), 166.9 (Cq), 153.3 (Cq), 147.3 (Cq), 144.3 
(CH), 144.0 (CH), 138.8 (Cq), 136.3 (Cq), 136.1 (Cq), 135.4 (Cq), 134.7 (Cq), 134.4 (CH), 131.5 
(Cq), 130.2 (CH), 129.5 (Cq), 129.2 (Cq), 129.1 (CH), 128.7 (CH), 128.6 (CH), 128.3 (CH), 
128.14 (CH), 128.08 (CH), 123.7 (CH), 120.3 (CH), 118.5 (CH), 55.5 (CH), 54.3 (CH2), 52.3 
(Cq), 28.2 (CH3), 28.0 (CH3), 26.3 (CH2), 21.3 (CH3), 20.0 (CH3), 19.9 (CH3). 19F NMR (282 
MHz, CDCl3): δ = -145.35 – -146.48 (m). IR (ATR): ṽ = 2926, 1713, 1571, 1382, 1106, 1067, 
722, 436, 394 cm-1. MS (ESI) m/z (relative intensity): 1451 (10) [2M+H]+, 748 (50) [M+Na]+, 
726 (100) [M+H]+. HR-MS (ESI): m/z calcd for C41H39BF2N7O3 [M+H]+: 726.3177; found: 










The general procedure B was followed using PhthN-Ala-NHTAM (105a) (41.7 mg, 0.1 mmol), 
iodo-BODIPY 109q (48.9 mg, 0.12 mmol) and Cu(OAc)2 (36.3 mg, 0.20 mmol). After 20 h, 
purification by HPLC (tr: 42.0 min) yielded 110bo (51.6 mg, 74%) as a red solid (M.p.: 135–
136 °C). 1H NMR (500 MHz, CDCl3): δ = 7.84 (s, 1H), 7.82 (dd, J = 5.5, 3.0 Hz, 2H), 7.73 (dd, 
J = 5.5, 3.0 Hz, 2H), 7.69 (s, 1H), 7.39 (s, 1H), 7.37–7.31 (m, 3H), 7.29–7.23 (m, 6H), 6.89 
(d, J = 4.1 Hz, 1H), 6.73 (s, 1H), 6.69 (s, 1H), 6.49 (dd, J = 4.2, 1.9 Hz, 1H), 5.45 (s, 2H), 
4.91 (dd, J = 10.1, 6.3 Hz, 1H), 3.43 (dd, J = 14.9, 10.1 Hz, 1H), 3.37 (dd, J = 14.9, 6.3 Hz, 
1H), 2.46 (s, 3H), 1.70 (s, 3H), 1.69 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 168.0 (Cq), 
167.0 (Cq), 153.4 (Cq), 147.4 (Cq), 143.9 (CH), 143.6 (CH), 141.6 (Cq), 135.0 (Cq), 134.8 (Cq), 
134.5 (CH), 131.6 (CH), 131.9 (Cq), 131.6 (Cq), 130.9 (Cq), 130.7 (CH), 130.1 (CH), 129.3 
(CH), 129.2 (CH), 129.1 (Cq), 128.8 (CH), 128.2 (CH), 123.9 (CH), 120.4 (CH), 118.4 (CH), 
55.5 (CH), 54.2 (CH2), 52.2 (Cq), 28.0 (CH3), 27.9 (CH3), 26.4 (CH2), 21.6 (CH3). 19F NMR 
(471 MHz, CDCl3): δ = -144.8 – -145.6 (m). IR (ATR): ṽ = 1710, 1538, 1380, 1362, 1256, 
1106, 1073, 718, 429, 405 cm-1. MS (ESI) m/z (relative intensity): 720 (100) [M+Na]+, 698 (25) 
[M+H]+. HR-MS (ESI): m/z calcd for C39H35BF2N7O3 [M+H]+: 698.2864; found: 698.2859. UV-











yl)propanamido]methyl}-1H-1,2,3triazol-1-yl)acetyl]-L-leucinate (111a)  
The general procedure C was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) (48.4 
mg, 0.1 mmol), iodo-BODIPY 109j (72.7 mg, 0.12 mmol) and AgOAc (33.3 mg, 0.20 mmol). 
After 20 h, purification by HPLC (tr: 41.0 min) yielded 24 (71.3 mg, 74%) as a purple solid 
(M.p.: 158–159 °C). 1H NMR (500 MHz, CDCl3): δ = 7.83 (d, J = 8.9 Hz, 4H), 7.77–7.69 (m, 
5H), 7.31 (d, J = 8.3 Hz, 2H), 7.26–7.19 (m, 3H), 6.93 (d, J = 8.9 Hz, 4H), 6.80 (d, J = 8.2 Hz, 
1H), 6.55–6.52 (m, 4H), 5.17 (dd, J = 11.2, 5.5 Hz, 1H), 5.08 (d, J = 16.4 Hz, 1H), 5.04 (d, J 
= 16.4 Hz, 1H), 4.63–4.59 (m, 1H), 4.53 (d, J = 5.5 Hz, 2H), 3.83 (s, 6H), 3.71 (dd, J = 13.9, 
5.5 Hz, 1H), 3.69 (s, 3H), 3.56 (dd, J = 13.9, 11.2 Hz, 1H), 1.63–1.54 (m, 2H), 1.53–1.51 (m, 
1H), 0.91 (d, J = 2.5 Hz, 3H), 0.90 (d, J = 2.5 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 173.1 
(Cq), 168.5 (Cq), 167.9 (Cq), 165.1 (Cq), 160.8 (Cq), 158.4 (Cq), 145.0 (Cq), 142.0 (Cq), 139.1 
(Cq), 136.2 (Cq), 134.6 (CH), 133.3 (Cq), 131.4 (Cq), 131.2 (CH), 130.8 (CH), 130.2 (CH), 
129.0 (CH), 125.2 (Cq), 124.4 (CH), 123.7 (CH), 120.5 (CH), 113.9 (CH), 55.4 (CH), 55.3 
(CH3), 52.8 (CH2), 52.6 (CH), 51.2 (CH3), 41.2 (CH2), 35.3 (CH2), 34.7 (CH2), 25.0 (CH), 22.9 
(CH3), 22.0 (CH3). 19F NMR (471 MHz, CDCl3): δ = -132.98 (q, JB-F = 32.3 Hz). IR (ATR): ṽ = 
1713, 1541, 1463, 1431, 1253, 1136, 1054, 717, 526, 405 cm-1. MS (ESI) m/z (relative 




[M+H]+: 963.3816; found: 963.3781. UV-Vis λmax (1.0 mg/L in EtOAc) = 576 nm. Em λmax (1.0 





The general procedure C was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) (48.4 
mg, 0.1 mmol), iodo-BODIPY 109i (72.7 mg, 0.12 mmol) and AgOAc (33.3 mg, 0.20 mmol). 
After 20 h, purification by HPLC (tr: 41.0 min) yielded 25 (51 mg, 53%) as a purple solid (M.p.: 
158–159 °C). 1H NMR (600 MHz, CDCl3): δ = 7.78–7.76 (m, 1H), 7.75 (dd, J = 5.6, 2.9 Hz, 
2H), 7.68 (dd, J = 5.6, 2.9 Hz, 2H), 7.51–7.47 (m, 2H), 7.39 (d, J = 8.0 Hz, 2H), 7.34–7.26 
(m, 6H), 7.15 (dd, J = 5.6, 5.6 Hz, 1H), 6.94 (dd, J = 8.0, 2.6 Hz, 2H), 6.71 (d, J = 8.2 Hz, 1H), 
6.58 (d, J = 4.3 Hz, 2H), 6.56 (d, J = 4.3 Hz, 2H), 5.17 (dd, J = 11.3, 5.6 Hz, 1H), 5.08 (d, J = 
16.4 Hz, 1H), 5.04 (d, J = 16.4 Hz, 1H), 4.62 (ddd, J = 8.2, 8.2, 4.9 Hz, 1H), 4.54 (d, J = 5.6 
Hz, 2H), 3.83 (s, 6H), 3.73–3.67 (m, 1H), 3.70 (s, 3H), 3.57 (dd, J = 14.0, 11.3 Hz, 1H), 1.64–
1.60 (m, 2H), 1.54–1.50 (m, 1H), 0.91 (d, J = 2.8 Hz, 3H), 0.90 (d, J = 2.8 Hz, 3H). 13C NMR 
(126 MHz, CDCl3): δ = 172.8 (Cq), 168.3 (Cq), 167.7 (Cq), 164.8 (Cq), 159.2 (Cq), 158.6 (Cq), 
144.9 (Cq), 143.6 (Cq), 139.3 (Cq), 136.2 (Cq), 134.6 (CH), 133.8 (Cq), 133.0 (Cq), 131.4 (Cq), 
130.8 (CH), 130.6 (CH), 129.2 (CH), 129.0 (CH), 124.2 (CH), 123.7 (CH), 122.0 (CH), 120.8 
(CH), 115.9 (CH), 114.7 (CH), 55.5 (CH3), 52.9 (CH2), 52.7 (CH), 51.3 (CH3), 41.3 (CH2), 35.5 




δ = -132.30 (q, JB-F = 31.9 Hz). IR (ATR): ṽ = 2927, 2160, 2034, 1543, 446, 394 cm-1. MS 
(ESI) m/z (relative intensity): 985 (100) [M+Na]+, 963 (30) [M+H]+. HR-MS (ESI): m/z calcd 
for C52H50BF2N8O8 [M+H]+: 963.3816; found: 963.3822. UV-Vis λmax (1.0 mg/L in EtOAc) = 




1H-1,2,3-triazol-1-yl) acetyl]-L-leucinate (111c) 
The general procedure C was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) (48.4 
mg, 0.1 mmol), iodo-BODIPY 109m (69.0 mg, 0.12 mmol) and AgOAc (33.3 mg, 0.20 mmol). 
After 20 h, purification by HPLC (tr: 41.0 min) yielded 111c (42.0 mg, 45%) as a purple solid 
(M.p.: 151–152 °C). 1H NMR (600 MHz, CDCl3): δ = 7.77 (dd, J = 5.5, 3.0, 2H), 7.76 (d, J = 
8.1 Hz, 2H), 7.75 (d, J = 8.2 Hz, 4H), 7.71 (dd, J = 5.5, 3.0 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 
7.27–7.26 (m, 1H), 7.21 (d, J = 8.2Hz, 4H), 7.11 (dd, J = 5.7, 5.7 Hz, 1H), 6.66 (d, J = 8.2 Hz, 
1H), 6.57 (d, J = 4.2 Hz, 2H), 6.52 (d, J = 4.2 Hz, 2H), 5.17 (dd, J = 11.2, 5.6 Hz, 1H), 5.06 
(d, J = 16.4 Hz, 1H), 4.99 (d, J = 16.4 Hz, 1H), 4.65–4.59 (m, 1H), 4.55 (dd, J = 5.7, 5.7 Hz, 
2H), 3.72–3.68 (m, 1H), 3.71 (s, 3H), 3.57 (dd, J = 13.9, 11.2 Hz, 1H), 2.37 (s, 6H), 1.65–1.58 
(m, 2H), 1.57–1.53 (m, 1H), 0.91 (d, J = 3.4 Hz, 3H), 0.90 (d, J = 3.4 Hz, 3H). 13C NMR (126 
MHz, CDCl3): δ = 172.7 (Cq), 168.3 (Cq), 167.8 (Cq), 164.8 (Cq), 158.9 (Cq), 145.0 (Cq), 142.8 
(Cq), 139.8 (Cq), 139.1 (Cq), 136.2 (Cq), 134.6 (CH), 133.2 (Cq), 131.4 (Cq), 130.8 (CH), 130.4 




55.4 (CH), 52.9 (CH2), 52.7 (CH), 51.3 (CH3), 41.4 (CH2), 35.5 (CH2), 34.9 (CH2), 25.1 (CH), 
23.0 (CH3), 22.1 (CH3), 21.7 (CH3). 19F NMR (282 MHz, CDCl3): δ = -132.79 (q, JB-F = 31.9 
Hz). IR (ATR): ṽ = 2052, 1957, 1067, 560, 526, 431, 407, 391 cm-1. MS (ESI) m/z (relative 
intensity): 953 (100) [M+Na]+, 931 (10) [M+H]+. HR-MS (ESI): m/z calcd for C52H50BF2N8O6 
[M+H]+: 931.3918; found: 931.3929. UV-Vis λmax (1.0 mg/L in EtOAc) = 560 nm. Em λmax (1.0 




1H-1,2,3-triazol-1-yl) acetyl]-L-leucinate (111d) 
The general procedure C was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) (48.4 
mg, 0.1 mmol), iodo-BODIPY 109b (65.5 mg, 0.12 mmol) and Ag2CO3 (27.5 mg, 0.10 mmol). 
After 20 h, purification by HPLC (tr: 41.0 min) yielded 111d (45.0 mg, 50%) as a purple solid 
(M.p.: 144–145 °C). 1H NMR (600 MHz, CDCl3): δ = 7.82 (dd, J = 7.7, 1.9 Hz, 4H), 7.79 (s, 
1H), 7.74 (dd, J = 5.4, 3.0 Hz, 2H), 7.70 (dd, J = 5.4, 3.0 Hz, 2H), 7.42–7.37 (m, 6H), 7.31 (d, 
J = 8.1 Hz, 2H), 7.25 (d, J = 8.1 Hz, 2H), 7.24 (s, 1H), 6.84 (d, J = 8.4 Hz, 1H), 6.57 (d, J = 
4.3 Hz, 2H), 6.52 (d, J = 4.3 Hz, 2H), 5.18 (dd, J = 11.1, 5.3 Hz, 1H), 5.06 (d, J = 16.4 Hz, 
1H), 4.98 (d, J = 16.4 Hz, 1H), 4.61 (ddd, J = 8.4, 8.4, 4.9 Hz, 1H), 4.53–4.51 (m, 2H), 3.71 
(dd, J = 14.0, 5.3 Hz, 1H), 3.72 (s, 3H), 3.58 (dd, J = 14.0, 11.1 Hz, 1H), 1.63–1.56 (m, 2H), 
1.54–1.51 (m, 1H), 0.91 (d, J = 3.2 Hz, 3H), 0.90 (d, J = 3.2 Hz, 3H). 13C NMR (126 MHz, 
CDCl3): δ = 172.9 (Cq), 168.3 (Cq), 167.7 (Cq), 164.9 (Cq), 158.9 (Cq), 144.9 (Cq), 143.6 (Cq), 




129.6 (CH), 129.5 (CH), 129.0 (CH), 128.3 (CH), 124.3 (CH), 123.6 (CH), 120.9 (CH), 55.2 
(CH), 52.7 (CH2), 52.5 (CH), 51.1 (CH3), 41.1 (CH2), 35.2 (CH2), 34.7 (CH2), 24.9 (CH), 22.8 
(CH3), 21.9 (CH3). 19F NMR (282 MHz, CDCl3): δ = -132.57 (q, JB-F = 31.7 Hz).  IR (ATR): ṽ 
= 1713, 1538, 1467, 1449, 1269, 1135, 1067, 718, 693, 404 cm-1. MS (ESI) m/z (relative 
intensity): 925 (100) [M+Na]+, 903 (20) [M+H]+. HR-MS (ESI): m/z calcd for C50H46BF2N8O6 
[M+H]+: 903.3604; found: 903.3610. UV-Vis λmax (1.0 mg/L in EtOAc) = 550 nm. Em λmax (1.0 




1H-1,2,3-triazol-1-yl) acetyl]-L-leucinate (111e) 
The general procedure C was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) (48.4 
mg, 0.1 mmol), iodo-BODIPY 109c (51.0 mg, 0.12 mmol) and AgOAc (33.3 mg, 0.20 mmol). 
After 20 h, purification by HPLC (tr: 41.0 min) yielded 111e (31.2 mg, 40%) as an orange solid 
(M.p.: 154–155 °C). 1H NMR (500 MHz, CDCl3): δ = 7.77 (s, 1H), 7.72 (dd, J = 5.5, 3.0 Hz, 
2H), 7.67 (dd, J = 5.5, 3.0 Hz, 2H), 7.30 (brs, 1H), 7.22 (d, J = 8.5 Hz, 2H), 7.19 (d, J = 8.5 
Hz, 2H), 6.87 (d, J = 7.9 Hz, 1H), 6.40 (d, J = 4.1 Hz, 2H), 6.18 (d, J = 4.1 Hz, 2H), 5.14 (dd, 
J = 11.2, 5.5 Hz, 1H), 5.07 (d, J = 16.4 Hz, 1H), 5.00 (d, J = 16.4 Hz, 1H), 4.59–4.54 (m, 1H), 
4.52–4.49 (m, 2H), 3.66 (s, 3H), 3.69–3.63 (m, 1H), 3.53 (dd, J = 13.9, 11.3 Hz, 1H), 2.60 (s, 
6H), 1.63–1.60 (m, 2H), 1.59–1.53 (m, 1H), 0.90 (d, J = 2.6 Hz, 3H), 0.89 (d, J = 2.6 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 173.1 (Cq), 168.5 (Cq), 167.9 (Cq), 165.1 (Cq), 157.6 (Cq), 
142.1 (Cq), 139.1 (Cq), 134.5 (CH), 134.4 (Cq), 134.0 (Cq), 132.8 (Cq), 131.4 (Cq), 130.6 (CH), 




(CH3), 51.2 (CH), 41.2 (CH2), 35.2 (CH2), 34.6 (CH2), 25.0 (CH3), 22.9 (CH), 21.9 (CH3), 15.0 
(CH3). 19F NMR (471 MHz, CDCl3): δ = -147.62 (q, JB-F = 32.1 Hz). IR (ATR): ṽ = 1979, 1971, 
1715, 1676, 1541, 1271, 1148, 402, 392 cm-1. MS (ESI) m/z (relative intensity): 801 (100) 
[M+Na]+, 779 (20) [M+H]+. HR-MS (ESI): m/z calcd for C40H42BF2N8O6 [M+H]+: 779.3290; 






The general procedure C was followed using PhthN-Ala-Gly-Tzl-Gly-Leu-OMe (107c) (48.4 
mg, 0.1 mmol), iodo-BODIPY 109a (54.0 mg, 0.12 mmol) and AgOAc (33.3 mg, 0.20 mmol). 
After 20 h, purification by HPLC (tr: 41.0 min) yielded 111f (38.0 mg, 47%) as an orange solid 
(M.p.: 143–144 °C). 1H NMR (600 MHz, CDCl3): δ = 7.76 (s, 1H), 7.73 (dd, J = 5.5, 3.3 Hz, 
2H), 7.69 (dd, J = 5.5, 3.3 Hz, 2H), 7.24 (d, J = 8.1 Hz, 2H), 7.13 (dd, J = 5.9, 5.6 Hz, 1H), 
7.05 (d, J = 8.1 Hz, 2H), 6.72 (d, J = 8.3 Hz, 1H), 5.88 (s, 2H), 5.21–5.17 (m, 1H), 5.08 (d, J 
= 16.4 Hz, 1H), 5.02 (d, J = 16.4 Hz, 1H), 4.63–4.57 (m, 1H), 4.54 (dd, J = 12.2, 5.6 Hz, 1H), 
4.52 (dd, J = 12.2, 5.9 Hz, 1H), 3.69 (s, 3H), 3.64–3.61 (m, 2H), 2.50 (s, 6H), 1.67–1.55 (m, 
2H), 1.54–1.50 (m, 1H), 1.05 (s, 6H), 0.90 (d, J = 2.5 Hz, 3H), 0.89 (d, J = 2.5 Hz, 3H). 13C 
NMR (126 MHz, CDCl3): δ = 172.8 (Cq), 168.23 (Cq), 167.6 (Cq), 164.8 (Cq), 155.5 (Cq), 144.9 
(Cq), 142.9 (Cq), 141.2 (Cq), 137.8 (Cq), 134.5 (CH), 133.7 (Cq), 131.3 (Cq), 131.3 (Cq), 129.8 
(CH), 128.3 (CH), 124.2 (CH), 123.6 (CH), 121.2 (CH), 55.4 (CH), 52.9 (CH2), 52.7 (CH3), 




14.4 (CH3). 19F NMR (282 MHz, CDCl3): δ = -146.40 (q, JB-F = 30.6 Hz). IR (ATR): ṽ = 1714, 
1541, 1509, 1382, 1188, 1155, 1085, 977, 717, 476 cm-1. MS (ESI) m/z (relative intensity): 
829 (100) [M+Na]+, 807 (80) [M+H]+. HR-MS (ESI): m/z calcd for C42H46BF2N8O6 [M+H]+: 
807.3603; found: 807.3600. UV-Vis λmax (1.0 mg/L in EtOAc) = 498 nm. Em λmax (1.0 mg/L 




yl)propanamido]methyl}-1H-1,2,3triazol-1-yl)acetyl]-L-alaninate (111g)  
The general procedure C was followed using PhthN-Ala-Gly-Tzl-Gly-Ala-OMe (107b) (44.2 
mg, 0.1 mmol), iodo-BODIPY 109j (72.7 mg, 0.12 mmol), Pd(OAc)2 (20 mol %) in DCE (0.5 
mL). After 20 h, purification by HPLC (tr: 41.0 min) yielded 111g (82.8 mg, 90%) as a purple 
solid (M.p.: 150–151 °C). 1H NMR (600 MHz, CDCl3): δ = 7.84 (d, J = 9.8 Hz, 4H), 7.77–7.69 
(m, 5H), 7.31(d, J = 8.1 Hz, 2H), 7.25(d, J = 8.1 Hz, 2H), 7.19 (dd, J = 5.7, 5.7 Hz, 1H), 6.93(d, 
J = 9.8 Hz, 4H), 6.80 (d, J = 7.2 Hz, 1H), 6.53 (s, 4H), 5.17 (dd, J = 11.2, 5.5 Hz, 1H), 5.05 
(d, J = 16.5 Hz, 1H), 5.01 (d, J = 16.5 Hz, 1H), 4.57 (dddd, J = 7.2, 7.2, 7.2, 7.2 Hz, 1H), 
4.54–4.52 (m, 2H), 3.84 (s, 6H), 3.73 (s, 3H), 3.72–3.68 (m, 1H), 3.56 (dd, J = 14.0, 11.2 Hz, 
1H), 1.39 (d, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 172.7 (Cq), 168.4 (Cq), 167.8 
(Cq), 164.6 (Cq), 160.8 (Cq), 158.3 (Cq), 141.9 (Cq), 139.0 (Cq), 136.2 (Cq), 134.5 (CH), 133.3 
(Cq), 131.4 (Cq), 131.1 (CH), 130.8 (CH), 130.1 (CH), 129.0 (CH), 125.2 (Cq), 124.3 (Cq), 




48.6 (CH3), 35.5 (CH2), 34.9 (CH2), 18.2 (CH3). 19F NMR (282 MHz, CDCl3): δ = -133.03 (q, 
JB-F = 32.5 Hz). IR (ATR): ṽ = 2033, 1993, 1716, 1547, 1467, 1258, 1141, 1071, 795, 490, 394 
cm-1. MS (ESI) m/z (relative intensity): 943 (100) [M+Na]+, 921 (20) [M+H]+. HR-MS (ESI): 
m/z calcd for C49H44BF2N8O8 [M+H]+: 921.3346; found: 921.3352. UV-Vis λmax (1.0 mg/L in 




1H-1,2,3triazol-1-yl)acetyl]-L-alaninate (111h)  
The general procedure C was followed using PhthN-Ala-Gly-Tzl-Gly-Ala-OMe (107b) (44.2 
mg, 0.1 mmol), iodo-BODIPY 109a (54.0 mg, 0.12 mmol), AgOAc (33.3 mg, 0.20 mmol) and 
Pd(OAc)2 (20 mol %) in DCE (0.5 mL) as solvent. After 20 h, purification by HPLC (tr: 41.0 
min) yielded 111h (42.0 mg, 55%) as an orange solid (M.p.: 151–152 °C). 1H NMR (600 MHz, 
CDCl3): δ = 7.76 (s, 1H), 7.72 (dd, J = 5.5, 3.0 Hz, 2H), 7.69 (dd, J = 5.5, 3.0 Hz, 2H), 7.26 
(s, 1H), 7.24 (d, J = 8.1 Hz, 2H), 7.04 (d, J = 8.1 Hz, 2H), 6.90 (d, J = 7.3 Hz, 1H), 5.88 (s, 
2H), 5.18 (dd, J = 10.9, 6.3 Hz, 1H), 5.06 (d, J = 16.4 Hz, 1H), 5.00 (d, J = 16.4 Hz, 1H), 4.55 
(dddd, J = 7.3, 7.3, 7.3, 7.3 Hz, 1H), 4.51–4.49 (m, 2H), 3.70 (s, 3H), 3.66–3.58 (m, 2H), 2.49 
(s, 6H), 1.39 (d, J = 7.3 Hz, 3H), 1.04 (s, 6H). 13C NMR (126 MHz, CDCl3): δ = 172.8 (Cq), 
168.4 (Cq), 167.6 (Cq), 164.6 (Cq), 155.5 (Cq), 144.9 (Cq), 142.9 (Cq), 141.3 (Cq), 137.9 (Cq), 
134.5 (CH), 133.7 (Cq), 131.3 (Cq), 129.8 (CH), 128.3 (CH), 124.3 (CH), 123.6 (CH), 121.2 
(CH), 121.0 (Cq), 55.3 (CH), 52.9 (CH2), 52.8 (CH), 48.6 (CH3), 35.4 (CH2), 34.6 (CH2), 18.2 
(CH3), 14.8 (CH3), 14.4 (CH3). 19F NMR (282 MHz, CDCl3): δ = -146.38 (q, JB-F = 31.5 Hz). IR 




787 (100) [M+Na]+, 765 (10) [M+H]+. HR-MS (ESI): m/z calcd for C39H40BF2N8O6 [M+H]+: 
765.3133; found: 765.3126. UV-Vis λmax (1.0 mg/L in EtOAc) = 498 nm. Em λmax (1.0 mg/L 
in EtOAc) = 510 nm. 





10-yl}phenyl) propanamido]methyl}-1H-1,2,3-triazol-1-yl)acetyl]-L-leucinate (111i)  
The compound 111a (192 mg, 0.2 mmol) was dissolved in EtOH/CH2Cl2 (0.4 mL/ 0.4 mL). 
Ethylenediamine (0.1 mL) was then added dropwise. The mixture was sealed and heated at 
40 °C for 4h. Then, the mixture was cooled to ambient temperature. H2O (2.0 mL) was added, 
and the solution was extracted with CH2Cl2 (3 × 5.0 mL). The organic phase was concentrated 
in vacuo. The crude amine was then dissolved in DMF (5.0 mL). At 0 °C, Boc-Ala-OH (0.2 
mmol) was added, followed by DIPEA (2.5 equiv.), HOBt (1.1 equiv.) and EDCꞏHCl (1.1 
equiv.). The mixture was stirred for 16 h at 25 °C. Purification by column chromatography on 
silica gel delivered hexapeptide 111i as a purple solid (80 mg, 40% yields for two steps) (M.p.: 
165–166 °C). 1H NMR (500 MHz, CDCl3): δ = 7.86 (d, J = 8.9 Hz, 4H), 7.85 (brs, 1H), 7.70 
(s, 1H), 7.46 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 7.31(brs, 1H), 6.97 (s, 1H), 6.95 (s, 
1H), 6.94 (d, J = 8.9 Hz, 4H), 6.78 (d, J = 4.3 Hz, 2H), 6.59 (d, J = 4.3 Hz, 2H), 5.07 (d, J = 




Hz, 2H), 4.16–4.09 (m, 1H), 3.84 (s, 6H), 3.69 (s, 3H), 3.30 (dd, J = 13.9, 6.3 Hz, 1H), 3.15 
(dd, J = 13.9, 7.5 Hz, 1H), 1.40 (s, 9H), 1.28 (d, J = 7.1 Hz, 3H), 1.25–1.21 (m, 2H), 0.89 (d, 
J = 2.8 Hz, 3H), 0.88 (d, J = 2.8 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 173.0 (Cq), 172.9 
(Cq), 170.8 (Cq), 165.1 (Cq), 160.9 (Cq), 158.4 (Cq), 156.0 (Cq), 145.0 (Cq), 142.1 (Cq), 139.1 
(Cq), 136.2 (Cq), 133.3 (Cq), 131.3 (CH), 131.0 (CH), 130.5 (CH), 129.3 (CH), 125.2 (Cq), 
124.2 (CH), 120.7 (CH), 113.9 (CH), 55.6 (CH3), 55.4 (CH3), 54.1 (CH), 52.61 (CH), 52.59 
(Cq), 51.3 (CH), 41.2 (CH2), 37.9 (CH2), 36.4 (CH2), 35.3 (CH2), 28.4 (CH3), 27.9 (CH), 25.0 
(CH3), 22.8 (CH3), 22.0 (CH3). 19F NMR (471 MHz, CDCl3): δ = -132.86 (q, JB-F = 32.0 Hz). IR 
(ATR): ṽ = 1640, 1541, 1463, 1432, 1253, 1137, 1070, 1054, 790, 714 cm-1. MS (ESI) m/z 
(relative intensity): 1026 (100) [M+Na]+, 1004 (80) [M+H]+. HR-MS (ESI): m/z calcd for 
C52H61BF2N9O9 [M+H]+: 1004.4657; found: 1004.4639. UV-Vis λmax (1.0 mg/L in EtOAc) = 






The compound 111a (192 mg, 0.2 mmol) was dissolved in EtOH/CH2Cl2 (0.4 mL/ 0.4 mL). 
Ethylenediamine (0.1 mL) was added dropwise. The mixture was sealed and heated at 40 °C 




(2.0 mL) was added, and the solution was extracted with CH2Cl2 (3 × 5.0 mL). The organic 
phase was concentrated in vacuo. The crude amine was then dissolved in DMF (5.0 mL). At 
0 °C, Boc-Val-Trp-OH (0.2 mmol) was added, followed by DIPEA (2.5 equiv.), HOBt (1.1 
equiv.) and EDCꞏHCl (1.1 equiv.). The mixture was stirred for 16 h at 25 °C. Purification by 
column chromatography on silica gel delivered heptapeptide 111j as a purple solid (97 mg, 
41% yields over two steps) (M.p.: 163–164 °C). 1H NMR (600 MHz, CDCl3): δ = 7.86 (brs, 
1H), 7.84 (d, J = 8.4 Hz, 4H), 7.69 (s, 1H), 7.63 (s, 1H), 7.43–7.41 (m, 2H), 7.30 (s, 1H), 7.24–
7.20 (m, 2H), 7.16–7.14 (m, 2H), 7.10–7.00 (m, 3H), 6.94 (s, 1H), 6.93 (d, J = 8.4 Hz, 4H), 
6.88 (s, 1H), 6.78 (s, 2H), 6.55 (s, 2H), 5.11–4.90 (m, 2H), 4.82–4.71 (m, 1H), 4.58–3.91 (m, 
2H), 3.84 (s, 6H), 3.68 (s, 3H), 3.31–3.22 (m, 1H), 3.26–3.10 (m, 2H), 3.00–2.90 (m, 1H), 
2.11–1.98 (m, 1H), 1.66–1.59 (m, 2H), 1.56–1.52 (m, 1H), 1.52–1.50 (m, 1H), 1.46–1.44 (m, 
1H), 1.43–1.39 (m, 2H), 1.36 (s, 9H), 0.99–0.81 (m, 12H). 13C NMR (126 MHz, CDCl3): δ = 
172.9 (Cq), 172.1 (Cq), 171.6 (Cq), 170.6 (Cq), 165.3 (Cq), 160.9 (CH), 160.7 (Cq), 158.3 (Cq), 
156.4 (Cq), 145.1 (Cq), 142.2 (Cq), 139.4 (Cq), 136.3 (Cq), 136.2 (Cq), 133.0 (Cq), 131.6 (CH), 
131.2 (CH), 130.8 (CH), 130.4 (CH), 129.1 (CH), 127.3 (Cq), 125.2 (Cq), 122.4 (CH), 120.6 
(CH), 119.9 (CH), 118.3 (CH), 113.9 (CH), 111.9 (CH), 109.6 (Cq), 55.6 (CH), 55.5 (CH3), 53.9 
(CH3), 52.7 (CH3), 51.5 (CH), 46.1 (Cq), 41.2 (CH2), 39.0 (CH2), 38.1 (CH2), 36.7 (CH2), 36.5 
(CH2), 28.5 (CH), 28.1 (CH), 25.1 (CH3), 22.9 (CH3), 22.1 (CH3), 19.5 (CH3), 18.9 (CH), 17.9 
(CH). 19F NMR (376 MHz, CDCl3): δ = -132.94 (q, JB-F = 32.0 Hz). IR (ATR): ṽ = 1633, 1541, 
1463, 1432, 1254, 1178, 1139, 1070, 1055, 793, 739 cm-1. MS (ESI) m/z (relative intensity): 
1240 (30) [M+Na]+, 1218 (100) [M+H]+. HR-MS (ESI): m/z calcd for C65H75BF2N11O10 [M+H]+: 
1218.5765; found: 1218.5753. UV-Vis λmax (1.0 mg/L in EtOAc) = 576 nm. Em λmax (1.0 mg/L 
in EtOAc) = 610 nm. 
5.3.2.4 Procedure and Characterization Data of TAM/PG Removed BODIPY 






ylidene)methyl] phenyl}-2-(1,3-dioxoisoindolin-2-yl)propanoate (110aaa)  
In a pressure tube, 110aa (74 mg, 0.10 mmol) was dissolved in dry MeOH (2.0 mL). Et2OꞏBF3 
(15 equiv) was added dropwise at 0 °C. The solution was stirred at 130 °C for 16 h. Then, the 
solvent was removed in vacuo and the crude product was purified by column chromatography 
on silica gel (n-hexane/EtOAc 1/2) to yield 110aaa (45 mg, 88%) as an orange solid (M.p.: 
209–210 °C). 1H NMR (500 MHz, CDCl3): δ = 7.76 (dd, J = 5.5, 3.1 Hz, 2H), 7.69 (dd, J = 5.5, 
3.1 Hz, 2H), 7.21 (d, J = 8.1 Hz, 2H), 7.09 (d, J = 8.1 Hz, 2H), 5.79 (s, 2H), 5.22 (dd, J = 10.9, 
6.5 Hz, 1H), 3.81 (s, 3H), 3.68–3.60 (m, 2H), 2.30 (s, 6H), 1.00 (s, 6H). 13C NMR (126 MHz, 
CDCl3): δ = 169.3 (Cq), 167.4 (Cq), 151.6 (Cq), 140.31 (Cq), 138.4 (Cq), 136.9 (Cq), 136.8 (Cq), 
136.3 (Cq), 134.3 (CH), 131.6 (Cq), 129.5 (CH), 129.4 (CH), 123.6 (CH), 119.6 (CH), 53.2 
(CH), 53.1 (CH3), 34.6 (CH2), 16.1 (CH3), 14.4 (CH3). IR (ATR): ṽ = 1740, 1711, 1386, 1366, 
1274, 1096, 941, 717, 703, 530 cm-1. MS (ESI) m/z (relative intensity): 508 (100) [M+H]+. HR-
MS (ESI): m/z calcd for C31H30N3O4 [M+H]+: 508.2231; found: 508.2216. UV-Vis λmax (1.0 






f][1,3,2]diaza borinin-10-yl}phenyl)-2-(1,3-dioxoisoindolin-2-yl)propanoate (110aab) 
In a 100 mL flask, 110aaa (51 mg, 0.10 mmol) was dissolved in dry CH2Cl2 (10 mL) at 25 °C. 
Et3N (10 equiv) was then added and the solution was stirred for 10 min. Et2OꞏBF3 (15 equiv) 
was then added dropwise. The solution was stirred at 25 °C for 4 h. The solvent was removed 
in vacuo and the crude product was purified by column chromatography on silica gel (n-
hexane/CH2Cl2 5/1) to yield 110aab (47 mg, 85%) as an orange solid (M.p.: 296–297 °C). 1H 
NMR (500 MHz, CDCl3): δ = 7.75 (dd, J = 5.6, 3.0 Hz, 2H), 7.70 (dd, J = 5.6, 3.0 Hz, 2H), 
7.25 (d, J = 8.1 Hz, 2H), 7.06 (d, J = 8.1 Hz, 2H), 5.89 (s, 2H), 5.20 (dd, J = 11.4, 5.7 Hz, 1H), 
3.81 (s, 3H), 3.66 (dd, J = 14.0, 5.7 Hz, 1H),3.61 (dd, J = 14.0, 5.7 Hz, 1H), 2.50 (s, 6H), 1.09 
(s, 6H). 13C NMR (126 MHz, CDCl3): δ = 169.2 (Cq), 167.3 (Cq), 155.5 (Cq), 143.1 (Cq), 141.4 
(Cq), 137.9 (Cq), 134.4 (CH), 133.8 (Cq), 131.5 (Cq), 131.4 (Cq), 129.9 (CH), 128.3 (CH), 123.6 
(CH), 121.3 (CH), 53.17 (CH), 53.16 (CH3), 34.6 (CH2), 14.7 (CH3), 14.3 (CH3). 19F NMR (471 
MHz, CDCl3): δ = -146.39 (q, JB-F = 32.3 Hz). IR (ATR): ṽ = 1922, 1958, 1717, 1543, 1508, 
510, 431, 402, 390 cm-1. MS (ESI) m/z (relative intensity): 578 (100) [M+Na]+, 556 (30) [M+H]+. 
HR-MS (ESI): m/z calcd for C31H29BF2N3O4 [M+H]+: 556.2219; found: 556.2227. UV-Vis λmax 
(1.0 mg/L in EtOAc) = 498 nm. Em λmax (1.0 mg/L in EtOAc) = 510 nm. 
 
Methyl-(S)-2-amino-3-(4-{5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-
c:2',1'-f] [1,3,2]diazaborinin-10-yl}phenyl)propanoate (110aac) 
110aab (55 mg, 0.10 mmol) was dissolved in a 1/1 mixture of CH2Cl2/EtOH (3.0 mL). 
Ethylenediamine (10 equiv) was added dropwise. The solution was stirred at 40 °C for 4 h. 
At ambient temperature, the solvent was removed in vacuo and the crude product was 
purified by column chromatography on silica gel (CH2Cl2/MeOH 50/1) to yield 110aac (22 mg, 




Hz, 2H), 7.21 (d, J = 8.1 Hz, 2H) 5.97 (s, 2H), 3.78 (dd, J = 6.9, 6.2 Hz, 1H), 3.67 (s, 3H), 
3.10 (dd, J = 13.4, 6.2 Hz, 1H), 3.00 (dd, J = 13.4, 6.9 Hz, 1H), 2.55 (s, 6H), 1.37 (s, 6H).  
13C NMR (126 MHz, CDCl3): δ = 175.3 (Cq), 155.6 (Cq), 143.1 (Cq), 141.6 (Cq), 138.3 (Cq), 
133.7 (Cq), 131.6 (Cq), 130.2 (CH), 128.3 (CH), 121.3 (CH), 56.0 (CH), 52.1 (CH3), 41.3 (CH2), 
14.7 (CH3), 14.5 (CH3). 19F NMR (471 MHz, CDCl3): δ = -146.32 (q, JB-F = 32.5 Hz). IR (ATR): 
ṽ = 2036, 1968, 1543, 1508, 1193, 432, 389, 382 cm-1. MS (ESI) m/z (relative intensity): 448 
(10) [M+Na]+, 426 (100) [M+H]+. HR-MS (ESI): m/z calcd for C23H27BF2N3O2 [M+H]+: 
426.2163; found: 426.2173. UV-Vis λmax (1.0 mg/L in EtOAc) = 500 nm. Em λmax (1.0 mg/L 
in EtOAc) = 512 nm. 
 
(S)-2-Amino-3-{4-(5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2] diazaborinin-10-yl)phenyl}propanoic acid (110aa’) 
In a 25 mL round bottom flask, NH2-Ala-(BODIPY)-OMe 110aac (42.5 mg, 0.10 mmol) was 
dissolved in dry MeOH (2.0 mL). LiOH (2N solution, 0.15 mL) was added dropwise at 0 °C. 
The solution was stirred at 28 °C for 16 h. HCl (4 N solution in dioxane, 75 μL) was then added 
dropwise at 0 °C. The resulting solution was stirred for 1 min. The solvent was removed in 
vacuo and the crude product was washed by n-hexane, ethyl acetate, suspended in 0.5 mL 
water, filtered and dried under vacuum to yield 110aa’ (39 mg, 92%) as an orange solid (M.p.: 
280–281 °C). 1H NMR (600 MHz, CD3OD): δ = 7.48 (d, J = 8.1 Hz, 2H), 7.27 (d, J = 8.1 Hz, 
2H), 6.04 (s, 2H), 3.85 (dd, J = 7.6, 5.1 Hz, 1H), 3.33 (dd, J = 14.4, 5.1 Hz, 1H), 3.16 (dd, J 
= 14.4, 7.6 Hz, 1H), 2.47 (s, 6H), 1.42 (s, 6H). 13C NMR (126 MHz, CD3OD): δ = 173.2 (Cq), 
156.5 (Cq), 144.6 (Cq), 143.1 (Cq), 138.6 (Cq), 135.0 (Cq), 132.5 (Cq), 131.3 (CH), 129.6 (CH), 
122.1 (CH), 57.1 (CH), 38.1 (CH2), 14.9 (CH3), 14.6 (CH3). 19F NMR (471 MHz, CD3OD): δ = 




476 cm-1. MS (ESI) m/z (relative intensity): 412 (100) [M+H]+. HR-MS (ESI): m/z calcd for 
C22H25BF2N3O2 [M+H]+: 412.2006; found: 412.2004. UV-Vis λmax (1.0 mg/L in MeOH) = 498 
nm. Em λmax (1.0 mg/L in MeOH) = 512 nm.  
 
(S)-2-Amino-3-{4-(5,5-difluoro-3,7-bis(4-methoxyphenyl)-5H-4λ4,5λ4-dipyrrolo[1,2-
c:2',1'-f] [1,3,2]diazaborinin-10-yl)phenyl}propanoic acid (110bg’) 
In a pressure tube, 110bg (89 mg, 0.10 mmol) was dissolved in dry MeOH (2.0 mL). Et2OꞏBF3 
(15 equiv) was added dropwise at 0 °C. The solution was stirred at 130 °C for 16 h. Then, the 
solvent was removed in vacuo and the crude product was purified by column chromatography 
on silica gel (n-hexane/EtOAc 1/2) to yield 110bga (50 mg, 76%) as a red solid. In a 100 mL 
flask, 110bga (66 mg, 0.10 mmol) was dissolved in dry Toluene (10 mL) at 25 °C. Et3N (10 
equiv) was then added and the solution was stirred for 10 min. Et2OꞏBF3 (15 equiv) was then 
added dropwise. The solution was stirred at 80 °C for 30 min. The solvent was removed in 
vacuo and the crude product was purified by column chromatography on silica gel (n-
hexane/CH2Cl2 5/1) to yield 110bgb (56 mg, 80%) as a dark purple solid. 110bgb (71 mg, 
0.10 mmol) was dissolved in a 1/1 mixture of CH2Cl2/EtOH (3.0 mL). Ethylenediamine (10 
equiv) was added dropwise. The solution was stirred at 40 °C for 16 hours. At ambient 
temperature, the solvent was removed in vacuo and the crude product was purified by column 
chromatography on silica gel (CH2Cl2/MeOH 50/1) to yield 110bgc (39 mg, 67%) as a purple 
oil. In a 25 mL round bottom flask, NH2-Ala-(BODIPY)-OMe 110bgc (50 mg, 0.086 mmol) 
was dissolved in dry MeOH (2.0 mL). LiOH (2N solution, 0.13 mL) was added dropwise at 




added dropwise at 0 °C. The resulting solution was stirred for 1 min. The solvent was removed 
in vacuo and the crude product was washed by n-hexane, ethyl acetate, suspended in 0.5 
mL water, filtered and dried under vacuum to yield 110bg’ (39 mg, 89%) as a dark purple 
solid (M.p.: 220–221 °C). 1H NMR (400 MHz, CD3OD): δ = 7.88 (d, J = 9.0 Hz, 4H), 7.60 (d, 
J = 8.1 Hz, 2H), 7.53 (d, J = 8.1 Hz, 2H), 6.98 (d, J = 9.0 Hz, 4H), 6.94 (d, J = 4.4 Hz, 2H), 
6.72 (d, J = 4.4 Hz, 2H), 3.89 (dd, J = 8.2, 4.8 Hz, 1H), 3.86 (s, 6H), 3.43 (dd, J = 14.4, 4.8 
Hz, 1H), 3.19 (dd, J = 14.4, 8.2 Hz, 1H). 13C NMR (126 MHz, CD3OD): δ = 162.4 (Cq), 162.2 
(Cq), 139.6 (Cq), 137.3 (Cq), 134.7 (Cq), 132.2 (CH), 132.1 (CH), 131.5 (Cq), 131.4 (CH), 130.4 
(CH), 126.3 (Cq), 121.4 (CH), 114.6 (CH), 106.0 (Cq), 55.8 (CH), 38.1 (CH2), 30.8 (CH3). 19F 
NMR (375 MHz, CD3OD): δ = -133.96 (q, JB-F = 32.3 Hz). IR (ATR): ṽ = 1605, 1570, 1545, 
1466, 1433, 1259, 1142, 1073, 797 cm-1. MS (ESI) m/z (relative intensity): 590 (100) [M+Na]+, 
568 (15) [M+H]+, 1157 (10) [2M+Na]+. HR-MS (ESI): m/z calcd for C32H29BF2N3O4 [M+H]+: 
568.2219; found: 568.2215. UV-Vis λmax (1.0 mg/L in MeOH) = 580 nm. Em λmax (1.0 mg/L 
in MeOH) = 613 nm.  
 
(2S,3R)-2-Amino-3-(4-{5,5-difluoro-3,7-bis(4-methoxyphenyl)-5H-4λ4,5λ4-dipyrrolo[1,2-
c:2',1'-f] [1,3,2]diazaborinin-10-yl}phenyl)-3-phenylpropanoic acid (110bk’) 
In a pressure tube, 110bk (97 mg, 0.10 mmol) was dissolved in dry MeOH (2.0 mL). Et2OꞏBF3 
(15 equiv) was added dropwise at 0 °C. The solution was stirred at 130 °C for 16 h. Then, the 
solvent was removed in vacuo and the crude product was purified by column chromatography 
on silica gel (n-hexane/EtOAc 1/2) to yield 110bka (48 mg, 65%) as a red solid. In a 100 mL 




equiv) was then added and the solution was stirred for 10 min. Et2OꞏBF3 (15 equiv) was then 
added dropwise. The solution was stirred at 80 °C for 30 min. The solvent was removed in 
vacuo and the crude product was purified by column chromatography on silica gel (n-
hexane/CH2Cl2 5/1) to yield 110bkb (64 mg, 82%) as a purple solid. 110bkb (79 mg, 0.10 
mmol) was dissolved in a 1/1 mixture of CH2Cl2/EtOH (3.0 mL). Ethylenediamine (10 equiv) 
was added dropwise. The solution was stirred at 40 °C for 16 hours. At ambient temperature, 
the solvent was removed in vacuo and the crude product was purified by column 
chromatography on silica gel (CH2Cl2/MeOH 50/1) to yield 110bkc (39 mg, 60%) as a purple 
oil. In a 10 mL round bottom flask, NH2-Phe-(BODIPY)-OMe 110bkc (35 mg, 0.05 mmol) was 
dissolved in dry MeOH (1.0 mL). LiOH (2N solution, 75 μL) was added dropwise at 0 °C. The 
solution was stirred at 28 °C for 24 h. HCl (4N solution in dioxane, 40 μL) was then added 
dropwise at 0 °C. The resulting solution was stirred for 1 min. The solvent was removed in 
vacuo and the crude product was washed by n-hexane, ethyl acetate, suspended in 0.5 mL 
water, filtered and dried under vacuum to yield 110bk’ (25 mg, 80%) as a dark purple solid 
(M.p.: 237–238 °C). 1H NMR (400 MHz, CD3OD+15% DMSO-d6): δ = 7.99–7.91 (m, 4H), 
7.69–7.57 (m, 5H), 7.54–7.42 (m, 3H), 7.40 (d, J = 7.2 Hz, 1H), 7.11–7.05 (m, 4H), 7.01 (d, J 
= 4.4 Hz, 2H), 6.79 (d, J = 4.4 Hz, 2H), 4.50–4.37 (m, 2H), 3.92 (s, 6H). 13C NMR (126 MHz, 
CD3OD): δ = 168.6 (Cq), 163.7 (Cq), 162.2 (Cq), 137.3 (Cq), 132.1 (CH), 132.0 (CH), 131.8 
(Cq), 131.6 (Cq), 131.5 (Cq), 130.3 (CH), 129.8 (CH), 129.7 (CH), 129.4 (CH), 129.3 (Cq), 
129.1 (CH), 127.1 (Cq), 126.2 (CH), 114.6 (CH), 55.8 (CH), 30.8 (CH), 23.8 (CH3). 19F NMR 
(376 MHz, CD3OD): δ = -133.95 (q, JB-F = 32.4 Hz). IR (ATR): ṽ = 1699, 1605, 1544, 1466, 
1257, 1142, 1072, 1059, 716 cm-1. MS (ESI) m/z (relative intensity): 666 (100) [M+Na]+, 644 
(10) [M+H]+, 1309 (5) [2M+H]+. HR-MS (ESI): m/z calcd for C38H33BF2N3O4 [M+H]+: 644.2533; 









PhthN-AlaBODIPY-Gly-Tzl-Gly-Leu-OMe 111f (0.1 mmol) was dissolved in a 1/1 mixture of 
CH2Cl2/EtOH (2.0 mL). Ethylenediamine (10 equiv) was added dropwise. The solution was 
stirred at 40 °C for 4 h. At ambient temperature, the solvent was removed in vacuo and the 
crude product was purified by column chromatography on silica gel (CH2Cl2/MeOH 50/1) to 
yield NH2-Ala-(BODIPY)Gly-Tzl-Gly-Leu-OMe 111fa (40 mg, 60%) as an orange oil. 111fa 
(40 mg, 0.06 mmol) was then dissolved in dry MeOH (1.0 mL) and LiOH (2N solution, 90 μL) 
was added dropwise at 0 °C. The solution was stirred at 28 °C for 24 h. HCl (4N solution in 
dioxane, 45 μL) was then added dropwise at 0 °C. The resulting solution was stirred for 1 
min. The solvent was removed in vacuo and the crude product was washed by n-hexane, 
ethyl acetate, dried under vacuum to yield 111fa’ (35 mg, 90%) as an orange solid (M.p.: 
251–252 °C). 1H NMR (600 MHz, CD3OD): δ = 8.03 (s, 1H), 7.39 (d, J = 8.1 Hz, 2H), 7.25 (d, 
J = 8.1 Hz, 2H), 6.04 (s, 2H), 5.12–5.08 (m, 2H), 4.55 (d, J = 15.4 Hz, 1H), 4.30 (dd, J = 10.4, 
3.7 Hz, 1H), 4.08 (d, J = 15.4 Hz, 1H), 3.91–3.86 (m, 1H), 3.16–3.10 (m, 2H), 2.47 (s, 6H), 
1.70–1.65 (m, 2H), 1.61–1.54 (m, 1H), 1.38 (s, 6H), 0.93 (d, J = 6.1 Hz, 3H), 0.91 (d, J = 6.1 
Hz, 3H). 13C NMR (126 MHz, CD3OD): δ = 179.3 (Cq), 172.1 (Cq), 166.9 (Cq), 156.5 (Cq), 
145.8 (Cq), 144.4 (Cq), 143.0 (Cq), 138.2 (Cq), 135.1 (Cq), 132.4 (Cq), 131.4 (CH), 129.5 (CH), 
125.7 (CH), 122.2 (CH), 56.5 (CH), 54.9 (CH3), 53.6 (CH2), 42.8 (CH2), 39.8 (CH2), 35.6 (CH2), 
26.3 (CH3), 23.8 (CH), 22.0 (CH), 14.9 (CH3), 14.6 (CH3). 19F NMR (376 MHz, CD3OD): δ = 
-147.01 (q, JB-F = 31.3 Hz). IR (ATR): ṽ = 1667, 1542, 1506, 1469, 1304, 1191, 1154, 973, 
476 cm-1. MS (ESI) m/z (relative intensity): 643 (100) [M-F]+, 663 (40) [M+H]+, 685 (30) 




UV-Vis λmax (1.0 mg/L in MeOH) = 498 nm. Em λmax (1.0 mg/L in MeOH) = 511 nm. 
5.3.3 BODIPY-Labeled Cyclobutanes by Secondary C(sp3)─H Arylations 





The general procedure D was followed using N-[2-(1-benzyl-1H-1,2,3-triazol-4-yl)propan-2-
yl]cyclobutanecarboxamide (112a) (60 mg, 0.2 mmol), iodo-BODIPY 109a (108 mg, 0.24 
mmol) and AgOAc (73 mg, 0.44 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 1:2) yielded 114a (65 mg, 52%) as an orange solid (M.p. = 124–125 °C). 
1H NMR (600 MHz, CDCl3): δ = 7.35–7.30 (m, 5H), 7.28 (s, 1H), 7.22 (dd, J = 7.5, 2.0 Hz, 
2H), 7.08 (d, J = 8.0 Hz, 2H), 6.20 (brs, 1H), 5.91 (s, 2H), 5.51–5.34 (m, 2H), 3.88 (q, J = 8.7 
Hz, 1H), 3.40–3.27 (m, 1H), 2.56 (dd, J = 18.8, 9.7 Hz, 1H), 2.52 (s, 6H), 2.38–2.28 (m, 2H), 
2.19 (dq, J = 11.3, 9.0, 8.5 Hz, 1H), 1.55 (s, 3H), 1.47 (s, 3H), 1.29 (s, 6H). 13C NMR (126 
MHz, CDCl3): δ = 171.6 (Cq), 155.1 (Cq), 153.9 (Cq), 143.1 (Cq), 142.7 (Cq), 142.0 (Cq), 134.4 
(Cq), 132.6 (Cq), 131.4 (Cq), 129.0 (CH), 128.7 (CH), 128.2 (CH), 128.0 (CH), 127.5 (CH), 
121.0 (CH), 119.8 (CH), 54.2 (CH2), 51.5 (Cq), 46.4 (CH), 42.5 (CH), 28.4 (CH3), 27.7 (CH3), 
26.0 (CH2), 21.5 (CH2), 14.7 (CH3), 14.6 (CH3). 19F NMR (282 MHz, CDCl3): δ = -146.33 (q, 
JB-F = 32.6 Hz). IR (ATR): ṽ = 2941, 1541, 1506, 1406, 1191, 973 cm–1. MS (ESI) m/z (relative 




for C36H40BF2N6O [M+H]+ 621.3325, found 621.3306. UV-Vis λmax (1.0 mg/L in EtOAc) = 495 





The general procedure D was followed using N-[2-(1-benzyl-1H-1,2,3-triazol-4-yl)propan-2-
yl]cyclobutanecarboxamide (112a) (60 mg, 0.2 mmol), iodo-BODIPY 109l (170 mg, 0.24 
mmol) and AgOAc (73 mg, 0.44 mmol). After 20 h, purification by column chromatography (n-
hexane/EtOAc 1:2) yielded 114b (104 mg, 59%) as a purple solid (M.p. = 154–155 °C). 1H 
NMR (500 MHz, CDCl3): δ = 7.85–7.73 (m, 4H), 7.44 (d, J = 8.2 Hz, 2H), 7.39 (d, J = 8.0 Hz, 
2H), 7.33–7.27 (m, 3H), 7.26–7.22 (m, 4H), 7.21–7.17 (m, 3H), 6.78 (d, J = 4.3 Hz, 2H), 6.55 
(d, J = 4.3 Hz, 2H), 6.06 (brs, 1H), 5.40 (d, J = 1.7 Hz, 2H), 3.99 (q, J = 8.8 Hz, 1H), 3.38 (td, 
J = 9.0, 4.8 Hz, 1H), 2.64 (ddd, J = 18.5, 10.7, 8.3 Hz, 1H), 2.57-2.40 (m, 3H), 2.34 (dtdd, J 
= 10.9, 8.9, 5.0, 1.7 Hz, 1H), 2.19 (dq, J = 11.4, 8.3 Hz, 1H), 1.94–1.80 (m, 8H), 1.77–1.70 
(m, 2H), 1.49–1.33 (m, 11H), 1.29–1.21 (m, 5H). 13C NMR (126 MHz, CDCl3): δ = 171.1 (Cq), 
158.6 (Cq), 154.0 (Cq), 149.5 (Cq), 143.5 (Cq), 143.2 (Cq), 136.2 (Cq), 134.4 (Cq), 132.5 (Cq), 
130.5 (CH), 130.4 (CH), 130.1 (Cq), 129.4 (CH), 129.0 (CH), 128.7 (CH), 128.0 (CH), 127.7 
(CH), 126.7 (CH), 120.7 (CH), 119.8 (CH), 54.1 (CH2), 51.2 (Cq), 46.3 (CH), 44.4 (CH), 42.6 




NMR (282 MHz, CDCl3): δ = -132.73 (q, JB-F = 31.9 Hz) IR (ATR): ṽ = 2920, 1538, 1466, 1131, 
1069, 966 cm–1. MS (ESI) m/z (relative intensity): 881 (100) [M+H]+, 903 (25) [M+Na]+, 919 
(10) [M+K]+. HR-MS (ESI) m/z calcd for C56H60BF2N6O [M+H]+ 881.4893, found 881.4883. 





The general procedure D was followed using N-[2-(1-benzyl-1H-1,2,3-triazol-4-yl)propan-2-
yl)]cyclobutanecarboxamide (112a) (60 mg, 0.2 mmol), iodo-BODIPY 109k (158 mg, 0.24 
mmol) and AgOAc (73 mg, 0.44 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 1:2) yielded 114c (68 mg, 41%) as a purple solid (M.p. = 125–126 °C). 1H 
NMR (400 MHz, CDCl3): δ = 7.78 (d, J = 8.1 Hz, 4H), 7.44 (d, J = 7.6 Hz, 2H), 7.39 (d, J = 
7.8 Hz, 2H), 7.34–7.26 (m, 3H), 7.21–7.16 (m, 7H), 6.78 (d, J = 4.3 Hz, 2H), 6.55 (d, J = 4.2 
Hz, 2H), 6.02 (brs, 1H), 5.41 (s, 2H), 4.01 (d, J = 9.1 Hz, 1H), 3.40 (s, 1H), 2.64 (p, J = 9.1 
Hz, 1H), 2.49 (d, J = 7.2 Hz, 4H), 2.47–2.43 (m, 1H) 2.35 (s, 1H), 2.27–2.16 (m, 1H), 1.89 
(hept, J = 6.8 Hz, 2H), 1.45 (s, 3H), 1.27 (s, 3H), 0.92 (d, J = 6.59 Hz, 12H). 13C NMR (101 
MHz, CDCl3): δ = 171.2 (Cq), 158.6 (Cq), 154.0 (Cq), 143.5 (Cq), 143.4 (Cq), 143.2 (Cq), 136.2 
(Cq), 134.4 (Cq), 132.6 (Cq), 130.6 (CH), 130.4 (CH), 130.0 (Cq), 129.2 (CH), 129.1 (CH), 




(Cq), 46.4 (CH), 45.4 (CH2), 42.7 (CH), 30.0 (CH), 28.0 (CH3), 27.2 (CH3), 24.2 (CH2), 22.5 
(CH3), 20.3 (CH2). 19F NMR (282 MHz, CDCl3): δ = -132.88 (q, JB-F = 32.0 Hz). IR (ATR): ṽ 
=2952, 1538, 1465, 1268, 1138, 1055, 789 cm–1. MS (ESI) m/z (relative intensity): 829 (100) 
[M+H]+, 851 (30) [M+Na]+. HR-MS (ESI) m/z calcd for C52H56BF2N6O [M+H]+ 829.4580, found 






The general procedure D was followed using N-[2-(1-benzyl-1H-1,2,3-triazol-4-yl)propan-2-
yl]cyclobutanecarboxamide (112a) (60 mg, 0.2 mmol), iodo-BODIPY 109j (145 mg, 0.24 
mmol) and AgOAc (73 mg, 0.44 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 1:2) yielded 114d (78 mg, 50%) as a purple solid (M.p. = 147–148 °C). 1H 
NMR (400 MHz, CDCl3): δ = 7.92–7.77 (m, 4H), 7.46–7.41 (m, 2H), 7.39 (d, J = 8.1 Hz, 2H), 
7.32–7.27 (m, 3H), 7.21–7.18 (m, 3H), 6.99–6.89 (m, 4H), 6.77 (d, J = 4.3 Hz, 2H), 6.53 (d, 
J = 4.3 Hz, 2H), 6.02 (brs, 1H), 5.41 (d, J = 1.8 Hz, 2H), 4.00 (q, J = 8.8 Hz, 1H), 3.83 (s, 6H), 
3.39 (td, J = 8.9, 4.8 Hz, 1H), 2.64 (ddd, J = 18.6, 10.1, 8.1 Hz, 1H), 2.51–2.41 (m, 1H), 2.35 
(dddd, J = 17.9, 8.7, 5.2, 1.6 Hz, 1H), 2.24–2.16 (m, 1H), 1.44 (s, 3H), 1.27 (s, 3H). 13C NMR 
(126 MHz, CDCl3): δ = 171.0 (Cq), 160.5 (Cq), 158.0 (Cq), 153.9 (Cq), 143.3 (Cq), 142.4 (Cq), 




(CH), 127.9 (CH), 127.7 (CH), 125.1 (Cq), 120.2 (CH), 119.7 (CH), 113.7 (CH), 55.3 (CH3), 
54.2 (CH2), 51.3 (Cq), 46.4 (CH), 42.7 (CH), 28.0 (CH3), 27.3 (CH3), 24.3 (CH2), 20.3 (CH2). 
19F NMR (282 MHz, CDCl3): δ = -132.96 (q, JB-F = 32.4 Hz). IR (ATR): ṽ = 2938, 1543, 1466, 
1142, 1072, 796 cm–1. MS (ESI) m/z (relative intensity): 777 (100) [M+H]+, 799 (50) [M+Na]+, 
1575 (10) [2M+Na]+. HR-MS (ESI) m/z calcd for C46H44BF2N6O3 [M+H]+ 777.3538, found 






The general procedure D was followed using methyl (1s,3s)-3-[2-(1-benzyl-1H-1,2,3-triazol-
4-yl)propan-2-yl]carbamoylcyclobutane-1-carboxylate 112b (71 mg, 0.2 mmol), iodo-
BODIPY 109p (174 mg, 0.4 mmol) and AgOAc (73 mg, 0.44 mmol). After 24 h, purification 
by column chromatography (n-hexane/EtOAc 1:3) yielded 114e (40 mg, 41%) as an orange 
solid (M.p. = 131–132 °C). 1H NMR (400 MHz, CDCl3): δ = 7.83 (d, J = 23.4 Hz, 2H), 7.43–
7.23 (m, 6H), 6.94 (s, 2H), 6.64 (d, J = 4.1 Hz, 1H), 6.57 (s, 1H), 6.45 (dd, J = 4.2, 1.8 Hz, 
1H), 6.13 (brs, 1H), 5.47 (s, 2H), 4.00 (d, J = 9.2 Hz, 1H), 3.67–3.36 (m, 4H), 3.30 (dd, J = 
17.2, 7.9 Hz, 1H), 2.97 (q, J = 11.0 Hz, 1H), 2.37 (s, 3H), 2.18 (d, J = 8.0 Hz, 1H), 2.05 (d, J 
= 2.9 Hz, 6H), 1.53 (s, 3H), 1.41 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 171.7 (Cq), 169.3 
(Cq), 153.8 (Cq), 147.3 (Cq), 145.0 (CH), 143.6 (CH), 138.8 (Cq), 136.0 (Cq), 135.2 (Cq), 
135.1(Cq), 134.6 (Cq), 130.0 (Cq), 129.8 (CH), 129.3 (Cq), 129.0 (CH), 128.6 (CH), 128.3 




40.5 (CH), 39.7 (CH), 39.0 (CH), 27.4 (CH3), 27.1 (CH3), 23.4 (CH2), 21.1 (CH3), 19.9 (CH3), 
19.8 (CH3). 19F NMR (377 MHz, CDCl3): δ = -144.36 (dq, JB-F = 104.0, 29.1 Hz), -146.43 (dq, 
JB-F = 104.2, 28.5 Hz). IR (ATR): ṽ =2948, 1499, 1248, 1099, 1020, 705 cm–1. MS (ESI) m/z 
(relative intensity): 687 (100) [M+Na]+, 665 (60) [M+H]+. HR-MS (ESI) m/z calcd for 
C37H40BF2N6O3 [M+H]+ 665.3224, found 665.3213. UV-Vis λmax (1.0 mg/L in EtOAc) = 510 
nm. Em λmax (1.0 mg/L in EtOAc) = 527 nm. 





The general procedure E was followed using 114d (155 mg, 0.2 mmol), 4-iodoanisole 11d 
(93.6 mg, 0.4 mmol) and AgOAc (100 mg, 0.6 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 1:2) yielded 115a (101 mg, 57%) as a purple solid (M.p. 
= 216–217 °C). 1H NMR (400 MHz, CDCl3): δ = 7.91–7.81 (m, 4H), 7.41 (d, J = 8.0 Hz, 2H), 
7.33 (d, J = 7.9 Hz, 2H), 7.27 (dq, J = 5.0, 3.6, 2.6 Hz, 3H), 7.19–7.14 (m, 2H), 7.10 (dd, J = 
7.3, 2.3 Hz, 2H), 6.97–6.89 (m, 4H), 6.83–6.76 (m, 5H), 6.55 (d, J = 4.3 Hz, 2H), 6.03 (brs, 
1H), 5.27 (s, 2H), 4.06–3.87 (m, 2H), 3.83 (s, 6H), 3.73 (s, 3H), 3.68 (td, J = 8.3, 2.9 Hz, 1H), 




13C NMR (101 MHz, CDCl3): δ = 169.4 (Cq), 160.6 (Cq), 158.0 (Cq), 157.9 (Cq), 153.4 (Cq), 
143.8 (Cq), 142.8 (Cq), 136.2 (Cq), 134.8 (Cq), 132.6 (Cq), 132.0 (Cq), 131.1 (CH), 130.4 (CH), 
130.2 (CH), 128.9 (CH), 128.4 (CH), 128.2 (CH), 127.6 (CH), 126.7 (CH), 125.2 (Cq), 120.3 
(CH), 113.8 (CH), 113.4 (CH), 55.3 (CH3), 53.7 (CH2), 53.4 (CH3), 51.4 (Cq), 37.9 (CH), 37.9 
(CH), 29.44 (CH2), 28.0 (CH3), 27.4 (CH3). 19F NMR (377 MHz, CDCl3): δ = -132.9 (q, JB-F = 
32.3 Hz). IR (ATR): ṽ = 2932, 1464, 1432, 1137, 1057, 965, 792 cm–1. MS (ESI) m/z (relative 
intensity): 883 (100) [M+H]+, 905 (40) [M+Na]+. HR-MS (ESI) m/z calcd for C53H50BF2N6O4 
[M+H]+ 883.3958, found 883.3959. UV-Vis λmax (1.0 mg/L in EtOAc) = 585 nm. Em λmax (1.0 





The general procedure E was followed using 114d (155 mg, 0.2 mmol), 4-iodo-1,2-
dimethoxybenzene 11m (106 mg, 0.4 mmol) and AgOAc (100 mg, 0.6 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 1:2) yielded 115b (128 mg, 70%) 
as a purple solid (M.p. = 134–135 °C). 1H NMR (400 MHz, CDCl3): δ = 7.91–7.79 (m, 4H), 
7.45–7.39 (m, 2H), 7.33 (d, J = 7.8 Hz, 2H), 7.30–7.25 (m, 3H), 7.14–7.07 (m, 2H), 6.96–6.89 
(m, 4H), 6.87 (s, 1H), 6.82–6.75 (m, 5H), 6.55 (d, J = 4.4 Hz, 2H), 6.15 (brs, 1H), 5.30 (d, J = 




3.70 (td, J = 8.3, 3.0 Hz, 1H), 3.39 (q, J = 10.8 Hz, 1H), 2.73–2.62 (m, 1H), 1.28 (d, J = 9.2 
Hz, 6H). 13C NMR (101 MHz, CDCl3): δ = 169.4 (Cq), 160.6 (Cq), 158.0 (Cq), 153.6 (Cq), 148.5 
(Cq), 147.2 (Cq), 143.7 (Cq), 142.8 (Cq), 136.2 (Cq), 134.7 (Cq), 133.3 (Cq), 132.0 (Cq), 131.0 
(CH), 130.4 (CH), 130.3 (CH), 128.9 (CH), 128.5 (CH), 127.7 (CH), 126.6 (CH), 125.2 (Cq), 
120.3 (CH), 120.1 (CH), 119.2 (CH), 113.7 (CH), 110.9 (CH), 110.4 (CH), 55.9 (CH3), 55.8 
(CH3), 55.2 (CH3), 53.8 (CH2), 53.3 (CH), 51.4 (Cq), 38.2 (CH), 37.9  (CH), 29.7 (CH2), 27.8 
(CH3), 27.5 (CH3). 19F NMR (377 MHz, CDCl3): δ = -132.9 (q, JB-F = 32.3 Hz). IR (ATR): ṽ = 
2934, 1462, 1431, 1253, 1055, 1021, 794cm–1. MS (ESI) m/z (relative intensity): 913 (100) 
[M+H]+, 935 (35) [M+Na]+. HR-MS (ESI) m/z calcd for C54H52BF2N6O5 [M+H]+ 913.4064, 
found 913.4045. UV-Vis λmax (1.0 mg/L in EtOAc) = 580 nm. Em λmax (1.0 mg/L in EtOAc) = 
619 nm. 
5.3.4 Peptide Late-Stage Diversifications by Rhodium-Catalyzed 
Tryptophan C7 Amidation 




The general procedure F was followed using Ac-Trppym-OMe (96aa) (68 mg, 0.2 mmol) and 
3-phenyl-1,4,2-dioxazol-5-one (116a) (66 mg, 0.4 mmol). After 24 h, purification by column 
chromatography (n-hexane/EtOAc 1:1 to 1:5) yielded 117aa (84 mg, 92%) as a white solid 
(M.p.: 222ꟷ223 °C). 1H NMR (400 MHz, CDCl3): δ = 13.00 (s, 1H), 8.49 (d, J = 4.9 Hz, 2H), 
8.34 (dd, J = 7.5, 1.6 Hz, 1H), 8.11 (s, 1H), 7.94–7.91 (m, 2H), 7.57–7.46 (m, 3H), 7.36–7.27 




(s, 3H), 3.34 (ddd, J = 14.8, 5.4, 0.9 Hz, 1H), 3.26 (ddd, J = 14.8, 5.4, 0.9 Hz, 1H), 1.99 (s, 
3H). 13C NMR (126 MHz, CDCl3): δ = 172.2 (Cq), 169.9 (Cq), 166.6 (Cq), 158.3 (CH), 156.9 
(Cq), 137.2 (Cq), 134.3 (Cq), 131.6 (CH), 128.7 (CH), 127.6 (CH), 127.2 (CH), 126.6 (Cq), 
126.4 (Cq), 123.6 (CH), 118.9 (CH), 116.4 (CH), 115.7 (Cq), 115.0 (CH), 52.8 (CH), 52.7 (CH3), 
27.4 (CH2), 23.4 (CH3). IR (ATR): ṽ = 3333, 1733, 1654, 1543, 1424, 1404, 1179, 791, 706, 
606 cm–1. MS (ESI) m/z (relative intensity): 937 (20) [2M+Na]+, 480 (90) [M+Na]+, 458 (100) 




The general procedure F was followed using Phth-Trppy-OMe (88aa) (85 mg, 0.2 mmol) and 
3-phenyl-1,4,2-dioxazol-5-one (116a) (66 mg, 0.4 mmol). After 24 h, purification by column 
chromatography (n-hexane/EtOAc 3:1 to 1:1) yielded 117ab (96 mg, 88%) as a light yellow 
oil. 1H NMR (400 MHz, CDCl3): δ = 11.59 (s, 1H), 8.14–8.09 (m, 2H), 7.79–7.77 (m, 1H), 
7.77–7.74 (m, 3H), 7.71 (ddd, J = 8.3, 7.4, 1.9 Hz, 1H), 7.65 (dd, J = 5.5, 3.0 Hz, 2H), 7.50–
7.46 (m, 1H), 7.43–7.38 (m, 3H), 7.24 (s, 1H), 7.23–7.19 (m, 2H), 7.00 (ddd, J = 7.4, 5.0, 0.9 
Hz, 1H), 5.32 (dd, J = 10.1, 5.9 Hz, 1H), 3.79 (s, 3H), 3.77–3.73 (m, 2H). 13C NMR (101 MHz, 
CDCl3): δ = 169.3 (Cq), 167.6 (Cq), 166.2 (Cq), 152.8 (Cq), 147.3 (CH), 139.7 (CH), 136.4 (Cq), 
134.1 (CH), 132.0 (Cq), 131.6 (Cq), 131.3 (CH), 128.3 (CH), 127.4 (CH), 126.9 (Cq), 126.8 
(CH), 125.3 (Cq), 123.5 (CH), 122.0 (CH), 120.3 (CH), 118.4 (CH), 117.4 (CH), 115.4 (Cq), 
115.0 (CH), 52.9 (CH3), 51.9 (CH), 24.6 (CH2). IR (ATR): ṽ = 1744, 1711, 1575, 1471, 1435, 
1386, 1364, 1220, 786, 717 cm–1. MS (ESI) m/z (relative intensity): 1111 (90) [2M+Na]+, 567 








The general procedure F was followed using Ac-Trppym-OH (96ab) (65 mg, 0.2 mmol) and 3-
phenyl-1,4,2-dioxazol-5-one (116a) (66 mg, 0.4 mmol). After 24 h, purification by column 
chromatography (EtOAc/MeOH 100:1 to 20:1) yielded 117ac (65 mg, 73%) as a white solid 
(M.p.: 223ꟷ224 °C). 1H NMR (400 MHz, DMSO-d6): δ = 12.09 (s, 1H), 8.64 (d, J = 4.9 Hz, 
2H), 8.03 (s, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.90–7.83 (m, 3H), 7.60–7.51 (m, 3H), 7.46 (dd, J 
= 7.8, 1.2 Hz, 1H), 7.27 (t, J = 7.8 Hz, 1H), 7.22 (t, J = 4.9 Hz, 1H), 4.42 (ddd, J = 7.6, 7.5, 
5.0 Hz, 1H), 3.23 (dd, J = 14.6, 5.0 Hz, 1H), 3.02 (dd, J = 14.6, 7.5 Hz, 1H), 1.78 (s, 3H). 13C 
NMR (101 MHz, DMSO-d6): δ = 173.6 (Cq), 168.9 (Cq), 164.8 (Cq), 158.6 (CH), 156.2 (Cq), 
135.5 (Cq), 133.8 (Cq), 131.5 (CH), 128.6 (CH), 127.2 (CH), 127.1 (CH), 126.3 (Cq), 125.4 
(Cq), 122.2 (CH), 118.9 (CH), 117.0 (CH), 116.9 (Cq), 115.6 (CH), 53.4 (CH), 27.0 (CH2), 22.7 
(CH3). IR (ATR): ṽ = 2925, 2161, 1653, 1576, 1566, 1540, 1422, 710, 413, 388 cm–1. MS 
(ESI) m/z (relative intensity): 466 (100) [M+Na]+, 444 (85) [M+H]+. HR-MS (ESI): m/z calcd 




The general procedure F was followed using Ac-Trppym-OMe (96aa) (68 mg, 0.2 mmol) and 




column chromatography (n-hexane/EtOAc 1:1 to 1:5) yielded 117ad (56 mg, 61%) as a white 
solid (M.p.: 212ꟷ213 °C). 1H NMR (300 MHz, CDCl3): δ = 12.73 (s, 1H), 8.55 (d, J = 4.9 Hz, 
2H), 8.25 (dd, J = 6.4, 2.7 Hz, 1H), 8.11 (s, 1H), 7.94 (dd, J = 3.1, 1.2 Hz, 1H), 7.53 (dd, J = 
5.0, 1.2 Hz, 1H), 7.40 (dd, J = 5.0, 3.1 Hz, 1H), 7.31–7.27 (m, 2H), 7.03 (t, J = 4.9 Hz, 1H), 
6.26 (d, J = 7.7 Hz, 1H), 4.98 (dt, J = 7.7, 5.5 Hz, 1H), 3.73 (s, 3H), 3.32 (dd, J = 14.7, 5.5 
Hz, 1H), 3.23 (dd, J = 14.7, 5.5 Hz, 1H), 2.00 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 172.1 
(Cq), 169.8 (Cq), 161.7 (Cq), 158.0 (CH), 156.7 (Cq), 139.8 (Cq), 134.1 (Cq), 127.8 (CH), 127.1 
(CH), 126.7 (CH), 126.4 (CH), 126.1 (Cq), 126.0 (Cq), 123.3 (CH), 118.8 (CH), 116.2 (CH), 
115.6 (Cq), 114.8 (CH), 52.6 (CH), 52.4 (CH3), 27.2 (CH2), 23.1 (CH3). IR (ATR): ṽ = 3330, 
2919, 2850, 1732, 1652, 1541, 1420, 790, 703, 596 cm–1. MS (ESI) m/z (relative intensity): 
949 (50) [2M+Na]+, 486 (100) [M+Na]+, 464 (40) [M+H]+. HR-MS (ESI): m/z calcd for 




The general procedure F was followed using Ac-Trppym-OMe (96aa) (68 mg, 0.2 mmol) and 
3-[((3r,5r,7r)-adamantan-1-yl)methyl]-1,4,2-dioxazol-5-one (116c) (94 mg, 0.4 mmol). After 
24 h, purification by column chromatography (n-hexane/EtOAc 1:1 to 1:5) yielded 117ae (84 
mg, 80%) as a white solid (M.p.: 245ꟷ246 °C). 1H NMR (300 MHz, CDCl3): δ = 11.99 (s, 1H), 
8.71 (d, J = 4.9 Hz, 2H), 8.29 (dd, J = 6.9, 2.2 Hz, 1H), 8.08 (s, 1H), 7.32–7.22 (m, 2H), 7.16 
(t, J = 4.9 Hz, 1H), 6.16 (d, J = 7.7 Hz, 1H), 4.98 (ddd, J = 7.7, 5.5, 5.4 Hz, 1H), 3.74 (s, 3H), 
3.33 (dd, J = 14.8, 5.5 Hz, 1H), 3.25 (dd, J = 14.8, 5.4 Hz, 1H), 2.09 (s, 2H), 2.00 (s, 3H), 
1.98–1.93 (m, 3H), 1.74–1.63 (m, 12H). 13C NMR (151 MHz, CDCl3): δ = 172.0 (Cq), 169.7 
(Cq), 168.8 (Cq), 158.0 (CH), 156.9 (Cq), 133.9 (Cq), 127.1 (CH), 126.3 (Cq), 125.9 (Cq), 123.4 




(CH2), 36.7 (CH2), 33.2 (Cq), 28.6 (CH), 27.2 (CH2), 23.2 (CH3). IR (ATR): ṽ = 3341, 2900, 
1725, 1677, 1579, 1418, 1403, 1137, 792, 556 cm–1. MS (ESI) m/z (relative intensity): 552 





The general procedure F was followed using Ac-Trppym-OMe (96aa) (68 mg, 0.2 mmol) and 
(Z)-3-(henicos-12-en-1-yl)-1,4,2-dioxazol-5-one (116d) (152 mg, 0.4 mmol). After 24 h, 
purification by column chromatography (n-hexane/EtOAc 1:1 to 0:100) yielded 117af (133 
mg, 99%) as a white solid (M.p.: 138ꟷ140 °C). 1H NMR (400 MHz, CDCl3): δ = 12.12 (s, 1H), 
8.66 (d, J = 4.8 Hz, 2H), 8.21 (d, J = 6.8 Hz, 1H), 8.06 (s, 1H), 7.25–7.21 (m, 2H), 7.11 (t, J 
= 4.8 Hz, 1H), 6.06 (d, J = 7.7 Hz, 1H), 5.48–5.13 (m, 2H), 4.94 (dt, J = 7.7, 5.4 Hz, 1H), 3.69 
(s, 3H), 3.30 (ddd, J = 14.8, 5.4, 0.9 Hz, 1H), 3.22 (ddd, J = 14.8, 5.4, 0.9 Hz, 1H), 2.31 (t, J 
= 7.5 Hz, 2H), 2.01–1.97 (m, 4H), 1.96 (s, 3H), 1.75–1.64 (m, 2H), 1.39–1.12 (m, 28H), 0.85 
(t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ = 172.1 (Cq), 171.0 (Cq), 169.7 (Cq), 158.0 
(CH), 157.0 (Cq), 134.0 (Cq), 129.9 (CH), 129.8 (CH), 127.0 (CH), 126.4 (Cq), 125.9 (Cq), 
123.5 (CH), 118.4 (CH), 116.3 (CH), 115.6 (Cq), 114.5 (CH), 52.6 (CH), 52.5 (CH3), 38.6 (CH2), 
31.9 (CH2), 29.8 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 29.6 (CH2) 29.5 (CH2), 29.5 (CH2), 
29.4 (CH2), 29.3 (CH2), 29.3 (CH2), 27.3 (CH2), 27.2 (3  CH2), 25.8 (2  CH2), 23.2 (CH3), 
22.7 (CH2), 14.1 (CH3). IR (ATR): ṽ = 3053, 1422, 1264, 896, 734, 705 cm–1. MS (ESI) m/z 
(relative intensity): 696 (100) [M+Na]+, 674 (13) [M+H]+. HR-MS (ESI): m/z calcd for 







The general procedure F was followed using Ac-Trppym-OMe (96aa) (68 mg, 0.2 mmol) and 
N-[(5-oxo-1,4,2-dioxazol-3-yl)methyl]benzamide (116e) (88 mg, 0.4 mmol). After 24 h, 
purification by column chromatography (n-hexane/EtOAc 1:1 to 0:100) yielded 117ag (66 mg, 
65%) as a white solid (M.p.: 243ꟷ244 °C). 1H NMR (400 MHz, DMSO-d6): δ = 11.43 (s, 1H), 
8.90 (t, J = 5.7 Hz, 1H), 8.79 (d, J = 4.9 Hz, 2H), 8.41 (d, J = 7.5 Hz, 1H), 8.06 (s, 1H), 7.88 
(d, J = 7.9 Hz, 1H), 7.85–7.78 (m, 2H), 7.58–7.53 (m, 1H), 7.50–7.44 (m, 2H), 7.38 (d, J = 
7.7 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.13 (t, J = 4.9 Hz, 1H), 4.56 (ddd, J = 8.6, 7.5, 
5.5 Hz, 1H), 4.03 (d, J = 5.7 Hz, 2H), 3.60 (s, 3H), 3.17 (dd, J = 14.8, 5.5 Hz, 1H), 3.06 (dd, 
J = 14.8, 8.6 Hz, 1H), 1.80 (s, 3H). 13C NMR (101 MHz, DMSO-d6): δ = 172.2 (Cq), 169.5 (Cq), 
167.1 (Cq), 166.6 (Cq), 158.8 (CH), 156.1 (Cq), 133.6 (Cq), 133.0 (Cq), 131.5 (CH), 128.3 (CH), 
127.4 (CH), 127.2 (CH), 126.0 (Cq), 125.3 (Cq), 122.5 (CH), 118.7 (CH), 117.1 (CH), 115.8 
(Cq), 114.9 (CH), 52.2 (CH), 51.9 (CH3), 44.2 (CH2), 26.4 (CH2), 22.3 (CH3). IR (ATR): ṽ = 
3286, 1732, 1653, 1581, 1416, 1294, 1225, 703, 690, 603 cm–1. MS (ESI) m/z (relative 
intensity): 537 (100) [M+Na]+, 515 (50) [M+H]+. HR-MS (ESI): m/z calcd for C27H27N6O5+ 







The general procedure F was followed using Ac-Trppym-OMe (96aa) (68 mg, 0.2 mmol) and 
(S)-2-[1-(5-oxo-1,4,2-dioxazol-3-yl)ethyl]isoindoline-1,3-dione (116f) (104 mg, 0.4 mmol). 
After 24 h, purification by column chromatography (n-hexane/EtOAc 1:1 to 0:100) yielded 
117ah (74 mg, 67%) as a white solid (M.p.: 207ꟷ208 °C). 1H NMR (300 MHz, CDCl3): δ = 
11.86 (s, 1H), 8.64 (d, J = 4.9 Hz, 2H), 8.12–8.05 (m, 1H), 8.04 (s, 1H), 7.87–7.79 (m, 2H), 
7.75–7.69 (m, 2H), 7.27 (d, J = 4.4 Hz, 2H), 7.01 (t, J = 4.9 Hz, 1H), 6.12 (d, J = 7.7 Hz, 1H), 
5.02 (q, J = 7.2 Hz, 1H), 4.96 (dt, J = 7.7, 5.5 Hz, 1H), 3.71 (s, 3H), 3.30 (dd, J = 14.8, 5.5 
Hz, 1H), 3.22 (dd, J = 14.8, 5.5 Hz, 1H), 2.01 (s, 3H), 1.78 (d, J = 7.2 Hz, 3H). 13C NMR (101 
MHz, CDCl3): δ = 172.0 (Cq), 169.7 (Cq), 167.7 (Cq), 166.9 (Cq), 158.1 (CH), 156.8 (Cq), 134.1 
(CH), 133.9 (Cq), 131.8 (Cq), 127.2 (CH), 126.4 (Cq), 125.4 (Cq), 123.4 (CH), 123.3 (CH), 
119.7 (CH), 116.1 (CH), 115.7 (Cq), 115.2 (CH), 52.5 (CH), 52.4 (CH3), 50.0 (CH), 27.2 (CH2), 
23.2 (CH3), 15.3 (CH3). IR (ATR): ṽ = 1706, 1670, 1567, 1512, 1421, 1368, 1175, 798, 720, 
497 cm–1. MS (ESI) m/z (relative intensity): 577 (50) [M+Na]+, 555 (100) [M+H]+. HR-MS (ESI): 




The general procedure F was followed using Ac-Trppym-OMe (96aa) (68 mg, 0.2 mmol) and 
(S)-2-[1-(5-oxo-1,4,2-dioxazol-3-yl)-2-phenylethyl]isoindoline-1,3-dione (116g) (134 mg, 0.4 
mmol). After 24 h, purification by column chromatography (n-hexane/EtOAc 1:1 to 0:100) 
yielded 117ai (50 mg, 40%) as a white solid (M.p.: 217ꟷ218 °C). 1H NMR (300 MHz, CDCl3): 
δ = 11.88 (s, 1H), 8.58 (d, J = 4.8 Hz, 2H), 8.12–8.05 (m, 1H), 8.02 (s, 1H), 7.78–7.65 (m, 
4H), 7.28–7.24 (m, 2H), 7.19–7.11 (m, 5H), 6.94 (t, J = 4.8 Hz, 1H), 6.10 (d, J = 7.7 Hz, 1H), 
5.13 (dd, J = 9.0, 7.1 Hz, 1H), 4.95 (dt, J = 7.7, 5.4 Hz, 1H), 3.69 (s, 3H), 3.66–3.57 (m, 2H), 




167.6 (Cq), 166.1 (Cq), 158.1 (CH), 156.7 (Cq), 137.0 (Cq), 134.1 (CH), 133.9 (Cq), 131.4 (Cq), 
128.9 (CH), 128.5 (CH), 127.3 (CH), 126.8 (CH), 126.4 (Cq), 125.2 (Cq), 123.4 (CH), 123.3 
(CH), 119.8 (CH), 116.1 (CH), 115.7 (Cq), 115.3 (CH), 56.2 (CH), 52.5 (CH), 52.4 (CH3), 34.8 
(CH2), 27.2 (CH2), 23.2 (CH3). IR (ATR): ṽ = 1743, 1714, 1676, 1565, 1524, 1420, 1381, 1336, 
720, 701 cm–1. MS (ESI) m/z (relative intensity): 653 (100) [M+Na]+, 631 (25) [M+H]+. HR-MS 




The general procedure F was followed using Ac-Trppym-OMe (96aa) (68 mg, 0.2 mmol) and 
2-[2-(5-oxo-1,4,2-dioxazol-3-yl)ethyl]isoindoline-1,3-dione (116h) (52 mg, 0.2 mmol). After 24 
h, purification by column chromatography (n-hexane/EtOAc 1:1 to 0:100) yielded 117aj (94 
mg, 85%) as a white solid (M.p.: 214ꟷ215 °C). 1H NMR (400 MHz, CDCl3): δ = 12.53 (s, 1H), 
8.70 (d, J = 4.9 Hz, 2H), 8.19 (dd, J = 6.3, 2.8 Hz, 1H), 8.05 (s, 1H), 7.80–7.75 (m, 2H), 7.67–
7.64 (m, 2H), 7.24–7.18 (m, 2H), 7.11 (t, J = 4.9 Hz, 1H), 6.12 (d, J = 7.7 Hz, 1H), 4.92 (dt, J 
= 7.7, 5.6 Hz, 1H), 4.07 (t, J = 7.3 Hz, 2H), 3.67 (s, 3H), 3.26 (ddd, J = 14.8, 5.6, 0.9 Hz, 1H), 
3.19 (ddd, J = 14.8, 5.6, 0.9 Hz, 1H), 2.75 (t, J = 7.3 Hz, 2H), 1.95 (s, 3H). 13C NMR (101 
MHz, CDCl3): δ = 172.0 (Cq), 169.8 (Cq), 168.0 (Cq), 167.3 (Cq), 158.1 (CH), 156.6 (Cq), 134.0 
(CH), 133.9 (Cq), 131.9 (Cq), 126.9 (CH), 126.0 (Cq), 125.7 (Cq), 123.4 (CH), 123.2 (CH), 
118.2 (CH), 116.4 (CH), 115.5 (Cq), 114.7 (CH), 52.5 (CH), 52.4 (CH3), 36.8 (CH2), 34.8 (CH2), 
27.2 (CH2), 23.2 (CH3). IR (ATR): ṽ = 3335, 2850, 1715, 1657, 1570, 1420, 1393, 1006, 713, 
506 cm–1. MS (ESI) m/z (relative intensity): 1131 (20) [2M+Na]+, 577 (100) [M+Na]+, 555 (40) 







The general procedure F was followed using Ac-Trppym-OMe (96aa) (68 mg, 0.2 mmol) and 
2-[1-(3-bromophenyl)-2-(5-oxo-1,4,2-dioxazol-3-yl)ethyl]isoindoline-1,3-dione (116i) (166 mg, 
0.4 mmol). After 24 h, purification by column chromatography (n-hexane/EtOAc 1:1 to 0:100) 
yielded 117ak (120 mg, 85%) as a white solid (M.p.: 111ꟷ112 °C). d.r. = 1:1. 1H NMR (500 
MHz, CDCl3): δ = 12.71–12.64 (m, 1H), 8.77 (d, J = 4.9 Hz, 2H), 8.11 (dd, J = 7.4, 1.7 Hz, 
1H), 8.06 (s, 1H), 7.72–7.67 (m, 2H), 7.65–7.62 (m, 1H), 7.61–7.57 (m, 2H), 7.42 (d, J = 7.8 
Hz, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.17 (t, J = 4.9 Hz, 1H), 7.20–7.10 (m, 3H), 6.25 (d, J = 7.5 
Hz, 1H), 6.01–5.93 (m, 1H), 4.93–4.86 (m, 1H), 3.67–3.61 (m, 4H), 3.29 (dd, J = 14.8, 6.4 
Hz, 1H), 3.22 (dd, J = 14.9, 5.3 Hz, 1H), 3.14 (dd, J = 14.9, 5.3 Hz, 1H), 1.92–1.90 (m, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.0 (Cq), 169.7 (Cq), 168.0 (Cq), 166.7 (Cq), 158.1 (CH), 
156.5 (Cq), 141.2 (Cq), 134.0 (CH), 133.8 (Cq), 131.4 (Cq), 131.1 (CH), 130.5 (CH), 130.2 
(CH), 126.9 (CH), 126.3 (CH), 125.8 (Cq), 125.6 (Cq), 123.2 (CH), 123.2 (CH), 122.6 (Cq), 
117.8 (CH), 116.5 (CH), 115.3 (Cq), 114.7 (CH), 52.4 (CH), 52.3 (CH3), 51.0 (CH), 40.0 (CH2), 
27.1 (CH2), 23.0 (CH3). IR (ATR): ṽ = 3292, 2918, 2850, 1634, 1566, 1418, 1331, 1213, 719, 
600 cm–1. MS (ESI) m/z (relative intensity): 733 (100) [M+Na]+ (81Br), 731 (97) [M+Na]+ (79Br), 
711 (50) [M+H]+ (81Br), 709 (49) [M+H]+ (79Br). HR-MS (ESI): m/z calcd for C35H30N6O679Br+ 
[M+H]+ 709.1405, found 709.1397. 








The general procedure F was followed using Ac-Trppym-Phe-OMe (96ba) (97 mg, 0.2 mmol) 
and 3-phenyl-1,4,2-dioxazol-5-one (116a) (66 mg, 0.4 mmol). After 24 h, purification by 
column chromatography (n-hexane/EtOAc 1:1 to 0:100) yielded 117ba (82 mg, 68%) as a 
white solid (M.p.: 220ꟷ221 °C). 1H NMR (400 MHz, DMSO-d6): δ = 12.08 (s, 1H), 8.68 (d, J 
= 4.9 Hz, 2H), 8.55 (d, J = 7.5 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 8.08 (s, 1H), 7.92 (dd, J = 
7.9, 1.1 Hz, 1H), 7.89–7.84 (m, 2H), 7.62–7.50 (m, 4H), 7.33–7.20 (m, 7H), 4.68 (dt, J = 8.4, 
4.9 Hz, 1H), 4.51 (ddd, J = 8.7, 7.5, 5.9 Hz, 1H), 3.55 (s, 3H), 3.12–3.00 (m, 2H), 2.99–2.86 
(m, 2H), 1.75 (s, 3H). 13C NMR (101 MHz, DMSO-d6): δ = 171.7 (Cq), 171.5 (Cq), 169.1 (Cq), 
164.8 (Cq), 158.7 (CH), 156.2 (Cq), 137.1 (Cq), 135.5 (Cq), 133.4 (Cq), 131.5 (CH), 129.1 (CH), 
128.7 (CH), 128.2 (CH), 127.5 (CH), 127.2 (CH), 126.5 (CH), 126.4 (Cq), 125.5 (Cq), 122.2 
(CH), 119.1 (CH), 117.1 (CH), 116.1 (Cq), 115.7 (CH), 53.6 (CH), 52.3 (CH), 51.8 (CH3), 36.6 
(CH2), 27.3 (CH2), 22.5 (CH3). IR (ATR): ṽ = 3279, 2927, 1750, 1637, 1538, 1418, 1315, 789, 
712, 601 cm–1. MS (ESI) m/z (relative intensity): 1231 (20) [2M+Na]+, 627 (100) [M+Na]+, 605 







The general procedure F was followed using Ac-Trppym-Ser-OMe (96bb) (85 mg, 0.2 mmol) 
and 3-phenyl-1,4,2-dioxazol-5-one (116a) (66 mg, 0.4 mmol). After 24 h, purification by 
column chromatography (n-hexane/EtOAc 1:1 to 0:100) yielded 117bb (43 mg, 40%) as a 
white solid (M.p.: 185ꟷ186 °C). 1H NMR (400 MHz, DMSO-d6): δ = 12.06 (s, 1H), 8.69 (d, J 
= 4.9 Hz, 2H), 8.50 (d, J = 7.6 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.11 (s, 1H), 7.91 (dd, J = 
7.8, 1.2 Hz, 1H), 7.89–7.84 (m, 2H), 7.62–7.53 (m, 4H), 7.30 (t, J = 7.8 Hz, 1H), 7.25 (t, J = 
4.9 Hz, 1H), 5.07 (t, J = 5.7 Hz, 1H), 4.76 (ddd, J = 9.0, 7.6, 4.3 Hz, 1H), 4.43–4.36 (m, 1H), 
3.74 (dd, J = 10.8, 5.7 Hz, 1H), 3.64 (dd, J = 10.8, 5.7 Hz, 1H), 3.60 (s, 3H), 3.15 (dd, J = 
15.0, 4.3 Hz, 1H), 2.95 (dd, J = 15.0, 9.0 Hz, 1H), 1.77 (s, 3H). 13C NMR (101 MHz, DMSO-
d6): δ = 171.7 (Cq), 170.9 (Cq), 169.2 (Cq), 164.8 (Cq), 158.7 (CH), 156.2 (Cq), 135.5 (Cq), 
133.5 (Cq), 131.5 (CH), 128.6 (CH), 127.6 (CH), 127.2 (CH), 126.4 (Cq), 125.4 (Cq), 122.1 
(CH), 119.0 (CH), 117.1 (CH), 116.1 (Cq). 115.8 (CH), 61.2 (CH2), 54.8 (CH), 52.4 (CH), 51.8 
(CH3), 27.5 (CH2), 22.5 (CH3). IR (ATR): ṽ = 3277, 1739, 1632, 1538, 1418, 1211, 1022, 797, 
706, 600 cm–1. MS (ESI) m/z (relative intensity): 1111 (20) [2M+Na]+, 567 (100) [M+Na]+, 545 




The general procedure F was followed using Ac-Ala-Trppym-OMe (96bc) (82 mg, 0.2 mmol) 
and 3-phenyl-1,4,2-dioxazol-5-one (116a) (66 mg, 0.4 mmol). After 24 h, purification by 
column chromatography (n-hexane/EtOAc 1:1 to 0:100) yielded 117bc (89 mg, 85%) as a 
white solid (M.p.: 213ꟷ214 °C). 1H NMR (400 MHz, DMSO-d6): δ = 12.04 (s, 1H), 8.68 (d, J 




Hz, 1H), 7.87 (d, J = 7.4 Hz, 2H), 7.65–7.50 (m, 3H), 7.45 (d, J = 7.7 Hz, 1H), 7.32 (t, J = 7.8 
Hz, 1H), 7.27 (t, J = 4.9 Hz, 1H), 4.62 (ddd, J = 8.5, 7.4, 5.5 Hz, 1H), 4.33 (dq, J = 7.8, 7.1 
Hz, 1H), 3.62 (s, 3H), 3.24 (dd, J = 14.9, 5.5 Hz, 1H), 3.14 (dd, J = 14.9, 8.5 Hz, 1H), 1.75 (s, 
3H), 1.16 (d, J = 7.1 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ = 172.6 (Cq), 171.9 (Cq), 
168.8 (Cq), 164.8 (Cq), 158.7 (CH), 156.2 (Cq), 135.4 (Cq), 133.0 (Cq), 131.5 (CH), 128.6 (CH), 
127.6 (CH), 127.2 (CH), 126.5 (Cq), 125.6 (Cq), 122.3 (CH), 119.2 (CH), 117.2 (CH), 115.3 
(Cq), 115.2 (CH), 52.1 (CH), 52.0 (CH3), 47.7 (CH), 26.3 (CH2), 22.4 (CH3), 18.2 (CH3). IR 
(ATR): ṽ = 3287, 2928, 1741, 1627, 1565, 1423, 1312, 1214, 790, 707 cm–1. MS (ESI) m/z 
(relative intensity): 551 (80) [M+Na]+, 529 (100) [M+H]+. HR-MS (ESI): m/z calcd for 




The general procedure F was followed using Ac-Trppym-Ser-OMe (96bb) (85 mg, 0.2 mmol) 
and (Z)-3-(henicos-12-en-1-yl)-1,4,2-dioxazol-5-one (116d) (76 mg, 0.2 mmol). After 24 h, 
purification by column chromatography (EtOAc/MeOH 100:1 to 20:1) yielded 117bd (88 mg, 
58%) as a white solid (M.p.: 184ꟷ185 °C). 1H NMR (300 MHz, DMSO-d6): δ = 11.44 (s, 1H), 
8.90 (d, J = 4.8 Hz, 2H), 8.47 (d, J = 7.7 Hz, 1H), 8.15 (d, J = 8.4 Hz, 1H), 8.08 (s, 1H), 7.84 
(d, J = 7.8 Hz, 1H), 7.52 (d, J = 7.7 Hz, 1H), 7.39 (t, J = 4.8 Hz, 1H), 7.22 (dd, J = 7.8, 7.7 Hz, 
1H), 5.32–5.29 (m, 2H), 5.06 (t, J = 5.6 Hz, 1H), 4.73 (ddd, J = 9.4, 8.4, 4.6 Hz, 1H), 4.42–
4.34 (m, 1H), 3.73 (dd, J = 11.1, 5.6 Hz, 1H), 3.67–3.62 (m, 1H), 3.60 (s, 3H), 3.12 (dd, J = 
14.7, 4.6 Hz, 1H), 2.92 (dd, J = 14.7, 9.4 Hz, 1H), 2.25 (t, J = 7.4 Hz, 2H), 2.02–1.94 (m, 4H), 
1.76 (s, 3H), 1.53–1.45 (m, 2H), 1.25–1.20 (m, 28H), 0.83 (t, J = 6.6 Hz, 3H). 13C NMR (101 




133.3 (Cq), 129.6 (2  CH), 127.5 (CH), 125.9 (Cq), 125.6 (Cq), 122.1 (CH), 118.2 (CH), 117.3 
(CH), 116.1 (Cq), 115.2 (CH), 61.2 (CH2), 54.7 (CH), 52.3 (CH), 51.8 (CH3), 36.9 (CH2), 31.3 
(CH2), 29.1 (2  CH2), 29.0 (CH2), 29.0 (CH2), 28.9 (CH2), 28.9 (CH2), 28.8 (CH2), 28.8 (CH2), 
28.7 (CH2), 28.6 (CH2), 28.6 (CH2), 28.5 (CH2), 27.4 (CH2), 26.5 (2  CH2), 25.0 (CH2), 22.5 
(CH3), 22.1 (CH2), 13.9 (CH3). IR (ATR): ṽ = 3290, 2918, 2850, 1740, 1633, 1566, 1419, 1212, 
779, 731 cm–1. MS (ESI) m/z (relative intensity): 783 (100) [M+Na]+, 761 (30) [M+H]+. HR-MS 




The general procedure F was followed using Ac-Ala-Trppym-OMe (96bc) (82 mg, 0.2 mmol) 
and 4-(5-oxo-1,4,2-dioxazol-3-yl)-N,N-dipropylbenzenesulfonamide (116j) (130 mg, 0.4 
mmol). After 24 h, purification by column chromatography (n-hexane/EtOAc 1:1 to 0:100) 
yielded 117be (121 mg, 88%) as a white solid (M.p.: 192ꟷ193 °C). 1H NMR (400 MHz, 
DMSO-d6): δ = 12.05 (s, 1H), 8.68 (d, J = 4.9 Hz, 2H), 8.39 (d, J = 7.5 Hz, 1H), 8.07 (s, 1H), 
8.06–7.94 (m, 5H), 7.84 (d, J = 7.8 Hz, 1H), 7.48 (d, J = 7.7 Hz, 1H), 7.33 (t, J = 7.8 Hz, 1H), 
7.24 (t, J = 4.9 Hz, 1H), 4.60 (ddd, J = 7.5, 7.0, 5.4 Hz, 1H), 4.31 (dq, J = 7.8, 7.0 Hz, 1H), 
3.62 (s, 3H), 3.23 (dd, J = 15.0, 5.4 Hz, 1H), 3.19–3.12 (m, 1H), 3.08 (t, J = 7.5 Hz, 4H), 1.74 
(s, 3H), 1.48 (qt, J = 7.5, 7.3 Hz, 4H), 1.15 (d, J = 7.0 Hz, 3H), 0.82 (t, J = 7.3 Hz, 6H). 13C 
NMR (101 MHz, DMSO-d6): δ = 172.6 (Cq), 171.9 (Cq), 168.8 (Cq), 163.5 (Cq), 158.6 (CH), 
156.2 (Cq), 142.0 (Cq), 138.7 (Cq), 133.0 (Cq), 128.3 (CH), 127.7 (CH), 127.1 (CH), 126.6 (Cq), 
125.1 (Cq), 122.3 (CH), 119.5 (CH), 117.2 (CH), 115.7 (CH), 115.2 (Cq), 52.1 (CH), 52.0 (CH3), 
49.4 (CH2), 47.7 (CH), 26.3 (CH2), 22.4 (CH3), 21.4 (CH2), 18.2 (CH3), 11.0 (CH3). IR (ATR): 




intensity): 714 (100) [M+Na]+, 692 (20) [M+H]+. HR-MS (ESI): m/z calcd for C34H42N7O7S+ 





The general procedure F was followed using Ac-Leu-Val-Trppym-OMe (96bd) (110 mg, 0.2 
mmol) and 2-{{1-[(5-oxo-1,4,2-dioxazol-3-yl)methyl]cyclohexyl}methyl}isoindoline-1,3-dione 
(116k) (137 mg, 0.4 mmol). After 24 h, purification by column chromatography 
(EtOAc/acetone 10:1) yielded 117bf (161 mg, 95%) as a white solid (M.p.: 178ꟷ179 °C). 1H 
NMR (300 MHz, DMSO-d6): δ = 11.34 (s, 1H), 8.88 (d, J = 4.9 Hz, 2H), 8.45 (d, J = 7.1 Hz, 
1H), 8.08 (s, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.83–7.79 (m, 5H), 7.63 (d, J = 9.0 Hz, 1H), 7.39–
7.34 (m, 2H), 7.25–7.18 (m, 1H), 4.58 (ddd, J = 8.3, 7.1, 5.7 Hz, 1H), 4.28 (dd, J = 9.0, 7.7 
Hz, 1H), 4.19 (dd, J = 8.1, 6.6 Hz, 1H), 3.66 (s, 2H), 3.58 (s, 3H), 3.20 (dd, J = 14.9, 5.7 Hz, 
1H), 3.09 (dd, J = 14.9, 8.3 Hz, 1H), 2.33 (s, 2H), 1.99–1.89 (m, 1H), 1.82 (s, 3H), 1.63–1.48 
(m, 6H), 1.39–1.32 (m, 4H), 1.29–1.22 (m, 3H), 0.83–0.74 (m, 12H). 13C NMR (101 MHz, 
DMSO-d6): δ = 171.8 (Cq), 171.7 (Cq), 171.0 (Cq), 169.1 (Cq), 168.7 (Cq), 168.5 (Cq), 158.7 
(CH), 156.2 (Cq), 134.2 (CH), 132.8 (Cq), 131.6 (Cq), 127.4 (CH), 126.0 (Cq), 125.6 (Cq), 122.9 
(CH), 122.3 (CH), 118.5 (CH), 117.4 (CH), 115.3 (Cq), 114.6 (CH), 57.1 (CH), 54.4 (Cq), 52.1 
(CH), 51.8 (CH3), 51.0 (CH), 45.7 (CH2), 42.6 (CH2), 32.8 (CH2), 32.8 (CH2), 31.0 (CH), 26.4 
(CH2), 25.2 (CH2), 24.1 (CH3), 22.9 (CH3), 22.4 (CH3), 21.5 (CH), 21.2 (CH2), 19.0 (CH3), 
17.8 (CH3). IR (ATR): ṽ = 3276, 1629, 1530, 1418, 1218, 1048, 1023, 997, 539, 479 cm–1. 








The general procedure F was followed using Ac-Trppy-ThrOBn-Phe-OMe (88ba) (135 mg, 0.2 
mmol) and 3-[((3r,5r,7r)-adamantan-1-yl)methyl]-1,4,2-dioxazol-5-one (116c) (94 mg, 0.4 
mmol). After 24 h, purification by column chromatography (n-hexane/EtOAc 1:1 to 1:3) 
yielded 117bg (142 mg, 82%) as a white solid (M.p.: 155ꟷ156 °C). 1H NMR (600 MHz, CDCl3): 
δ = 10.43 (s, 1H), 8.50 (ddd, J = 5.0, 1.9, 0.8 Hz, 1H), 8.03 (dd, J = 7.8, 1.1 Hz, 1H), 7.79 
(ddd, J = 8.2, 7.4, 1.9 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.40 (dd, J = 7.8, 1.1 Hz, 1H), 7.31–
7.26 (m, 3H), 7.25 (s, 1H), 7.23–7.19 (m, 3H), 7.17–7.13 (m, 4H), 7.06 (d, J = 7.5 Hz, 1H), 
6.97–6.94 (m, 2H), 6.77 (d, J = 6.6 Hz, 1H), 6.31 (d, J = 7.4 Hz, 1H), 4.78 (td, J = 6.9, 5.5 Hz, 
1H), 4.64 (td, J = 7.5, 5.5 Hz, 1H), 4.50 (d, J = 11.6 Hz, 1H), 4.43–4.40 (m, 2H), 3.95 (dq, J 
= 6.4, 3.2 Hz, 1H), 3.61 (s, 3H), 3.26 (dd, J = 14.9, 5.5 Hz, 1H), 3.14 (dd, J = 14.9, 6.9 Hz, 
1H), 3.02 (dd, J = 13.9, 5.5 Hz, 1H), 2.90 (dd, J = 13.9, 7.3 Hz, 1H), 1.93 (s, 3H), 1.90 (s, 2H), 
1.86–1.84 (m, 3H), 1.62 (d, J = 12.1 Hz, 3H), 1.53 (d, J = 12.1 Hz, 3H), 1.49–1.47 (m, 6H), 
0.97 (d, J = 6.4 Hz, 3H). 13C NMR (151 MHz, CDCl3): δ = 171.4 (Cq), 171.0 (Cq), 170.1 (Cq), 
169.0 (Cq), 168.6 (Cq), 153.2 (Cq), 147.2 (CH), 139.8 (CH), 137.6 (Cq), 135.7 (Cq), 132.1 (Cq), 
129.0 (CH), 128.5 (CH), 128.4 (CH), 127.8 (CH), 127.7 (CH), 127.7 (CH), 127.1 (CH), 126.7 
(Cq), 125.2 (Cq), 122.1 (CH), 120.7 (CH), 118.3 (CH), 117.9 (CH), 114.8 (CH), 114.5 (Cq), 
73.8 (CH), 71.2 (CH2), 55.9 (CH), 53.6 (CH), 53.6 (CH), 53.2 (CH2), 52.1 (CH3), 42.5 (CH2), 
37.6 (CH2), 36.7 (CH2), 33.0 (Cq), 28.6 (CH), 27.9 (CH2), 23.2 (CH3), 14.6 (CH3). IR (ATR): ṽ 
= 3279, 2901, 1740, 1632, 1538, 1417, 1370, 1212, 780, 696 cm–1. MS (ESI) m/z (relative 









The general procedure F was followed using Ac-Trppy-AspOBn-Phe-OMe (88bb) (138 mg, 0.2 
mmol) and 2-{{1-[(5-oxo-1,4,2-dioxazol-3-yl)methyl]cyclohexyl}methyl}isoindoline-1,3-dione 
(116k) (137 mg, 0.4 mmol). After 24 h, purification by column chromatography (n-
hexane/EtOAc 1:1 to 1:3) yielded 117bh (179 mg, 91%) as a white solid (M.p.: 115ꟷ116 °C). 
1H NMR (300 MHz, CDCl3): δ = 10.58 (s, 1H), 8.52 (dd, J = 5.1, 1.8 Hz, 1H), 7.97 (d, J = 7.8 
Hz, 1H), 7.85 (dd, J = 5.5, 3.1 Hz, 2H), 7.81–7.76 (m, 1H), 7.74 (dd, J = 5.5, 3.1 Hz, 2H), 
7.47–7.42 (m, 2H), 7.33–7.28 (m, 5H), 7.26 (s, 1H), 7.25–7.18 (m, 5H), 7.17–7.10 (m, 3H), 
7.02 (d, J = 7.7 Hz, 1H), 6.30 (d, J = 7.3 Hz, 1H), 5.03 (s, 2H), 4.81–4.66 (m, 3H), 3.79 (s, 
2H), 3.66 (s, 3H), 3.24 (dd, J = 15.0, 6.0 Hz, 1H), 3.18–3.11 (m, 1H), 3.11–3.00 (m, 2H), 2.90 
(dd, J = 17.2, 4.7 Hz, 1H), 2.63 (dd, J = 17.2, 6.8 Hz, 1H), 2.22 (s, 2H), 1.94 (s, 3H), 1.73–
1.55 (m, 5H), 1.38–1.26 (m, 5H). 13C NMR (101 MHz, DMSO-d6): δ = 171.5 (Cq), 171.4 (Cq), 
170.3 (Cq), 169.8 (Cq), 169.5 (Cq), 168.7 (Cq), 168.6 (Cq), 151.9 (Cq), 147.4 (CH), 139.3 (CH), 
136.9 (Cq), 135.9 (Cq), 134.3 (CH), 131.9 (Cq), 131.6 (Cq), 129.0 (CH), 128.3 (CH), 128.2 
(CH), 127.9 (CH), 127.8 (CH), 127.2 (Cq), 126.5 (CH), 124.0 (Cq), 123.0 (CH), 122.9 (CH), 
121.1 (CH), 120.6 (CH), 119.0 (CH), 118.1 (CH), 115.8 (CH), 114.3 (Cq), 65.7 (CH2), 54.9 
(Cq), 53.8 (CH), 52.8 (CH), 51.8 (CH3), 49.3 (CH), 45.6 (CH2), 42.1 (CH2), 36.5 (CH2), 36.0 
(CH2), 32.5 (CH2), 27.2 (CH2), 25.1 (CH2), 22.5 (CH3), 21.1 (CH2). IR (ATR): ṽ = 3280, 2927, 









The general procedure F was followed using Ac-Leu-Val-Trppym-OMe (96bd) (110 mg, 0.2 
mmol) and (Z)-3-(henicos-12-en-1-yl)-1,4,2-dioxazol-5-one (116d) (152 mg, 0.4 mmol). After 
24 h, purification by column chromatography (CH2Cl2/acetone 3:1) yielded 117bi (138 mg, 
78%) as a white solid (M.p.: 203ꟷ204 °C). 1H NMR (400 MHz, DMSO-d6): δ = 11.47 (s, 1H), 
8.89 (d, J = 4.9 Hz, 2H), 8.43 (d, J = 7.0 Hz, 1H), 8.08 (s, 1H), 7.98 (d, J = 8.2 Hz, 1H), 7.86 
(d, J = 7.8 Hz, 1H), 7.61 (d, J = 9.0 Hz, 1H), 7.40 (t, J = 4.9 Hz, 1H), 7.35 (d, J = 7.7 Hz, 1H), 
7.22 (dd, J = 7.8, 7.7 Hz, 1H), 5.31–5.28 (m, 2H), 4.57 (ddd, J = 8.4, 7.0, 5.8 Hz, 1H), 4.27 
(dt, J = 8.2, 7.3 Hz, 1H), 4.18 (dd, J = 9.0, 6.7 Hz, 1H), 3.57 (s, 3H), 3.18 (dd, J = 14.9, 5.8 
Hz, 1H), 3.08 (dd, J = 14.9, 8.4 Hz, 1H), 2.25 (t, J = 7.3 Hz, 2H), 1.97–1.94 (m, 4H), 1.81 (s, 
3H), 1.52–1.43 (m, 3H), 1.36 (t, J = 7.3 Hz, 2H), 1.24–1.18 (m, 28H), 0.84–0.79 (m, 7H), 
0.77–0.75 (m, 9H). 13C NMR (101 MHz, DMSO-d6): δ = 171.8 (Cq), 171.7 (Cq), 171.0 (Cq), 
170.1 (Cq), 169.1 (Cq), 158.8 (CH), 156.2 (Cq), 132.8 (Cq), 129.6 (2  CH), 127.4 (CH), 125.9 
(Cq), 125.8 (Cq), 122.4 (CH), 118.3 (CH), 117.4 (CH), 115.3 (Cq), 114.5 (CH), 57.0 (CH), 52.1 
(CH), 51.8 (CH3), 51.0 (CH), 40.3 (CH2), 36.9 (CH2), 31.3 (CH2), 31.0 (CH), 29.1 (CH2), 29.0 
(CH2), 28.9 (CH2), 28.9 (CH2), 28.8 (CH2), 28.8 (CH2), 28.8 (CH2), 28.7 (CH2), 28.6 (CH2), 
28.5 (CH2), 26.5 (3  CH2), 26.4 (CH2), 25.0 (2  CH2), 24.1 (CH), 22.9 (CH3), 22.4 (CH3), 
22.1 (CH2), 21.5 (CH3), 19.0 (CH3), 17.8 (CH3), 13.9 (CH3). IR (ATR): ṽ = 3270, 2923, 2852, 
1626, 1530, 1417, 1293, 1210, 735 cm–1. MS (ESI) m/z (relative intensity): 908 (100) [M+Na]+, 







The general procedure A was followed using Ac-Trppy-Ala-Leu-Val-Gly-Phe-OMe (88bc) (156 
mg, 0.2 mmol) and 3-phenyl-1,4,2-dioxazol-5-one (116a) (66 mg, 0.4 mmol). After 24 h, 
purification by column chromatography (EtOAc/acetone 3:1) yielded 117bj (104 mg, 55%) as 
a white solid (M.p.: 249ꟷ250 °C). 1H NMR (300 MHz, DMSO-d6): δ = 10.38 (s, 1H), 8.60 (dd, 
J = 5.0, 1.8 Hz, 1H), 8.32–8.27 (m, 2H), 8.16 (t, J = 5.8 Hz, 1H), 8.02–7.94 (m, 3H), 7.92–
7.84 (m, 3H), 7.63–7.58 (m, 2H), 7.54–7.49 (m, 3H), 7.36 (dd, J = 7.5, 4.9 Hz, 1H), 7.30–7.25 
(m, 3H), 7.24–7.22 (m, 1H), 7.20–7.19 (m, 2H), 7.18 (s, 1H), 7.18–7.15 (m, 1H), 4.72–4.63 
(m, 1H), 4.48 (dd, J = 8.1, 5.9 Hz, 1H), 4.32–4.24 (m, 2H), 4.15 (dd, J = 8.6, 6.4 Hz, 1H), 
3.73–3.68 (m, 2H), 3.58 (s, 3H), 3.12 (dd, J = 14.4, 4.7 Hz, 1H), 3.02 (dd, J = 13.7, 5.9 Hz, 
1H), 2.96–2.86 (m, 2H), 1.98–1.90 (m, 1H), 1.79 (s, 3H), 1.22–1.17 (m, 3H), 0.85–0.77 (m, 
12H), 0.74 (d, J = 6.4 Hz, 3H). 13C NMR (151 MHz, DMSO-d6): δ = 172.2 (Cq), 171.8 (Cq), 
171.7 (Cq), 171.5 (Cq), 170.9 (Cq), 169.5 (Cq), 168.6 (Cq), 167.7 (Cq), 149.8 (Cq), 148.9 (CH), 
138.7 (CH), 137.0 (Cq), 134.1 (Cq), 133.2 (Cq), 132.1 (CH), 129.7 (Cq), 129.0 (CH), 128.5 
(CH), 128.2 (CH), 127.7 (CH), 126.6 (CH), 126.5 (Cq), 122.8 (CH), 122.0 (CH), 120.5 (CH), 
119.6 (CH), 119.5 (CH), 111.4 (CH), 108.4 (Cq), 59.7 (CH2), 57.4 (CH), 53.6 (CH), 53.0 (CH), 
51.8 (CH3), 51.2 (CH), 48.4 (CH), 41.4 (CH2), 36.8 (CH2), 30.7 (CH), 26.5 (CH2), 24.0 (CH), 
23.0 (CH3), 22.5 (CH3), 21.4 (CH3), 19.1 (CH3), 17.9 (CH3), 17.7 (CH3). IR (ATR): ṽ = 3270, 
2958, 2930, 1741, 1629, 1589, 1520, 1436, 1216, 697 cm–1. MS (ESI) m/z (relative intensity): 
966 (100) [M+Na]+, 944 (10) [M+H]+. HR-MS (ESI): m/z calcd for C51H62N9O9+ [M+H]+ 




5.3.4.3 Procedure and Characterization Data for Difunctionalized Amino Acids 




The general procedure F was followed using Ac-Trppym-OMe (96aa) (68 mg, 0.2 mmol) and 
2-[2-(5-oxo-1,4,2-dioxazol-3-yl)ethyl]isoindoline-1,3-dione (116h) (208 mg, 0.8 mmol). After 
24 h, purification by column chromatography (n-hexane/EtOAc 1:1 to 0:100) yielded 118a 
(133 mg, 90%) as a white solid (M.p.: 253ꟷ254 °C). 1H NMR (400 MHz, DMSO-d6): δ = 9.93 
(s, 1H), 9.46 (s, 1H), 8.76 (d, J = 4.8 Hz, 2H), 8.20 (d, J = 6.9 Hz, 1H), 7.86–7.81 (m, 8H), 
7.44 (dd, J = 7.8, 1.2 Hz, 1H), 7.37 (t, J = 4.8 Hz, 1H), 7.17 (t, J = 7.7 Hz, 1H), 7.07 (dd, J = 
7.8, 1.2 Hz, 1H), 4.50 (dt, J = 8.6, 6.9 Hz, 1H), 3.74 (t, J = 7.3 Hz, 2H), 3.59–3.53 (m, 5H), 
3.11 (dd, J = 14.4, 6.9 Hz, 1H), 2.98 (dd, J = 14.4, 8.6 Hz, 1H), 2.64 (t, J = 7.5 Hz, 2H), 2.18 
(t, J = 7.5 Hz, 2H), 1.75 (s, 3H). 13C NMR (101 MHz, DMSO-d6): δ = 172.3 (Cq), 170.6 (Cq), 
169.4 (Cq), 167.6 (2  Cq), 167.5 (Cq), 167.5 (Cq), 157.7 (CH), 155.4 (Cq), 134.3 (2  CH), 
131.6 (2  Cq), 131.0 (Cq), 128.9 (Cq), 128.1 (Cq), 123.0 (2  CH), 121.7 (CH), 120.8 (CH), 
119.1 (CH), 116.4 (CH), 108.3 (Cq), 52.4 (CH), 51.9 (CH3), 33.8 (CH2), 33.7 (CH2), 33.5 (CH2), 
33.3 (CH2), 25.5 (CH2), 22.2 (CH3). IR (ATR): ṽ = 3290, 2919, 2850, 1634, 1566, 1419, 1373, 
1213, 719, 731 cm–1. MS (ESI) m/z (relative intensity): 793 (100) [M+Na]+, 771 (10) [M+H]+. 







To an oven-dried Schlenk tube was added 117aa (46 mg, 0.1 mmol), tosyl azide (40 mg, 0.2 
mmol), [RhCp*Cl2]2 (1.5 mg, 2.5 mol %) and AgSbF6 (3.4 mg, 10 mol %). The tube was 
evacuated and purged with N2 three times. Then, TFE (0.4 mL) was added. The tube was 
sealed and heated at 110 °C for 24 h. After cooling to room temperature, the resulting mixture 
was diluted with CH2Cl2 and concentrated in vacuo. Purification of the residue by column 
chromatography on silica gel (n-hexane/acetone 3:1) yielded 118b (47 mg, 76%) as a white 
solid (M.p.: 123ꟷ124 °C). 1H NMR (400 MHz, CDCl3): δ = 10.70 (s, 1H), 8.43 (s, 1H), 8.25 
(d, J = 4.9 Hz, 2H), 8.01 (d, J = 7.8 Hz, 1H), 7.71–7.68 (m, 2H), 7.51–7.48 (m, 2H), 7.44–
7.39 (m, 2H), 7.30 (t, J = 7.8 Hz, 1H), 7.17–7.14 (m, 2H), 6.98–6.95 (m, 2H), 6.86 (t, J = 4.9 
Hz, 1H), 6.63 (d, J = 7.3 Hz, 1H), 4.98 (ddd, J = 7.3, 7.3, 5.7 Hz, 1H), 3.77 (s, 3H), 3.41 (dd, 
J = 14.8, 7.3 Hz, 1H), 3.36 (dd, J = 14.8, 5.7 Hz, 1H), 2.31 (s, 3H), 1.87 (s, 3H). 13C NMR 
(101 MHz, CDCl3): δ = 172.3 (Cq), 170.2 (Cq), 165.8 (Cq), 157.6 (CH), 155.9 (Cq), 143.8 (Cq), 
135.7 (Cq), 135.4 (Cq), 131.6 (CH), 129.8 (Cq), 129.6 (CH), 128.5 (CH), 127.2 (CH), 126.7 
(CH), 125.8 (Cq), 124.9 (Cq), 123.1 (CH), 120.5 (CH), 117.2 (CH), 116.3 (CH), 115.2 (Cq), 
109.9 (Cq), 52.5 (CH3), 51.9 (CH), 26.0 (CH2), 22.9 (CH3), 21.4 (CH3). IR (ATR): ṽ = 1740, 
1653, 1566, 1415, 1336, 1290, 1161, 1089, 659, 535 cm–1. MS (ESI) m/z (relative intensity): 
1275 (10) [2M+Na]+, 649 (100) [M+Na]+, 627 (30) [M+H]+. HR-MS (ESI): m/z calcd for 








To a solution of 117bf (85 mg, 0.1 mmol), MnBr(CO)5 (1.2 mg, 5.0 mol %) and Cy2NH (36 mg, 
0.2 mmol) in DCE (0.5 mL) in the oven-dried Schlenk tube, (bromoethynyl)triisopropylsilane 
71a (52 mg, 0.2 mmol) was added. The mixture was stirred at 80 °C for 16 h. After completion 
of the reaction, CH2Cl2 (3.0 mL) was added at ambient temperature and the volatiles were 
removed in vacuo. Purification of the residue by chromatography on silica gel (n-
hexane/EtOAc 1:2) afforded the desired product 118c (67 mg, 66%) as a colorless oil. 
1H NMR (600 MHz, DMSO-d6): δ = 9.20 (s, 1H), 8.87 (d, J = 4.8 Hz, 2H), 8.64 (d, J = 6.4 Hz, 
1H), 8.02 (d, J = 8.3 Hz, 1H), 7.89–7.87 (m, 2H), 7.85–7.83 (m, 2H), 7.65 (d, J = 9.2 Hz, 1H), 
7.56 (t, J = 4.8 Hz, 1H), 7.48 (dd, J = 7.9, 1.3 Hz, 1H), 7.19–7.17 (m, 1H), 7.14 (dd, J = 7.2, 
1.3 Hz, 1H), 4.46 (ddd, J = 9.8, 6.4, 6.1 Hz, 1H), 4.35–4.31 (m, 1H), 4.25 (dd, J = 9.2, 6.8 Hz, 
1H), 3.53 (s, 2H), 3.36 (s, 3H), 3.28 (dd, J = 14.0, 9.8 Hz, 1H), 3.22 (dd, J = 14.0, 6.1 Hz, 1H), 
1.94–1.90 (m, 1H), 1.83 (s, 3H), 1.82 (s, 2H), 1.62–1.54 (m, 2H), 1.45–1.41 (m, 4H), 1.32–
1.28 (m, 3H), 1.16–1.09 (m, 4H), 1.00–0.97 (m, 21H), 0.87 (d, J = 6.6 Hz, 3H), 0.84–0.82 (m, 
6H), 0.80 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, DMSO-d6): δ = 171.9 (Cq), 171.6 (Cq), 
170.8 (Cq), 169.1 (Cq), 168.8 (Cq), 168.7 (Cq), 158.3 (CH), 156.2 (Cq), 134.3 (CH), 131.7 (Cq), 
130.2 (Cq), 129.2 (Cq), 123.6 (CH), 123.2 (Cq), 123.0 (CH), 121.4 (CH), 121.1 (Cq), 120.4 (Cq), 
119.8 (CH), 117.0 (CH), 100.9 (Cq), 96.3 (Cq), 65.7 (Cq), 56.8 (CH), 52.9 (CH), 51.6 (CH3), 
51.0 (CH), 45.5 (CH2), 40.5 (CH2), 32.6 (2  CH2), 31.1 (CH), 27.3 (CH2), 24.2 (CH), 23.1 




IR (ATR): ṽ = 3275, 2926, 2864, 1713, 1638, 1561, 1419, 1292, 1026, 725 cm–1. MS (ESI) 
m/z (relative intensity): 1051 (100) [M+Na]+, 1029 (10) [M+H]+. HR-MS (ESI): m/z calcd for 




A suspension of amino acid 117af (67 mg, 0.1 mmol), MBH adduct ethyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 100a (69 mg, 0.3 mmol), MnBr(CO)5 (2.8 mg, 10 mol %) 
and NaOAc (2.5 mg, 30 mol %) in 1,4-dioxane (0.3 mL) was stirred at 80 °C for 16 h under 
N2. After cooling to ambient temperature, CH2Cl2 (10 mL) was added and the mixture was 
concentrated in vacuo. Purification of the residue by column chromatography on silica gel (n-
hexane/EtOAc 1:1 to 1:4) yielded 7d (56 mg, 71%) as a colorless oil. 1H NMR (600 MHz, 
CDCl3): δ = 8.75 (d, J = 4.9 Hz, 2H), 8.67 (s, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.35 (d, J = 7.7 
Hz, 1H), 7.24–7.19 (m, 2H), 6.15 (d, J = 7.5 Hz, 1H), 5.84 (brs, 1H), 5.34–5.31 (m, 2H), 4.91–
4.86 (m, 2H), 4.13 (q, J = 7.1 Hz, 2H), 4.01–3.96 (m, 2H), 3.64 (s, 3H), 3.29–3.26 (m, 2H), 
2.00–1.97 (m, 4H), 1.92 (s, 3H), 1.47–1.42 (m, 2H), 1.31–1.28 (m, 3H), 1.27–1.18 (m, 30H), 
0.86 (d, J = 7.1 Hz, 3H). 13C NMR (151 MHz, CDCl3): δ = 172.2 (Cq), 170.8 (Cq), 169.7 (Cq), 
166.1 (Cq), 158.2 (CH), 158.1 (Cq), 138.0 (Cq), 135.8 (Cq), 131.3 (Cq), 129.9 (CH), 129.8 (CH), 
128.1 (Cq), 125.2 (CH2), 123.6 (Cq), 121.9 (CH), 120.1 (CH), 118.3 (CH), 115.5 (CH), 113.7 
(Cq), 60.9 (CH2), 52.6 (CH), 52.5 (CH3), 37.8 (CH2), 31.9 (CH2), 29.7 (CH2), 29.7 (CH2), 29.7 
(CH2), 29.6 (CH2), 29.6 (2  CH2), 29.5 (CH2), 29.5 (CH2), 29.4 (CH2), 29.4 (CH2), 29.3 (CH2), 
29.3 (CH2), 29.2 (CH2), 27.6 (CH2), 27.2 (CH2), 27.0 (CH2), 25.6 (CH2), 23.1 (CH3), 22.6 (CH2), 
14.2 (CH3), 14.1 (CH3). IR (ATR): ṽ = 3022, 2556, 1568, 1428, 1392, 1233, 992, 887, 712, 
649 cm–1. MS (ESI) m/z (relative intensity): 808 (100) [M+Na]+, 786 (5) [M+H]+. HR-MS (ESI): 








A mixture of 117bi (89 mg, 0.1 mmol), MBH adduct ethyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 100a (69 mg, 0.3 mmol), MnBr(CO)5 (2.8 mg, 10 mol %) 
and NaOAc (2.5 mg, 30 mol %) in 1,4-dioxane (0.3 mL) was stirred at 80 °C for 16 h under 
N2. After cooling to ambient temperature, CH2Cl2 (10 mL) was added and the mixture was 
concentrated in vacuo. Purification of the residue by column chromatography on silica gel (n-
hexane/EtOAc 1:1 to 1:4) yielded 7e (52 mg, 52%) as a white solid (M.p.: 176ꟷ177 °C). 1H 
NMR (400 MHz, DMSO-d6): δ = 9.02 (s, 1H), 8.80 (d, J = 4.8 Hz, 2H), 8.54 (d, J = 7.1 Hz, 
1H), 8.04 (d, J = 8.2 Hz, 1H), 7.63 (d, J = 8.9 Hz, 1H), 7.51–7.40 (m, 2H), 7.18–7.10 (m, 1H), 
7.04 (d, J = 7.6 Hz, 1H), 5.74 (brs, 1H), 5.34–5.29 (m, 2H), 4.81 (brs, 1H), 4.50 (ddd, J = 8.3, 
7.1, 6.4 Hz, 1H), 4.32 (dt, J = 8.2, 7.8 Hz, 1H), 4.21 (dd, J = 8.9, 7.9 Hz, 1H), 4.08 (q, J = 7.1 
Hz, 2H), 4.00 (d, J = 17.8 Hz, 1H), 3.89 (d, J = 17.7 Hz, 1H), 3.47 (s, 3H), 3.19 (dd, J = 14.6, 
8.3 Hz, 1H), 3.09 (dd, J = 14.6, 6.4 Hz, 1H), 2.08–1.96 (m, 4H), 1.84 (s, 3H), 1.79–1.71 (m, 
2H), 1.62–1.54 (m, 1H), 1.43 (t, J = 7.3 Hz, 2H), 1.30–1.21 (s, 30H), 0.88–0.81 (m, 19H). 13C 
NMR (101 MHz, DMSO-d6): δ = 172.4 (Cq), 172.3 (Cq), 171.4 (Cq), 170.6 (Cq), 169.6 (Cq), 
166.0 (Cq), 158.7 (CH), 157.3 (Cq), 137.8 (Cq), 135.6 (Cq), 131.0 (Cq), 130.7 (Cq), 130.1 (2  
CH), 125.3 (CH2), 123.7 (Cq), 122.1 (CH), 121.1 (CH), 119.5 (CH), 116.3 (CH), 112.4 (Cq), 
60.8 (CH2), 57.5 (CH), 53.4 (CH), 52.2 (CH3), 51.5 (CH), 40.9 (CH2), 35.6 (CH2), 31.8 (CH2), 
31.4 (CH), 29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 29.5 (CH2), 29.4 (CH2), 29.4 (CH2), 29.3 (CH2), 
29.3 (CH2), 29.2 (CH2), 29.2 (CH2), 29.1 (CH2), 29.1 (CH2), 27.0 (2  CH2), 26.8 (CH2), 25.2 
(CH2), 24.7 (CH), 23.5 (CH3), 22.9 (CH3), 22.6 (CH2), 22.0 (CH3), 19.5 (CH3), 18.3 (2  CH3), 




692 cm–1. MS (ESI) m/z (relative intensity): 1020 (100) [M+Na]+, 998 (10) [M+H]+. HR-MS 
(ESI): m/z calcd for C57H88N7O8+ [M+H]+ 998.6689, found 998.6670. 




To a stirred solution of 117ab (0.5 mmol, 1.0 equiv) in CH2Cl2 (0.5 M) was added MeOTf (2.0 
equiv) at 0 °C under N2. After 30 min, the mixture was allowed to warm to 28 °C and stirred 
for 18 h. The crude mixture was concentrated under reduced pressure to afford a bright yellow 
solid. In a sealed-tube, the crude product, Pd(OH)2/C (20 wt.-%, 10 mol %), and HCO2NH4 
(30.0 equiv) were dissolved in AcOH (0.25 M), and stirred at 60 °C for 18 h. The mixture was 
filtered through a short pad of celite, concentrated under reduced pressure and purified by 
column chromatography to get the product 117ab’ as a light yellow oil (180 mg, 77%). 1H 
NMR (300 MHz, CDCl3): δ = 9.72 (s, 1H), 8.09 (s, 1H), 7.92–7.87 (m, 2H), 7.78 (dd, J = 5.5, 
3.1 Hz, 2H), 7.68 (dd, J = 5.5, 3.1 Hz, 2H), 7.60–7.47 (m, 4H), 7.05 (s, 1H), 7.05–7.00 (m, 
1H), 6.81 (d, J = 7.5 Hz, 1H), 5.34–5.27 (m, 1H), 3.82 (s, 3H), 3.81–3.70 (m, 2H). 13C NMR 
(151 MHz, CDCl3): δ = 169.6 (Cq), 167.6 (Cq), 165.5 (Cq), 134.2 (Cq), 134.0 (CH), 132.1 (CH), 
131.7 (Cq), 130.1 (Cq), 128.9 (CH), 128.4 (Cq), 127.2 (CH), 123.6 (CH), 123.4 (CH), 122.4 
(Cq), 119.2 (CH), 116.2 (CH), 113.6 (CH), 110.9 (Cq), 52.8 (CH3), 52.5 (CH), 24.8 (CH2). IR 
(ATR): ṽ = 3353, 2923, 1710, 1524, 1435, 1388, 1249, 1104, 718, 530 cm–1. MS (ESI) m/z 
(relative intensity): 490 (100) [M+Na]+, 468 (60) [M+H]+. HR-MS (ESI): m/z calcd for 
C27H22N3O5+ [M+H]+ 468.1554, found 468.1547. 








To a solution of 117ae (52 mg, 0.1 mmol) in acetic acid (1.0 mL) in a 25 mL Schlenk tube was 
added Pd/C (16 mg, 15 wt.-%). Then the Schlenk tube slowly evacuated and purged with H2 
three times through a H2-filled balloon. The mixture was stirred at 100 °C for 6 h. Then, the 
reaction mixture was filtered through a short pad of celite. The residue was concentrated in 
vacuo. The crude mixture was purified by flash column chromatography on silica gel 
(CH2Cl2/MeOH = 100:1 to 30:1) to yield 117aea (28 mg, 52%) as a colorless oil. 1H NMR (300 
MHz, DMSO-d6): δ = 11.44 (brs), 8.40 (d, J = 7.6 Hz, 1H), 7.80–7.51 (m, 1H), 7.46 (s, 1H), 
7.37 (d, J = 7.9 Hz, 1H), 7.24–7.15 (m, 1H), 4.54 (ddd, J = 8.3, 7.6, 5.5 Hz, 1H), 3.62 (s, 3H), 
3.54–3.44 (m, 4H), 3.13 (dd, J = 14.8, 5.5 Hz, 1H), 3.03 (dd, J = 14.8, 8.3 Hz, 1H), 2.09 (s, 
2H), 1.97–1.92 (m, 3H), 1.92–1.91 (m, 2H), 1.84 (s, 3H), 1.72–1.60 (m, 12H). 13C NMR (101 
MHz, DMSO-d6): δ = 172.1 (Cq), 172.0 (Cq), 169.5 (Cq), 168.7 (Cq), 149.0 (Cq), 131.4 (Cq), 
126.0 (CH), 125.2 (Cq), 125.1 (Cq), 121.8 (CH), 114.8 (CH), 113.9 (CH), 52.3 (CH), 52.0 (CH3), 
42.1 (CH2), 36.4 (CH2), 32.8 (CH2), 29.0 (Cq), 28.0 (CH), 26.4 (CH2), 22.4 (CH3), 21.1 (CH2), 
19.4 (CH2). IR (ATR): ṽ = 3240, 2900, 1741, 1622, 1535, 1444, 1201, 920, 726, 643 cm–1. 
MS (ESI) m/z (relative intensity): 556 (20) [M+Na]+, 534 (100) [M+H]+. HR-MS (ESI): m/z 








To a solution of 117ae (52 mg, 0.1 mmol) in acetic acid (1.0 mL) in a 25 mL Schlenk tube was 
added Pd/C (16 mg, 15 wt.-%). Then the Schlenk tube slowly evacuated and purged with H2 
three times through a H2-filled balloon. The mixture was stirred at 100 °C for 12 h. Then, the 
reaction mixture was filtered through a short pad of celite. The residue was concentrated in 
vacuo under 37 °C. The crude mixture was purified by flash column chromatography on silica 
gel (CH2Cl2/MeOH/Et3N = 100:1:1 to 100:5:1) to yield 117aeb (51 mg, 95%) as a colorless 
oil. 1H NMR (300 MHz, DMSO-d6): δ = 11.87 (s, 1H), 8.46 (d, J = 7.6 Hz, 1H), 7.66–7.58 (m, 
1H), 6.92 (s, 1H), 6.91–6.87 (m, 1H), 5.36–5.29 (m, 1H), 4.31 (ddd, J = 11.3, 7.6, 4.2 Hz, 1H), 
4.06–3.95 (m, 1H), 3.64 (s, 3H), 3.62–3.60 (m, 1H), 3.36–3.26 (m, 4H), 1.95–1.91 (m, 5H), 
1.90 (s, 3H), 1.76–1.68 (m, 4H), 1.66–1.56 (m, 12H). 13C NMR (75 MHz, DMSO-d6): δ = 173.0 
(Cq), 170.2 (Cq), 167.8 (Cq), 151.4 (Cq), 137.0 (Cq), 135.2 (Cq), 130.5 (CH), 126.3 (Cq), 122.6 
(CH), 122.4 (CH), 119.3 (CH), 63.0 (CH), 56.4 (CH2), 52.9 (CH2), 52.5 (CH3), 52.4 (CH2), 50.5 
(CH), 42.8 (CH2), 36.9 (CH2), 33.0 (Cq), 28.5 (CH), 22.8 (CH3), 21.3 (CH2). IR (ATR): ṽ = 3432, 
2899, 2249, 1660, 1032, 1024, 1012, 822, 760, 613 cm–1. MS (ESI) m/z (relative intensity): 
558 (10) [M+Na]+, 536 (100) [M+H]+. HR-MS (ESI): m/z calcd for C30H42N5O4+ [M+H]+ 
536.3231, found 536.3234. 





N-pyrimidyl tryptophan (96a) (68 mg, 0.2 mmol), [RhCl2Cp*]2 (3.0 mg, 2.5 mol %), AgSbF6 
(6.8 mg, 10 mol %), MesCO2H (5.4 mg, 30 mol %), TFE (0.36 mL) and CD3OD (0.04 mL) 
were placed in a 25 mL Schlenk tube under N2 and were then stirred at 110 °C for 24 h. At 
ambient temperature, the reaction mixture was diluted with H2O (5 mL) and extracted with 
EtOAc (3 × 5 mL). The combined organic layer was dried with Na2SO4 and concentrated 
under reduced pressure. Purification of the residue by column chromatography (n-
hexane/EtOAc 5:1 to 1:1) yielded 96a’ (64 mg, 95%) as a light yellow oil, The D incorporation 
was determined by 1H NMR spectroscopy.  
 
N-pyrimidyl tryptophan (96a) (68 mg, 0.2 mmol), 3-phenyl-1,4,2-dioxazol-5-one (116a) (65 
mg, 0.4 mmol), [RhCl2Cp*]2 (3.0 mg, 2.5 mol %), AgSbF6 (6.8 mg, 10 mol %), MesCO2H (5.4 
mg, 30 mol %), TFE (0.36 mL) and CD3OD (0.04 mL) were placed in a 25 mL Schlenk tube 
under N2 and were then stirred at 110 °C for 24 h. At ambient temperature, the reaction 
mixture was diluted with H2O (5 mL) and extracted with EtOAc (3 × 5 mL). The combined 
organic layer was dried with Na2SO4 and concentrated under reduced pressure. Purification 
of the residue by column chromatography (n-hexane/EtOAc 5:1 to 1:1) yielded 96a’’ (45 mg, 





The general procedure F was followed using N-pyrimidyl indole (96a) (98 mg, 0.5 mmol) and 
3-phenyl-1,4,2-dioxazol-5-one (116a) (82 mg, 0.5 mmol). After 24 h, purification of the 
residue by column chromatography on silica gel (n-hexane/EtOAc 5:1 to 1:1) yielded 117a 
(13 mg, 8%) as a light yellow oil, and 117a’ (28 mg, 18%) as light yellow oil. The substrate 
96a was also recovered in 66%. 
 
N-[1-(pyrimidin-2-yl)-1H-indol-2-yl]benzamide (117a’) 
1H NMR (600 MHz, DMSO-d6): δ = 12.84 (s, 1H), 9.03 (d, J = 4.9 Hz, 2H), 8.60 (ddt, J = 6.0, 
3.3, 0.7 Hz, 1H), 8.01–7.99 (m, 2H), 7.68–7.64 (m, 1H), 7.64–7.60 (m, 2H), 7.59–7.56 (m, 
1H), 7.48 (t, J = 4.9 Hz, 1H), 7.25 (d, J = 0.7 Hz, 1H), 7.23–7.19 (m, 2H). 13C NMR (151 MHz, 
DMSO-d6): δ = 163.0 (Cq), 158.7 (CH), 157.8 (Cq), 135.2 (Cq), 133.7 (Cq), 132.2 (CH), 132.1 
(Cq), 129.1 (CH), 129.0 (Cq), 127.0 (CH), 122.7 (CH), 122.2 (CH), 119.6 (CH), 117.5 (CH), 
115.7 (CH), 94.7 (CH). IR (ATR): ṽ = 3409, 2253, 2126, 1993, 1666, 1427, 1025, 823, 762, 
539 cm–1. MS (ESI) m/z (relative intensity): 651 (50) [2M+Na]+, 337 (100) [M+Na]+, 315 (90) 
[M+H]+. HR-MS (ESI): m/z calcd for C19H15N4O+ [M+H]+ 315.1240, found 315.1237. 
 
N-[1-(pyrimidin-2-yl)-1H-indol-7-yl]benzamide (117a) 
1H NMR (400 MHz, DMSO-d6): δ = 10.63 (s, 1H), 8.89 (d, J = 4.8 Hz, 2H), 8.16 (dd, J = 8.3, 
1.0 Hz, 1H), 7.77 (dt, J = 8.0, 1.1 Hz, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.45 (t, J = 4.8 Hz, 1H), 
7.38 (dd, J = 8.3, 7.1 Hz, 1H), 7.35–7.31 (m, 2H), 7.30–7.27 (m, 2H), 7.09 (dd, J = 8.6, 7.1 
Hz, 1H). 13C NMR (101 MHz, DMSO-d6): δ = 160.1 (Cq), 158.7 (CH), 156.7 (Cq), 139.2 (Cq), 




(CH), 119.7 (CH), 118.6 (CH), 113.2 (CH), 109.9 (CH). IR (ATR): ṽ = 3050, 1667, 1598, 1541, 
1423, 1312, 1193, 1006, 813, 752 cm–1. MS (ESI) m/z (relative intensity): 651 (70) [2M+Na]+, 
337 (100) [M+Na]+, 315 (80) [M+H]+. HR-MS (ESI): m/z calcd for C19H15N4O+ [M+H]+ 
315.1240, found 315.1231. 
5.3.5 C─H Activations for Peptide-Carbohydrate Conjugation by 
Manganese(I)-Catalysis  






The general procedure G was followed using Boc-Trppy-OBn 88ad (47.1 mg, 0.1 mmol) and 
allyl furanose carbonate 119a (72.8 mg, 0.2 mmol). Purification by column chromatography 
(n-pentane/EtOAc 5:1) yielded 120aa (57.4 mg, 76%, E/Z = 13:1 determined by 1H NMR) as 
a yellow oil. 1H NMR (400 MHz, CDCl3): δ = 8.59 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.76 (dd, J 
= 7.9, 2.0 Hz, 1H), 7.59–7.52 (m, 1H), 7.33–7.30 (m, 2H), 7.29–7.26 (m, 3H), 7.25–7.21 (m, 
4H), 7.19–7.13 (m, 6H), 5.92 (d, J = 3.8 Hz, 0.07H, Z isomer), 5.85 (d, J = 3.8 Hz, 1H), 5.76 
(dt, J = 15.6, 5.8 Hz, 1H), 5.40 (dd, J = 15.6, 7.4 Hz, 1H), 5.18 (d, J = 8.3 Hz, 1H), 5.07 (d, J 
= 12.3 Hz, 1H), 4.99 (d, J = 12.3 Hz, 1H), 4.68 (q, J = 6.9 Hz, 1H), 4.54 (d, J = 4.0 Hz, 1H), 
4.52 (d, J = 12.0 Hz, 1H), 4.48–4.43 (m, 1H), 4.41 (d, J = 12.0 Hz, 1H), 3.70 (d, J = 3.1 Hz, 




NMR (101 MHz, CDCl3): δ = 172.3 (Cq), 155.2 (Cq), 151.3 (Cq), 149.5 (CH), 138.3 (CH), 137.6 
(Cq), 136.9 (Cq), 135.6 (Cq), 135.3 (Cq), 132.0 (CH), 128.8 (Cq), 128.6 (CH), 128.5 (CH), 128.4 
(CH), 128.3 (CH), 127.9 (CH), 127.5 (CH), 125.4 (CH), 122.4 (CH), 122.2 (CH), 121.4 (CH), 
120.7 (CH), 118.7 (CH), 111.4 (Cq), 110.4 (CH), 109.6 (Cq), 104.7 (CH), 83.5 (CH), 82.8 (CH), 
80.9 (CH), 79.9 (Cq), 72.0 (CH2), 67.3 (CH2), 54.3 (CH), 28.4 (CH3), 28.0 (CH2), 27.7 (CH2), 
26.8 (CH3), 26.3 (CH3). IR (ATR): ṽ = 2978, 2929, 1709, 1586, 1471, 1457, 1351, 1162, 1072, 
1015 cm–1. MS (ESI) m/z (relative intensity): 782 (90) [M+Na]+, 760 (100) [M+H]+. HR-MS 





The general procedure G was followed using Boc-Trppy-OMe 88ab (39.5 mg, 0.1 mmol) and 
allyl ribose carbonate 119b (70.2 mg, 0.2 mmol). Purification by column chromatography (n-
pentane/EtOAc 5:1) yielded 120ab (57.3 mg, 79%, E/Z = 10:1 determined by 1H NMR) as a 
yellow oil. 1H NMR (400 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.83 (dd, J = 
7.7, 2.0 Hz, 1H), 7.58 – 7.52 (m, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.29 (ddd, J = 7.7, 4.9, 1.1 Hz, 
2H), 7.18–7.05 (m, 2H), 5.58 (dt, J = 15.5, 6.0 Hz, 1H), 5.32 (dd, J = 15.5, 7.4 Hz, 1H), 5.21 
(d, J = 8.2 Hz, 1H), 4.81 (dd, J = 6.0, 1.0 Hz, 0.1H, Z isomer), 4.74 (dd, J = 6.0, 1.0 Hz, 1H), 
4.68–4.55 (m, 1H), 4.50–4.41 (m, 1H), 4.29 (dd, J = 7.4, 4.1 Hz, 1H), 3.99 (t, J = 3.7 Hz, 1H), 
3.70–3.62 (m, 7H), 3.32 (d, J = 6.0 Hz, 2H), 1.42 (s, 12H), 1.31 (s, 3H), 0.85 (s, 9H), 0.02 (s, 
3H), 0.01 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 172.8 (Cq), 155.2 (Cq), 151.3 (Cq), 149.5 




122.1 (CH), 121.6 (CH), 120.6 (CH), 118.6 (CH), 112.1 (Cq), 110.2 (CH), 109.6 (Cq), 84.3 
(CH), 83.4 (CH), 83.3 (CH), 83.2 (CH), 79.8 (Cq), 65.0 (CH2), 54.3 (CH), 52.4 (CH3), 28.6 
(CH3), 28.4 (CH2), 27.6 (CH2), 26.6 (CH3), 26.1 (CH3), 25.3 (CH3), 18.3 (Cq), –5.3 (CH3), –
5.4 (CH3). IR (ATR): ṽ = 2951, 2930, 2856, 1743, 1712, 1471, 1459, 1366, 1252, 1162 cm–1. 
MS (ESI) m/z (relative intensity): 744 (100) [M+Na]+, 722 (50) [M+H]+. HR-MS (ESI): m/z 





The general procedure G was followed using Ac-Trppy-OMe 88ae (33.7 mg, 0.1 mmol) and 
allyl furanose carbonate 119c (70.2 mg, 0.2 mmol). Purification by column chromatography 
(n-pentane/EtOAc 3:2) yielded 120ac (60.2 mg, 98%, E/Z = 16:1 determined by 1H NMR) as 
a yellow oil. 1H NMR (300 MHz, CDCl3): δ = 8.49 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 8.17 (ddd, J 
= 5.0, 2.0, 0.8 Hz, 1H), 7.63–7.53 (m, 2H), 7.52–7.44 (m, 1H), 7.26–7.21 (m, 2H), 7.15–7.09 
(m, 2H), 7.00 (ddd, J = 7.5, 4.9, 0.9 Hz, 1H), 6.92 (ddd, J = 7.1, 4.9, 0.9 Hz, 1H), 6.64 (d, J = 
8.4 Hz, 1H), 6.12 (d, J = 8.0 Hz, 1H), 5.95 (d, J = 3.9 Hz, 0.07H, Z isomer), 5.85 (d, J = 3.9 
Hz, 1H), 5.75 (dt, J = 15.5, 5.6 Hz, 1H), 5.36 (dd, J = 15.5, 7.6 Hz, 1H), 5.19 (d, J = 3.0 Hz, 
1H), 4.90 (dt, J = 8.0, 5.7 Hz, 1H), 4.57(dd, J = 8.6, 3.4 Hz, 2H), 3.65–3.61 (m, 5H), 3.21 (d, 
J = 5.6 Hz, 2H), 1.94 (s, 3H), 1.49 (s, 3H), 1.27 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 
172.4 (Cq), 169.7 (Cq), 162.3 (Cq), 151.1 (Cq), 149.3 (CH), 146.9 (CH), 138.9 (CH), 138.1 
(CH), 136.7 (Cq), 135.5 (Cq), 132.7 (CH), 128.7 (Cq), 124.7 (CH), 122.4 (CH), 122.1 (CH), 
121.2 (CH), 120.7 (CH), 118.4 (CH), 117.5 (CH), 111.7 (Cq), 111.5 (CH), 110.2 (CH), 109.4 




(CH2), 26.8 (CH3), 26.3 (CH3), 23.3 (CH3). IR (ATR): ṽ = 2990, 1740, 1590, 1570, 1469, 1432, 
1371, 1285, 1214, 1068 cm–1. MS (ESI) m/z (relative intensity): 635 (60) [M+Na]+, 613 (100) 
[M+H]+. HR-MS (ESI): m/z calcd for C34H37N4O7+ [M+H]+ 613.2657, found 613.2654. 
The general procedure G was followed using Boc-Trppy-OBn 88ad (47.1 mg, 0.1 mmol) and 
allyl galactose carbonate 119d (68.8 mg, 0.2 mmol). Purification by column chromatography 
(n-hexane/EtOAc 10:1 to 3:1) yielded 120ad (48.0 mg, 65%) as a light yellow oil and 120ae 





1H NMR (600 MHz, CDCl3): δ = 8.62 (dd, J = 5.0, 1.9 Hz, 1H), 7.81 (dd, J = 7.7, 1.9 Hz, 1H), 
7.58–7.56 (m, 1H), 7.35 (d, J = 7.9 Hz, 1H), 7.30–7.26 (m, 5H), 7.20–7.17 (m, 2H), 7.14–7.12 
(m, 2H), 5.61 (dt, J = 15.6, 5.7 Hz, 1H), 5.46 (d, J = 5.0 Hz, 1H), 5.26 (d, J = 8.2 Hz, 1H), 
5.21 (dd, J = 15.6, 5.9 Hz, 1H), 5.09 (d, J = 12.2 Hz, 1H), 4.99 (d, J = 12.2 Hz, 1H), 4.66–
4.59 (m, 1H), 4.49 (dd, J = 7.9, 2.3 Hz, 1H), 4.22 (dd, J = 5.0, 2.3 Hz, 1H), 4.04–3.99 (m, 1H), 
3.91 (dd, J = 7.9, 1.9 Hz, 1H), 3.66–3.60 (m, 2H), 3.46–3.21 (m, 2H), 1.45 (s, 3H), 1.41 (s, 
9H), 1.36 (s, 3H), 1.29 (s, 3H), 1.28 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 172.3 (Cq), 
155.2 (Cq), 151.3 (Cq), 149.5 (CH), 138.2 (CH), 136.9 (Cq), 135.7 (Cq), 135.4 (Cq), 129.8 (CH), 
128.9 (Cq), 128.5 (CH), 128.3 (CH), 128.2 (CH), 127.4 (CH), 122.3 (CH), 122.2 (CH), 121.6 
(CH), 120.6 (CH), 118.8 (CH), 110.2 (CH), 109.7 (Cq), 109.0 (Cq), 108.4 (Cq), 96.4 (CH), 79.8 
(Cq), 73.3 (CH), 70.9 (CH), 70.6 (CH), 68.3 (CH), 67.3 (CH2), 54.4 (CH), 28.6 (CH3), 28.2 




1711, 1587, 1437, 1369, 1164, 1064, 994, 740 cm–1. MS (ESI) m/z (relative intensity): 762 






1H NMR (600 MHz, CDCl3): δ = 8.65 (dd, J = 4.9, 1.8 Hz, 1H), 7.84 (dd, J = 7.7, 2.0 Hz, 1H), 
7.60–7.56 (m, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.31–7.27 (m, 5H), 7.25–7.17 (m, 2H), 7.15–7.12 
(m, 2H), 5.54 (d, J = 5.2 Hz, 1H), 5.49–5.39 (m, 2H), 5.35 (d, J = 8.5 Hz, 1H), 5.13 (d, J = 
12.4 Hz, 1H), 5.05 (d, J = 12.4 Hz, 1H), 4.71 (q, J = 7.1 Hz, 1H), 4.57 (dd, J = 7.9, 2.4 Hz, 
1H), 4.55 (dd, J = 6.3, 1.9 Hz, 1H), 4.29 (dd, J = 5.2, 2.4 Hz, 1H), 3.95 (d, J = 7.9 Hz, 1H), 
3.88–3.72 (m, 2H), 3.35–3.26 (m, 2H), 1.67 (s, 3H), 1.43 (s, 3H), 1.40 (s, 9H), 1.36 (s, 3H), 
1.31 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 172.4 (Cq), 155.3 (Cq), 154.6 (CH), 151.3 (Cq), 
149.9 (CH), 138.3 (CH), 136.7 (Cq), 136.5 (Cq), 135.5 (Cq), 131.7 (CH), 128.7 (Cq), 128.5 
(CH), 128.2 (CH), 125.4 (CH), 122.4 (CH), 121.9 (CH), 121.1 (CH), 120.8 (CH), 118.7 (CH), 
110.1 (CH), 109.6 (Cq), 109.2 (Cq), 108.5 (Cq), 96.7 (CH), 79.8 (Cq), 73.0 (CH), 71.0 (CH), 
70.3 (CH), 67.2 (CH2), 63.7 (CH), 54.4 (CH), 28.6 (CH3), 28.1 (CH2), 27.7 (CH2), 26.3 (CH3), 
26.2 (CH3), 25.1 (CH3), 24.6 (CH3). IR (ATR): ṽ = 3354, 2980, 1712, 1472, 1458, 1368, 1255, 
1066, 995, 742 cm-1. MS (ESI) m/z (relative intensity): 762 (30) [M+Na]+, 740 (100) [M+H]+. 








The general procedure G was followed using Brevianamide Fpy 88af (36.0 mg, 0.1 mmol) and 
allyl galactose carbonate 119d (68.8 mg, 0.2 mmol). Purification by column chromatography 
(n-hexane/EtOAc 10:1 to 3:1) yielded 120af (34.5 mg, 55%, E/Z = 6:1 determined by 1H NMR) 
as a light yellow oil. 1H NMR (400 MHz, CDCl3): δ = 8.63 (dd, J = 4.8, 1.6 Hz, 1H), 7.86 (dd, 
J = 8.0, 1.9 Hz, 1H), 7.58–7.55 (m, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.35–7.30 (m, 2H), 7.19–
7.15 (m, 2H), 5.74–5.72 (m, 1H), 5.45 (d, J = 5.0 Hz, 1H), 5.31 (dd, J = 16.2, 6.3 Hz, 1H), 
4.50 (dd, J = 7.8, 2.0 Hz, 1H), 4.46–4.38 (m, 1H), 4.22 (dd, J = 5.0, 2.3 Hz, 1H), 4.09–4.04 
(m, 2H), 3.98 (dd, J = 7.8, 2.0 Hz, 1H), 3.72–3.66 (m, 3H), 3.61–3.54 (m, 1H), 3.06 (dd, J = 
15.1, 11.3 Hz, 1H), 2.35–2.26 (m, 1H), 2.17–2.16 (m, 1H), 2.08–1.78 (m, 4H), 1.46 (s, 3H), 
1.38 (s, 3H), 1.28 (s, 6H). 13C NMR (126 MHz, CDCl3): δ = 169.3 (Cq), 165.7 (Cq), 151.0 (Cq), 
149.6 (CH), 138.4 (CH), 137.1 (Cq), 136.2 (Cq), 130.1 (CH), 128.1 (Cq), 127.7 (CH), 122.8 
(CH), 122.5 (CH), 121.7 (CH), 121.1 (CH), 118.1 (CH), 110.7 (CH), 109.1 (Cq), 108.7 (Cq), 
108.5 (Cq), 96.5 (CH), 73.4 (CH), 71.0 (CH), 70.5 (CH), 68.3 (CH), 59.3 (CH), 55.1 (CH), 45.6 
(CH2), 28.5 (CH2), 28.3 (CH2), 26.3 (CH3), 26.3 (CH3), 25.9 (CH2), 25.1 (CH3), 24.7 (CH3), 
22.9 (CH2). IR (ATR): ṽ = 2985, 1667, 1588, 1471, 1371, 1256, 1167, 1066, 994, 745 cm–1. 
MS (ESI) m/z (relative intensity): 651 (100) [M+Na]+, 629 (90) [M+H]+. HR-MS (ESI): m/z 
calcd for C35H41N4O7 [M+H]+ 629.2970, found 629.2967.  








The general procedure H was followed using Boc-Gly-Trppy-OMe 88bd (45.3 mg, 0.1 mmol), 
allyl furanose carbonate 119a (72.8 mg, 0.20 mmol). Purification by column chromatography 
(n-hexane/Acetone 10:1 to 3:1) yielded 120ba (50.0 mg, 68 %, E/Z = 14:1 determined by 1H 
NMR) as a light yellow oil. 1H NMR (600 MHz, CDCl3): δ = 8.56 (dd, J = 5.0, 1.4 Hz, 1H), 7.79 
(dd, J = 7.8, 2.1 Hz, 1H), 7.52 (d, J = 7.5 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.29–7.26 (m, 
2H), 7.26–7.22 (m, 2H), 7.21–7.18 (m, 2H), 7.16–7.14 (m, 3H), 6.55 (d, J = 7.7 Hz, 1H), 5.95 
(d, J = 3.8 Hz, 0.07H, Z isomer), 5.88 (d, J = 3.8 Hz, 1H), 5.81 (d, J = 15.5, 5.1 Hz, 1H), 5.45 
(dd, J = 15.5, 6.0 Hz, 1H), 5.33–5.15 (m, 1H), 4.92 (q, J = 6.5 Hz, 1H), 4.59–4.55 (m, 2H), 
4.47–4.40 (m, 2H), 3.74–3.68 (m, 4H), 3.64 (s, 3H), 3.37–3.25 (m, 2H), 1.44 (s, 3H), 1.39 (s, 
9H), 1.28 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 172.0 (Cq), 169.1 (Cq), 155.1 (Cq), 151.0 
(Cq), 149.3 (CH), 138.2 (CH), 137.3 (Cq), 136.7 (Cq), 135.5 (Cq), 128.4 (Cq), 128.3 (CH), 127.7 
(CH), 127.4 (CH), 125.1 (CH), 122.4 (CH), 122.1 (CH), 121.2 (CH), 120.7 (CH), 118.2 (CH), 
114.5 (CH), 111.4 (Cq), 110.2 (CH), 109.4 (Cq), 104.5 (CH), 83.1 (CH), 82.5 (CH), 80.5 (CH), 
79.8 (Cq), 71.8 (CH2), 52.8 (CH), 52.4 (CH3), 44.0 (CH2), 28.3 (CH3), 27.9 (CH2), 27.1 (CH2), 
26.7 (CH3), 26.2 (CH3). IR (ATR): ṽ = 3356, 2979, 2023, 1716, 1519, 1472, 1369, 1165, 1020, 
468 cm–1. MS (ESI) m/z (relative intensity): 1503 (40) [2M+Na]+, 763 (100) [M+Na]+, 741 (60) 








The general procedure H was followed using Boc-Trppy-Ala-OBn 88be (54.2 mg, 0.1 mmol), 
allyl furanose carbonate 119a (72.8 mg, 0.20 mmol). Purification by column chromatography 
(n-hexane/Acetone 10:1 to 3:1) yielded 120bb (62.3 mg, 75%, E/Z = 15:1 determined by 1H 
NMR) as a yellow solid (M.p. = 83–84 °C). 1H NMR (600 MHz, CDCl3): δ = 8.54 (dd, J = 4.9, 
1.9 Hz, 0.06H, Z isomer), 8.59 (dd, J = 4.9, 1.9 Hz, 1H), 7.78 (dd, J = 7.7, 1.9 Hz, 1H), 7.65 
(d, J = 6.5 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.35–7.27 (m, 5H), 7.26–7.23 (m, 5H), 7.19–
7.16 (m, 2H), 7.15–7.12 (m, 2H), 6.32 (d, J = 5.9 Hz, 1H), 5.84 (d, J = 3.8 Hz, 1H), 5.80 (dt, 
J = 15.5, 5.2 Hz, 1H), 5.47 (dt, J = 15.5, 7.5 Hz, 1H), 5.00 (s, 2H), 4.53 (s, 1H), 4.52 (d, J = 
6.8 Hz, 1H), 4.49–4.42 (m, 4H), 3.73 (d, J = 2.9 Hz, 1H), 3.69 (d, J = 5.2 Hz, 2H), 3.37–3.26 
(m, 1H), 3.19–3.09 (m, 1H), 1.43 (s, 3H), 1.41 (s, 9H), 1.27 (s, 3H), 1.26 (d, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 171.7 (Cq), 170.9 (Cq), 151.2 (Cq), 149.3 (CH), 138.1 (CH), 
137.4 (Cq), 136.8 (Cq), 135.4 (Cq), 135.3 (Cq), 132.2 (CH), 128.5 (CH), 128.4 (CH), 128.3 
(Cq), 128.2 (CH), 127.9 (CH), 127.7 (CH), 127.4 (CH), 125.3 (CH), 122.3 (CH), 122.0 (CH), 
121.3 (CH), 120.7 (CH), 118.7 (CH), 111.3 (Cq), 110.3 (CH), 109.8 (2Cq), 104.6 (CH), 83.4 
(CH), 82.8 (CH), 80.9 (CH), 79.8 (Cq), 72.0 (CH2), 66.9 (CH2), 54.9 (CH), 48.3 (CH), 28.4 
(CH3), 29.8 (CH2), 28.0 (CH2), 26.8 (CH3), 26.3 (CH3), 18.4 (CH3). IR (ATR): ṽ = 1668, 1471, 
1438, 1367, 1161, 1072, 1016, 739, 797 cm–1. MS (ESI) m/z (relative intensity): 853 (80) 









The general procedure H was followed using Boc-Trppy-Trp-OMe 88bf (58.1 mg, 0.1 mmol), 
allyl furanose carbonate 119c (70.3 mg, 0.20 mmol). Purification by column chromatography 
(n-hexane/Acetone 10:1 to 3:1) yielded 120bc (58.3 mg, 68%, E/Z = 11:1 determined by 1H 
NMR) as a white solid (M.p. = 118–119 °C). 1H NMR (600 MHz, CDCl3): δ = 8.78 (s, 1H), 
8.58 (dd, J = 5.0, 1.3 Hz, 1H), 8.15 (ddd, J = 5.0, 2.0, 0.7 Hz, 1H), 7.68–7.63 (m, 2H), 7.56 
(ddd, J = 8.4, 7.0, 2.0 Hz, 1H), 7.31 (d, J = 7.0 Hz, 1H), 7.25–7.18 (m, 3H), 7.17–7.12 (m, 
3H), 7.09–7.05 (m, 1H), 7.00–6.95 (m, 1H), 6.90 (dd, J = 7.1, 5.0 Hz, 1H), 6.64 (d, J = 8.3 
Hz, 1H), 6.44–6.35 (m, 1H), 6.20–6.10 (m, 1H), 5.90 (dd, J = 3.7 Hz, 0.1H, Z isomer), 5.85 
(dd, J = 3.7 Hz, 1H), 5.77 (dt, J = 15.3, 5.9 Hz, 1H), 5.38 (dd, J = 15.3, 7.5 Hz, 1H), 5.27 (d, 
J = 2.4 Hz, 1H), 5.12–5.06 (m, 1H), 4.70–4.62 (m, 2H), 4.59 (d, J = 3.7 Hz, 1H), 4.51–4.43 
(m, 1H), 3.69–3.58 (m, 2H), 3.53 (s, 3H), 3.37–3.20 (m, 1H), 3.07 (d, J = 5.9 Hz, 2H), 3.02–
2.91 (m, 1H), 1.53 (s, 3H), 1.41 (s, 9H), 1.30 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 171.3 
(Cq), 170.8 (Cq), 162.2 (Cq), 155.0 (Cq), 151.0 (Cq), 149.1 (CH), 146.8 (CH), 138.9 (CH), 138.3 
(CH), 136.8 (Cq), 135.9 (Cq), 135.5 (Cq), 132.4 (CH), 128.3 (Cq), 127.2 (Cq), 124.7 (CH), 122.9 
(CH), 122.3 (CH), 122.2 (CH), 121.7 (CH), 121.5 (CH), 120.8 (CH), 119.2 (CH), 119.1 (CH), 
118.2 (CH), 117.4 (CH), 111.6 (Cq), 111.3 (CH), 111.1 (CH), 110.1 (CH), 109.8 (Cq), 109.1 




(CH3), 45.9 (CH2), 28.4 (CH3), 27.9 (CH2), 27.3 (CH2), 26.7 (CH3), 26.2 (CH3). IR (ATR): ṽ = 
1671, 1588, 1471, 1367, 1163, 1014, 854, 781, 740, 698 cm–1. MS (ESI) m/z (relative 
intensity): 879 (80) [M+Na]+, 857 (100) [M+H]+. HR-MS (ESI): m/z calcd for C48H53N6O9+ 





The general procedure H was followed using Boc-Trppy-Val-OMe 88bg (49.5 mg, 0.1 mmol), 
allyl furanose carbonate 119a (72.8 mg, 0.20 mmol). Purification by column chromatography 
(n-hexane/Acetone 10:1 to 3:1) yielded 120bd (52.5 mg, 67%, only traces of Z isomer 
observed by 1H NMR) as a white solid (M.p. = 86–87 °C). 1H NMR (600 MHz, CDCl3): δ = 
8.59 (ddd, J = 4.9, 1.9, 0.7 Hz, 1H), 7.78 (dd, J = 7.7, 1.9 Hz, 1H), 7.64 (d, J = 6.4 Hz, 1H), 
7.43 (m, 1H), 7.31–7.28 (m, 1H), 7.26–7.24 (m, 3H), 7.24–7.23 (m, 1H), 7.19–7.16 (m, 2H), 
7.16–7.13 (m, 2H), 6.16 (d, J = 8.3 Hz, 1H), 5.84 (d, J = 3.8 Hz, 1H), 5.78 (dt, J = 15.6, 5.1 
Hz, 1H), 5.46 (dd, J = 15.6, 7.5 Hz, 1H), 5.31–5.22 (m, 1H), 4.53 (dd, J = 7.9, 4.1 Hz, 2H), 
4.48–4.46 (m, 1H), 4.46–4.42 (m, 2H), 4.34 (dd, J = 8.3, 5.1 Hz, 1H), 3.73 (d, J = 3.1 Hz, 1H), 
3.72–3.68 (m, 2H), 3.52 (s, 3H), 3.33–3.25 (m, 1H), 3.20–3.12 (m, 1H), 2.03–1.97 (m, 1H), 
1.43 (s, 3H), 1.42 (s, 9H), 1.27 (s, 3H), 0.79 (d, J = 6.9 Hz, 3H), 0.77 (d, J = 6.9 Hz, 3H). 13C 
NMR (126 MHz, CDCl3): δ = 171.2 (Cq), 171.1 (Cq), 155.2 (Cq), 151.1 (Cq), 149.3 (CH), 138.1 
(CH), 137.4 (Cq), 136.8 (Cq), 135.4 (Cq), 132.1 (CH), 128.3 (CH), 128.2 (Cq), 127.7 (CH), 




(Cq), 110.2 (CH), 109.8 (Cq), 104.6 (CH), 83.4 (CH), 82.7 (CH), 80.8 (CH), 79.8 (Cq), 72.0 
(CH2), 57.3 (CH), 55.2 (CH), 52.0 (CH3), 31.9 (CH2), 31.6 (CH), 28.4 (CH3), 28.0 (CH2), 26.8 
(CH3), 26.2 (CH3), 18.7 (CH3), 18.0 (CH3). IR (ATR): ṽ = 2977, 1674, 1437, 1211, 1069, 994, 
861, 741, 699, 507 cm–1. MS (ESI) m/z (relative intensity): 805 (100) [M+Na]+, 783 (80) 





The general procedure H was followed using Boc-Trppy-Phe-OMe 88bh (54.2 mg, 0.1 mmol), 
allyl furanose carbonate 119a (72.8 mg, 0.20 mmol). Purification by column chromatography 
(n-hexane/Acetone 10:1 to 3:1) yielded 120be (56.5 mg, 68%, only traces of Z isomer 
observed by 1H NMR) as a yellow solid (M.p. = 86–87 °C). 1H NMR (600 MHz, CDCl3): δ = 
8.58 (ddd, J = 4.9, 2.0, 0.6 Hz, 1H), 7.77 (dd, J = 7.7, 2.0 Hz, 1H), 7.65 (d, J = 6.1 Hz, 1H), 
7.40 (dd, J = 7.7, 1.0 Hz, 1H), 7.29 (dd, J = 6.8, 1.7 Hz, 1H), 7.26–7.23 (m, 4H), 7.19–7.15 
(m, 3H), 7.15 (dd, J = 2.2, 1.3 Hz, 1H), 7.14–7.12 (m, 3H), 6.87 (d, J = 3.0 Hz, 2H), 6.15–
6.04 (m, 1H), 5.84 (d, J = 3.8 Hz, 1H), 5.79 (dt, J = 15.5, 5.9 Hz, 1H), 5.45 (dd, J = 15.6, 7.6 
Hz, 1H), 5.30–5.19 (m, 1H), 4.66–4.59 (m, 1H), 4.54 (d, J = 1.9 Hz, 1H), 4.53 (d, J = 10.0 Hz, 
1H), 4.48–4.45 (m, 3H), 3.74–3.68 (m, 3H), 3.50 (s, 3H), 3.32–3.23 (m, 1H), 3.14–3.06 (m, 
1H), 3.00–2.88 (m, 2H), 1.43 (s, 3H), 1.41 (s, 9H), 1.27 (s, 3H). 13C NMR (126 MHz, CDCl3): 
δ = 170.9 (Cq), 170.8 (Cq), 155.0 (Cq), 151.0 (Cq), 149.3 (CH), 138.1 (CH), 137.4 (Cq), 136.8 




127.7 (CH), 127.4 (CH), 126.8 (CH), 125.3 (CH), 122.3 (CH), 122.1 (CH), 121.3 (CH), 120.8 
(CH), 118.7 (CH), 111.3 (Cq), 110.2 (CH), 109.7 (Cq), 104.5 (CH), 83.4 (CH), 82.7 (CH), 80.8 
(CH), 79.8 (Cq), 72.0 (CH2), 54.9 (CH), 53.5 (CH), 52.1 (CH3), 52.0 (CH2), 38.1 (CH2), 28.3 
(CH3), 28.0 (CH2), 26.8 (CH3), 26.2 (CH3). IR (ATR): ṽ = 1711, 1471, 1212, 1164, 1067, 994, 
899, 741, 700, 508 cm-1. MS (ESI) m/z (relative intensity): 853 (100) [M+Na]+, 831 (70) 





The general procedure H was followed using Boc-Trppy-AspOMe-OMe 88bi (52.5 mg, 0.1 
mmol), allyl furanose carbonate 119a (72.8 mg, 0.20 mmol). Purification by column 
chromatography (n-hexane/Acetone 10:1 to 3:1) yielded 120bf (67.5 mg, 83%, only traces of 
Z isomer observed by 1H NMR) as a white solid. M.p. = 92–93 °C. 1H NMR (600 MHz, CDCl3): 
δ = 8.58 (dd, J = 4.9, 1.9 Hz, 1H), 7.78 (dd, J = 7.7, 1.9 Hz, 1H), 7.66–7.60 (m, 1H), 7.43 (d, 
J = 7.9 Hz, 1H), 7.28 (dd, J = 6.6, 2.6 Hz, 1H), 7.25–7.23 (m, H), 7.15–7.12 (m, 2H), 7.16–
7.11 (m, 2H), 6.63 (d, J = 7.4 Hz, 1H), 5.84 (d, J = 3.8 Hz, 1H), 5.79 (dt, J = 15.6, 6.0 Hz, 
1H), 5.45 (dd, J = 15.6, 7.5 Hz, 1H), 5.27–5.17 (m, 1H), 4.65 (dt, J = 7.5, 4.8 Hz, 1H), 4.54 
(s, 1H), 4.52 (d, J = 8.5 Hz, 1H), 4.48 – 4.45 (m, 1H), 4.43 (d, J = 12.0 Hz, 1H), 3.72 (d, J = 
3.1 Hz, 1H), 3.70 (d, J = 6.0 Hz, 2H), 3.57 (s, 3H), 3.56 (s, 3H), 3.34–3.23 (m, 1H), 3.22–3.14 
(m, 1H), 2.85 (dd, J = 17.0, 4.5 Hz, 1H), 2.77 (dd, J = 17.0, 5.1 Hz, 1H), 1.43 (s, 3H), 1.41 (s, 




(Cq), 149.3 (CH), 138.1 (CH), 137.4 (Cq), 136.8 (Cq), 135.5 (2Cq), 132.0 (CH), 128.3 (CH), 
128.3 (Cq), 127.7 (CH), 127.4 (CH), 125.3 (CH), 122.2 (CH), 122.1 (CH), 121.3 (CH), 120.7 
(CH), 118.5 (CH), 111.3 (Cq), 110.2 (CH), 109.6 (Cq), 104.5 (CH), 83.3 (CH), 82.7 (CH), 80.8 
(CH), 79.9 (Cq), 72.0 (CH2), 52.7 (CH), 51.9 (2CH3), 48.9 (CH), 36.1 (CH2), 28.3 (CH3), 28.0 
(CH2), 27.8 (CH2), 26.8 (CH3), 26.2 (CH3). IR (ATR): ṽ = 2162, 1739, 1437, 1367, 1213, 1164, 
1072, 1014, 740, 415 cm–1. MS (ESI) m/z (relative intensity): 835 (100) [M+Na]+, 813 (80) 





The general procedure H was followed using Ac-Trppy-Leu-OMe 88bj (45.1 mg, 0.1 mmol), 
allyl furanose carbonate 119a (72.8 mg, 0.20 mmol). Purification by column chromatography 
(n-hexane/Acetone 10:1 to 3:1) yielded 120bg (48.0 mg, 65%, only traces of Z isomer 
observed by 1H NMR) as a yellow solid (M.p. = 96–97 °C). 1H NMR (600 MHz, CDCl3): δ = 
8.59 (ddd, J = 4.9, 1.9, 0.7 Hz, 1H), 7.80 (dd, J = 7.7, 2.0 Hz, 1H), 7.72–7.69 (m, 1H), 7.45 
(d, J = 8.0 Hz, 1H), 7.31–7.30 (m, 1H), 7.27–7.24 (m, 4H), 7.21–7.18 (m, 2H), 7.17–7.13 (m, 
2H), 6.34 (d, J = 7.4 Hz, 1H), 6.21 (d, J = 7.9 Hz, 1H), 5.85 (dt, J = 15.6, 5.1 Hz, 1H), 5.84 (d, 
J = 3.7 Hz, 1H), 5.55 (dd, J = 15.6, 7.7 Hz, 1H), 4.78 (dt, J = 7.6, 7.0 Hz, 1H), 4.54 (dd, J = 
8.0, 4.1 Hz, 2H), 4.50–4.41 (m, 3H), 3.75 (d, J = 3.1 Hz, 1H), 3.73–3.68 (m, 2H), 3.54 (s, 3H), 
3.28 (dd, J = 14.4, 6.2 Hz, 1H), 3.14 (dd, J = 14.4, 8.7 Hz, 1H), 1.95 (s, 3H), 1.52–1.44 (m, 




Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 172.1 (Cq), 170.8 (Cq), 169.8 (Cq), 151.1 (Cq), 149.3 
(CH), 138.1 (CH), 137.4 (Cq), 136.7 (Cq), 135.4 (Cq), 132.6 (CH), 128.3 (CH), 128.2 (Cq), 
127.7 (CH), 127.4 (CH), 125.3 (CH), 122.3 (CH), 122.0 (CH), 121.3 (CH), 120.8 (CH), 118.6 
(CH), 111.3 (Cq), 110.2 (CH), 109.9 (Cq), 104.5 (CH), 83.3 (CH), 82.7 (CH), 80.9 (CH), 72.0 
(CH2), 53.6 (CH), 52.2 (CH3), 50.9 (CH), 41.7 (CH2), 28.2 (CH2), 27.8 (CH2), 26.7 (CH), 26.2 
(CH3), 24.7 (CH3), 23.2 (CH3), 22.6 (CH3), 22.1 (CH3). IR (ATR): ṽ = 1710, 1652, 1437, 1215, 
1163, 1073, 1016, 861, 740, 698 cm–1. MS (ESI) m/z (relative intensity): 761 (100) [M+Na]+, 





The general procedure H was followed using Boc-Trppy-SerOTBDMS-OMe 88bk (59.7 mg, 0.1 
mmol), allyl furanose carbonate derivative 119c (70.3 mg, 0.20 mmol). Purification by column 
chromatography (n-hexane/Acetone 10:1 to 3:1) yielded 120bh (43.6 mg, 50%, E/Z = 10:1 
determined by 1H NMR) as a yellow solid (M.p. = 91–92 °C). 1H NMR (600 MHz, CDCl3): δ = 
8.50 (dd, J = 4.8, 1.2 Hz, 1H), 8.16 (dd, J = 5.0, 1.9 Hz, 1H), 7.65–7.55 (m, 3H), 7.31 (d, J = 
7.8 Hz, 1H), 7.25–7.22 (m, 1H), 7.13–7.08 (m, 2H), 7.03–7.00 (m, 1H), 6.91 (dd, J = 7.1, 5.0 
Hz, 1H), 6.65 (d, J = 8.3 Hz, 1H), 6.41 (d, J = 7.8 Hz, 1H), 5.84 (d, J = 3.7 Hz, 1H), 5.74 (dt, 
J = 15.1, 5.9 Hz, 1H), 5.36 (dd, J = 15.3, 7.5 Hz, 1H), 5.21 (d, J = 2.9 Hz, 1H), 5.20–5.16 (m, 
1H), 4.59 (d, J = 5.9 Hz, 1H), 4.56 (d, J = 3.8 Hz, 1H), 4.49–4.41 (m, 2H), 3.89 (dd, J = 10.1, 




3.26–3.14 (m, 1H), 3.11–3.02 (m, 1H), 1.49 (s, 3H), 1.42 (s, 9H), 1.27 (s, 3H), 0.76 (s, 9H), 
–0.08 (s, 3H), –0.10 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 171.2 (Cq), 171.1 (Cq), 169.9 
(CH), 162.3 (Cq), 151.1 (Cq), 149.2 (CH), 146.8 (CH), 138.8 (CH), 137.9 (CH), 136.7 (Cq), 
135.4 (Cq), 132.5 (CH), 128.3 (Cq), 124.5 (CH), 122.2 (CH), 121.9 (CH), 121.2 (CH), 120.6 
(CH), 117.3 (CH), 111.5 (2Cq), 111.4 (CH), 110.0 (CH), 109.6 (Cq), 104.4 (CH), 83.4 (CH), 
79.8 (CH), 79.7 (Cq), 78.7 (CH), 63.4 (CH2), 54.5 (2CH), 52.2 (CH3), 28.4 (CH3), 28.0 (CH2), 
27.9 (CH2), 26.7 (CH3), 26.3 (CH3), 25.7 (CH3), 18.1 (Cq), –5.5 (CH3), –5.6 (CH3). IR (ATR): 
ṽ = 2928, 1681, 1592, 1471, 1434, 1368, 1252, 1164, 1069, 1015, 835, 778, 740 cm–1. MS 
(ESI) m/z (relative intensity): 895 (80) [M+Na]+, 872 (100) [M+H]+. HR-MS (ESI): m/z calcd 





The general procedure H was followed using Boc-Trppy-Ile-OMe 88bl (50.9 mg, 0.1 mmol), 
allyl furanose carbonate 119c (70.3 mg, 0.20 mmol). Purification by column chromatography 
(n-hexane/Acetone 10:1 to 3:1) yielded 120bi (34.7 mg, 47%, only traces of Z isomer 
observed by 1H NMR) as a light yellow solid (M.p. = 99–100 °C). 1H NMR (600 MHz, CDCl3): 
δ = 8.51 (dd, J = 5.0, 1.8 Hz, 1H), 8.16 (dd, J = 5.2, 1.9 Hz, 1H), 7.67–7.54 (m, 3H), 7.33 (d, 
J = 7.9 Hz, 1H), 7.27–7.22 (m, 1H), 7.15–7.08 (m, 2H), 7.08–7.02 (m, 1H), 6.91 (dd, J = 7.1, 
5.1 Hz, 1H), 6.64 (d, J = 8.3 Hz, 1H), 6.18 (d, J = 8.2 Hz, 1H), 5.85 (d, J = 3.8 Hz, 1H), 5.78 




Hz, 1H), 4.64–4.59 (m, 1H), 4.57 (d, J = 3.8 Hz, 1H), 4.43–4.38 (m, 1H), 4.36 (dd, J = 8.1, 
5.0 Hz, 1H), 3.66 (d, J = 5.9 Hz, 2H), 3.51 (s, 3H), 3.21–3.12 (m, 1H), 3.08–2.97 (m, 1H), 
1.77–1.67 (m, 1H), 1.49 (s, 3H), 1.43 (s, 9H), 1.34–1.28 (m, 1H), 1.27 (s, 3H), 1.06–0.98 (m, 
1H), 0.82 (t, J = 7.4 Hz, 3H), 0.71 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 171.1 
(Cq), 171.0 (Cq), 162.3 (Cq), 151.1 (Cq), 149.2 (CH), 146.8 (CH), 138.8 (CH), 137.9 (CH), 
136.7 (Cq), 135.3 (Cq), 132.6 (CH), 128.2 (Cq), 124.6 (CH), 122.2 (CH), 121.9 (CH), 121.2 
(CH), 120.6 (CH), 118.5 (CH), 117.3 (CH), 111.5 (2Cq), 111.4 (CH), 110.0 (CH), 109.8 (Cq), 
104.5 (CH), 83.4 (CH), 79.9 (CH), 79.7 (Cq), 78.7 (CH), 56.6 (CH), 55.1 (CH), 51.9 (CH3), 
38.1 (CH), 28.4 (CH3), 28.0 (CH2), 27.7 (CH2), 26.7 (CH3), 26.3 (CH3), 25.2 (CH2), 15.1 (CH3), 
11.6 (CH3). IR (ATR): ṽ = 2963, 1656, 1470, 1368, 1254, 1068, 1015, 859, 779, 739 cm–1. 
MS (ESI) m/z (relative intensity): 806 (60) [M+Na]+, 784 (100) [M+H]+. HR-MS (ESI): m/z 





The general procedure H was followed using Ac-Trppy-Leu-OMe 88bj (45.1 mg, 0.1 mmol), 
allyl galactose carbonate 119d (68.9 mg, 0.20 mmol). Purification by column chromatography 
(n-hexane/Acetone 10:1 to 3:1) yielded 120bj (61.1 mg, 85%, only traces of Z isomer 
observed by 1H NMR) as a light yellow oil. 1H NMR (600 MHz, CDCl3): δ = 8.62 (ddd, J = 5.0, 
2.0, 0.8 Hz, 1H), 7.83 (dd, J = 7.7, 2.0 Hz, 1H), 7.72–7.69 (m, 1H), 7.48 (dd, J = 7.7, 1.0 Hz, 
1H), 7.32–7.27 (m, 2H), 7.16–7.11 (m, 2H), 6.36 (d, J = 7.4 Hz, 1H), 6.18 (d, J = 7.8 Hz, 1H), 




(ddd, J = 8.6, 7.4, 6.0 Hz, 1H), 4.51 (dd, J = 7.9, 2.3 Hz, 1H), 4.42 (td, J = 8.1, 5.3 Hz, 1H), 
4.24–4.19 (m, 1H), 4.06 (d, J = 6.6 Hz, 1H), 4.00 (dd, J = 7.9, 1.9 Hz, 1H), 3.70–3.64 (m, 2H), 
3.55 (s, 3H), 3.34 (dd, J = 14.5, 6.1 Hz, 1H), 3.15 (dd, J = 14.5, 8.7 Hz, 1H), 1.98 (s, 3H), 
1.52–1.46 (m, 2H), 1.44 (s, 3H), 1.43–1.40 (m, 1H), 1.39 (s, 3H), 1.29 (s, 3H), 1.28 (s, 3H), 
0.85 (d, J = 6.2 Hz, 3H), 0.83 (d, J = 6.2 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 172.1 (Cq), 
170.9 (Cq), 169.8 (Cq), 151.2 (Cq), 149.3 (CH), 138.0 (CH), 136.7 (Cq), 135.7 (Cq), 130.4 (CH), 
128.2 (Cq), 127.4 (CH), 122.2 (CH), 122.0 (CH), 121.5 (CH), 120.7 (CH), 118.6 (CH), 110.2 
(CH), 109.7 (Cq), 108.9 (Cq), 108.2 (Cq), 96.3 (CH), 73.3 (CH), 70.7 (CH), 70.4 (CH), 68.4 
(CH), 53.8 (CH), 52.2 (CH3), 51.0 (CH), 41.8 (CH2), 28.2 (CH2), 27.7 (CH2), 26.1 (CH3), 26.1 
(CH3), 24.9 (CH3), 24.7 (CH), 24.4 (CH3), 23.4 (CH3), 22.7 (CH3), 22.1 (CH3). IR (ATR): ṽ = 
3277, 2957, 1743, 1644, 1471, 1370, 1165, 993, 781, 741 cm–1. MS (ESI) m/z (relative 
intensity): 741 (100) [M+Na]+, 719 (60) [M+H]+. HR-MS (ESI): m/z calcd for C39H51N4O9+ 





The general procedure H was followed using Boc-Trppy-Val-OMe 88bg (49.5 mg, 0.1 mmol), 
allyl galactose carbonate 119d (68.9 mg, 0.20 mmol). Purification by column chromatography 
(n-hexane/Acetone 10:1 to 3:1) yielded 120bk (48.1 mg, 63%, only traces of Z isomer 
observed by 1H NMR) as a white solid (M.p. = 101–102 °C). 1H NMR (500 MHz, CDCl3): δ = 
8.62 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.83 (dd, J = 7.7, 2.0 Hz, 1H), 7.69–7.61 (m, 1H), 7.46 




(dt, J = 15.5, 6.1 Hz, 1H), 5.46 (d, J = 5.0 Hz, 1H), 5.42–5.33 (m, 1H), 5.30 (dd, J = 15.5, 5.5 
Hz, 1H), 4.51 (dd, J = 7.9, 2.3 Hz, 1H), 4.41 (q, J = 7.5 Hz, 1H), 4.35 (dd, J = 8.3, 5.1 Hz, 
1H), 4.22 (dd, J = 5.1, 2.3 Hz, 1H), 4.11–4.03 (m, 1H), 3.99 (dd, J = 7.9, 1.9 Hz, 1H), 3.66 (d, 
J = 6.1 Hz, 2H), 3.54 (s, 3H), 3.42–3.30 (m, 1H), 3.26–3.15 (m, 1H), 2.01 (pq, J = 6.9, 5.0 
Hz, 1H), 1.45 (s, 3H), 1.42 (s, 9H), 1.39 (s, 3H), 1.30 (s, 3H), 1.29 (s, 3H), 0.81 (d, J = 6.9 
Hz, 3H), 0.78 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 171.5 (Cq), 171.3 (Cq), 
151.3 (Cq), 149.4 (CH), 138.1 (CH), 136.8 (Cq), 135.6 (Cq), 129.9 (CH), 128.4 (Cq), 127.3 
(CH), 122.2 (CH), 122.1 (CH), 121.5 (CH), 120.7 (CH), 118.6 (CH), 110.2 (CH), 109.8 (Cq), 
108.9 (2Cq), 108.3 (Cq), 96.3 (CH), 79.8 (Cq), 73.2 (CH), 70.7 (CH), 70.3 (CH), 68.2 (CH), 
57.3 (CH), 55.3 (CH), 51.9 (CH3), 31.4 (CH), 28.3 (CH3), 28.0 (CH2), 27.4 (CH2), 26.1 (CH3), 
26.0 (CH3), 24.9 (CH3), 24.3 (CH3), 18.7 (CH3), 17.8 (CH3). IR (ATR): ṽ = 2974, 1658, 1368, 
1253, 1165, 1068, 860, 780, 741, 412 cm–1. MS (ESI) m/z (relative intensity): 785 (95) 





d]pyran-5-yl]allyl}-1H-indol-3-yl]propanoyl}-L-phenylalaninate (120bl)  
The general procedure H was followed using Boc-Trppy-Phe-OMe 88bh (54.3 mg, 0.1 mmol), 
allyl galactose carbonate 119d (68.9 mg, 0.20 mmol). Purification by column chromatography 
(n-hexane/Acetone 10:1 to 3:1) yielded 120bl (40.5 mg, 50%, only traces of Z isomer 
observed by 1H NMR) as a yellow solid (M.p. = 100–101 °C). 1H NMR (600 MHz, CDCl3): δ 




1H), 7.30–7.27 (m, 2H), 7.19–7.10 (m, 5H), 6.92–6.87 (m, 2H), 6.26–6.11 (m, 1H), 5.66 (dt, 
J = 16.3, 5.8 Hz, 1H), 5.45 (d, J = 5.0 Hz, 1H), 5.36–5.22 (m, 2H), 4.68–4.60 (m, 1H), 4.50 
(d, J = 7.8 Hz, 1H), 4.45–4.37 (m, 1H), 4.25–4.20 (m, 1H), 4.09–4.03 (m, 1H), 3.97 (d, J = 
7.8 Hz, 1H), 3.67 (d, J = 5.8 Hz, 2H), 3.52 (s, 3H), 3.39–3.29 (m, 1H), 3.19–3.12 (m, 1H), 
2.99–2.89 (m, 2H), 1.46 (s, 3H), 1.41 (s, 9H), 1.39 (s, 3H), 1.29 (s, 6H). 13C NMR (126 MHz, 
CDCl3): δ = 171.0 (Cq), 170.9 (Cq), 151.1 (Cq), 149.3 (CH), 138.0 (CH), 136.8 (Cq), 135.7 
(2Cq), 129.9 (CH), 129.1 (CH), 128.3 (CH), 128.2 (Cq), 127.4 (CH), 126.8 (CH), 122.2 (CH), 
122.1 (CH), 121.5 (CH), 120.7 (CH), 118.7 (CH), 110.1 (CH), 109.7 (Cq), 108.9 (2Cq), 108.2 
(Cq), 96.3 (CH), 79.8 (Cq), 73.2 (CH), 70.7 (CH), 70.4 (CH), 68.2 (CH), 55.0 (CH), 53.5 (CH), 
52.1 (CH3), 38.0 (CH2), 28.3 (CH3), 28.2 (CH2), 27.9 (CH2), 26.2 (CH3), 26.0 (CH3), 25.0 
(CH3), 24.4 (CH3). IR (ATR): ṽ = 1674, 1471, 1253, 1210, 1065, 993, 899, 701, 508, 413 cm–
1. MS (ESI) m/z (relative intensity): 833 (100) [M+Na]+, 811 (75) [M+H]+. HR-MS (ESI): m/z 





The general procedure H was followed using Boc-Trppy-AspOMe-OMe 88bi (52.5 mg, 0.1 
mmol), allyl galactose carbonate 119d (68.9 mg, 0.20 mmol). Purification by column 
chromatography (n-hexane/Acetone 10:1 to 3:1) yielded 120bm (67.4 mg, 85%, Z traces 
determined by 1H NMR) as a white solid (M.p. = 92–93 °C). 1H NMR (600 MHz, CDCl3): δ = 
8.61 (dd, J = 5.0, 2.0 Hz, 1H), 7.83 (dd, J = 7.7, 2.0 Hz, 1H), 7.66–7.59 (m, 1H), 7.46 (dd, J 




J = 15.3, 6.3 Hz, 1H), 5.46 (d, J = 5.0 Hz, 1H), 5.37–5.23 (m, 1H), 4.66 (dt, J = 7.5, 4.7 Hz, 
1H), 4.50 (dd, J = 7.9, 2.2 Hz, 1H), 4.46–4.36 (m, 1H), 4.22 (dd, J = 5.0, 2.2 Hz, 1H), 4.12–
4.03 (m, 1H), 3.99 (dd, J = 7.9, 1.9 Hz, 1H), 3.66 (d, J = 6.3 Hz, 2H), 3.58 (s, 6H), 3.42–3.30 
(m, 1H), 3.25–3.16 (m, 1H), 2.86 (dd, J = 17.0, 4.5 Hz, 1H), 2.77 (dd, J = 17.0, 5.1 Hz, 1H), 
1.45 (s, 3H), 1.41 (s, 9H), 1.39 (s, 3H), 1.30 (s, 3H), 1.28 (s, 3H). 13C NMR (126 MHz, CDCl3): 
δ = 171.4 (Cq), 170.8 (Cq), 170.3 (Cq), 155.0 (Cq), 151.2 (Cq), 149.3 (CH), 138.0 (CH), 136.8 
(Cq), 135.6 (Cq), 129.9 (CH), 128.4 (Cq), 127.3 (CH), 122.1 (CH), 122.0 (CH), 121.5 (CH), 
120.6 (CH), 110.1 (CH), 109.6 (CH), 108.9 (2Cq), 108.2 (Cq), 96.3 (CH), 79.8 (Cq), 73.2 (CH), 
70.7 (CH), 70.4 (CH), 68.2 (CH), 55.0 (CH), 52.6 (CH3), 51.9 (CH3), 48.9 (CH), 36.1 (CH2), 
28.3 (CH3), 28.2 (CH2), 27.9 (CH2), 26.1 (CH3), 26.0 (CH3), 24.9 (CH3), 24.4 (CH3). IR (ATR): 
ṽ = 1672, 1471, 1437, 1368, 1210, 1164, 1066, 994, 897, 742 cm–1. MS (ESI) m/z (relative 
intensity): 815 (100) [M+Na]+, 793 (50) [M+H]+. HR-MS (ESI): m/z calcd for C41H53N4O12+ 






The general procedure H was followed using Boc-Trppy-SerOTBDMS-OMe 88bk (59.7 mg, 0.1 
mmol), allyl galactose carbonate 119d (68.9 mg, 0.20 mmol). Purification by column 
chromatography (n-hexane/Acetone 10:1 to 3:1) yielded 120bn (65.7 mg, 76%, E/Z = 9:1 
determined by 1H NMR) as a white solid. M.p. = 90–91 °C. 1H NMR (400 MHz, CDCl3): δ = 




7.49–7.42 (m, 1H), 7.31–7.27 (m, 2H), 7.14–7.10 (m, 2H), 6.50 (d, J = 7.8 Hz, 1H), 6.43 (d, 
J = 7.8 Hz, 0.09H, Z isomer), 5.63 (dt, J = 15.5, 6.2 Hz, 1H), 5.45 (d, J = 5.0 Hz, 1H), 5.28 
(dd, J = 15.5, 5.9 Hz, 2H), 4.52–4.46 (m, 3H), 4.21 (dd, J = 5.1, 2.3 Hz, 1H), 4.04 (d, J = 6.2 
Hz, 1H), 3.97 (dd, J = 7.9, 1.8 Hz, 1H), 3.92 (dd, J = 10.0, 2.9 Hz, 1H), 3.70–3.64 (m, 3H), 
3.58 (s, 3H), 3.43–3.30 (m, 1H), 3.27–3.17 (m, 1H), 1.45 (s, 3H), 1.41 (s, 9H), 1.39 (s, 3H), 
1.29 (d, J = 3.9 Hz, 6H), 0.78 (s, 9H), -0.08 (s, 3H), -0.06 (s, 3H). 13C NMR (126 MHz, CDCl3): 
δ = 171.3 (Cq), 169.9 (Cq), 151.2 (Cq), 149.3 (CH), 138.0 (CH), 136.8 (Cq), 135.7 (Cq), 129.8 
(CH), 128.4 (Cq), 127.3 (CH), 122.1 (CH), 122.0 (CH), 121.5 (CH), 120.5 (CH), 118.6 (CH), 
110.1 (CH), 109.6 (Cq), 108.9 (2Cq), 108.2 (Cq), 96.3 (CH), 79.7 (Cq), 73.3 (CH), 70.8 (CH), 
70.4 (CH), 68.2 (CH), 63.4 (CH2), 54.5 (CH), 54.2 (CH), 52.2 (CH3), 28.3 (CH3), 28.1 (CH2), 
26.2 (CH3), 26.1 (CH3), 25.7 (CH3), 25.0 (CH3), 24.4 (CH3), 18.1 (CH2), –5.5 (CH3), –5.6 
(CH3). IR (ATR): ṽ = 2931, 1712, 1438, 1212, 1150, 1103, 1067, 994, 779, 742 cm–1. MS 
(ESI) m/z (relative intensity): 887 (75) [M+Na]+, 865 (100) [M+H]+. HR-MS (ESI): m/z calcd 





The general procedure H was followed using Boc-Trppy-Ile-OMe 88bl (50.9 mg, 0.1 mmol), 
allyl galactose carbonate 119d (68.9 mg, 0.20 mmol). Purification by column chromatography 
(n-hexane/Acetone 10:1 to 3:1) yielded 120bo (41.2 mg, 53%, only traces of Z isomer 
observed by 1H NMR) as a yellow solid (M.p. = 93–94 °C). 1H NMR (600 MHz, CDCl3): δ = 




7.46 (dd, J = 8.0, 1.0 Hz, 1H), 7.31–7.27 (m, 2H), 7.15–7.10 (m, 2H), 6.28 (d, J = 8.2 Hz, 1H), 
5.67 (dt, J = 15.6, 6.1 Hz, 1H), 5.46 (d, J = 5.0 Hz, 1H), 5.39 – 5.34 (m, 1H), 5.30 (dd, J = 
15.6, 5.8 Hz, 1H), 4.50 (dd, J = 8.0, 2.3 Hz, 1H), 4.45–4.41 (m, 1H), 4.40 (dd, J = 8.0, 5.0 Hz, 
1H), 4.22 (dd, J = 5.0, 2.3 Hz, 1H), 4.08–4.01 (m, 1H), 3.99 (dd, J = 7.9, 1.9 Hz, 1H), 3.66 (d, 
J = 6.1 Hz, 2H), 3.53 (s, 3H), 3.47–3.12 (m, 2H), 1.78–1.70 (m, 1H), 1.45 (s, 3H), 1.45–1.42 
(m, 9H), 1.39 (s, 3H), 1.30 (s, 3H), 1.29 (s, 3H), 1.08 – 0.99 (m, 1H), 0.84 (t, J = 7.4 Hz, 3H), 
0.74 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 171.1 (Cq), 151.2 (Cq), 149.3 (CH), 
138.0 (CH), 136.8 (Cq), 135.6 (Cq), 129.9 (CH), 128.3 (Cq), 127.9 (Cq), 127.3 (CH), 122.1 
(CH), 122.0 (CH), 121.5 (CH), 120.6 (CH), 118.6 (CH), 110.1 (CH), 109.8 (Cq), 108.9 (2Cq), 
108.2 (Cq), 96.3 (CH), 79.8 (Cq), 73.3 (CH), 70.8 (CH), 70.4 (CH), 68.2 (CH), 56.6 (CH), 51.9 
(CH3), 38.1 (CH), 28.4 (CH3), 28.1 (CH2), 27.6 (CH2), 26.2 (CH3), 26.1 (CH3), 25.2 (CH2), 
25.0 (CH), 24.4 (CH3), 15.2 (2CH3), 11.6 (CH3). IR (ATR): ṽ = 2975, 1674, 1437, 1209, 1165, 
1065, 993, 899, 741, 512 cm–1. MS (ESI) m/z (relative intensity): 799 (100) [M+Na]+, 777 
(100) [M+H]+. HR-MS (ESI): m/z calcd for C42H57N4O10+ [M+H]+ 777.4069, found 777.4073. 
5.3.5.3 Characterization Data of Hexapeptide and BODIPY-Peptide 









The general procedure H was followed using hexapeptide Boc-Trppy-Ala-Leu-Val-Gly-Phe-
OMe 88bm (88.3 mg, 0.1 mmol), allyl galactose carbonate 119d (68.9 mg, 0.20 mmol) and 
MnBr(CO)5 (27.4 mg, 0.1 mmol). Purification by column chromatography (EtOAc/MeOH 
100:1 to 10:1) yielded 120ca (95.6 mg, 83%) as a white solid (M.p. = 206–208 °C). 1H NMR 
(500 MHz, DMSO-d6): δ = 8.62–8.14 (m, 1H), 8.31 (d, J = 7.7 Hz, 1H), 8.22–8.13 (m, 2H), 
8.05–7.90 (m, 2H), 7.69–7.55 (m, 2H), 7.53–7.42 (m, 2H), 7.32–7.24 (m, 2H), 7.22–7.19 (m, 
3H), 7.15–7.04 (m, 2H), 7.02–6.87 (m, 1H), 5.59–5.41 (m, 1H), 5.39–5.28 (m, 1H), 5.09 (dd, 
J = 15.5, 6.5 Hz, 1H), 4.40–4.29 (m, 2H), 4.27–4.18 (m, 2H), 4.16 (dd, J = 8.6, 6.5 Hz, 1H), 
3.93–3.82 (m, 2H), 3.75–3.59 (m, 4H), 3.58 (s, 3H), 3.20–3.09 (m, 1H), 3.06–2.94 (m, 2H), 
2.94–2.88 (m, 1H), 1.98–1.90 (m, 1H), 1.61–1.55 (m, 1H), 1.46 (t, J = 7.4 Hz, 2H), 1.41–1.33 
(m, 3H), 1.32–1.17 (m, 19H), 1.14 (s, 2H), 1.02–0.91 (m, 2H), 0.90–0.76 (m, 13H). 13C NMR 
(126 MHz, DMSO-d6): δ = 171.9 (Cq), 171.7 (Cq), 171.6 (Cq), 171.0 (Cq), 170.9 (Cq), 168.6 
(Cq), 155.0 (Cq), 150.5 (Cq), 149.2 (CH), 138.8 (CH), 136.9 (Cq), 136.2 (Cq), 135.5 (Cq), 129.1 
(CH), 129.0 (CH), 128.2 (CH), 128.1 (Cq), 127.4 (CH), 126.5 (CH), 122.5 (CH), 121.7 (CH), 
121.2 (CH), 119.9 (CH), 118.5 (CH), 110.1 (Cq), 109.8 (CH), 107.9 (Cq), 107.4 (Cq), 95.5 
(CH), 78.2 (Cq), 72.5 (CH), 70.0 (CH), 69.6 (CH), 68.5 (CH2), 67.7 (CH), 57.4 (CH), 55.8 
(CH2), 53.6 (CH), 51.8 (CH3), 51.1 (CH), 47.9 (CH), 41.4 (CH2), 36.9 (CH2), 30.7 (CH), 29.6 
(CH), 28.0 (CH), 26.9 (CH2), 25.9 (CH3), 24.8 (CH3), 24.1 (CH3), 24.0 (CH3), 23.0 (CH3), 21.5 
(CH3), 19.1 (CH3), 17.9 (CH3). IR (ATR): ṽ = 3297, 2165, 1992, 1633, 1369, 1166, 739, 696, 
580, 413 cm–1. MS (ESI) m/z (relative intensity): 1173 (100) [M+Na]+, 1151 (40) [M+H]+. HR-









The general procedure H was followed using BODIPY peptide Boc-Trppy-PheBODIPY-OMe 
88bn (78.9 mg, 0.1 mmol), allyl furanose carbonate 119c (70.3 mg, 0.20 mmol) and NaOAc 
(16.4 mg, 0.2 mmol). Purification by column chromatography (n-hexane/Acetone 10:1 to 3:1) 
yielded 10b (63.8 mg, 60%, Z traces determined by 1H NMR) as an orange solid (M.p. = 136–
138 °C). 1H NMR (600 MHz, CDCl3): δ = 8.42 (dd, J = 5.0, 2.0 Hz, 1H), 8.14 (dd, J = 5.0, 2.0 
Hz, 1H), 7.66–7.63 (m, 1H), 7.61 (dd, J = 7.7, 2.0 Hz, 1H), 7.54 (ddd, J = 8.9, 7.3, 2.0 Hz, 
1H), 7.27 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 7.9 Hz, 1H), 7.14–7.07 (m, 2H), 7.08–6.96 (m, 4H), 
6.90–6.86 (m, 4H), 6.60 (d, J = 8.3 Hz, 1H), 6.10 (d, J = 7.3 Hz, 1H), 5.95–5.93 (m, 1H), 5.83 
(d, J = 3.8 Hz, 1H), 5.75 (dt, J = 15.6, 6.0 Hz, 1H), 5.37 (dd, J = 15.6, 7.7 Hz, 1H), 5.23 (d, J 
= 3.1 Hz, 1H), 5.21–5.07 (m, 1H), 4.66 (q, J = 6.4 Hz, 1H), 4.65–4.61 (m, 1H), 4.55 (d, J = 
3.8 Hz, 1H), 4.47–4.32 (m, 1H), 3.71–3.59 (m, 2H), 3.48 (s, 3H), 3.32–3.20 (m, 1H), 3.01–
2.87 (m, 2H), 2.52 (s, 6H), 1.47 (s, 3H), 1.41 (s, 9H), 1.25 (s, 3H), 1.22 (s, 6H). 13C NMR (126 
MHz, CDCl3): δ = 170.8 (Cq), 170.6 (Cq), 162.2 (Cq), 155.2 (2Cq), 150.9 (Cq), 149.3 (CH), 




(Cq), 133.4 (Cq), 132.4 (CH), 131.3 (Cq), 129.8 (CH), 128.1 (Cq), 128.0 (CH), 124.7 (CH), 
122.4 (CH), 122.0 (CH), 121.1 (CH), 121.0 (CH), 120.8 (CH), 118.8 (CH), 117.4 (CH), 111.6 
(Cq), 111.4 (CH), 110.1 (CH), 109.8 (Cq), 109.6 (Cq), 104.5 (CH), 83.4 (CH), 80.0 (Cq), 79.9 
(CH), 78.7 (CH), 54.7 (CH), 53.4 (CH), 52.2 (CH3), 38.1 (CH2), 28.4 (CH3), 28.1 (CH2), 27.7 
(CH2), 26.7 (CH3), 26.2 (CH3), 14.6 (CH3), 14.4 (CH3). 19F NMR (282 MHz, CDCl3): δ = –
146.27. IR (ATR): ṽ = 2221, 1682, 1508, 1470, 1366, 1192, 1068, 975, 778, 414 cm–1. MS 
(ESI) m/z (relative intensity): 1086 (75) [M+Na]+, 1064 (100) [M+H]+. HR-MS (ESI): m/z calcd 
for C59H65BF2N7O9+ [M+H]+ 1064.4909, found 1064.4892. UV-Vis Absorption λmax (1.0 mg/L 
in EtOAc) = 498 nm. Em λmax (1.0 mg/L in EtOAc) = 510 nm. 




yl}propanoic acid (120aa’) 
To a stirred solution of 120ad and 120ae mixture (0.2 mmol, 1.0 equiv) in CH2Cl2 (0.25 M) 
was added MeOTf (1.0 equiv) at 0 °C under N2. After 30 min, the mixture was allowed to 
warm to 27 °C and stirred for 18 h. The crude mixture was concentrated under reduced 
pressure to afford a bright yellow solid. In a sealed-tube, the crude product, Pd(OH)2/C (20 
wt.-%, 10 mol %), and NH4O2CH (20.0 equiv) were dissolved in MeOH (0.5 M), and stirred at 
60 °C for 16 h. The mixture was filtered through a short pad of celite, concentrated under 
reduced pressure and purified by column chromatography to get the product 120aa’ as a light 




pyridyl removal process. 1H NMR (600 MHz, CDCl3): δ = 8.12 (s, 1H), 7.55 (d, J = 7.7 Hz, 
1H), 7.25 (d, J = 7.8 Hz, 1H), 7.11 (t, J = 7.0 Hz, 1H), 7.06 (t, J = 7.2 Hz, 1H), 5.59 (d, J = 5.1 
Hz, 1H), 4.60 (dd, J = 7.9, 2.3 Hz, 1H), 4.33 (dd, J = 5.1, 2.3 Hz, 1H), 4.15 (d, J = 7.8 Hz, 
1H), 3.83–3.75 (m, 1H), 3.30–3.19 (m, 2H), 2.75–2.68 (m, 2H), 1.80–1.75 (m, 2H), 1.54 (s, 
3H), 1.53–1.51 (m, 2H), 1.47 (s, 3H), 1.46–1.45 (m, 2H), 1.43 (s, 9H), 1.35 (s, 3H), 1.34 (3H). 
13C NMR (126 MHz, CDCl3): δ = 174.3 (Cq), 155.2 (Cq), 137.1 (Cq), 135.2 (Cq), 128.9 (Cq), 
121.2 (CH), 119.4 (CH), 118.4 (CH), 110.2 (CH), 109.2 (Cq), 108.6 (Cq), 105.5 (Cq), 96.5 
(CH), 79.8 (Cq), 73.0 (CH), 70.9 (CH), 70.4 (CH), 67.6 (CH), 54.1 (CH3), 29.6 (CH2), 28.4 
(CH3), 28.0 (CH), 27.4 (CH2), 26.2 (CH2), 26.1 (CH3), 25.8 (CH2), 24.9 (CH3), 24.5 (CH3). IR 
(ATR): ṽ = 2985, 1745, 1382, 1210, 1167, 1066, 999, 898, 742, 511 cm-1. MS (ESI) m/z 
(relative intensity): 597 (100) [M+Na]+, 575 (80) [M+H]+. HR-MS (ESI): m/z calcd for 
C30H43N2O9 [M+H]+ 575.2963, found 575.2959.  
 
(S)-2-Amino-3-{2-{3-[(2R,3R,4S,5R,6R)-3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-
yl]propyl}-1H-indol-3-yl}propanoic acid (120aa’’) 
To the solution of TFA/H2O (0.5 mL/0.5 mL) was added 120aa’ (0.1 mmol) at 0 °C. The mixture 
was allowed to warm to 27 °C and stirred for 24 h. The crude mixture was concentrated under 
reduced pressure to afford a yellow oil. The product 120aa’’ was recrystallized from a solution 
of MeOH/Et2O = 1:5 to give a white solid (29 mg, 75%, β/α = 3:1). M.p. = 240–242 °C. 1H 
NMR (400 MHz, D2O): δ = 7.52 (d, J = 7.7 Hz, 1H), 7.38–7.31 (m, 1H), 7.09 (dd, J = 16.3, 
8.3 Hz, 2H), 5.10 (d, J = 3.0 Hz, 0.27 H, α anomer), 4.34 (d, J = 7.3 Hz, 1H, β anomer), 3.96–
3.86 (m, 1H), 3.69–3.65 (m, 1H), 3.59 (d, J = 3.1 Hz, 1H), 3.38–3.29 (m, 2H), 3.26 (s, 1H), 
3.10 (dd, J = 15.4, 8.7 Hz, 1H), 2.77–2.59 (m, 2H), 1.67–1.41 (m, 4H). 13C NMR (101 MHz, 




117.6 (CH), 111.1 (CH), 103.4 (Cq), 96.3 (CH), 74.3 (CH), 73.0 (CH), 71.8 (CH), 70.2 (CH), 
68.3 (CH), 29.4 (CH2), 25.6 (CH2), 25.1 (CH2), 25.0 (CH2). 13C NMR (101 MHz, D2O): α 
anomer δ = 170.4 (Cq), 139.1 (Cq), 135.6 (Cq), 127.5 (Cq), 121.5 (CH), 119.4 (CH), 117.3 (CH), 
111.2 (CH), 103.5 (Cq), 94.8 (CH), 92.1 (CH), 70.7 (CH), 69.5 (CH), 69.4 (CH), 66.0 (CH), 
29.3 (CH2), 25.1 (CH2), 25.0 (CH2), 24.8 (CH2). IR (ATR): ṽ = 3586, 2276, 2209, 2015, 2000, 
1625,1052, 742, 499, 463 cm-1. MS (ESI) m/z (relative intensity): 395 (100) [M+H]+, 417 (15) 
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